Cancer immunoediting: from immunosurveillance to tu

Nature Immunology

3, 991-998

DOI: 10.1038/ni1102-991

Citation Report

#	Article	IF	Citations
1	ecancermedicalscience. Ecancermedicalscience, 2013, 7, 320.	0.6	23
2	Plasma Fibrinogen Levels and the Clinical Course of Acute Myocardial Infarction. Angiology, 1983, 34, 693-698.	0.8	22
3	Differential effects of malignant mesothelioma cells on THP-1 monocytes and macrophages. International Journal of Oncology, 1992, 34, 543.	1.4	8
4	Review reopens old disagreements. Nature Medicine, 2002, 8, 1337-1337.	15.2	7
5	B7-H1 pathway and its role in the evasion of tumor immunity. Journal of Molecular Medicine, 2003, 81, 281-287.	1.7	249
6	Gene therapeutic approaches for medullary thyroid carcinoma treatment. Journal of Molecular Medicine, 2003, 81, 411-419.	1.7	18
7	HLA-G and IL-10 expression in human cancerâ€"different stories with the same message. Seminars in Cancer Biology, 2003, 13, 337-342.	4.3	91
8	HLA-G in melanoma: can the current controversies be solved?. Seminars in Cancer Biology, 2003, 13, 361-369.	4.3	47
9	Cancer immunotherapy: an embarrassment of riches?. Drug Discovery Today, 2003, 8, 253-258.	3.2	32
10	Immunotherapy for Renal Cell Carcinoma. European Urology, 2003, 44, 65-75.	0.9	104
11	Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines. Biochimica Et Biophysica Acta: Reviews on Cancer, 2003, 1653, 61-71.	3.3	18
12	Immunotherapy of melanoma: the good news, the bad ones and what to do next. Seminars in Cancer Biology, 2003, 13, 387-389.	4.3	25
13	Local delivery of poxvirus vaccines for melanoma. Seminars in Cancer Biology, 2003, 13, 417-422.	4.3	12
14	Active-specific immunization against melanoma: Is the problem at the receiving end?. Seminars in Cancer Biology, 2003, 13, 473-480.	4.3	55
15	Perforin and the granule exocytosis cytotoxicity pathway. Current Opinion in Immunology, 2003, 15, 522-527.	2.4	134
16	Harnessing immunity for cancer marker discovery. Nature Biotechnology, 2003, 21, 37-38.	9.4	84
17	Human dendritic cells genetically engineered to express cytosolically retained fragment of prostate-specific membrane antigen prime cytotoxic T-cell responses to multiple epitopes. Cancer Gene Therapy, 2003, 10, 907-917.	2.2	15
18	Observing the invisible: successful tumor immunity in humans. Nature Immunology, 2003, 4, 201-201.	7.0	47

#	Article	IF	Citations
19	Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nature Medicine, 2003, 9, 1377-1382.	15.2	386
20	The circadian clock: pacemaker and tumour suppressor. Nature Reviews Cancer, 2003, 3, 350-361.	12.8	596
21	Occurrence of leukaemia following gene therapy of X-linked SCID. Nature Reviews Cancer, 2003, 3, 477-488.	12.8	323
22	Targeting tumours with genetically enhanced T lymphocytes. Nature Reviews Cancer, 2003, 3, 35-45.	12.8	467
23	Sequence-based cancer genomics: progress, lessons and opportunities. Nature Reviews Genetics, 2003, 4, 409-418.	7.7	69
24	Cancer vaccines: between the idea and the reality. Nature Reviews Immunology, 2003, 3, 630-641.	10.6	562
25	Roles of the NKG2D immunoreceptor and its ligands. Nature Reviews Immunology, 2003, 3, 781-790.	10.6	1,161
26	Potential Prophylactic Measures Against Postoperative Immunosuppression: Could They Reduce Recurrence Rates in Oncological Patients?. Annals of Surgical Oncology, 2003, 10, 972-992.	0.7	294
27	HLA-G in skin cancer: a wolf in sheep's clothing?. Human Immunology, 2003, 64, 1073-1080.	1.2	15
28	Differential in vivo and in vitro HLA-G expression in melanoma cells: potential mechanisms. Human Immunology, 2003, 64, 1057-1063.	1.2	45
29	The interferon in TLR signaling: more than just antiviral. Trends in Immunology, 2003, 24, 534-539.	2.9	181
30	Biology of FasL. Cytokine and Growth Factor Reviews, 2003, 14, 325-335.	3.2	67
31	Chemical Carcinogens as Foreign Bodies and Some Pitfalls Regarding Cancer Immune Surveillance. Advances in Cancer Research, 2003, 90, 179-207.	1.9	33
32	Premalignant Lesions as Targets for Cancer Vaccines. Journal of Experimental Medicine, 2003, 198, 1623-1626.	4.2	53
33	Î³Î´ T Cells Provide an Early Source of Interferon Î³ in Tumor Immunity. Journal of Experimental Medicine, 2003, 198, 433-442.	4.2	382
34	Transforming Growth Factor-Î² Production and Myeloid Cells Are an Effector Mechanism through Which CD1d-restricted T Cells Block Cytotoxic T Lymphocyteâ€“mediated Tumor Immunosurveillance. Journal of Experimental Medicine, 2003, 198, 1741-1752.	4.2	508
35	Spontaneous regression of advanced cancer: Identification of a unique genetically determined, age-dependent trait in mice. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6682-6687.	3.3	82
36	Novel cancer vaccines: an update. Expert Opinion on Therapeutic Patents, 2003, 13, 1787-1799.	2.4	0

#	Article	IF	Citations
37	IMMUNOLOGY: Hide and Seek in the Peptidome. Science, 2003, 301, 1334-1335.	6.0	39
38	Targeting Adult and Pediatric Cancers via Cell-Based Vaccines and the Prospect of Activated B Lymphocytes as a Novel Modality. Cancer Biology and Therapy, 2003, 2, 466-470.	1.5	9
39	An Essential Role of Th1 Responses and Interferon-gamma in Infection-Mediated Suppression of Neoplastic Growth. Cancer Biology and Therapy, 2003, 2, 685-691.	1.5	73
40	Proper Costimulation of Tumor-Reactive T Lymphocytes May Provide a Key to Unlock Their Antitumor Activity. Cancer Biology and Therapy, 2003, 2, 587-588.	1.5	1
41	Invariant NKT Cells as Initiators, Licensors, and Facilitators of the Adaptive Immune Response. Journal of Experimental Medicine, 2003, 198, 1779-1783.	4.2	27
42	Nonlinear Dose-Response Relationship in the Immune System following Exposure to Ionizing Radiation: Mechanisms and Implications. Nonlinearity in Biology, Toxicology, Medicine, 2003, 1, 154014203908444.	0.4	79
43	Chemokines and Breast Cancer: A Gateway to Revolutionary Targeted Cancer Treatments?. Current Medicinal Chemistry, 2003, 10, 579-592.	1.2	26
44	Immunosurveillance against Cancer and Immunotherapy â€" Synergy or Antagonism?. New England Journal of Medicine, 2003, 348, 252-254.	13.9	23
45	Molecular Mechanisms of Bone Metastasis and Therapeutic Implications. Clinical Orthopaedics and Related Research, 2003, 415, S100-S104.	0.7	32
46	IGF-1 down-regulates IFN-Î³R2 chain surface expression and desensitizes IFN-Î³/STAT-1 signaling in human T lymphocytes. Blood, 2003, 102, 2933-2939.	0.6	45
47	Constitutive nuclear factor ÎºB activity is required to elicit interferon-Î³-induced expression of chemokine CXC ligand 9 (CXCL9) and CXCL10 in human tumour cell lines. Biochemical Journal, 2003, 376, 393-402.	1.7	48
48	HLA class I defects in malignant lesions: What have we learned?. Keio Journal of Medicine, 2003, 52, 220-229.	0.5	61
49	Anti-tumor Immunity Failure in Mammals. , 2004, , 85-134.		0
50	Antagonists of Tumor-Specific Immunity: Tumor-Induced Immune Suppression and Host Genes that Co-opt the Anti-Tumor Immune Response. Breast Disease, 2004, 20, 127-135.	0.4	10
51	Hormonal and Biochemical Normalization and Tumor Shrinkage Induced by Anti-Parathyroid Hormone Immunotherapy in a Patient with Metastatic Parathyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3413-3420.	1.8	113
52	Mammaglobin-Based Strategies for Treatment of Breast Cancer. Current Cancer Drug Targets, 2004, 4, 531-542.	0.8	25
55	Vesicular Stomatitis Virus as an Oncolytic Vector. Viral Immunology, 2004, 17, 516-527.	0.6	125
56	Immunological monitoring of cancer vaccine therapy. Expert Opinion on Biological Therapy, 2004, 4, 1677-1684.	1.4	26

#	Article	IF	Citations
57	Histone-Deacetylase Inhibitors for the Treatment of Cancer. Cell Cycle, 2004, 3, 777-786.	1.3	127
58	Host Acid Sphingomyelinase Regulates Microvascular Function Not Tumor Immunity. Cancer Research, 2004, 64, 8285-8291.	0.4	41
59	Role of IFN Regulatory Factor-1 and IL-12 in Immunological Resistance to Pathogenesis of N-Methyl-N-Nitrosourea-Induced T Lymphoma. Journal of Immunology, 2004, 173, 1184-1193.	0.4	35
60	Effector Function of Human Tumor-Specific CD8 T Cells in Melanoma Lesions: A State of Local Functional Tolerance. Cancer Research, 2004, 64, 2865-2873.	0.4	351
61	Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer (E7897): A Trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 2004, 22, 2122-2132.	0.8	226
63	A Spontaneously Arising Pancreatic Tumor Does Not Promote the Differentiation of Naive CD8+T Lymphocytes into Effector CTL. Journal of Immunology, 2004, 172, 6558-6567.	0.4	70
64	Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. Journal of Clinical Pathology, 2004, 57, 630-636.	1.0	220
65	CpG Oligodeoxynucleotide Enhances Tumor Response to Radiation. Cancer Research, 2004, 64, 5074-5077.	0.4	145
66	Discovery and Immunologic Validation of New Antigens for Therapeutic Cancer Vaccines. International Archives of Allergy and Immunology, 2004, 133, 179-197.	0.9	21
67	Over-expressed IgG2 antibodies against O-acetylated sialoglycoconjugates incapable of proper effector functioning in childhood acute lymphoblastic leukemia. International Immunology, 2004, 17, 177-191.	1.8	17
68	Anticancer vaccination strategies. Annals of Oncology, 2004, 15, iv153-iv160.	0.6	23
69	No Intrinsic Deficiencies in CD8+ T Cell-Mediated Antitumor Immunity with Aging. Journal of Immunology, 2004, 173, 835-844.	0.4	21
70	Pulmonary Tumors Inefficiently Prime Tumor-Specific T Cells. Journal of Immunology, 2004, 172, 310-317.	0.4	2
71	Genome-Wide Analysis of Molecular Changes in IL-12-Induced Control of Mammary Carcinoma via IFN-Î³-Independent Mechanisms. Journal of Immunology, 2004, 172, 4111-4122.	0.4	31
72	p53-Based Immunotherapy of Cancer. , 2004, 62, 134-150.		3
73	Regulation of Tumor Progression by Anti-Neoplastic T Cell Responses. Cancer Biology and Therapy, 2004, 3, 140-146.	1.5	9
74	Anomalous expression of the HLA-DR alpha and beta chains in ovarian and other cancers. Cancer Biology and Therapy, 2004, 3, 1021-1027.	1.5	157
75	Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. British Journal of Cancer, 2004, 91, 1711-1717.	2.9	180

#	Article	IF	Citations
76	Role of infiltrated leucocytes in tumour growth and spread. British Journal of Cancer, 2004, 90, 2053-2058.	2.9	234
77	Inflammatory and Anti-glioma Effects of an Adenovirus Expressing Human Soluble Fms-like Tyrosine Kinase 3 Ligand (hsFlt3L): Treatment with hsFlt3L Inhibits Intracranial Glioma Progression. Molecular Therapy, 2004, 10, 1071-1084.	3.7	86
78	PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells. Cancer Research, 2004, 64, 1140-1145.	0.4	679
79	Regulation of antitumour immunity by CD1d-restricted NKT cells. Immunology and Cell Biology, 2004, 82, 323-331.	1.0	54
80	Somatic Cell Engineering and the Immunotherapy of Leukemias and Lymphomas. Advances in Pharmacology, 2004, 51, 347-370.	1.2	3
81	Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells. Journal of Leukocyte Biology, 2004, 76, 338-351.	1.5	26
82	Regulation of antitumour immunity by CD1d-restricted NKT cells. Immunology and Cell Biology, 2004, 82, 323-331.	1.0	19
83	Immunity against mouse thymus-leukemia antigen (TL) protects against development of lymphomas induced by a chemical carcinogen, N-butyl-N-nitrosourea. Cancer Science, 2004, 95, 914-919.	1.7	1
84	Perspectives on cancer immuno-epidemiology. Cancer Science, 2004, 95, 921-929.	1.7	46
85	The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Science, 2004, 95, 697-703.	1.7	137
86	Characterizing the Protective Component of the Î±Î² T Cell Response to Transplantable Squamous Cell Carcinoma. Journal of Investigative Dermatology, 2004, 122, 699-706.	0.3	30
87	Cytokines in cancer immunity and immunotherapy. Immunological Reviews, 2004, 202, 275-293.	2.8	346
88	Primitive immune systems: Are your ways my ways?. Immunological Reviews, 2004, 198, 25-35.	2.8	43
89	A cancer immunosurveillance controversy. Nature Immunology, 2004, 5, 3-4.	7.0	58
90	Response to 'A cancer immunosurveillance controversy'. Nature Immunology, 2004, 5, 4-5.	7.0	18
91	Bystander elimination of antigen loss variants in established tumors. Nature Medicine, 2004, 10, 294-298.	15.2	235
92	Cytokines in cancer pathogenesis and cancer therapy. Nature Reviews Cancer, 2004, 4, 11-22.	12.8	1,263
93	Paraneoplastic neurological degenerations: keys to tumour immunity. Nature Reviews Cancer, 2004, 4, 36-44.	12.8	154

#	Article	IF	Citations
94	Tumour-educated macrophages promote tumour progression and metastasis. Nature Reviews Cancer, 2004, 4, 71-78.	12.8	2,971
95	The promise of cancer vaccines. Nature Reviews Cancer, 2004, 4, 401-411.	12.8	255
96	A new modality for immunosuppression: targeting the JAK/STAT pathway. Nature Reviews Drug Discovery, 2004, 3, 555-564.	21.5	275
97	Ido expression by dendritic cells: tolerance and tryptophan catabolism. Nature Reviews Immunology, 2004, 4, 762-774.	10.6	2,071
98	Induction of T-cell antitumor immunity and protection against tumor growth by secretion of soluble human CD70 molecules. Cancer Gene Therapy, 2004, 11, 497-507.	2.2	26
99	Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO Journal, 2004, 23, 3051-3060.	3.5	133
100	Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells. Oncogene, 2004, 23, 3732-3736.	2.6	119
101	Dendritic cell-based immunotherapy for cancer and relevant challenges for transfusion medicine. Transfusion Medicine Reviews, 2004, 18, 189-202.	0.9	12
102	Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection. Cancer Cell, 2004, 5, 241-251.	7.7	497
103	Lymphocyte composition of tumor draining lymph nodes from cervical and endometrial cancer patients. Gynecologic Oncology, 2004, 92, 106-115.	0.6	59
104	Upregulation of FasL by LPA on ovarian cancer cell surface leads to apoptosis of activated lymphocytes. Gynecologic Oncology, 2004, 95, 488-495.	0.6	17
105	Vaccine and antibody-directed T cell tumour immunotherapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2004, 1704, 11-35.	3.3	41
106	Inhibition of NF-Î²B in cancer cells converts inflammation- induced tumor growth mediated by TNFÎ± to TRAIL-mediated tumor regression. Cancer Cell, 2004, 6, 297-305.	7.7	583
107	Cytokine Polymorphism and Its Possible Impact on Cancer. Immunologic Research, 2004, 30, 181-190.	1.3	27
108	p53 Expression in circulating lymphocytes of non-melanoma skin cancer patients from an arsenic contaminated region in Mexico. A pilot study. Molecular and Cellular Biochemistry, 2004, 255, 25-31.	1.4	18
109	Cellular Immunotherapy with Dendritic Cells in Cancer: Current Status. Stem Cells, 2004, 22, 501-513.	1.4	44
110	A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 236-247.	1.4	59
112	Prolonged neoadjuvant treatment plus GM-CSF in locally advanced breast cancer: clinical and biological concepts. Clinical and Translational Oncology, 2004, 6, 130-139.	1.2	0

#	Article	IF	Citations
113	Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunology, Immunotherapy, 2004, 53, 73-78.	2.0	105
114	Tumour escape: antitumour effectors too much of a good thing?. Cancer Immunology, Immunotherapy, 2004, 53, 262-274.	2.0	86
115	Immunological inhibition of carcinogenesis. Cancer Immunology, Immunotherapy, 2004, 53, 204-216.	2.0	30
116	The effect of aging on cellular immunity against cancer in SR/CR mice. Cancer Immunology, Immunotherapy, 2004, 53, 473-478.	2.0	14
117	The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunology, Immunotherapy, 2004, 53, 904-10.	2.0	239
118	Autologous tumor vaccines processed to express ?-gal epitopes: a practical approach to immunotherapy in cancer. Cancer Immunology, Immunotherapy, 2004, 53, 935-45.	2.0	28
119	The paradox of T cell?mediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunology, Immunotherapy, 2004, 53, 855-64.	2.0	63
120	Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunology, Immunotherapy, 2004, 53, 844-54.	2.0	163
121	Evidence for immune defects in breast and lung cancer patients. Cancer Immunology, Immunotherapy, 2004, 53, 1146-1152.	2.0	87
122	Effective immunotherapy against cancer. Cancer Immunology, Immunotherapy, 2004, 53, 879-92.	2.0	126
123	Overview of melanoma vaccines and promising approaches. Current Oncology Reports, 2004, 6, 414-420.	1.8	4
124	Complexity in the immune system: New opportunities for chemical engineering research. AICHE Journal, 2004, 50, 734-738.	1.8	4
125	Cross-priming of CD8+ Tâ€„cells by viral and tumor antigens is a robust phenomenon. European Journal of Immunology, 2004, 34, 194-199.	1.6	77
126	A new murine model of humoral immuno-deficiency specifically affects class switching to T-independent antigens. European Journal of Immunology, 2004, 34, 1807-1816.	1.6	3
127	Determining control parameters for dendritic cell-cytotoxic T lymphocyte interaction. European Journal of Immunology, 2004, 34, 2407-2418.	1.6	51
128	Neoadjuvant therapy changes the lymphocyte composition of tumor-draining lymph nodes in cervical carcinoma. Cancer, 2004, 100, 1418-1428.	2.0	29
129	A new multi-parameter flow cytometric assay for monitoring lymphoma growth and spread in a pre-clinical murine model for human lymphoma. Cytometry, 2004, 60A, 8-20.	1.8	7
130	Human mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+T-cell immune response. International Journal of Cancer, 2004, 109, 909-918.	2.3	78

#	Article	IF	Citations
131	Breast carcinoma cells promote the differentiation of CD34+ progenitors towards 2 different subpopulations of dendritic cells with CD1ahighCD86?Langerin- and CD1a+CD86+Langerin+ phenotypes. International Journal of Cancer, 2004, 110, 710-720.	2.3	50
132	HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis?. Current Opinion in Immunology, 2004, 16, 644-650.	2.4	45
133	Dynamic response of cancer under the influence of immunological activity and therapy. Journal of Theoretical Biology, 2004, 227, 335-348.	0.8	109
134	Cellular immunotherapy for cancer: current concepts and clinical perspectives. Clinical Oncology, 2004, 16, 356-365.	0.6	3
135	Interferon-Î³: an overview of signals, mechanisms and functions. Journal of Leukocyte Biology, 2004, 75, 163-189.	1.5	3,315
136	Vaccination with T cell-defined antigens. Expert Opinion on Biological Therapy, 2004, 4, 697-707.	1.4	4
137	Les cellules dendritiques dans le microenvironnement tumoral. Annales De Pathologie, 2004, 24, 36-37.	0.1	0
138	Colorectal cancer vaccines: Principles, results, and perspectives. Gastroenterology, 2004, 127, 1821-1837.	0.6	31
139	Reciprocal Changes in Tumor Antigenicity and Antigen-specific T Cell Function during Tumor Progression. Journal of Experimental Medicine, 2004, 200, 1581-1592.	4.2	96
140	Tumorâ€“Host Immune Interactions and Dendritic Cell Dysfunction. Advances in Cancer Research, 2004, 92, 13-27.	1.9	193
141	Immunotherapy for melanoma. Clinics in Dermatology, 2004, 22, 251-265.	0.8	50
142	Walker 256 tumor MHC class I expression during the shift from A variant to the immunogenic AR variant. Cancer Letters, 2004, 211, 119-127.	3.2	11
143	Cancer vaccine development: on the way to break immune tolerance to malignant cells. Experimental Cell Research, 2004, 299, 267-278.	1.2	32
144	Computational peptide dissection of Melan-a/MART-1 oncoprotein antigenicity. Peptides, 2004, 25, 1865-1871.	1.2	34
145	Differential regulation of resveratrol on lipopolysacchride-stimulated human macrophages with or without IFN-Î³ pre-priming. International Immunopharmacology, 2004, 4, 713-720.	1.7	31
146	From interception to incorporation: degeneracy and promiscuous recognition as precursors of a paradigm shift in immunology. Molecular Immunology, 2004, 40, 985-991.	1.0	40
147	IDO and tolerance to tumors. Trends in Molecular Medicine, 2004, 10, 15-18.	3.5	237
148	Do T lymphocytes correlate danger signals to antigen?. Medical Hypotheses, 2004, 62, 898-906.	0.8	3

#	Article	IF	Citations
149	Hematopoietic stem cell transplantation for complete IFN-Î³ receptor 1 deficiency: A multi-institutional survey. Journal of Pediatrics, 2004, 145, 806-812.	0.9	92
150	The Three Es of Cancer Immunoediting. Annual Review of Immunology, 2004, 22, 329-360.	9.5	2,422
151	The Immunobiology of Cancer Immunosurveillance and Immunoediting. Immunity, 2004, 21, 137-148.	6.6	2,486
152	Exploiting Dendritic Cells for Active Immunotherapy of Cancer and Chronic Infection. , 2005, , 001-018.		3
153	Halo naevus: a visible case of immunosurveillance in humans?. Lancet Oncology, The, 2004, 5, 397-398.	5.1	9
154	Recent Progress in Immunotherapy for Malignant Glioma: Treatment Strategies and Results from Clinical Trials. Cancer Control, 2004, 11, 192-207.	0.7	47
155	Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood, 2004, 104, 2235-2246.	0.6	319
156	Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood, 2004, 104, 1970-1978.	0.6	83
157	T-Cell Responses to Cancer. Methods in Cell Biology, 2004, 75, 513-531.	0.5	3
158	Role of Mast Cells in Pancreatic Carcinoma. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2005, 3, 383-389.	0.0	0
159	Rapid Assessment of Recognition Efficiency and Functional Capacity of Antigen-Specific T-Cell Responses. Journal of Immunotherapy, 2005, 28, 297-305.	1.2	15
160	TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver. Blood, 2005, 105, 2082-2089.	0.6	237
161	IFN Unresponsiveness in LNCaP Cells Due to the Lack of JAK1 Gene Expression. Cancer Research, 2005, 65, 3447-3453.	0.4	161
162	A general framework for modeling tumor-immune system competition and immunotherapy: Mathematical analysis and biomedical inferences. Physica D: Nonlinear Phenomena, 2005, 208, 220-235.	1.3	228
163	Combining radiotherapy and immunotherapy: A revived partnership. International Journal of Radiation Oncology Biology Physics, 2005, 63, 655-666.	0.4	320
164	Surveillance against tumorsâ€"is it mainly immunological?. Immunology Letters, 2005, 100, 29-33.	1.1	45
165	Radiation-induced cell death and dendritic cells: potential for cancer immunotherapy?. Clinical Oncology, 2005, 17, 1-11.	0.6	29
166	Immune Response to Premalignancy: Insights from Patients with Monoclonal Gammopathy. Annals of the New York Academy of Sciences, 2005, 1062, 22-28.	1.8	8

#	Article	IF	Citations
167	Manipulating the Local Tumor Microenvironment with Poxviruses Expressing Costimulatory Molecules. Annals of the New York Academy of Sciences, 2005, 1062, 41-50.	1.8	6
168	CD25⁺CD4⁺ Regulatory T-Cells in Cancer. Immunologic Research, 2005, 32, 155-168.	1.3	101
169	Interferon-Î³ and Cancer Immunoediting. Immunologic Research, 2005, 32, 231-246.	1.3	123
170	Dendritic cell vaccines and immunity in glioma patients. Frontiers in Bioscience - Landmark, 2005, 10, 2861.	3.0	5
171	The Î±â€gal epitope and the antiâ€Gal antibody in xenotransplantation and in cancer immunotherapy. Immunology and Cell Biology, 2005, 83, 674-686.	1.0	299
172	CTL-Based Cancer Preventive/Therapeutic Vaccines for Carcinomas: Role of Tumour-Associated Carbohydrate Antigens. Scandinavian Journal of Immunology, 2005, 61, 391-397.	1.3	15
173	Intratumoral immunotherapy: using the tumour against itself. Immunology, 2005, 114, 11-22.	2.0	67
174	Type I interferon and cancer immunoediting. Nature Immunology, 2005, 6, 646-648.	7.0	24
175	A critical function for type I interferons in cancer immunoediting. Nature Immunology, 2005, 6, 722-729.	7.0	516
176	Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nature Medicine, 2005, 11, 1314-1321.	15.2	917
177	Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Reviews Cancer, 2005, 5, 263-274.	12.8	1,858
178	Depletion of CD25+ cells from human T-cell enriched fraction eliminates immunodominance during priming with dendritic cells genetically modified to express a secreted protein. Cancer Gene Therapy, 2005, 12, 185-197.	2.2	4
179	In vivo targeting of vaccinating tumor cells to antigen-presenting cells by a gene therapy method with adenovirus containing the Î±1,3galactosyltransferase gene. Cancer Gene Therapy, 2005, 12, 528-539.	2.2	24
180	Immunosurveillance of childhood ALL: polymorphic interferon-Î³ alleles are associated with age at diagnosis and clinical risk groups. Leukemia, 2005, 19, 44-48.	3.3	20
181	Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene, 2005, 24, 5226-5234.	2.6	69
182	Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature, 2005, 437, 141-146.	13.7	385
183	Cat and mouse games. Nature, 2005, 437, 41-42.	13.7	13
184	Expression of melanoma-associated antigens in melanoma cell cultures. Experimental Dermatology, 2005, 14, 491-497.	1.4	18

#	Article	IF	Citations
185	De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell, 2005, 7, 411-423.	7.7	723
186	Chromosomal instability in mouse metastatic pancreatic cancerâ€"itâ€™s Kras and Tp53 after all. Cancer Cell, 2005, 7, 405-407.	7.7	12
187	The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged sword. Cancer Cell, 2005, 7, 403-405.	7.7	26
188	Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. Experimental Hematology, 2005, 33, 1521-1530.	0.2	44
189	HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambertâ€"Eaton myasthenic syndrome. Journal of Neuroimmunology, 2005, 159, 230-237.	1.1	80
190	Current concepts of tumor-infiltrating lymphocytes in human malignancies. Journal of Reproductive Immunology, 2005, 67, 35-50.	0.8	80
191	Impact of p53-based immunization on primary chemically-induced tumors. International Journal of Cancer, 2005, 113, 961-970.	2.3	11
192	Folate receptor-targeted immunotherapy: Induction of humoral and cellular immunity against hapten-decorated cancer cells. International Journal of Cancer, 2005, 116, 710-719.	2.3	71
193	Selective infiltration of CCR5+CXCR3+ T lymphocytes in human colorectal carcinoma. International Journal of Cancer, 2005, 116, 949-956.	2.3	131
194	Generation of RAGE-1 and MAGE-9 peptide-specific cytotoxic T-Lymphocyte lines for transfer in patients with renal cell carcinoma. International Journal of Cancer, 2005, 117, 256-264.	2.3	27
195	A different pattern of cytotoxic T lymphocyte recognition against primary and metastatic tumor cells in a patient with nonsmall cell lung carcinoma. Cancer, 2005, 103, 200-208.	2.0	14
196	Entropy, disease, and new opportunities for chemical engineering research. AICHE Journal, 2005, 51, 3086-3090.	1.8	4
197	Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunology, Immunotherapy, 2005, 54, 307-314.	2.0	509
198	Harnessing host immune responses to preneoplasia: promise and challenges. Cancer Immunology, Immunotherapy, 2005, 54, 409-413.	2.0	26
199	Tumor sensitivity to IFN-? is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors. Cancer Immunology, Immunotherapy, 2005, 54, 477-488.	2.0	31
200	Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunology, Immunotherapy, 2005, 54, 1137-1142.	2.0	108
201	Tumor immunity via homeostatic T cell proliferation: mechanistic aspects and clinical perspectives. Seminars in Immunopathology, 2005, 27, 75-85.	4.0	22
202	Understanding the response to immunotherapy in humans. Seminars in Immunopathology, 2005, 27, 105-117.	4.0	12

#	Article	IF	Citations
203	The common sense of the self-nonself discrimination. Seminars in Immunopathology, 2005, 27, 3-17.	4.0	37
204	Host defense peptides as new weapons in cancer treatment. Cellular and Molecular Life Sciences, 2005, 62, 784-790.	2.4	434
205	Mechanisms of the self/non-self-survey in the defense against cancer: Potential for chemoprevention?. Critical Reviews in Oncology/Hematology, 2005, 56, 5-22.	2.0	8
206	Targeting STAT3 affects melanoma on multiple fronts. Cancer and Metastasis Reviews, 2005, 24, 315-327.	2.7	255
207	Cancer vaccines: the challenge of developing an ideal tumor killing system. Frontiers in Bioscience - Landmark, 2005, 10, 2285.	3.0	16
208	Are Fat-Soluble Vitamins Effective in Enhancing Tumoricidal Cell Activity?. Journal of Nutrition, 2005, 135, 2918S.	1.3	0
209	Immune Modulations. , 2005, , 475-490.		0
210	Role of B7-H1 and B7-H4 molecules in down-regulating effector phase of T-cell immunity: novel cancer escaping mechanisms. Frontiers in Bioscience - Landmark, 2005, 10, 2856.	3.0	55
211	Therapeutic Cancer Vaccines: At Midway Between Immunology and Pharmacology. Current Cancer Drug Targets, 2005, 5, 611-627.	0.8	19
212	Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Annals of Oncology, 2005, 16, 590-596.	0.6	88
213	Peptimmunology: Immunogenic Peptides and Sequence Redundancy. Current Drug Discovery Technologies, 2005, 2, 239-244.	0.6	22
214	A Privileged View of NKT Cells and Peripheral Tolerance Through the Eye. Ocular Immunology and Inflammation, 2005, 13, 111-117.	1.0	6
215	Ex Vivo Characterization of Multiepitopic Tumor-Specific CD8 T Cells in Patients with Chronic Myeloid Leukemia: Implications for Vaccine Development and Adoptive Cellular Immunotherapy. Journal of Immunology, 2005, 174, 8210-8218.	0.4	101
216	CpG Immunomer DNA Enhances Antisense Protein Kinase A RIÎ± Inhibition of Multidrug-Resistant Colon Carcinoma Growth in Nude Mice: Molecular Basis for Combinatorial Therapy. Clinical Cancer Research, 2005, 11, 5950-5955.	3.2	8
217	Endogenous Retrovirus Expression Is Required for Murine Melanoma Tumor Growth In vivo. Cancer Research, 2005, 65, 2588-2591.	0.4	61
218	Mechanisms of Tumor Evasion. , 2005, 123, 61-88.		56
219	Apical role for BRG1 in cytokine-induced promoter assembly. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14611-14616.	3.3	87
220	Mathematical models of cancer dormancy. Leukemia and Lymphoma, 2005, 46, 313-327.	0.6	48

#	Article	IF	Citations
221	Cancer Cells Regulate Lymphocyte Recruitment and Leukocyte-Endothelium Interactions in the Tumor-Draining Lymph Node. Cancer Research, 2005, 65, 11639-11648.	0.4	56
222	Classical and Nonclassical HLA Class I Antigen and NK Cellâ€“Activating Ligand Changes in Malignant Cells: Current Challenges and Future Directions. Advances in Cancer Research, 2005, 93, 189-234.	1.9	102
223	Reduction of Myeloid-Derived Suppressor Cells and Induction of M1 Macrophages Facilitate the Rejection of Established Metastatic Disease. Journal of Immunology, 2005, 174, 636-645.	0.4	411
225	Immune Selection of Hot-Spot Î²2-Microglobulin Gene Mutations, HLA-A2 Allospecificity Loss, and Antigen-Processing Machinery Component Down-Regulation in Melanoma Cells Derived from Recurrent Metastases following Immunotherapy. Journal of Immunology, 2005, 174, 1462-1471.	0.4	96
226	Geranylgeranyl transferase inhibition stimulates antimelanoma immune response through MHC class I and costimulatory molecule expression. FASEB Journal, 2005, 19, 1513-1515.	0.2	27
227	Interleukin-13â€“regulated M2 Macrophages in Combination with Myeloid Suppressor Cells Block Immune Surveillance against Metastasis. Cancer Research, 2005, 65, 11743-11751.	0.4	279
228	Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opinion on Therapeutic Targets, 2005, 9, 831-849.	1.5	100
231	Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyteâ€“Associated Antigen 4 Monoclonal Antibody CP-675,206. Journal of Clinical Oncology, 2005, 23, 8968-8977.	0.8	563
232	Therapeutic Vaccination against Murine Lymphoma by Intratumoral Injection of Naive Dendritic Cells. Cancer Research, 2005, 65, 5958-5964.	0.4	53
233	Tumor Necrosis Factor: How to Make a Killer Molecule Tumor-Specific?. Current Cancer Drug Targets, 2005, 5, 381-392.	0.8	21
234	Fas Ligand and TNF-Related Apoptosis-Inducing Ligand Induction on Infiltrating Lymphocytes in Bladder Carcinoma by Bacillus Calmette-GuÃ©rin Treatment. Urologia Internationalis, 2005, 75, 80-87.	0.6	13
235	Robust prostate cancer marker genes emerge from direct integration of inter-study microarray data. Bioinformatics, 2005, 21, 3905-3911.	1.8	119
236	Matrix Metalloproteinases: Mediators of Tumour-Host Cell Interactions. , 2005, , 81-126.		0
237	Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer. New England Journal of Medicine, 2005, 353, 2654-2666.	13.9	1,860
238	Shear stress and shear rate differentially affect the multi-step process of leukocyte-facilitated melanoma adhesion. Experimental Cell Research, 2005, 310, 282-292.	1.2	68
239	Strategies of Tumor Immune Evasion. BioDrugs, 2005, 19, 347-354.	2.2	120
240	Do Glucose and Lipid Metabolism Affect Cancer Development in Nagasaki Atomic Bomb Survivors?. Nutrition and Cancer, 2005, 52, 115-120.	0.9	1
241	Effect of d-limonene on immune response in BALB/c mice with lymphoma. International Immunopharmacology, 2005, 5, 829-838.	1.7	78

#	Article	IF	Citations
242	Is the liver an important site for the development of immune tolerance to tumours?. Medical Hypotheses, 2005, 64, 751-754.	0.8	14
243	TWEAK mediates anti-tumor effect of tumor-infiltrating macrophage. Biochemical and Biophysical Research Communications, 2005, 331, 384-390.	1.0	21
244	Why are systemic glioblastoma metastases rare? Systemic and cerebral growth of mouse glioblastoma. World Neurosurgery, 2005, 63, 511-519.	1.3	58
245	Screening and identification of differentially expressed transcripts in circulating cells of prostate cancer patients using suppression subtractive hybridization. Molecular Cancer, 2005, 4, 30.	7.9	5
246	T cell responses against tumor associated antigens and prognosis in colorectal cancer patients. Journal of Translational Medicine, 2005, 3, 3.	1.8	23
247	The changes of CD4+CD25+/CD4+ proportion in spleen of tumor-bearing BALB/c mice. Journal of Translational Medicine, 2005, 3, 5.	1.8	22
248	Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy. Journal of Translational Medicine, 2005, 3, 8.	1.8	96
249	Modulation of monocyte matrix metalloproteinase-2 by breast adenocarcinoma cells. Breast Cancer Research, 2005, 7, R661-8.	2.2	10
251	Non-Classical HLA-G Antigen and Its Role in the Cancer Progression. Cancer Investigation, 2006, 24, 178-186.	0.6	52
252	Cancer Drug Resistance. , 2006, , .		21
253	Inflammation, a Key Event in Cancer Development. Molecular Cancer Research, 2006, 4, 221-233.	1.5	913
254	Innate Immune Recognition and Suppression of Tumors. Advances in Cancer Research, 2006, 95, 293-322.	1.9	55
255	LOOKING FOR NEW PARADIGMS TOWARDS A BIOLOGICAL-MATHEMATICAL THEORY OF COMPLEX MULTICELLULAR SYSTEMS. Mathematical Models and Methods in Applied Sciences, 2006, 16, 1001-1029.	1.7	58
256	Inflammation Induces Myeloid-Derived Suppressor Cells that Facilitate Tumor Progression. Journal of Immunology, 2006, 176, 284-290.	0.4	497
257	Development of the PANVACâ„¢-VF vaccine for pancreatic cancer. Expert Review of Vaccines, 2006, 5, 9-19.	2.0	56
258	Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome. Science, 2006, 313, 1960-1964.	6.0	5,356
259	Immunobiology of the sentinel lymph node and its potential role for antitumour immunity. Lancet Oncology, The, 2006, 7, 1006-1016.	5.1	53
260	Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunology, Immunotherapy, 2006, 55, 1432-1442.	2.0	78

#	Article	IF	Citations
261	CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors. Radiotherapy and Oncology, 2006, 80, 192-198.	0.3	47
262	Viral Vaccines for Cancer Immunotherapy. Hematology/Oncology Clinics of North America, 2006, 20, 661-687.	0.9	11
263	Immunoprevention of Cancer. Hematology/Oncology Clinics of North America, 2006, 20, 735-750.	0.9	12
264	Vaccination for Treatment and Prevention of Cancer in Animal Models. Advances in Immunology, 2006, 90, 175-213.	1.1	75
265	Cancer Immunosurveillance and Immunoediting: The Roles of Immunity in Suppressing Tumor Development and Shaping Tumor Immunogenicity. Advances in Immunology, 2006, 90, 1-50.	1.1	689
266	Interferon-Î³: Gene and Protein Structure, Transcription Regulation, and Actions. , 2006, , 85-111.		1
267	The immune system as a foundation for immunologic therapy and hematologic malignancies: a historical perspective. Best Practice and Research in Clinical Haematology, 2006, 19, 637-653.	0.7	16
268	Immunodominance and Immunodomination: Critical Factors in Developing Effective CD8+ Tâ€Cellâ€“Based Cancer Vaccines. Advances in Cancer Research, 2006, 95, 203-247.	1.9	70
269	Clonal Origin and Evolution of a Transmissible Cancer. Cell, 2006, 126, 477-487.	13.5	375
270	The tumor microenvironment in the post-PAGET era. Cancer Letters, 2006, 242, 1-10.	3.2	135
271	Cytokine gene expression in Walker 256: A comparison of variants A (aggressive) and AR (regressive). Cytokine, 2006, 36, 123-133.	1.4	5
272	Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumourâ€“host interactions. European Journal of Cancer, 2006, 42, 751-759.	1.3	179
273	Neoplasia in the etiology of sarcoidosis. European Journal of Internal Medicine, 2006, 17, 81-87.	1.0	24
274	No cancer in cancers: Evolutionary trade-off between successful viviparity and tumor escape from the adaptive immune system. Medical Hypotheses, 2006, 66, 888-897.	0.8	21
275	MHC class II molecules in tumour immunology: Prognostic marker and target for immune modulation. Immunobiology, 2006, 211, 619-625.	0.8	39
276	Pro- and Antiinflammatory Cytokine Signaling: Reciprocal Antagonism Regulates Interferon-gamma Production by Human Natural Killer Cells. Immunity, 2006, 24, 575-590.	6.6	235
277	Clinical and dermatoscopic fading of post-transplant eruptive melanocytic nevi after suspension of immunosuppressive therapy. Journal of the American Academy of Dermatology, 2006, 54, 338-340.	0.6	30
278	NKG2D and cytotoxic effector function in tumor immune surveillance. Seminars in Immunology, 2006, 18, 176-185.	2.7	78

#	Article	IF	Citations
279	Infection & Neoplastic Growth 101. Cancer Treatment and Research, 2006, , 167-197.	0.2	6
280	Colon cancer and the immune system: The role of tumor invading T cells. World Journal of Gastroenterology, 2006, 12, 7233.	1.4	77
283	Tumor-Reactive T-Cells for Adoptive Immunotherapy. , 2006, , 167-179.		0
284	Therapeutic potential of immunostimulatory monoclonal antibodies. Clinical Science, 2006, 111, 93-106.	1.8	15
285	Fast-Lane Evolution in the Tumor Microenvironment. , 2006, , 317-329.		1
286	Induction of cytotoxic T-lymphocyte responses using dendritic cells transfected with hepatocellular carcinoma mRNA. British Journal of Biomedical Science, 2006, 63, 123-128.	1.2	5
287	Genetically Induced Pancreatic Adenocarcinoma Is Highly Immunogenic and Causes Spontaneous Tumor-Specific Immune Responses. Cancer Research, 2006, 66, 508-516.	0.4	40
288	Biomarkers for development of cancer vaccines. Personalized Medicine, 2006, 3, 79-88.	0.8	0
289	Future directions for immunotherapeutic intervention against sarcomas. Current Opinion in Oncology, 2006, 18, 363-368.	1.1	17
290	Desmoplastic melanoma: comparison of expression of differentiation antigens and cancer testis antigens. Melanoma Research, 2006, 16, 347-355.	0.6	14
291	Intrapatient Dose Escalation of Antiâ€“CTLA-4 Antibody in Patients With Metastatic Melanoma. Journal of Immunotherapy, 2006, 29, 455-463.	1.2	246
292	IL-12 + GM-CSF Microsphere Therapy Induces Eradication of Advanced Spontaneous Tumors in her-2/neu Transgenic Mice But Fails to Achieve Long-Term Cure Due to the Inability to Maintain Effector T-Cell Activity. Journal of Immunotherapy, 2006, 29, 10-20.	1.2	41
294	Tumor-Induced Immune Suppression and Immune Escape. , 2006, , 263-284.		0
295	Adenovirus Subversion of Immune Surveillance, Apoptotic and Growth Regulatory Pathways: A Model for Tumorigenesis. Acta Microbiologica Et Immunologica Hungarica, 2006, 53, 145-169.	0.4	4
296	Cancer vaccines: a clinical perspective. British Journal of Hospital Medicine (London, England: 2005), 2006, 67, 365-369.	0.2	0
297	In vitroImmunomodulatory activities of a newly concocted traditional Chinese medicine formula: VI-28. Phytotherapy Research, 2006, 20, 883-888.	2.8	10
298	Presence of prostate cancer metastasis correlates with lower lymph node reactivity. Prostate, 2006, 66, 1710-1720.	1.2	28
299	Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma. Tissue Antigens, 2006, 68, 303-310.	1.0	35

#	Article	IF	Citations
300	Preliminary evidence that the allogeneic response might trigger antitumour immunity in patients with advanced prostate cancer. BJU International, 2006, 98, 989-995.	1.3	12
301	The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunological Reviews, 2006, 214, 229-238.	2.8	235
302	Strong HLA-DR antigen expression on cancer cells relates to better prognosis of colorectal cancer patients: Possible involvement of c-myc suppression by interferon-gammain situ. Cancer Science, 2006, 97, 57-63.	1.7	71
303	Antitumor activity of chimeric immunoreceptor gene-modified Tc1 and Th1 cells against autologous carcinoembryonic antigen-expressing colon cancer cells. Cancer Science, 2006, 97, 920-927.	1.7	11
304	Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nature Reviews Cancer, 2006, 6, 613-625.	12.8	239
305	Interferons, immunity and cancer immunoediting. Nature Reviews Immunology, 2006, 6, 836-848.	10.6	1,312
306	The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-Î³ inducibility of TAP1 and LMP2. Oncogene, 2006, 25, 4016-4026.	2.6	54
307	DNA vaccines for cancer. Frontiers in Bioscience - Landmark, 2006, 11, 1189.	3.0	7
308	Natural IgM antibodies: The orphaned molecules in immune surveillance. Advanced Drug Delivery Reviews, 2006, 58, 755-765.	6.6	79
309	Combined chemoimmunotherapy of solid tumours: Improving vaccines?. Advanced Drug Delivery Reviews, 2006, 58, 975-990.	6.6	90
310	Social Support and Health: A Review of Physiological Processes Potentially Underlying Links to Disease Outcomes. Journal of Behavioral Medicine, 2006, 29, 377-387.	1.1	1,823
311	Ex-Vivo Analysis of CD8+ T Cells Infiltrating Colorectal Tumors Identifies a Major Effector-Memory Subset with Low Perforin Content. Journal of Clinical Immunology, 2006, 26, 447-456.	2.0	31
312	Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce â€œdanger signalsâ€• Breast Cancer Research and Treatment, 2006, 96, 233-241.	1.1	20
313	The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer and Metastasis Reviews, 2006, 25, 387-408.	2.7	495
314	Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2006, 132, 293-301.	1.2	89
315	Immunotherapeutic potential of DISC-HSV and OX40L in cancer. Cancer Immunology, Immunotherapy, 2006, 55, 104-111.	2.0	14
316	Mouse models of efficient and inefficient anti-tumor immunity, with emphasis on minimal residual disease and tumor escape. Cancer Immunology, Immunotherapy, 2006, 55, 1-22.	2.0	10
317	Development of a whole cell vaccine for acute myeloid leukaemia. Cancer Immunology, Immunotherapy, 2006, 55, 68-75.	2.0	19

#	Article	IF	Citations
318	Cancer vaccines as a therapeutic modality: the long trek. Cancer Immunology, Immunotherapy, 2006, 55, 1025-32.	2.0	39
319	Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas. Cancer Immunology, Immunotherapy, 2006, 55, 1491-1503.	2.0	47
320	Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunology, Immunotherapy, 2006, 55, 1524-1533.	2.0	104
321	Epigenetic regulation of immune escape genes in cancer. Cancer Immunology, Immunotherapy, 2006, 55, 1159-1184.	2.0	108
322	CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunology, Immunotherapy, 2006, 56, 271-285.	2.0	100
323	Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells. Archivum Immunologiae Et Therapiae Experimentalis, 2006, 54, 323-333.	1.0	49
324	Dynamic response of cancer under the influence of immunological activity and therapy. Journal of Theoretical Biology, 2006, 240, 162-163.	0.8	26
325	STAT1 acts as a tumor promoter for leukemia development. Cancer Cell, 2006, 10, 77-87.	7.7	136
326	Epm2a suppresses tumor growth in an immunocompromised host by inhibiting Wnt signaling. Cancer Cell, 2006, 10, 179-190.	7.7	54
327	Escape from immune- and nonimmune-mediated tumor surveillance. Seminars in Cancer Biology, 2006, 16, 16-31.	4.3	58
328	T cell dysfunction in cancer: Role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress. Seminars in Cancer Biology, 2006, 16, 66-72.	4.3	65
329	DNA vaccines: Successes and limitations in cancer and infectious disease. Journal of Cellular Biochemistry, 2006, 98, 235-242.	1.2	38
330	Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. International Journal of Cancer, 2006, 118, 129-138.	2.3	110
331	Antigen-independent accumulation of activated effector/memory T lymphocytes into human and murine tumors. International Journal of Cancer, 2006, 118, 1205-1214.	2.3	22
332	HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma. International Journal of Cancer, 2006, 118, 2657-2664.	2.3	79
333	A recombinant endogenous retrovirus amplified in a mouse neuroblastoma is involved in tumor growthin vivo. International Journal of Cancer, 2006, 119, 815-822.	2.3	23
334	Chemotherapy pretreatment sensitizes solid tumor-derived cell lines to VÎ±24+ NKT cell-mediated cytotoxicity. International Journal of Cancer, 2006, 119, 1630-1637.	2.3	42
335	History of allergies and risk of glioma in adults. International Journal of Cancer, 2006, 119, 2165-2172.	2.3	87

#	Article	IF	Citations
336	HLA-class II haplotype associations with ovarian cancer. International Journal of Cancer, 2006, 119, 2980-2985.	2.3	29
337	Strong-arming immune regulation: suppressing regulatory T-cell function to treat cancers. Future Oncology, 2006, 2, 379-389.	1.1	6
338	The Interaction Mode of Premalignant Schwann and Immune Effector Cells during Chemically Induced Carcinogenesis in the Rat Peripheral Nervous System Is Strongly Influenced by Genetic Background. Cancer Research, 2006, 66, 4708-4714.	0.4	13
339	Immunosurveillance and Survivin-Specific T-Cell Immunity in Children With High-Risk Neuroblastoma. Journal of Clinical Oncology, 2006, 24, 5725-5734.	0.8	84
341	Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. European Respiratory Journal, 2006, 27, 1086-1095.	3.1	144
342	Leukocyte Infiltration in Cancer Creates an Unfavorable Environment for Antitumor Immune Responses: A Novel Target for Therapeutic Intervention. Immunological Investigations, 2006, 35, 327-357.	1.0	36
343	Autologous Tumor Rejection in Humans: Trimming the Myths. Immunological Investigations, 2006, 35, 437-458.	1.0	10
344	The Coincidence of Chromosome 15 Aberrations and Î²2-Microglobulin Gene Mutations Is Causative for the Total Loss of Human Leukocyte Antigen Class I Expression in Melanoma. Clinical Cancer Research, 2006, 12, 3297-3305.	3.2	39
345	Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1428-1433.	3.3	51
346	An Overview of the Immune System and Technical Advances in Tumor Antigen Discovery and Validation. , 2007, 360, 277-318.		5
347	Correlations between Serum Monocyte Chemotactic Protein-1 Levels, Clinical Prognostic Factors, and HER-2/neu Vaccine-Related Immunity in Breast Cancer Patients. Clinical Cancer Research, 2006, 12, 478-486.	3.2	45
348	History of Allergic Disease and Risk of Meningioma. American Journal of Epidemiology, 2006, 165, 477-485.	1.6	30
349	Association of Antigen-Processing Machinery and HLA Antigen Phenotype of Melanoma Cells with Survival in American Joint Committee on Cancer Stage III and IV Melanoma Patients. Cancer Research, 2006, 66, 6405-6411.	0.4	56
350	Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage. Clinical Cancer Research, 2006, 12, 764-771.	3.2	212
351	Prevalence of FOXP3+ Regulatory T Cells Increases During the Progression of Pancreatic Ductal Adenocarcinoma and Its Premalignant Lesions. Clinical Cancer Research, 2006, 12, 5423-5434.	3.2	709
352	Radiofrequency Thermal Ablation of Hepatocellular Carcinoma Liver Nodules Can Activate and Enhance Tumor-Specific T-Cell Responses. Cancer Research, 2006, 66, 1139-1146.	0.4	236
353	Striking Immunodominance Hierarchy of Naturally Occurring CD8+ and CD4+ T Cell Responses to Tumor Antigen NY-ESO-1. Journal of Immunology, 2006, 176, 5908-5917.	0.4	37
354	Comparative Analysis of Regulatory and Effector T Cells in Progressively Growing versus Rejecting Tumors of Similar Origins. Cancer Research, 2006, 66, 7301-7309.	0.4	98

#	Article	IF	Citations
355	CD1d-Restricted Natural Killer T Cells Can Down-regulate Tumor Immunosurveillance Independent of Interleukin-4 Receptor-Signal Transducer and Activator of Transcription 6 or Transforming Growth Factor-Î². Cancer Research, 2006, 66, 3869-3875.	0.4	54
356	Lenalidomide: Cancer Therapy via Antiangiogenesis and Immunomodulation. Current Cancer Therapy Reviews, 2006, 2, 223-229.	0.2	1
357	Coexpression of NRASQ61R and BRAFV600E in Human Melanoma Cells Activates Senescence and Increases Susceptibility to Cell-Mediated Cytotoxicity. Cancer Research, 2006, 66, 6503-6511.	0.4	81
358	Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.. Clinical Cancer Research, 2006, 12, 1144-1151.	3.2	564
359	Immunoediting of Cancers May Lead to Epithelial to Mesenchymal Transition. Journal of Immunology, 2006, 177, 1526-1533.	0.4	116
360	IFN-Î³ and T-bet Expression in Human Dendritic Cells from Normal Donors and Cancer Patients Is Controlled through Mechanisms Involving ERK-1/2-Dependent and IL-12-Independent Pathways. Journal of Immunology, 2006, 177, 3554-3563.	0.4	15
361	Termination of Systemic Immunity in the Presence of Intraocular Tumors: Influence of Ocular Immune Privilege on Tumor Vaccines. Current Eye Research, 2006, 31, 43-55.	0.7	2
362	Clinical applications of virosomes in cancer immunotherapy. Expert Opinion on Biological Therapy, 2006, 6, 1113-1121.	1.4	16
363	The Heat Shock Protein 90-CDC37 Chaperone Complex Is Required for Signaling by Types I and II Interferons. Journal of Biological Chemistry, 2006, 281, 1876-1884.	1.6	56
364	IFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors. Journal of Immunology, 2006, 176, 905-913.	0.4	94
365	Tumor Escape Mutants Develop within an Immune-Privileged Environment in the Absence of T Cell Selection. Journal of Immunology, 2006, 177, 162-168.	0.4	10
366	Characterization of a cancer/testis (CT) antigen gene family capable of eliciting humoral response in cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18066-18071.	3.3	32
367	HLA Class I Antigen Down-regulation in Primary Laryngeal Squamous Cell Carcinoma Lesions as a Poor Prognostic Marker. Cancer Research, 2006, 66, 9281-9289.	0.4	165
368	An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme1. Neuro-Oncology, 2006, 8, 234-243.	0.6	253
371	Synergistic Antitumor Effects of Immune Cell-Viral Biotherapy. Science, 2006, 311, 1780-1784.	6.0	243
372	Cancer immunotherapy using virally transduced dendritic cells: animal studies and human clinical trials. Expert Review of Vaccines, 2006, 5, 717-732.	2.0	25
373	Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. Journal of Neurosurgery, 2006, 105, 430-437.	0.9	126
374	Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination. Expert Review of Vaccines, 2006, 5, 233-247.	2.0	48

#	Article	IF	Citations
375	Inhibitory Effects of B Cells on Antitumor Immunity. Cancer Research, 2006, 66, 7741-7747.	0.4	300
376	The Tumor-Promoting Effect of TNF-Î± Involves the Induction of Secretory Leukocyte Protease Inhibitor. Journal of Immunology, 2006, 177, 8046-8052.	0.4	20
377	Inhibition of Tumor Growth and Elimination of Multiple Metastases in Human Prostate and Breast Xenografts by Systemic Inoculation of a Host Defenseâ€“Like Lytic Peptide. Cancer Research, 2006, 66, 5371-5378.	0.4	122
378	Emerging Mechanisms of Immunosuppression in Oral Cancers. Journal of Dental Research, 2006, 85, 1061-1073.	2.5	70
379	Development of Vaccines for High-Risk Ductal Carcinoma In situ of the Breast. Cancer Research, 2007, 67, 6531-6534.	0.4	35
380	The Varicellovirus-Encoded TAP Inhibitor UL49.5 Regulates the Presentation of CTL Epitopes by Qa-1b1. Journal of Immunology, 2007, 178, 657-662.	0.4	36
381	Repression of IFN Regulatory Factor 8 by DNA Methylation Is a Molecular Determinant of Apoptotic Resistance and Metastatic Phenotype in Metastatic Tumor Cells. Cancer Research, 2007, 67, 3301-3309.	0.4	82
382	Host Perforin Reduces Tumor Number but Does Not Increase Survival in Oncogene-Driven Mammary Adenocarcinoma. Cancer Research, 2007, 67, 5454-5460.	0.4	45
383	Antimicrobial Peptides in Oral Cancer. Current Pharmaceutical Design, 2007, 13, 3119-3130.	0.9	31
384	Tryptophan Catabolism in IDO+ Plasmacytoid Dendritic Cells. Current Drug Metabolism, 2007, 8, 209-216.	0.7	59
385	Cancer Immunoediting: From Immune Surveillance to Immune Escape. , 2007, , 9-27.		29
386	Costimulation, Coinhibition and Cancer. Current Cancer Drug Targets, 2007, 7, 15-30.	0.8	86
387	Sensors of ionizing radiation effects on the immunological microenvironment of cancer. International Journal of Radiation Biology, 2007, 83, 819-825.	1.0	109
388	Influence of Immune Surveillance and Immune Privilege on Formation of Intraocular Tumors. , 2007, 92, 276-289.		4
389	The Ubiquitin E3 Ligase Cbl-b in T Cells Tolerance and Tumor Immunity. Cell Cycle, 2007, 6, 2478-2485.	1.3	15
390	Melanoma Cells Exhibit Variable Signal Transducer and Activator of Transcription 1 Phosphorylation and a Reduced Response to IFN-Î± Compared with Immune Effector Cells. Clinical Cancer Research, 2007, 13, 5010-5019.	3.2	36
391	CD8 T Cell Help for Innate Antitumor Immunity. Journal of Immunology, 2007, 179, 6651-6662.	0.4	94
392	Tumor Necrosis Factor-Î± Promotes Malignant Pleural Effusion. Cancer Research, 2007, 67, 9825-9834.	0.4	102

#	Article	IF	Citations
393	Attenuation of the Glucocorticoid Response during Ad5IL-12 Adenovirus Vector Treatment Enhances Natural Killer Cellâ€“Mediated Killing of MHC Class Iâ€“Negative LNCaP Prostate Tumors. Cancer Research, 2007, 67, 2290-2297.	0.4	31
394	Frequent and specific immunity to the embryonal stem cellâ€“associated antigen SOX2 in patients with monoclonal gammopathy. Journal of Experimental Medicine, 2007, 204, 831-840.	4.2	175
395	Psychosocial Influences in Oncology: An Expanded Model of Biobehavioral Mechanisms. , 2007, , 869-895.		14
396	A Comparison of 3 Tumor Markers (MIA, TA90IC, S100B) in Stage III Melanoma Patients. Cancer Investigation, 2007, 25, 285-293.	0.6	28
397	Human Leukocyte Antigen Class I Antigen Expression Is an Independent Prognostic Factor in Ovarian Cancer. Clinical Cancer Research, 2007, 13, 3591-3596.	3.2	54
398	Regulation of Carcinogenesis by IL-5 and CCL11: A Potential Role for Eosinophils in Tumor Immune Surveillance. Journal of Immunology, 2007, 178, 4222-4229.	0.4	176
399	Intratumoral Injection of Î±-gal Glycolipids Induces Xenograft-Like Destruction and Conversion of Lesions into Endogenous Vaccines. Journal of Immunology, 2007, 178, 4676-4687.	0.4	63
400	RE: "CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA AND INFECTIONS IN THE FIRST YEAR OF LIFE: A REPORT FROM THE UNITED KINGDOM CHILDHOOD CANCER STUDY". American Journal of Epidemiology, 2007, 166, 364-365.	1.6	8
401	Induction of Protective CTL Immunity against Peptide Transporter TAP-Deficient Tumors through Dendritic Cell Vaccination. Cancer Research, 2007, 67, 8450-8455.	0.4	31
402	Evolution and Clinical Significance of the Î±-Gal Epitope. , 2007, , 225-236.		0
403	Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25â^' into CD25+ T regulatory cells. Blood, 2007, 109, 2871-2877.	0.6	357
404	From brain to testis: immune escape and clonal selection in a B cell lymphoma with selective out-growth in two immune sanctuariesy. Haematologica, 2007, 92, e69-e71.	1.7	19
405	Stat3 as a Potential Target for Cancer Immunotherapy. Journal of Immunotherapy, 2007, 30, 131-139.	1.2	80
406	HLA-A, -B, -C Expression in Colon Carcinoma Mimics That of the Normal Colonic Mucosa and is Prognostically Relevant. American Journal of Surgical Pathology, 2007, 31, 76-84.	2.1	22
407	A Critical Analysis of Nine Premises Underlying Lung Cancer Screening. Clinical Pulmonary Medicine, 2007, 14, 32-37.	0.3	1
408	Individual trajectories in stress covary with immunity during recovery from cancer diagnosis and treatments. Brain, Behavior, and Immunity, 2007, 21, 185-194.	2.0	59
409	Cytokine-driven regulation of NK cell functions in tumor immunity: Role of the MICA-NKG2D system. Cytokine and Growth Factor Reviews, 2007, 18, 159-170.	3.2	73
410	Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine and Growth Factor Reviews, 2007, 18, 171-182.	3.2	161

#	Article	IF	Citations
411	Low dose Zebularine treatment enhances immunogenicity of tumor cells. Cancer Letters, 2007, 257, 107-115.	3.2	20
412	Immunology and immunotherapy approaches for prostate cancer. Prostate Cancer and Prostatic Diseases, 2007, 10, 224-236.	2.0	11
413	Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends in Immunology, 2007, 28, 207-212.	2.9	124
414	Functional components of REM sleep programmed to exert natural anti-epileptogenic influence. Medical Hypotheses, 2007, 68, 1186-1187.	0.8	1
415	Occurrence of the acquired immunity in early vertebrates due to danger of transmissible cancers similar to canine venereal tumors. Medical Hypotheses, 2007, 68, 1185-1186.	0.8	4
416	Tumor markers in ovarian carcinoma. International Journal of Gynecology and Obstetrics, 2007, 97, 175-181.	1.0	13
417	Xenovaccinotherapy for colorectal cancer. Biomedicine and Pharmacotherapy, 2007, 61, 125-130.	2.5	15
418	Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?. Current Opinion in Immunology, 2007, 19, 203-208.	2.4	270
419	Enhanced Expression of Interferon-Î³-Induced Antigen-Processing Machinery Components in a Spontaneously Occurring Cancer. Neoplasia, 2007, 9, 960-969.	2.3	23
420	Epidemiology of Brain Tumors. Neurologic Clinics, 2007, 25, 867-890.	0.8	387
421	A Prey-Predator Model for Immune Response and Drug Resistance in Tumor Growth. , 2007, , 171-178.		5
422	Microarray Technology and Cancer Gene Profiling. , 2007, , .		6
423	Adoptive transfer of tumor-primed, in vitroâ€“activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response. Blood, 2007, 109, 4865-4876.	0.6	53
424	Interactions with the Immune System. , 2007, , 389-411.		0
425	Anti-CD3 scFv-B7.1 fusion protein expressed on the surface of HeLa cells provokes potent T-lymphocyte activation and cytotoxicityThis paper is one of a selection of papers in this Special Issue, entitled International Symposium on Recent Advances in Molecular, Clinical, and Social Medicine, and has undergone the Journal's usual peer-review process.. Biochemistry and Cell Biology, 2007, 85, 196-202.	0.9	4
426	Tumor Microenvironment and the Immune Response. Surgical Oncology Clinics of North America, 2007, 16, 737-753.	0.6	7
427	Immunosuppressive Therapy and Malignancy in Organ Transplant Recipients. Drugs, 2007, 67, 1167-1198.	4.9	333
428	Differential targeting of tryptophan catabolism in tumors and in tumor-draining lymph nodes by stereoisomers of the IDO inhibitor 1-methyl-tryptophan. International Congress Series, 2007, 1304, 250-261.	0.2	1

#	Article	IF	Citations
429	MHC Class I Antigens and Immune Surveillance in Transformed Cells. International Review of Cytology, 2007, 256, 139-189.	6.2	128
430	Immunological responses can have both pro- and antitumour effects: implications for immunotherapy. Expert Reviews in Molecular Medicine, 2007, 9, 1-20.	1.6	199
431	Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation. Translational Lung Cancer Research, 2007, 6, 148-158.	1.3	33
432	Cytokine Regulation of Immune Tolerance to Tumors. , 2007, , 43-61.		1
433	Indoleamine 2,3-Dioxygenase in Immune Escape: Regulation and Therapeutic Inhibition. , 2007, , 347-368.		0
434	Immune surveillance of tumors. Journal of Clinical Investigation, 2007, 117, 1137-1146.	3.9	1,198
435	Tumor-Associated Myeloid-Derived Suppressor Cells. , 2007, , 309-331.		1
436	Immune responses to tumours: current concepts and applications. , 0, , 163-198.		0
437	Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck. International Journal of Cancer, 2007, 120, 2618-2624.	2.3	35
438	The 8.1 ancestral MHC haplotype is strongly associated with colorectal cancer risk. International Journal of Cancer, 2007, 121, 1744-1748.	2.3	33
439	Alternative production of Bcl-2 and Bax by tumor cells determines the rates of in vivo tumor progression: Suggested mechanisms. Journal of Cellular Biochemistry, 2007, 101, 1148-1164.	1.2	2
440	HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. European Journal of Immunology, 2007, 37, 675-685.	1.6	92
441	Targeting cytotoxic Tâ€lymphocyte antigenâ€4 (CTLAâ€4). Cancer, 2007, 110, 2614-2627.	2.0	275
442	Tumor Microenvironment Promotes Cancer Progression, Metastasis, and Therapeutic Resistance. Current Problems in Cancer, 2007, 31, 36-100.	1.0	91
443	Tumor immune escape mediated by indoleamine 2,3-dioxygenase. Immunology Letters, 2007, 111, 69-75.	1.1	102
444	Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nature Medicine, 2007, 13, 84-88.	15.2	1,177
445	Are oncoantigens suitable targets for anti-tumour therapy?. Nature Reviews Cancer, 2007, 7, 707-713.	12.8	55
446	Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nature Reviews Immunology, 2007, 7, 41-51.	10.6	1,588

#	Article	IF	Citations
447	Nonâ€classical major histocompatibility complex proteins as determinants of tumour immunosurveillance. EMBO Reports, 2007, 8, 1024-1030.	2.0	44
448	Immunoepigenetics: the unseen side of cancer immunoediting. Immunology and Cell Biology, 2007, 85, 55-59.	1.0	21
449	Downregulation of CD4+CD25+ regulatory T cells may underlie enhanced Th1 immunity caused by immunization with activated autologous T cells. Cell Research, 2007, 17, 627-637.	5.7	29
450	Adaptive immunity maintains occult cancer in an equilibrium state. Nature, 2007, 450, 903-907.	13.7	1,204
451	Interleukin-12- and interferon-?-mediated natural killer cell activation by Agaricus blazei Murill. Immunology, 2007, 121, 197-206.	2.0	54
452	Cancer immunoediting from immune surveillance to immune escape. Immunology, 2007, 121, 1-14.	2.0	863
453	Regulatory T cells and tumour immunity â€“ observations in mice and men. Immunology, 2008, 123, 157-163.	2.0	94
454	Combined treatment with intratumoral injection of dendritic cells and topical application of imiquimod for murine melanoma. Clinical and Experimental Dermatology, 2007, 32, 541-549.	0.6	13
455	Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro. Clinical and Experimental Immunology, 2007, 148, 136-145.	1.1	21
456	REVIEW ARTICLE: Harnessing the Immune System for Ovarian Cancer Therapy. American Journal of Reproductive Immunology, 2008, 59, 62-74.	1.2	20
457	Challenges and prospects of immunotherapy as cancer treatment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2007, 1776, 108-123.	3.3	43
458	Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy. Clinical Immunology, 2007, 123, 155-165.	1.4	41
459	Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. Clinical Immunology, 2007, 125, 76-87.	1.4	55
460	Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones. Virology, 2007, 364, 155-168.	1.1	4
461	Making the tumor-specific effectors ineffective. Seminars in Cancer Biology, 2007, 17, 265-266.	4.3	0
462	Do autochthonous tumors interfere with effector T cell responses?. Seminars in Cancer Biology, 2007, 17, 267-274.	4.3	14
463	Immune-refractory cancers and their little helpersâ€"An extended role for immunetolerogenic MHC molecules HLA-G and HLA-E?. Seminars in Cancer Biology, 2007, 17, 459-468.	4.3	56
464	Retroviral insertions in the VISION database identify molecular pathways in mouse lymphoid leukemia and lymphoma. Mammalian Genome, 2007, 18, 709-722.	1.0	14

#	Article	IF	Citations
465	Immune reconstitution prevents metastatic recurrence of murine osteosarcoma. Cancer Immunology, Immunotherapy, 2007, 56, 1037-1046.	2.0	29
466	Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunology, Immunotherapy, 2007, 56, 739-745.	2.0	412
467	Flt3-L gene therapy enhances immunocytokine-mediated antitumor effects and induces long-term memory. Cancer Immunology, Immunotherapy, 2007, 56, 1765-1774.	2.0	12
468	Tumor resistance to CD8+ T cell-based therapeutic vaccination. Archivum Immunologiae Et Therapiae Experimentalis, 2007, 55, 205-217.	1.0	8
469	Towards progress on DNA vaccines for cancer. Cellular and Molecular Life Sciences, 2007, 64, 2391-2403.	2.4	43
470	VRP immunotherapy targeting neu: treatment efficacy and evidence for immunoediting in a stringent rat mammary tumor model. Breast Cancer Research and Treatment, 2007, 106, 371-382.	1.1	13
471	Chemokines: novel targets for breast cancer metastasis. Cancer and Metastasis Reviews, 2007, 26, 401-420.	2.7	155
472	WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism?. Acta Neuropathologica, 2007, 114, 111-119.	3.9	55
473	Exploiting dendritic cells for active immunotherapy of cancer and chronic infections. Molecular Biotechnology, 2007, 36, 131-141.	1.3	19
474	Peritumoral Inflammatory Infiltrate is not a Prognostic Factor in Distal Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. Journal of Gastrointestinal Surgery, 2007, 11, 1534-1540.	0.9	15
475	The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes. Cancer Immunology, Immunotherapy, 2008, 57, 389-398.	2.0	37
476	Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines. Cancer Immunology, Immunotherapy, 2008, 57, 719-729.	2.0	43
477	Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation. Cancer Immunology, Immunotherapy, 2008, 57, 907-912.	2.0	29
478	Spontaneous immune responses to sporadic tumors: tumor-promoting, tumor-protective or both?. Cancer Immunology, Immunotherapy, 2008, 57, 1531-1539.	2.0	27
479	Tumor vaccines in renal cell carcinoma. World Journal of Urology, 2008, 26, 147-154.	1.2	13
480	IDO-expressing regulatory dendritic cells in cancer and chronic infection. Journal of Molecular Medicine, 2008, 86, 145-160.	1.7	92
481	Targeting Cancer Stem Cells in Cancer Prevention and Therapy. Stem Cell Reviews and Reports, 2008, 4, 211-216.	5.6	11
482	Antimicrobial peptides of the Cecropin-family show potent antitumor activity against bladder cancer cells. BMC Urology, 2008, 8, 5.	0.6	141

#	Article	IF	Citations
483	Vasculatureâ€targeted tumor necrosis factorâ€alpha increases the therapeutic index of doxorubicin against prostate cancer. Prostate, 2008, 68, 1105-1115.	1.2	47
484	Clonal Tâ€cell response against autologous pleomorphic malignant fibrous histiocytoma antigen presented by retrieved HLAâ€A*0206. Journal of Orthopaedic Research, 2008, 26, 271-278.	1.2	3
485	Apoptosisâ€Inducing High [.]NO Concentrations Are Not Sustained Either in Nascent or in Developed Cancers. ChemMedChem, 2008, 3, 1493-1499.	1.6	25
486	Treatment with ozone/oxygenâ€pneumoperitoneum results in complete remission of rabbit squamous cell carcinomas. International Journal of Cancer, 2008, 122, 2360-2367.	2.3	33
487	Î±â€Galactosylceramideâ€loaded, antigenâ€expressing B cells prime a wide spectrum of antitumor immunity. International Journal of Cancer, 2008, 122, 2774-2783.	2.3	37
488	Opposite impact of NKG2D genotype by lifestyle exposure to risk of aerodigestive tract cancer among Japanese. International Journal of Cancer, 2008, 123, 181-186.	2.3	17
489	Genetic alterations of HLAâ€class II in ovarian cancer. International Journal of Cancer, 2008, 123, 1350-1356.	2.3	18
490	Inverse opal hydrogelâ€collagen composite scaffolds as a supportive microenvironment for immune cell migration. Journal of Biomedical Materials Research - Part A, 2008, 85A, 815-828.	2.1	103
491	Optimising antiâ€tumour CD8 Tâ€cell responses using combinations of immunomodulatory antibodies. European Journal of Immunology, 2008, 38, 2499-2511.	1.6	52
492	Spontaneous regression of cutaneous head and neck melanoma: Implications for the immunologic control of neoplasia. Head and Neck, 2008, 30, 267-272.	0.9	9
493	A Pilot study of allogeneic cellular therapy for patients with advanced hematologic malignancies. Leukemia Research, 2008, 32, 1842-1848.	0.4	14
494	On the kinetic theory for active particles: A model for tumorâ€“immune system competition. Mathematical and Computer Modelling, 2008, 47, 196-209.	2.0	24
495	From the mathematical kinetic theory of active particles to multiscale modelling of complex biological systems. Mathematical and Computer Modelling, 2008, 47, 687-698.	2.0	9
496	Editorial overview. Current Opinion in Immunology, 2008, 20, 208-210.	2.4	5
497	The Immune System â€" is it Relevant to Cancer Development, Progression and Treatment?. Clinical Oncology, 2008, 20, 101-112.	0.6	93
498	Why Do Patients with Low-Grade Soft Tissue Sarcoma Die?. Annals of Surgical Oncology, 2008, 15, 3550-3560.	0.7	64
499	Cancer Immunology. New England Journal of Medicine, 2008, 358, 2704-2715.	13.9	781
500	Tumor dormancy of primary and secondary cancers. Apmis, 2008, 116, 615-628.	0.9	69

#	Article	IF	Citations
501	Tumorâ€induced tolerance and immune suppression by myeloid derived suppressor cells. Immunological Reviews, 2008, 222, 162-179.	2.8	569
502	Ex vivo priming of CD4 T cells converts immunological tolerance into effective antitumor immunity in a murine model of acute lymphoblastic leukemia. Leukemia, 2008, 22, 2070-2079.	3.3	7
503	Polarized immune responses differentially regulate cancer development. Immunological Reviews, 2008, 222, 145-154.	2.8	172
504	Cancer-associated antigens and antigen arrays in serological diagnostics of malignant tumors. Biochemistry (Moscow), 2008, 73, 562-572.	0.7	12
505	The Janus face of dendritic cells in cancer. Oncogene, 2008, 27, 5920-5931.	2.6	80
506	HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene, 2008, 27, 5869-5885.	2.6	356
507	Cancer and the immune system: an overview. Oncogene, 2008, 27, 5868-5868.	2.6	17
508	Modulation of the antitumor immune response by complement. Nature Immunology, 2008, 9, 1225-1235.	7.0	612
509	The â€˜kiss of deathâ€™ by dendritic cells to cancer cells. Cell Death and Differentiation, 2008, 15, 58-69.	5.0	65
510	Tumor stress, cell death and the ensuing immune response. Cell Death and Differentiation, 2008, 15, 21-28.	5.0	77
511	T-cell death and cancer immune tolerance. Cell Death and Differentiation, 2008, 15, 70-79.	5.0	92
512	Expression of Ligands to NKp46 in Benign and Malignant Melanocytes. Journal of Investigative Dermatology, 2008, 128, 972-979.	0.3	42
513	HOST RESPONSE TO COLORECTAL CANCER. ANZ Journal of Surgery, 2008, 78, 745-753.	0.3	19
514	Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands. Tissue Antigens, 2008, 72, 321-334.	1.0	72
515	Tumourâ€specific induction of immune complexes: DCPâ€IgM in hepatocellular carcinoma. European Journal of Clinical Investigation, 2008, 38, 571-577.	1.7	27
516	Tollâ€like receptor signalling on Tregs: to suppress or not to suppress?. Immunology, 2008, 124, 445-452.	2.0	87
517	Inhibition of Serineâ€Peptidase Activity Enhances the Generation of a Survivinâ€Derived HLAâ€A2â€Presented CTL Epitope in Colonâ€Carcinoma Cells. Scandinavian Journal of Immunology, 2008, 68, 579-588.	1.3	8
519	Roles of a metastasis-associated molecule, RTVP-1, in cancer immunosurveillance. Journal of Medical Colleges of PLA, 2008, 23, 189-198.	0.1	0

#	Article	IF	Citations
520	Molecular and Immunologic Mechanisms of Cancer Pathogenesis in Solid Organ Transplant Recipients. American Journal of Transplantation, 2008, 8, 2205-2211.	2.6	64
521	Molecular Concepts of Virus Infections Causing Skin Cancer in Organ Transplant Recipients. American Journal of Transplantation, 2008, 8, 2199-2204.	2.6	50
522	Macrophage polarization in tumour progression. Seminars in Cancer Biology, 2008, 18, 349-355.	4.3	1,026
523	Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies. Expert Review of Anticancer Therapy, 2008, 8, 561-572.	1.1	85
524	Indoleamine 2,3-Dioxygenase Is the Anticancer Target for a Novel Series of Potent Naphthoquinone-Based Inhibitors. Journal of Medicinal Chemistry, 2008, 51, 1706-1718.	2.9	151
525	Local control by radiotherapy: is that all there is?. Breast Cancer Research, 2008, 10, 215.	2.2	51
526	Immune-mediated dormancy: an equilibrium with cancer. Journal of Leukocyte Biology, 2008, 84, 988-993.	1.5	253
527	Novel therapeutic strategies for treating esophageal adenocarcinoma: The potential of dendritic cell immunotherapy and combinatorial regimens. Human Immunology, 2008, 69, 614-624.	1.2	11
528	Elevated Fas Expression Is Related to Increased Apoptosis of Circulating CD8+ T Cell in Patients With Gastric Cancer. Journal of Surgical Research, 2008, 148, 143-151.	0.8	25
529	Impaired anti-leukemic immune response in PKCÎ¸-deficient mice. Molecular Immunology, 2008, 45, 3463-3469.	1.0	21
530	NKG2D-Deficient Mice Are Defective in Tumor Surveillance in Models of Spontaneous Malignancy. Immunity, 2008, 28, 571-580.	6.6	721
531	Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer. Trends in Immunology, 2008, 29, 235-241.	2.9	32
532	Immunity to self and self-maintenance: what can tumor immunology teach us about ALS and Alzheimer's disease?. Trends in Pharmacological Sciences, 2008, 29, 287-293.	4.0	29
533	Induction of CCL2 by siMAML1 through upregulation of TweakR in melanoma cells. Biochemical and Biophysical Research Communications, 2008, 372, 629-633.	1.0	7
534	NK cells and surveillance in humans. Reproductive BioMedicine Online, 2008, 16, 192-201.	1.1	14
535	Development of multi-epitope vaccines targeting wild-typesequence p53 peptides. Expert Review of Vaccines, 2008, 7, 1031-1040.	2.0	33
536	Rebuilding immunity in cancer patients. Blood Cells, Molecules, and Diseases, 2008, 40, 94-100.	0.6	20
537	Human Leukocyte Antigenâ€“G and Cancer Immunoediting. Cancer Research, 2008, 68, 627-630.	0.4	81

#	Article	IF	Citations
538	Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding. Expert Review of Vaccines, 2008, 7, 1-5.	2.0	34
539	Regulation of tumor immunity: the role of NKT cells. Expert Opinion on Biological Therapy, 2008, 8, 725-734.	1.4	26
540	Tumour-immune cell interactions modulated by chemokines. Expert Opinion on Biological Therapy, 2008, 8, 269-290.	1.4	37
541	Serum soluble interleukin 2 receptor Î± in human cancer of adults and children: a review. Biomarkers, 2008, 13, 1-26.	0.9	122
542	Complex Multicellular Systems and Immune Competition: New Paradigms Looking for a Mathematical Theory. Current Topics in Developmental Biology, 2008, 81, 485-502.	1.0	58
543	An Immunotolerant HER-2/neuTransgenic Mouse Model of Metastatic Breast Cancer. Clinical Cancer Research, 2008, 14, 6116-6124.	3.2	24
544	Decreased risk of colorectal cancer with the high natural killer cell activity NKG2D genotype in Japanese. Carcinogenesis, 2008, 29, 316-320.	1.3	46
545	Evidence that Natural Immunity to Breast Cancer and Prostate Cancer Exists in the Majority of Their Risk Populations Is Predicted by a Novel, Inherently Saturated, Ordered Mutation Model. Computational and Mathematical Methods in Medicine, 2008, 9, 1-26.	0.7	1
546	Distinct Role for CD8 T Cells toward Cutaneous Tumors and Visceral Metastases. Journal of Immunology, 2008, 180, 130-137.	0.4	55
547	Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2008, 14, 5220-5227.	3.2	547
548	The essential role of the in situ immune reaction in human colorectal cancer. Journal of Leukocyte Biology, 2008, 84, 981-987.	1.5	106
549	An innate immune response of blood cells to tumors and tissue damage in Drosophila. DMM Disease Models and Mechanisms, 2008, 1, 144-154.	1.2	267
550	ON THE FOUNDATIONS OF CANCER MODELLING: SELECTED TOPICS, SPECULATIONS, AND PERSPECTIVES. Mathematical Models and Methods in Applied Sciences, 2008, 18, 593-646.	1.7	341
551	Spontaneous and treatment-induced cancer rejection in humans. Expert Opinion on Biological Therapy, 2008, 8, 337-349.	1.4	20
552	Strategies of Natural Killer (NK) Cell Recognition and Their Roles in Tumor Immunosurveillance. , 2008, , 37-81.		1
553	Intracellular Retention of the NKG2D Ligand MHC Class I Chain-Related Gene A in Human Melanomas Confers Immune Privilege and Prevents NK Cell-Mediated Cytotoxicity. Journal of Immunology, 2008, 180, 4606-4614.	0.4	92
554	Resistance of Tumor Cells to Cytolytic T Lymphocytes Involves Rho-GTPases and Focal Adhesion Kinase Activation. Journal of Biological Chemistry, 2008, 283, 31665-31672.	1.6	16
555	Exuberated Numbers of Tumor-Specific T Cells Result in Tumor Escape. Cancer Research, 2008, 68, 3450-3457.	0.4	29

#	Article	IF	Citations
556	Involvement of the Leptin Receptor in the Immune Response in Intestinal Cancer. Cancer Research, 2008, 68, 9413-9422.	0.4	40
557	A critical appraisal of overdiagnosis: estimates of its magnitude and implications for lung cancer screening. Thorax, 2008, 63, 377-383.	2.7	73
559	Toll-Like Receptors in Endocrine Disease and Diabetes. NeuroImmunoModulation, 2008, 15, 54-60.	0.9	30
561	Stat3 mediates myeloid cellâ€“dependent tumor angiogenesis in mice. Journal of Clinical Investigation, 2008, 118, 3367-3377.	3.9	473
562	ECSA/DPPA2 is an Embryo-Cancer Antigen that Is Coexpressed with Cancer-Testis Antigens in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2008, 14, 3291-3298.	3.2	32
563	Targeted Therapies to Improve Tumor Immunotherapy. Clinical Cancer Research, 2008, 14, 4385-4391.	3.2	110
564	A Central Role for Tumor-derived Monocyte Chemoattractant Protein-1 in Malignant Pleural Effusion. Journal of the National Cancer Institute, 2008, 100, 1464-1476.	3.0	88
565	Vaccination Elicits Correlated Immune and Clinical Responses in Glioblastoma Multiforme Patients. Cancer Research, 2008, 68, 5955-5964.	0.4	266
566	Human CD4+ T Lymphocytes Recognize a Vascular Endothelial Growth Factor Receptor-2â€“Derived Epitope in Association with HLA-DR. Clinical Cancer Research, 2008, 14, 4306-4315.	3.2	6
567	Immunosuppression Routed Via the Kynurenine Pathway: A Biochemical and Pathophysiologic Approach. Advances in Clinical Chemistry, 2008, 45, 155-197.	1.8	36
568	Modulation of the Tumor Cell Phenotype by IFN-Î³ Results in Resistance of Uveal Melanoma Cells to Granule-Mediated Lysis by Cytotoxic Lymphocytes. Journal of Immunology, 2008, 180, 3766-3774.	0.4	44
569	Induction of Both CD8+ and CD4+ T-Cellâ€“Mediated Responses in Colorectal Cancer Patients by Colon Antigen-1. Clinical Cancer Research, 2008, 14, 7292-7303.	3.2	10
570	Transforming Growth Factor Î² Subverts the Immune System into Directly Promoting Tumor Growth through Interleukin-17. Cancer Research, 2008, 68, 3915-3923.	0.4	233
571	The anticancer immune response: indispensable for therapeutic success?. Journal of Clinical Investigation, 2008, 118, 1991-2001.	3.9	520
572	Interferon Î² Augments Tuberous Sclerosis Complex 2 (TSC2)-Dependent Inhibition of TSC2-Null ELT3 and Human Lymphangioleiomyomatosis-Derived Cell Proliferation. Molecular Pharmacology, 2008, 73, 778-788.	1.0	19
573	Host Nuclear Factor-ÎºB Activation Potentiates Lung Cancer Metastasis. Molecular Cancer Research, 2008, 6, 364-371.	1.5	55
574	Negative Feedback Regulation of IFN-Î³ Pathway by IFN Regulatory Factor 2 in Esophageal Cancers. Cancer Research, 2008, 68, 1136-1143.	0.4	41
575	Occurrence of Autoantibodies to Annexin I, 14-3-3 Theta and LAMR1 in Prediagnostic Lung Cancer Sera. Journal of Clinical Oncology, 2008, 26, 5060-5066.	0.8	178

#	Article	IF	Citations
577	Signal interception-based therapies â€“ A double-edged sword in Bcr/abl-induced malignancies?. Leukemia and Lymphoma, 2008, 49, 620-624.	0.6	5
578	Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. Journal of Experimental Medicine, 2008, 205, 1687-1700.	4.2	105
579	Bisindolylmaleimides in anti-cancer therapy - more than PKC inhibitors. Advances in Medical Sciences, 2008, 53, 21-31.	0.9	20
580	Leukemic challenge unmasks a requirement for PI3KÎ´ in NK cellâ€“mediated tumor surveillance. Blood, 2008, 112, 4655-4664.	0.6	48
581	AZGP1 Autoantibody Predicts Survival and Histone Deacetylase Inhibitors Increase Expression in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2008, 3, 1236-1244.	0.5	47
582	Dendritic Cell Immunotherapy for Malignant Gliomas. Reviews on Recent Clinical Trials, 2008, 3, 10-21.	0.4	21
583	TRANSLATIONAL IMPACT. DMM Disease Models and Mechanisms, 2008, 1, 153-153.	1.2	0
584	Soluble NKG2D ligands: prevalence, release, and functional impact. Frontiers in Bioscience - Landmark, 2008, Volume, 3448.	3.0	119
585	TNM Staging and T-cell Receptor Gamma Expression in Colon Adenocarcinoma. Correlation with Disease Progression?. Tumori, 2008, 94, 384-388.	0.6	4
586	Stat1 Phosphorylation Determines Ras Oncogenicity by Regulating p27Kip1. PLoS ONE, 2008, 3, e3476.	1.1	27
587	èŸ¹ã«ç™Œã¸ã•–ï¼šæ‚ªæ€§è…«ç˜ é•ŽçºŸã¯é²åŒ–ã®ä¸Šã§ã®ãƒãƒ¼ã‚¯ãƒ¼ã•. Journal of the Nihon University Medical Associa	0.1	0
588	Impaired T lymphocyte function increases tumorigenicity and decreases tumor latency in a mouse model of head and neck cancer. International Journal of Oncology, 2009, 35, 1211-21.	1.4	5
590	Infectious agents and human malignancies. Frontiers in Bioscience - Landmark, 2009, Volume, 3455.	3.0	19
591	Fusion induced reversal of dendritic cell maturation: An altered expression of inflammatory chemokine and chemokine receptors in dendritomas. Oncology Reports, 2009, 23, .	1.2	1
592	Immunomodulation in Endometrial Cancer. International Journal of Gynecological Cancer, 2009, 19, 734-740.	1.2	14
593	Chemical Probes that Competitively and Selectively Inhibit Stat3 Activation. PLoS ONE, 2009, 4, e4783.	1.1	109
594	STAT1 Pathway Mediates Amplification of Metastatic Potential and Resistance to Therapy. PLoS ONE, 2009, 4, e5821.	1.1	104
595	Genetic Polymorphisms in Cytotoxic T-Lymphocyte Antigen 4 and Cancer: The Dialectical Nature of Subtle Human Immune Dysregulation. Cancer Research, 2009, 69, 6011-6014.	0.4	58

#	Article	IF	Citations
596	MAGE A3 antigen-specific cancer immunotherapeutic. Immunotherapy, 2009, 1, 19-25.	1.0	60
597	Developing dendritic cell-based therapies to condition immune responses to novel oncogenic proteins and stem cells. Expert Review of Clinical Pharmacology, 2009, 2, 517-526.	1.3	0
598	Protein Kinase C-Î¸ Is Required for NK Cell Activation and In Vivo Control of Tumor Progression. Journal of Immunology, 2009, 182, 1972-1981.	0.4	33
599	CD94 Defines Phenotypically and Functionally Distinct Mouse NK Cell Subsets. Journal of Immunology, 2009, 183, 4968-4974.	0.4	28
600	Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines. Molecular Cancer Therapeutics, 2009, 8, 2726-2735.	1.9	90
601	Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy. British Journal of Cancer, 2009, 101, 1321-1328.	2.9	22
602	MHC Class I TCR Engineered Anti-Tumor CD4 T Cells: Implications For Cancer Immunotherapy. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2009, 9, 344-352.	0.6	11
603	The Impact of Multiple Malignancies on Patients with Bladder Carcinoma: A Population-Based Study Using the SEER Database. Advances in Urology, 2009, 2009, 1-7.	0.6	1
604	Host-Derived Interleukin-1Î± Is Important in Determining the Immunogenicity of 3-Methylcholantrene Tumor Cells. Journal of Immunology, 2009, 182, 4874-4881.	0.4	29
605	Mathematical Modelling of Tumour Dormancy. Mathematical Modelling of Natural Phenomena, 2009, 4, 68-96.	0.9	6
606	Perforin-mediated suppression of B-cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2723-2728.	3.3	40
607	DNA repair-deficient Xpa/p53 knockout mice are sensitive to the non-genotoxic carcinogen cyclosporine A: escape of initiated cells from immunosurveillance?. Carcinogenesis, 2009, 30, 538-543.	1.3	13
609	Invariant Natural Killer T Cells Regulate Breast Cancer Response to Radiation and CTLA-4 Blockade. Clinical Cancer Research, 2009, 15, 597-606.	3.2	87
610	Immunotherapy for HIV-associated non-Hodgkin's lymphoma. Expert Opinion on Biological Therapy, 2009, 9, 1313-1324.	1.4	2
612	A conditional mouse model for human MUC1-positive endometriosis shows the presence of anti-MUC1 antibodies and Foxp3+ regulatory T cells. DMM Disease Models and Mechanisms, 2009, 2, 593-603.	1.2	42
613	Mast Cells as Target in Cancer Therapy. Current Pharmaceutical Design, 2009, 15, 1868-1878.	0.9	69
614	The Prevalence of FOXP3⁺ Regulatory T-Cells in Peripheral Blood of Patients with NSCLC. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 357-367.	0.7	42
615	A Preliminary Operational Classification System for Nonmutagenic Modes of Action for Carcinogenesis. Critical Reviews in Toxicology, 2009, 39, 97-138.	1.9	25

#	Article	IF	Citations
616	Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial. Clinical Cancer Research, 2009, 15, 2123-2129.	3.2	127
617	Antiâ€"Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factorâ€"Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors. Clinical Cancer Research, 2009, 15, 1623-1634.	3.2	174
618	Combination approaches to immunotherapy: the radiotherapy example. Immunotherapy, 2009, 1, 1025-1037.	1.0	29
619	Treatment of Chronic Lymphocytic Leukemia with a Hypomethylating Agent Induces Expression of NXF2, an Immunogenic Cancer Testis Antigen. Clinical Cancer Research, 2009, 15, 3406-3415.	3.2	38
620	Epigenetic Silencing of Interferon-Î² in Human Papillomavirus Type 16â€"Positive Cells. Cancer Research, 2009, 69, 8718-8725.	0.4	109
621	Skin Inflammation Is Not Sufficient to Break Tolerance Induced against a Novel Antigen. Journal of Immunology, 2009, 183, 1133-1143.	0.4	19
622	Natural Killer Cells Require Selectins for Suppression of Subcutaneous Tumors. Cancer Research, 2009, 69, 2531-2539.	0.4	20
623	Rag-dependent and Rag-independent mechanisms of Notch1 rearrangement in thymic lymphomas of Atmâ^'/â^' and scid mice. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009, 660, 22-32.	0.4	19
624	Immune escape mechanisms of intraocular tumors. Progress in Retinal and Eye Research, 2009, 28, 329-347.	7.3	91
625	Decline of T cell-related immune functions in cancer patients and an attempt to restore them through infusion of activated autologous T cells. Mechanisms of Ageing and Development, 2009, 130, 86-91.	2.2	31
626	Visualizing CTL/melanoma cell interactions: multiple hits must be delivered for tumour cell annihilation. Journal of Cellular and Molecular Medicine, 2009, 13, 3834-3846.	1.6	39
627	Defective Î³Î´ T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients. Experimental Hematology, 2009, 37, 838-848.	0.2	45
628	Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment. Cancer Cell, 2009, 15, 114-123.	7.7	431
629	FOCUS on FOCIS: Combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer. Clinical Immunology, 2009, 131, 1-10.	1.4	36
630	Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies. Clinical Immunology, 2009, 133, 184-197.	1.4	16
631	Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology, 2009, 50, 799-807.	3.6	532
632	WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor. International Journal of Cancer, 2009, 125, 381-387.	2.3	35
633	Gadd45b and Gadd45g are important for antiâ€tumor immune responses. European Journal of Immunology, 2009, 39, 3010-3018.	1.6	62

#	Article	IF	Citations
634	Immune manipulation of advanced breast cancer: An interpretative model of the relationship between immune system and tumor cell biology. Medicinal Research Reviews, 2009, 29, 436-471.	5.0	32
635	Toward general prophylactic cancer vaccination. BioEssays, 2009, 31, 1071-1079.	1.2	15
636	Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clinical and Experimental Metastasis, 2009, 26, 633-640.	1.7	132
637	Differences in the sialylation patterns of membrane stress proteins in chemical carcinogen-induced tumors developed in BALB/c and IL-1Î± deficient mice. Glycoconjugate Journal, 2009, 26, 1181-1195.	1.4	12
639	Anaplastic lymphoma kinase: an oncogene for tumor vaccination. Journal of Molecular Medicine, 2009, 87, 669-677.	1.7	10
640	Immunosensitization with a Bcl-2 small molecule inhibitor. Cancer Immunology, Immunotherapy, 2009, 58, 699-708.	2.0	19
641	Targets for active immunotherapy against pediatric solid tumors. Cancer Immunology, Immunotherapy, 2009, 58, 831-841.	2.0	10
642	Ablation of T cell immunity differentially influences tumor risk in inbred BD rat strains. Cancer Immunology, Immunotherapy, 2009, 58, 1287-1295.	2.0	7
643	Intratumoral injection of Î±-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity. Cancer Immunology, Immunotherapy, 2009, 58, 1545-1556.	2.0	31
644	The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma. Cancer Immunology, Immunotherapy, 2009, 58, 1599-1608.	2.0	14
645	The immunologic aspects of poxvirus oncolytic therapy. Cancer Immunology, Immunotherapy, 2009, 58, 1355-1362.	2.0	40
646	Colitis-associated cancer: the role of T cells in tumor development. Seminars in Immunopathology, 2009, 31, 249-256.	2.8	92
647	Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3⁺ T cells in lymphocyteâ€rich gastric carcinoma. Journal of Pathology, 2009, 217, 21-31.	2.1	112
648	Immunotherapy for neuroblastoma: Turning promise into reality. Pediatric Blood and Cancer, 2009, 53, 931-940.	0.8	13
649	Serum Soluble Interleukinâ€2 Receptor, Beta2â€Microglobulin, Lactate Dehydrogenase and Erythrocyte Sedimentation Rate in Children with Hodgkinâ€™s Lymphoma. Scandinavian Journal of Immunology, 2009, 70, 490-500.	1.3	22
650	Does our Current Understanding of Immune Tolerance, Autoimmunity, and Immunosuppressive Mechanisms Facilitate the Design of Efficient Cancer Vaccines?. Scandinavian Journal of Immunology, 2009, 70, 516-525.	1.3	29
651	Development of vitiligo during melanoma treatment with a novel survivin inhibitor: a case report and review of the literature. International Journal of Dermatology, 2009, 48, 426-430.	0.5	6
652	Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clinical and Experimental Immunology, 2009, 157, 9-19.	1.1	126

#	Article	IF	Citations
653	Paradoxical Roles of IL-4 in Tumor Immunity. Cellular and Molecular Immunology, 2009, 6, 415-422.	4.8	110
654	Immunotherapy of tumors with recombinant adenovirus encoding macrophage inflammatory protein 3Î² induces tumor-specific immune response in immunocompetent tumor-bearing mice. Acta Pharmacologica Sinica, 2009, 30, 355-363.	2.8	10
655	Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nature Reviews Immunology, 2009, 9, 568-580.	10.6	333
656	A critical analysis of the tumour immunosurveillance controversy for 3-MCA-induced sarcomas. British Journal of Cancer, 2009, 101, 381-386.	2.9	36
657	Highâ€risk pregnancy in rhesus monkeys (Macaca mulatta): a case of ectopic, abdominal pregnancy with birth of a live, term infant, and a case of gestational diabetes complicated by preâ€eclampsia. Journal of Medical Primatology, 2009, 38, 252-256.	0.3	18
658	Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma. Tissue Antigens, 2009, 74, 1-10.	1.0	14
659	Characterization of HLAâ€G expression in renal cell carcinoma. Tissue Antigens, 2009, 74, 213-221.	1.0	40
660	Antitumor Immunity and Cancer Stem Cells. Annals of the New York Academy of Sciences, 2009, 1176, 154-169.	1.8	145
661	Natural antibodies and cancer. New Biotechnology, 2009, 25, 294-298.	2.4	97
662	Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma. Leukemia Research, 2009, 33, 525-538.	0.4	9
663	T-cells in CLL: Victims or villains?. Leukemia Research, 2009, 33, 752.	0.4	0
664	Tumor agonist peptides break tolerance and elicit effective CTL responses in an inducible mouse model of hepatocellular carcinoma. Immunology Letters, 2009, 123, 31-37.	1.1	22
665	In Vivo Studies on the Effect of Co-Encapsulation of CpG DNA and Antigen in Acid-Degradable Microparticle Vaccines. Molecular Pharmaceutics, 2009, 6, 1160-1169.	2.3	70
666	Immunologic Mechanisms in Lung Carcinogenesis and Metastasis. , 2009, , 111-134.		0
667	A Combined Chemoimmunotherapy Approach Using a Plasmidâ^'Doxorubicin Complex. Molecular Pharmaceutics, 2009, 6, 1019-1028.	2.3	46
668	Temperature sensitivity of human perforin mutants unmasks subtotal loss of cytotoxicity, delayed FHL, and a predisposition to cancer. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9809-9814.	3.3	114
669	Pharmaceutical Perspectives of Cancer Therapeutics. , 2009, , .		15
670	Melanoma prognostic factors found in the dermatopathology report. Clinics in Dermatology, 2009, 27, 53-74.	0.8	52

#	Article	IF	Citations
671	Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma. Clinics in Dermatology, 2009, 27, 603-613.	0.8	17
672	In situ adenovirus vaccination engages T effector cells against cancer. Vaccine, 2009, 27, 4225-4239.	1.7	43
673	Human embryo immune escape mechanisms rediscovered by the tumor. Immunobiology, 2009, 214, 61-76.	0.8	17
674	Cellular and molecular pathways linking inflammation and cancer. Immunobiology, 2009, 214, 761-777.	0.8	238
675	Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends in Immunology, 2009, 30, 286-292.	2.9	123
676	Melanoma vaccines: The problems of local immunosuppression. Human Immunology, 2009, 70, 331-339.	1.2	27
677	Protumorigenic Function of Dendritic Cells. , 2009, , 243-256.		2
678	Molecular Mechanisms of Traditional Chinese Medicine Re-sculpture Effect on the Process of Tumor Immunoediting. World Science and Technology, 2009, 11, 747-752.	0.1	3
679	Immunotherapy in Nonâ€“Small-Cell Lung Carcinoma: From Inflammation to Vaccination. Clinical Lung Cancer, 2009, 10, 99-105.	1.1	15
680	Stochastic model for tumor growth with immunization. Physical Review E, 2009, 79, 051903.	0.8	71
682	Enhancing the efficacy of cancer vaccines in urologic oncology: new directions. Nature Reviews Urology, 2009, 6, 540-549.	1.9	30
683	Immunotherapy in renal cell carcinoma. Immunotherapy, 2009, 1, 97-107.	1.0	5
684	Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses. Expert Review of Anticancer Therapy, 2009, 9, 1317-1332.	1.1	61
685	Dendritic cell preparation for immunotherapeutic interventions. Immunotherapy, 2009, 1, 289-302.	1.0	17
686	Targeting Transduction Pathways for Research and Medical Intervention. , 2009, , 735-761.		0
687	Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut, 2009, 58, 520-529.	6.1	228
688	Found in transcription: gene expression and other novel blood biomarkers for the early detection of breast cancer. Expert Review of Anticancer Therapy, 2009, 9, 1115-1123.	1.1	11
689	The role of human endogenous retroviruses in melanoma. British Journal of Dermatology, 2009, 161, 1225-1231.	1.4	32

#	Article	IF	Citations
690	Coordinates in the Universe of Node-Negative Breast Cancer Revisited. Cancer Research, 2009, 69, 2695-2698.	0.4	39
691	Effect of Fish Oil Supplementation for Two Generations on Changes of Lymphocyte Function Induced by Walker 256 Cancer Cachexia in Rats. Nutrition and Cancer, 2009, 61, 670-679.	0.9	21
692	Immunotherapy in Acute Leukemia. Seminars in Hematology, 2009, 46, 89-99.	1.8	9
693	Systemic effects of local radiotherapy. Lancet Oncology, The, 2009, 10, 718-726.	5.1	822
694	Autoantibody Profiling for Cancer Detection. Clinics in Laboratory Medicine, 2009, 29, 31-46.	0.7	29
695	Immunosuppression and melanocyte proliferation. Melanoma Research, 2009, 19, 63-68.	0.6	61
696	Current developments with peptide-based human tumor vaccines. Current Opinion in Oncology, 2009, 21, 524-530.	1.1	26
697	Autoimmune hypophysitis: expanding the differential diagnosis to CTLA-4 blockade. Expert Review of Endocrinology and Metabolism, 2009, 4, 681-698.	1.2	19
698	Non-0002030-defining malignancies in HIV-infected persons: etiologic puzzles, epidemiologic perils, prevention opportunities. Aids, 2009, 23, 875-885.	1.0	98
699	The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood, 2009, 113, 2394-2401.	0.6	237
700	Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. Blood, 2009, 113, 85-94.	0.6	36
701	Imaging for Radiotherapy Treatment Planning. , 2009, , 1201-1225.		0
702	STAT3 as a Central Regulator of Tumor Metastases. Current Molecular Medicine, 2009, 9, 626-633.	0.6	159
703	The Immunomodulatory Role of Angiocidin, a Novel Angiogenesis Inhibitor. Current Pharmaceutical Design, 2009, 15, 1937-1948.	0.9	7
704	Targeting the Immune System in Cancer. Current Pharmaceutical Biotechnology, 2009, 10, 166-184.	0.9	62
705	Behavior of immune players in the tumor microenvironment. Current Opinion in Oncology, 2009, 21, 53-59.	1.1	71
706	Intratumoral CD8+ T/FOXP3+ cell ratio is a predictive marker for survival in patients with colorectal cancer. Cancer Immunology, Immunotherapy, 2010, 59, 653-661.	2.0	147
707	Comparison of AAV/IL-7 autocrine (T cell) versus paracrine (DC) gene delivery for enhancing CTL stimulation and function. Cancer Immunology, Immunotherapy, 2010, 59, 779-787.	2.0	6

#	Article	IF	Citations
708	Testing the theory of immune selection in cancers that break the rules of transplantation. Cancer Immunology, Immunotherapy, 2010, 59, 643-651.	2.0	24
709	Chronic alcohol consumption enhances myeloid-derived suppressor cells in B16BL6 melanoma-bearing mice. Cancer Immunology, Immunotherapy, 2010, 59, 1151-1159.	2.0	24
710	Intravital imaging of anti-tumor immune response and the tumor microenvironment. Seminars in Immunopathology, 2010, 32, 305-317.	2.8	23
711	Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Current Opinion in Immunology, 2010, 22, 231-237.	2.4	1,270
712	T Cell Density and Location Can Influence the Prognosis of Ovarian Cancer. Pathology and Oncology Research, 2010, 16, 361-370.	0.9	12
713	T Cells and Stromal Fibroblasts in Human Tumor Microenvironments Represent Potential Therapeutic Targets. Cancer Microenvironment, 2010, 3, 29-47.	3.1	53
714	Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcoma. Protein and Cell, 2010, 1, 711-717.	4.8	11
715	A new pharmacological approach to gastrointestinal cancer at high risk of relapse based on maintenance of the cytostatic effect. Tumor Biology, 2010, 31, 523-532.	0.8	6
716	Stem/Precursor Cell-Based CNS Therapy: The Importance of Circumventing Immune Suppression by Transplanting Autologous Cells. Stem Cell Reviews and Reports, 2010, 6, 405-410.	5.6	19
717	Regression of advanced melanoma upon withdrawal of immunosuppression: case series and literature review. Medical Oncology, 2010, 27, 1127-1132.	1.2	16
718	Tumorvakzinierung beim metastasierten Nierenzellkarzinom. Onkopipeline, 2010, 3, 4-10.	0.0	0
719	Effects of irradiation on tumor cell survival, invasion and angiogenesis. Journal of Neuro-Oncology, 2010, 100, 323-338.	1.4	63
720	T-cell function in chronic lymphocytic leukaemia. Seminars in Cancer Biology, 2010, 20, 431-438.	4.3	44
721	High number of CD45RO+ tumor infiltrating lymphocytes is an independent prognostic factor in non-metastasized (stage I-IIA) esophageal adenocarcinoma. BMC Cancer, 2010, 10, 608.	1.1	51
722	Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1805, 53-71.	3.3	292
723	Association of interleukin-23 receptor gene polymorphisms with risk of ovarian cancer. Cancer Genetics and Cytogenetics, 2010, 196, 146-152.	1.0	30
724	CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation. Cancer Cell, 2010, 18, 485-498.	7.7	304
725	Clinical relevance and functional implications for human leucocyte antigenâ€g expression in nonâ€smallâ€cell lung cancer. Journal of Cellular and Molecular Medicine, 2010, 14, 2318-2329.	1.6	53

#	Article	IF	Citations
726	Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. Journal of Cellular and Molecular Medicine, 2010, 14, 2748-2759.	1.6	61
727	Antiâ€inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitorâ€treated gastrointestinal stromal tumors. International Journal of Cancer, 2010, 127, 899-909.	2.3	92
728	In vivo tumor suppression activity by T cellâ€specific Tâ€bet restoration. International Journal of Cancer, 2010, 127, 2129-2137.	2.3	37
729	ILâ€2â€activated haploidentical NK cells restore NKG2Dâ€mediated NKâ€cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA. European Journal of Immunology, 2010, 40, 3255-3267.	1.6	77
730	Cancer immunoediting and â€œspontaneousâ€•tumor regression. Pathology Research and Practice, 2010, 206, 1-8.	1.0	49
731	Modeling the hidingâ€“learning dynamics in large living systems. Applied Mathematics Letters, 2010, 23, 907-911.	1.5	25
732	Immunosenescence and cancer. Critical Reviews in Oncology/Hematology, 2010, 75, 165-172.	2.0	110
733	Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling?. Cell Division, 2010, 5, 14.	1.1	220
734	Proteomic and PROTEOMEX profiling of mammary cancer progression in a HERâ€2/neu oncogeneâ€driven animal model system. Proteomics, 2010, 10, 3835-3853.	1.3	10
735	High frequencies of less differentiated and more proliferative WT1â€specific CD8⁺ T cells in bone marrow in tumorâ€bearing patients: An important role of bone marrow as a secondary lymphoid organ. Cancer Science, 2010, 101, 848-854.	1.7	23
736	Identification of a lung cancer antigen evading CTL attack due to loss of human leukocyte antigen (HLA) class I expression. Cancer Science, 2010, 101, 2115-2120.	1.7	9
737	Evidence for Immunosurveillance in Intestinal Premalignant Lesions. Scandinavian Journal of Immunology, 2010, 71, 362-368.	1.3	18
738	Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene, 2010, 29, 1093-1102.	2.6	942
739	Perforin deficiency and susceptibility to cancer. Cell Death and Differentiation, 2010, 17, 607-615.	5.0	61
740	Breast and prostate cancer: more similar than different. Nature Reviews Cancer, 2010, 10, 205-212.	12.8	212
741	Perforin: structure, function, and role in human immunopathology. Immunological Reviews, 2010, 235, 35-54.	2.8	171
742	Recent Advances in Epidemiology of Brain Tumors. Blue Books of Neurology, 2010, , 37-53.	0.1	1
743	Cancer immunoediting and dioxin-activating aryl hydrocarbon receptor: a missing link in the shift toward tumor immunoescape?. Journal of Nucleic Acids Investigation, 2010, 1, 6.	0.5	0

#	Article	IF	Citations
744	Clinical Immunology. , 2010, , 82-90.		1
745	In Situ Conversion of Melanoma Lesions into Autologous Vaccine by Intratumoral Injections of Î±-gal Glycolipids. Cancers, 2010, 2, 773-793.	1.7	10
746	Advanced Malignant Melanoma: Immunologic and Multimodal Therapeutic Strategies. Journal of Oncology, 2010, 2010, 1-8.	0.6	28
747	Melanoma Cells Treated with GGTI and IFN-Î³ Allow Murine Vaccination and Enhance Cytotoxic Response against Human Melanoma Cells. PLoS ONE, 2010, 5, e9043.	1.1	17
748	Alphavirus Replicon Particles Expressing TRP-2 Provide Potent Therapeutic Effect on Melanoma through Activation of Humoral and Cellular Immunity. PLoS ONE, 2010, 5, e12670.	1.1	57
749	Predicting Outcomes of Prostate Cancer Immunotherapy by Personalized Mathematical Models. PLoS ONE, 2010, 5, e15482.	1.1	107
750	Tumor growth characteristics of the Walker 256 AR tumor, a regressive variant of the rat Walker 256 A tumor. Brazilian Archives of Biology and Technology, 2010, 53, 1101-1108.	0.5	4
751	Immunity and Cancer: The Role of PSA igM Immune Complexes for Prostate Cancer. Urologia, 2010, 77, 1-3.	0.3	11
752	Liposomes targeting tumour stromal cells. Molecular Membrane Biology, 2010, 27, 328-340.	2.0	7
753	Inflammatory and MicroRNA Gene Expression as Prognostic Classifier of Barrett's-Associated Esophageal Adenocarcinoma. Clinical Cancer Research, 2010, 16, 5824-5834.	3.2	62
754	Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia. Immunotherapy, 2010, 2, 85-97.	1.0	20
755	Solannm lyratum extract affected immune response in normal and leukemia murine animal in vivo. Human and Experimental Toxicology, 2010, 29, 359-367.	1.1	20
756	Immunological Factors Relating to the Antitumor Effect of Temozolomide Chemoimmunotherapy in a Murine Glioma Model. Vaccine Journal, 2010, 17, 143-153.	3.2	65
757	Cancer and the Complement Cascade. Molecular Cancer Research, 2010, 8, 1453-1465.	1.5	206
758	Bacteria-Induced Gap Junctions in Tumors Favor Antigen Cross-Presentation and Antitumor Immunity. Science Translational Medicine, 2010, 2, 44ra57.	5.8	162
759	Serum Cytokine Analysis in a Positive Chemoprevention Trial: Selenium, Interleukin-2, and an Association with Squamous Preneoplastic Disease. Cancer Prevention Research, 2010, 3, 810-817.	0.7	5
760	Harnessing the Effect of Adoptively Transferred Tumor-Reactive T Cells on Endogenous (Host-Derived) Antitumor Immunity. Clinical and Developmental Immunology, 2010, 2010, 1-11.	3.3	5
761	Widespread Immunity to Breast and Prostate Cancers is Predicted by a Novel Model that also Determines Sporadic and Hereditary Susceptible Population Sizes. Mathematical Modelling of Natural Phenomena, 2010, 5, 134-164.	0.9	0

#	Article	IF	Citations
762	Interaction Between 5 Genetic Variants and Allergy in Glioma Risk. American Journal of Epidemiology, 2010, 171, 1165-1173.	1.6	47
763	Experimental validation of specificity of the squamous cell carcinoma antigen-immunoglobulin M (SCCA-IgM) assay in patients with cirrhosis. Clinical Chemistry and Laboratory Medicine, 2010, 48, 217-23.	1.4	11
764	Anti-tumor Immunity and Mechanism of Immunosuppression Mediated by Tumor Cells: Role of Tumor-Derived Soluble Factors and Cytokines. International Reviews of Immunology, 2010, 29, 421-458.	1.5	9
766	Critical Review of Preclinical Approaches to Evaluate the Potential of Immunosuppressive Drugs to Influence Human Neoplasia. International Journal of Toxicology, 2010, 29, 435-466.	0.6	66
767	Host Factors and Cancer Progression: Biobehavioral Signaling Pathways and Interventions. Journal of Clinical Oncology, 2010, 28, 4094-4099.	0.8	195
768	Acute Myelogenous Leukemia. Cancer Treatment and Research, 2010, , .	0.2	1
769	Overcoming the Hurdles of Tumor Immunity by Targeting Regulatory Pathways in Innate and Adaptive Immune Cells. Current Pharmaceutical Design, 2010, 16, 255-267.	0.9	25
770	Vaccine Prevention of Cancer: Can Endogenous Antigens Be Targeted?. Cancer Prevention Research, 2010, 3, 410-415.	0.7	24
771	Oxidative Phosphorylation Induces De Novo Expression of the MHC Class I in Tumor Cells through the ERK5 Pathway. Journal of Immunology, 2010, 185, 3498-3503.	0.4	58
772	Vaccines against Human Carcinomas: Strategies to Improve Antitumor Immune Responses. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-12.	3.0	41
773	IL-15 has innate anti-tumor activity independent of NK and CD8 T cells. Journal of Leukocyte Biology, 2010, 88, 529-536.	1.5	23
774	T regulatory cells in cancer: recent advances and therapeutic potential. Expert Opinion on Biological Therapy, 2010, 10, 1573-1586.	1.4	94
775	Antibodies in cancer immunotherapy. Cancer Biomarkers, 2010, 6, 291-305.	0.8	2
776	Using peripheral blood mRNA signature to distinguish between breast cancer and benign breast disease in non-conclusive mammography patients. Cancer Biology and Therapy, 2010, 10, 1235-1239.	1.5	7
777	Autoantibodies to Tumor-Associated Antigens as Cancer Biomarkers. Current Molecular Medicine, 2010, 10, 115-122.	0.6	13
778	Impact of stress on cancer metastasis. Future Oncology, 2010, 6, 1863-1881.	1.1	350
779	Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses. Expert Opinion on Biological Therapy, 2010, 10, 735-748.	1.4	9
780	Efficacy, Biodistribution, and Pharmacokinetics of CD22-Targeted Pegylated Liposomal Doxorubicin in a B-cell Nonâ€“Hodgkin's Lymphoma Xenograft Mouse Model. Clinical Cancer Research, 2010, 16, 2760-2768.	3.2	49

#	Article	IF	Citations
781	Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. Haematologica, 2010, 95, 2022-2030.	1.7	95
782	Virally Mediated Immunotherapy for Brain Tumors. Neurosurgery Clinics of North America, 2010, 21, 167-179.	0.8	8
783	Loss of STAT1 from Mouse Mammary Epithelium Results in an Increased Neu-Induced Tumor Burden. Neoplasia, 2010, 12, 899-905.	2.3	89
784	Cancer Immunoediting from Immunosurveillance to Tumor Escape in Microvillus-Formed Niche: A Study of Syngeneic Orthotopic Rat Bladder Cancer Model in Comparison with Human Bladder Cancer. Neoplasia, 2010, 12, 434-442.	2.3	37
785	Comprehensive Nanorobotic Control of Human Morbidity and Aging. , 2010, , 685-805.		6
786	Regulatory T Cells in Cancer. Advances in Cancer Research, 2010, 107, 57-117.	1.9	320
787	HLA-G expression in hematologic malignancies. Expert Review of Hematology, 2010, 3, 67-80.	1.0	17
788	Immune responses to malignancies. Journal of Allergy and Clinical Immunology, 2010, 125, S272-S283.	1.5	160
789	Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer. Lung Cancer, 2010, 70, 188-194.	0.9	43
790	Developments in Cancer Immunotherapy. Digestive Diseases, 2010, 28, 51-56.	0.8	10
791	A multiscale systems perspective on cancer, immunotherapy, and Interleukin-12. Molecular Cancer, 2010, 9, 242.	7.9	15
792	Secretome Analysis of Multiple Pancreatic Cancer Cell Lines Reveals Perturbations of Key Functional Networks. Journal of Proteome Research, 2010, 9, 4376-4392.	1.8	45
793	Sequencing and Quantifying IgG Fragments and Antigen-Binding Regions by Mass Spectrometry. Journal of Proteome Research, 2010, 9, 2937-2945.	1.8	32
794	Serum Autoantibody Profiling Using a Natural Glycoprotein Microarray for the Prognosis of Early Melanoma. Journal of Proteome Research, 2010, 9, 6044-6051.	1.8	23
795	Metronomic chemotherapy: new rationale for new directions. Nature Reviews Clinical Oncology, 2010, 7, 455-465.	12.5	553
796	Deregulation of Interferon Signaling in Malignant Cells. Pharmaceuticals, 2010, 3, 406-418.	1.7	26
797	Autoantibodies against tumor-related antigens: Incidence and biologic significance. Human Immunology, 2010, 71, 643-651.	1.2	47
798	Tumor-specific upregulation of human leukocyte antigenâ€“G expression in bladder transitional cell carcinoma. Human Immunology, 2010, 71, 899-904.	1.2	19

#	Article	IF	Citations
799	IL-6-transfected tumor cells modulate the status of CD8+ and CD4+ T cells to control tumor growth. Immunobiology, 2010, 215, 486-491.	0.8	6
800	Implications for immunotherapy of tumor-mediated T-cell apoptosis associated with loss of the tumor suppressor PTEN in glioblastoma. Journal of Clinical Neuroscience, 2010, 17, 1543-1547.	0.8	30
801	Immunosenescence and cancer. Journal of Geriatric Oncology, 2010, 1, 20-26.	0.5	8
802	Lymphocytes in cancer development: Polarization towards pro-tumor immunity. Cytokine and Growth Factor Reviews, 2010, 21, 3-10.	3.2	198
803	Synergism between immunostimulation and prevention of surgery-induced immune suppression: An approach to reduce post-operative tumor progression. Brain, Behavior, and Immunity, 2010, 24, 952-958.	2.0	33
804	Gene Expression Profiling and Pathway Analysis of Superficial Bladder Cancer in Rats. Urology, 2010, 75, 742-749.	0.5	10
805	Tumor immunogenicity and responsiveness to cancer vaccine therapy: The state of the art. Seminars in Immunology, 2010, 22, 105-112.	2.7	44
806	Vaccines based on abnormal self-antigens as tumor-associated antigens: Immune regulation. Seminars in Immunology, 2010, 22, 125-131.	2.7	24
807	Role of Chemokines in the Biology of Natural Killer Cells. Current Topics in Microbiology and Immunology, 2010, 341, 37-58.	0.7	179
808	Mechanisms of Local Immunoresistance in Glioma. Neurosurgery Clinics of North America, 2010, 21, 17-29.	0.8	67
809	STAT3: A Target to Enhance Antitumor Immune Response. Current Topics in Microbiology and Immunology, 2010, 344, 41-59.	0.7	97
810	Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia. Immunotherapy, 2010, 2, 69-83.	1.0	22
811	Immunologic mechanisms in RCC and allogeneic renal transplant rejection. Nature Reviews Urology, 2010, 7, 339-347.	1.9	13
812	Gene expression profiling of peripheral blood cells for early detection of breast cancer. Breast Cancer Research, 2010, 12, R7.	2.2	95
813	â€œIn vivoâ€•murine macrophages activation by a dichloromethane extract ofTilia x viridis. Immunopharmacology and Immunotoxicology, 2010, 32, 473-480.	1.1	1
814	Mutations in Bone Marrow-Derived Stromal Stem Cells Unmask Latent Malignancy. Stem Cells and Development, 2010, 19, 1153-1166.	1.1	34
815	Ultrastructural Descriptions of Heterotypic Aggregation between Eosinophils and Tumor Cells in Human Gastric Carcinomas. Ultrastructural Pathology, 2011, 35, 145-149.	0.4	33
816	Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function. Scandinavian Journal of Gastroenterology, 2011, 46, 156-164.	0.6	132

#	Article	IF	Citations
817	A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. Blood, 2011, 117, 1565-1573.	0.6	193
818	Regulation of Cancer Stem Cells by Cytokine Networks: Attacking Cancer's Inflammatory Roots. Clinical Cancer Research, 2011, 17, 6125-6129.	3.2	290
819	Gene Therapy for Lung Neoplasms. Clinics in Chest Medicine, 2011, 32, 865-885.	0.8	21
820	RegresiÃ³n espontÃ¡nea en cÃ¡ncer: el regalo de un amigo invisible. Revista MÃ©dica De HomeopatÃa, 2011, 4, 84-87.	0.1	1
821	Biobehavioral Influences on Cancer Progression. Immunology and Allergy Clinics of North America, 2011, 31, 109-132.	0.7	101
822	Thymic peptides for treatment of cancer patients. The Cochrane Library, 2011, , CD003993.	1.5	19
823	Noise-assisted interactions of tumor and immune cells. Physical Review E, 2011, 84, 021927.	0.8	18
825	Oncolytic viruses: a step into cancer immunotherapy. Virus Adaptation and Treatment, 0, , 1.	1.5	4
826	NF-KappaB-Mediated Regulation of Tumour-Associated Macrophages: Mechanisms and Significance. , 2011, , 153-165.		5
827	Prognostic effect of stromal lymphocyte infiltration in thrymic carcinoma. Lung Cancer, 2011, 74, 338-343.	0.9	6
829	High-Grade Gliomas: Dendritic Cell Therapy. , 2011, , 313-333.		0
831	Type I interferon is selectively required by dendritic cells for immune rejection of tumors. Journal of Experimental Medicine, 2011, 208, 1989-2003.	4.2	874
832	Sarcoma Immunotherapy. Cancers, 2011, 3, 4139-4150.	1.7	3
833	Tumors of the Central Nervous System, Volume 2. , 2011, , .		3
834	Elimination of Oncogenic Neighbors by JNK-Mediated Engulfment in Drosophila. Developmental Cell, 2011, 20, 315-328.	3.1	181
835	Mechanisms linking pathogens-associated inflammation and cancer. Cancer Letters, 2011, 305, 250-262.	3.2	97
836	Contribution of CD8 T lymphocytes to the immuno-pathogenesis of multiple sclerosis and its animal models. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 151-161.	1.8	61
837	Increased expression of IL-21 reduces tumor growth by modulating the status of tumor-infiltrated lymphocytes. Immunobiology, 2011, 216, 491-496.	0.8	8

#	Article	IF	Citations
838	Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: Their relationship to KRAS mutational status and disease recurrence. Human Immunology, 2011, 72, 1022-1028.	1.2	42
839	Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C). Vaccine, 2011, 29, 984-993.	1.7	40
840	Immunopathogenic behaviors of canine transmissible venereal tumor in dogs following an immunotherapy using dendritic/tumor cell hybrid. Veterinary Immunology and Immunopathology, 2011, 139, 187-199.	0.5	18
841	Alterations of lymphocyte subpopulations in healthy dogs with aging and in dogs with cancer. Veterinary Immunology and Immunopathology, 2011, 142, 189-200.	0.5	31
842	Neoplasm Incidence in Simultaneous Pancreas and Kidney Transplantation: A Single-Center Analysis. Transplantation Proceedings, 2011, 43, 3288-3291.	0.3	12
843	Thymic function, anti-thymocytes globulins, and cancer after renal transplantation. Transplant Immunology, 2011, 25, 56-60.	0.6	26
844	Tumor-Infiltrating CD8⁺ Lymphocytes Predict Clinical Outcome in Breast Cancer. Journal of Clinical Oncology, 2011, 29, 1949-1955.	0.8	1,232
845	Galectin-1 and immunotherapy for brain cancer. Expert Review of Neurotherapeutics, 2011, 11, 533-543.	1.4	23
846	The Potential Role of CD133 in Immune Surveillance and Apoptosis: A Mitochondrial Connection?. Antioxidants and Redox Signaling, 2011, 15, 2989-3002.	2.5	8
847	Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy. Pigment Cell and Melanoma Research, 2011, 24, 334-344.	1.5	45
848	Thymosin plus cisplatin with vinorelbine or gemcitabine for nonâ€small cell lung cancer: A systematic review and metaâ€analysis of randomized controlled trials. Thoracic Cancer, 2011, 2, 213-220.	0.8	12
849	Vaccination therapy in renal cell carcinoma: current position and future options in metastatic and localized disease. Expert Review of Vaccines, 2011, 10, 837-852.	2.0	14
850	Combined Treatment with Anticancer Vaccine Using Genetically Modified Endothelial Cells and Imatinib in Bladder Cancer. Korean Journal of Urology, 2011, 52, 327.	1.2	0
851	Drugs that Kill Cancer Stem-like Cells. , 2011, , .		2
852	Gene Therapy of Some Genetic Diseases by Transferring Normal Human Genomic DNA into Somatic Cells and Stem Cells from Patients. , 0, , .		2
853	Tumor Induced Inactivation of Natural Killer Cell Cytotoxic Function; Implication in Growth, Expansion and Differentiation of Cancer Stem Cells. Journal of Cancer, 2011, 2, 443-457.	1.2	56
854	Social ties and resilience in chronic disease. , 2011, , 76-89.		7
855	Unexpected benefits of allergies and cigarette smoking: two examples of paradox in neuroepidemiology. , 0, , 261-273.		1

#	Article	IF	Citations
857	HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2011, 11, 76-89.	0.6	54
858	Molecular Approach to Uterine Leiomyosarcoma: LMP2-Deficient Mice as an Animal Model of Spontaneous Uterine Leiomyosarcoma. Sarcoma, 2011, 2011, 1-6.	0.7	20
859	Why Do CD8+ T Cells become Indifferent to Tumors: A Dynamic Modeling Approach. Frontiers in Physiology, 2011, 2, 32.	1.3	3
860	Dendritic Cell Based Tumor Vaccination in Prostate and Renal Cell Cancer: A Systematic Review and Meta-Analysis. PLoS ONE, 2011, 6, e18801.	1.1	184
861	Transcriptome Profiling of Whole Blood Cells Identifies PLEK2 and C1QB in Human Melanoma. PLoS ONE, 2011, 6, e20971.	1.1	38
862	Detection of Intra-Tumor Self Antigen Recognition during Melanoma Tumor Progression in Mice Using Advanced Multimode Confocal/Two Photon Microscope. PLoS ONE, 2011, 6, e21214.	1.1	12
863	Loss of the Promyelocytic Leukemia Protein in Gastric Cancer: Implications for IP-10 Expression and Tumor-Infiltrating Lymphocytes. PLoS ONE, 2011, 6, e26264.	1.1	19
864	Pathway-Based Analysis of a Melanoma Genome-Wide Association Study: Analysis of Genes Related to Tumour-Immunosuppression. PLoS ONE, 2011, 6, e29451.	1.1	18
865	Malignant Disease Within 5 Years After Surgery in Relation to Duration of Sevoflurane Anesthesia and Time with Bispectral Index Under 45. Anesthesia and Analgesia, 2011, 113, 778-783.	1.1	18
866	Restoration of tumor equilibrium after immunotherapy for advanced melanoma. Melanoma Research, 2011, 21, 152-159.	0.6	11
867	The Role of Tumor-Infiltrating Immune Cells and Chronic Inflammation at the Tumor Site on Cancer Development, Progression, and Prognosis: Emphasis on Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 824-833.	0.5	276
868	Clinical Relevance of Autoantibody Detection in Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 955-962.	0.5	30
869	Exploring immune therapy for renal cancer. International Journal of Urology, 2011, 18, 412-421.	0.5	0
870	Roles of the immune system in skin cancer. British Journal of Dermatology, 2011, 165, 953-965.	1.4	151
871	Evolving Insights in the Pathogenesis and Therapy of Cutaneous Tâ€cell lymphoma (Mycosis Fungoides) Tj ETQq0 0 0 rgBT /Overlock 10	1.2	127
872	Association of CD8+ T cell infiltration in oesophageal carcinoma lesions with human leucocyte antigen (HLA) class I antigen expression and survival. Clinical and Experimental Immunology, 2011, 164, 50-56.	1.1	34
873	Studies on the antigenicity of the NKG2D ligand H60a in tumour cells. Immunology, 2011, 133, 197-205.	2.0	2
874	Dendritic cells and immunity against cancer. Journal of Internal Medicine, 2011, 269, 64-73.	2.7	143

#	Article	IF	Citations
875	Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunological Reviews, 2011, 241, 104-118.	2.8	229
876	Tumour infiltrating CD25+ FoxP3+ regulatory T cells (Tregs) relate to tumour grade and stromal inflammation in oral squamous cell carcinoma. Journal of Oral Pathology and Medicine, 2011, 40, 636-642.	1.4	29
877	Receptorâ€Mediated ER Export of Human MHC Class I Molecules Is Regulated by the Câ€Terminal Single Amino Acid. Traffic, 2011, 12, 42-55.	1.3	15
878	The ecology of brain tumors: lessons learned from neurofibromatosis-1. Oncogene, 2011, 30, 1135-1146.	2.6	18
879	Immune regulation of the tumor/bone vicious cycle. Annals of the New York Academy of Sciences, 2011, 1237, 71-78.	1.8	26
880	MicroRNAs in inflammation and response to injuries induced by environmental pollution. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2011, 717, 46-53.	0.4	54
881	Cancer stem cells in solid tumors: Is â€˜evading apoptosisâ€™ a hallmark of cancer?. Progress in Biophysics and Molecular Biology, 2011, 106, 391-399.	1.4	57
882	Methylation of the promoter of human leukocyte antigen class I in human esophageal squamous cell carcinoma and its histopathological characteristics. Journal of Thoracic and Cardiovascular Surgery, 2011, 141, 808-814.	0.4	29
883	Development of a murine model of lymph node metastases suitable for immunotoxicity studies. Journal of Pharmacological and Toxicological Methods, 2011, 63, 236-249.	0.3	9
884	Cancer Immunotherapy: Sipuleucelâ€T and Beyond. Pharmacotherapy, 2011, 31, 813-828.	1.2	79
886	Mitochondrial targeting of Î±-tocopheryl succinate enhances its pro-apoptotic efficacy: A new paradigm for effective cancer therapy. Free Radical Biology and Medicine, 2011, 50, 1546-1555.	1.3	100
887	Endogenous T Cell Responses to Antigens Expressed in Lung Adenocarcinomas Delay Malignant Tumor Progression. Cancer Cell, 2011, 19, 72-85.	7.7	209
888	NKT ligand-loaded, antigen-expressing B cells function as long-lasting antigen presenting cells in vivo. Cellular Immunology, 2011, 270, 135-144.	1.4	11
889	Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer. Clinical Immunology, 2011, 138, 23-32.	1.4	18
890	The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. Clinical Immunology, 2011, 141, 338-347.	1.4	70
891	Natural Innate and Adaptive Immunity to Cancer. Annual Review of Immunology, 2011, 29, 235-271.	9.5	1,691
892	Translating Tumor Antigens into Cancer Vaccines. Vaccine Journal, 2011, 18, 23-34.	3.2	183
893	Cancer Immunoediting: Integrating Immunityâ€™s Roles in Cancer Suppression and Promotion. Science, 2011, 331, 1565-1570.	6.0	4,987

#	Article	IF	Citations
894	High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer. Breast Cancer Research and Treatment, 2011, 125, 395-406.	1.1	41
895	Pulmonary metastasectomy. European Surgery - Acta Chirurgica Austriaca, 2011, 43, 262-269.	0.3	5
896	The n3-polyunsaturated fatty acid docosahexaenoic acid induces immunogenic cell death in human cancer cell lines via pre-apoptotic calreticulin exposure. Cancer Immunology, Immunotherapy, 2011, 60, 1503-1507.	2.0	22
897	Fluctuations induced extinction and stochastic resonance effect in a model of tumor growth with periodic treatment. Physics Letters, Section A: General, Atomic and Solid State Physics, 2011, 375, 886-890.	0.9	34
898	PPARÎ³ Agonist Suppresses TLR4 Expression and TNF-Î± Production in LPS Stimulated Monocyte Leukemia Cells. Cell Biochemistry and Biophysics, 2011, 60, 167-172.	0.9	17
899	Tumour-associated antigens: considerations for their use in tumour immunotherapy. International Journal of Hematology, 2011, 93, 263-273.	0.7	14
900	Immunosuppressive Tumor Microenvironment in Cervical Cancer Patients. Cancer Microenvironment, 2011, 4, 361-375.	3.1	105
901	Immunobiology of Merkel Cell Carcinoma: Implications for Immunotherapy of a Polyomavirus-Associated Cancer. Current Oncology Reports, 2011, 13, 488-497.	1.8	92
902	ICOS gene polymorphisms are associated with sporadic breast cancer: a case-control study. BMC Cancer, 2011, 11, 392.	1.1	15
903	Novel innate cancer killing activity in humans. Cancer Cell International, 2011, 11, 26.	1.8	11
904	High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. Journal of Translational Medicine, 2011, 9, 184.	1.8	55
905	Understanding tumor heterogeneity as functional compartments - superorganisms revisited. Journal of Translational Medicine, 2011, 9, 79.	1.8	33
906	Development of metastatic HER2⁺ breast cancer is independent of the adaptive immune system. Journal of Pathology, 2011, 224, 56-66.	2.1	21
907	Revisiting cancer immunoediting by understanding cancer immune complexity. Journal of Pathology, 2011, 224, 5-9.	2.1	23
908	Bacillus Calmetteâ€Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class Iâ€deficient tumor cells. International Journal of Cancer, 2011, 129, 839-846.	2.3	52
909	Tetraspanins in the immune response against cancer. Immunology Letters, 2011, 138, 129-136.	1.1	37
910	T Cell Surveillance of Oncogene-Induced Prostate Cancer Is Impeded by T Cell-Derived TGF-Î²1 Cytokine. Immunity, 2011, 35, 123-134.	6.6	109
911	On the modelling of genetic mutations and immune system competition. Computers and Mathematics With Applications, 2011, 61, 2362-2375.	1.4	14

#	Article	IF	Citations
912	Dimercaptosuccinic acid-coated magnetite nanoparticles for magnetically guided in vivo delivery of interferon gamma for cancer immunotherapy. Biomaterials, 2011, 32, 2938-2952.	5.7	170
913	Targeting immune suppressing myeloid-derived suppressor cells in oncology. Critical Reviews in Oncology/Hematology, 2011, 77, 12-19.	2.0	134
914	Stat3-driven cancer-related inflammation as a key therapeutic target for cancer immunotherapy. Immunotherapy, 2011, 3, 587-590.	1.0	8
915	P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer. Modern Pathology, 2011, 24, 64-81.	2.9	60
916	Conceptual aspects of self and nonself discrimination. Self/nonself, 2011, 2, 19-25.	2.0	27
917	Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment. Immunotherapy, 2011, 3, 213-227.	1.0	53
918	Epithelial delamination and migration. Cell Adhesion and Migration, 2011, 5, 366-372.	1.1	24
919	Targeting the tumor microenvironment by immunotherapy: part 2. Immunotherapy, 2011, 3, 1385-1408.	1.0	7
920	Myeloid-Derived Suppressor Cell Inhibition of the IFN Response in Tumor-Bearing Mice. Cancer Research, 2011, 71, 5101-5110.	0.4	170
921	Absence of Class IIâ€“Associated Invariant Chain Peptide on Leukemic Blasts of Patients Promotes Activation of Autologous Leukemia-Reactive CD4+ T Cells. Cancer Research, 2011, 71, 2507-2517.	0.4	21
922	Targeted Therapeutic Remodeling of the Tumor Microenvironment Improves an HER-2 DNA Vaccine and Prevents Recurrence in a Murine Breast Cancer Model. Cancer Research, 2011, 71, 5688-5696.	0.4	61
923	Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools. Molecular Cancer Therapeutics, 2011, 10, 1127-1136.	1.9	27
924	Immune Modulation by Chemotherapy or Immunotherapy to Enhance Cancer Vaccines. Cancers, 2011, 3, 3114-3142.	1.7	64
925	Conversion of Tumors into Autologous Vaccines by Intratumoral Injection of <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi mathvariant="bold">Î±</mml:mi></mml:math>-Gal Glycolipids that Induce Anti-Gal/<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi mathvariant="bold">Î±</mml:mi></mml:math>-Gal Epitope Interaction. Clinical and Developmental Immunology, 2011, 2011, 1-10.	3.3	10
926	Involvement of proteasome Î²1i subunit, LMP2, on development of uterin leiomyosarcma. North American Journal of Medical Sciences, 2011, 3, 394-399.	1.7	3
927	The Amount of Surface HLA-I on T Lymphocytes Decreases in Breast Infiltrating Ductal Carcinoma Patients. Journal of International Medical Research, 2011, 39, 508-513.	0.4	3
928	CD8+ T Cells Regulate Bone Tumor Burden Independent of Osteoclast Resorption. Cancer Research, 2011, 71, 4799-4808.	0.4	75
929	NKT Cell Exacerbation of Liver Metastases Arising from Melanomas Transplanted into Either the Eyes or Spleens of Mice. , 2011, 52, 3094.		32

#	Article	IF	Citations
930	Failing to adapt â€“ the ageing immune system's role in cancer pathogenesis. Reviews in Clinical Gerontology, 2011, 21, 209-218.	0.5	2
931	A Human NK Cell Activation/Inhibition Threshold Allows Small Changes in the Target Cell Surface Phenotype To Dramatically Alter Susceptibility to NK Cells. Journal of Immunology, 2011, 186, 1538-1545.	0.4	49
932	Monitoring the Systemic Human Memory B Cell Compartment of Melanoma Patients for Anti-Tumor IgG Antibodies. PLoS ONE, 2011, 6, e19330.	1.1	72
933	The Inflammasomes. , 2011, , .		9
934	Epigenetic quantification of tumor-infiltrating T-lymphocytes. Epigenetics, 2011, 6, 236-246.	1.3	80
935	Lasso-watershed algorithm used to identify individual cells undergoing autophagy in immunofluorescent microscopic images. , 2011, , .		0
936	Apolipoprotein B Binding Domains: Evidence That They Are Cell-Penetrating Peptides That Efficiently Deliver Antigenic Peptide for Cross-Presentation of Cytotoxic T Cells. Journal of Immunology, 2011, 186, 5004-5011.	0.4	7
937	Although Divergent in Residues of the Peptide Binding Site, Conserved Chimpanzee Patr-AL and Polymorphic Human HLA-A*02 Have Overlapping Peptide-Binding Repertoires. Journal of Immunology, 2011, 186, 1575-1588.	0.4	21
938	Recent Developments in Cancer Vaccines. Journal of Immunology, 2011, 186, 1325-1331.	0.4	168
939	Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis. Genes and Development, 2011, 25, 1510-1527.	2.7	335
940	Cancer Immunoediting of the NK Group 2D Ligand H60a. Journal of Immunology, 2011, 187, 3538-3545.	0.4	26
941	Supernatants from lymphocytes stimulated with Bacillus Calmette-Guerin can modify the antigenicity of tumours and stimulate allogeneic T-cell responses. British Journal of Cancer, 2011, 105, 687-693.	2.9	7
942	Localization and Density of Immune Cells in the Invasive Margin of Human Colorectal Cancer Liver Metastases Are Prognostic for Response to Chemotherapy. Cancer Research, 2011, 71, 5670-5677.	0.4	369
943	Overview of Cell Death Mechanisms Induced by Rose Bengal Acetate-Photodynamic Therapy. International Journal of Photoenergy, 2011, 2011, 1-11.	1.4	39
944	The Confluence of Stereotactic Ablative Radiotherapy and Tumor Immunology. Clinical and Developmental Immunology, 2011, 2011, 1-7.	3.3	149
945	Extracellular NM23 Signaling in Breast Cancer: Incommodus Verum. Cancers, 2011, 3, 2844-2857.	1.7	13
946	Emerging Cancer Vaccines: The Promise of Genetic Vectors. Cancers, 2011, 3, 3687-3713.	1.7	16
947	Role of Gene Methylation in Antitumor Immune Response: Implication for Tumor Progression. Cancers, 2011, 3, 1672-1690.	1.7	26

#	Article	IF	Citations
948	Oncolytic Activities of Host Defense Peptides. International Journal of Molecular Sciences, 2011, 12, 8027-8051.	1.8	93
949	Hodgkin Disease and the Role of the Immune System. Pediatric Hematology and Oncology, 2011, 28, 176-186.	0.3	34
951	Immunodeficiency as a Risk Factor for Non-AIDS-Defining Malignancies in HIV-1-Infected Patients Receiving Combination Antiretroviral Therapy. Clinical Infectious Diseases, 2011, 52, 1458-1465.	2.9	85
952	From Tumor Immunosuppression to Eradication: Targeting Homing and Activity of Immune Effector Cells to Tumors. Clinical and Developmental Immunology, 2011, 2011, 1-15.	3.3	123
953	Variable Resistance of RMS to Interferon Î³ Signaling. ISRN Oncology, 2012, 2012, 1-10.	2.1	1
954	Nutraceuticals and Cancer. , 2012, , .		7
955	An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma. Annals of Oncology, 2012, 23, 1314-1319.	0.6	45
956	Selected anti-tumor vaccines merit a place in multimodal tumor therapies. Frontiers in Oncology, 2012, 2, 132.	1.3	23
957	Immunotherapy: Shifting the Balance of Cell-Mediated Immunity and Suppression in Human Prostate Cancer. Cancers, 2012, 4, 1333-1348.	1.7	4
958	A Race between Tumor Immunoescape and Genome Maintenance Selects for Optimum Levels of (epi)genetic Instability. PLoS Computational Biology, 2012, 8, e1002370.	1.5	9
959	Soluble Human Leukocyte Antigen-G and Its Insertion/Deletion Polymorphism in Papillary Thyroid Carcinoma: Novel Potential Biomarkers of Disease?. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4080-4086.	1.8	32
960	Role of T lymphocytes in tumor response to radiotherapy. Frontiers in Oncology, 2012, 2, 95.	1.3	137
961	Inhibitory Roles of Signal Transducer and Activator of Transcription 3 in Antitumor Immunity during Carcinogen-Induced Lung Tumorigenesis. Cancer Research, 2012, 72, 2990-2999.	0.4	48
962	Contribution of ER Stress to Immunogenic Cancer Cell Death. , 2012, , 413-428.		2
963	CpG plus radiotherapy: a review of preclinical works leading to clinical trial. Frontiers in Oncology, 2012, 2, 101.	1.3	27
964	Stage I non-small cell lung cancer: the presence of the lymphocyte-specific protein tyrosin kinase in the tumour infiltrate is associated with a better long-term prognosis. Interactive Cardiovascular and Thoracic Surgery, 2012, 15, 148-151.	0.5	5
965	Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. Journal of Experimental Medicine, 2012, 209, 2113-2126.	4.2	130
966	Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape. Science Translational Medicine, 2012, 4, 127ra37.	5.8	1,837

#	Article	IF	Citations
967	Induction of Abscopal Anti-Tumor Immunity and Immunogenic Tumor Cell Death by Ionizing Irradiation - Implications for Cancer Therapies. Current Medicinal Chemistry, 2012, 19, 1751-1764.	1.2	127
968	Prophylactic Vaccine Approach for Colon and Pancreatic Cancers: Present and Future. Current Medicinal Chemistry, 2012, 19, 3664-3678.	1.2	3
969	Role of the microenvironment in the tumourigenesis of microsatellite unstable and MUTYH-associated polyposis colorectal cancers. Mutagenesis, 2012, 27, 247-253.	1.0	9
970	Treg infiltration in glioma: a hurdle for antiglioma immunotherapy. Immunotherapy, 2012, 4, 675-678.	1.0	23
971	Specificity may be overrated in cancer immunotherapy. OncoImmunology, 2012, 1, 1208-1210.	2.1	2
972	Gene-modified lymphocytes: from caution to promise for effective cancer immunotherapy. Immunotherapy, 2012, 4, 241-244.	1.0	0
973	The local immunological microenvironment in colorectal cancer as a prognostic factor for treatment decisions in the clinic. OncoImmunology, 2012, 1, 62-66.	2.1	6
974	CD8⁺T lymphocytes infiltrating breast cancer. OncoImmunology, 2012, 1, 364-365.	2.1	41
975	DNA vaccination against oncoantigens. OncoImmunology, 2012, 1, 316-325.	2.1	34
976	How can cytoreduction surgery improve the prospects for cancer patients receiving immunotherapy?. Immunotherapy, 2012, 4, 1077-1080.	1.0	4
977	Targeting NKG2D in tumor surveillance. Expert Opinion on Therapeutic Targets, 2012, 16, 587-599.	1.5	21
978	IRF-1 is critical for IFNÎ³ mediated immune surveillance. OncoImmunology, 2012, 1, 533-534.	2.1	6
979	Expansion of effector T cells associated with decreased PD-1 expression in patients with indolent B cell lymphomas and chronic lymphocytic leukemia. Leukemia and Lymphoma, 2012, 53, 1785-1794.	0.6	30
980	Development of immune memory to glial brain tumors after tumor regression induced by immunotherapeutic Toll-like receptor 7/8 activation. OncoImmunology, 2012, 1, 298-305.	2.1	19
981	Modulation of antigenâ€presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. Immunology and Cell Biology, 2012, 90, 55-65.	1.0	59
982	Advances in Cancer Stem Cell Biology. , 2012, , .		3
983	Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape. Cancer Research, 2012, 72, 917-927.	0.4	1,311
984	Expression of Forkhead box P3 in tumour cells causes immunoregulatory function of signet ring cell carcinoma of the stomach. British Journal of Cancer, 2012, 106, 1668-1674.	2.9	39

#	Article	IF	Citations
985	Vanilloid Receptor-1 Regulates Neurogenic Inflammation in Colon and Protects Mice from Colon Cancer. Cancer Research, 2012, 72, 1705-1716.	0.4	50
986	Protein Kinase C-Î¸ (PKC-Î¸) in Natural Killer Cell Function and Anti-Tumor Immunity. Frontiers in Immunology, 2012, 3, 187.	2.2	31
987	Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Constructs. Antibodies, 2012, 1, 172-198.	1.2	28
988	Lessons from Cancer Immunoediting in Cutaneous Melanoma. Clinical and Developmental Immunology, 2012, 2012, 1-14.	3.3	18
989	Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies. Advances in Hematology, 2012, 2012, 1-9.	0.6	50
990	Cytotoxic Chemotherapy and CD4+ Effector T Cells: An Emerging Alliance for Durable Antitumor Effects. Clinical and Developmental Immunology, 2012, 2012, 1-12.	3.3	45
991	FES Kinase Promotes Mast Cell Recruitment to Mammary Tumors via the Stem Cell Factor/KIT Receptor Signaling Axis. Molecular Cancer Research, 2012, 10, 881-891.	1.5	11
992	Nanovectorized radiotherapy: a new strategy to induce anti-tumor immunity. Frontiers in Oncology, 2012, 2, 136.	1.3	10
993	New Challenges for Cancer Systems Biomedicine. SIMAI Springer Series, 2012, , .	0.4	8
994	BCR/ABL1 Fusion Transcripts Generated from Alternative Splicing: Implications for Future Targeted Therapies in Ph+ Leukaemias. Current Molecular Medicine, 2012, 12, 547-565.	0.6	6
995	Tobacco, Inflammation, and Respiratory Tract Cancer. Current Pharmaceutical Design, 2012, 18, 3901-3938.	0.9	52
996	TGF-Beta: a Master Switch in Tumor Immunity. Current Pharmaceutical Design, 2012, 18, 4126-4134.	0.9	40
997	Profiling the Immune Stromal Interface in Breast Cancer and Its Potential for Clinical Impact. Breast Care, 2012, 7, 273-280.	0.8	7
998	Potential Use of Vaccines in the Primary Prevention of Breast Cancer in High-Risk Patients. Breast Care, 2012, 7, 281-287.	0.8	11
999	Polysialyltransferase: A New Target in Metastatic Cancer. Current Cancer Drug Targets, 2012, 12, 925-939.	0.8	86
1000	Natural Killer Cells Preferentially Target Cancer Stem Cells; Role of Monocytes in Protection Against NK Cell Mediated Lysis of Cancer Stem Cells. Current Drug Delivery, 2012, 9, 5-16.	0.8	70
1001	Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma Treatment. Current Topics in Medicinal Chemistry, 2012, 12, 11-31.	1.0	8
1002	Prostate Cancer Immunotherapy: An Evolving Field. Current Cancer Therapy Reviews, 2012, 8, 274-282.	0.2	0

#	Article	IF	Citations
1003	Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients â€“ an immunohistochemical study of cd8+ and foxp3+ using double immunostaining with correlation to the pathobiological response of the patients. International Journal of Biological Markers, 2012, 27, 295-304.	0.7	33
1004	Psychoneuroimmunology and Cancer: Biobehavioral Influences on Tumor Progression. , 2012, , .		0
1005	Cancer Immunoediting in Malignant Glioma. Neurosurgery, 2012, 71, 201-223.	0.6	79
1006	â€œLetting the Air Inâ€•Can Set the Stage for Tumor Recurrences. Current Cancer Therapy Reviews, 2012, 8, 293-303.	0.2	0
1007	Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy. International Journal of Oncology, 2012, 40, 929-934.	1.4	66
1008	Pancreatic Ductal Adenocarcinoma. Journal of Investigative Medicine, 2012, 60, 643-663.	0.7	65
1009	Endogenous antigen presentation impacts on T-box transcription factor expression and functional maturation of CD8+ T cells. Blood, 2012, 120, 3237-3245.	0.6	25
1010	Molecular Pathways: Next-Generation Immunotherapyâ€”Inhibiting Programmed Death-Ligand 1 and Programmed Death-1. Clinical Cancer Research, 2012, 18, 6580-6587.	3.2	543
1012	The sweet side of tumor immunotherapy. Immunotherapy, 2012, 4, 719-734.	1.0	17
1013	Anticancer activity of small amphipathic Î²2,2-amino acid derivatives. European Journal of Medicinal Chemistry, 2012, 58, 22-29.	2.6	20
1014	Integrating Biomolecular and Clinical Data for Cancer Research: Concepts and Challenges. , 2012, , 159-172.		0
1015	Targeting CSCs within the tumor microenvironment for cancer therapy: a potential role of mesenchymal stem cells. Expert Opinion on Therapeutic Targets, 2012, 16, 1041-1054.	1.5	40
1016	Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study. Lancet Oncology, The, 2012, 13, 598-606.	5.1	147
1017	Bioinformatics for cancer immunology and immunotherapy. Cancer Immunology, Immunotherapy, 2012, 61, 1885-1903.	2.0	40
1018	Adaptive Immune Responses Associated with Breast Cancer Relapse. Archivum Immunologiae Et Therapiae Experimentalis, 2012, 60, 345-350.	1.0	13
1019	A review of the anticancer and immunomodulatory effects of Lycium barbarum fruit. Inflammopharmacology, 2012, 20, 307-314.	1.9	107
1020	Cigarette smoking strongly modifies the association of complement factor H variant and the risk of lung cancer. Cancer Epidemiology, 2012, 36, e111-e115.	0.8	11
1021	Interleukin-4 -590T/C Polymorphism Influences the Susceptibility to Nonsmall Cell Lung Cancer. DNA and Cell Biology, 2012, 31, 797-800.	0.9	18

#	Article	IF	Citations
1022	Sarcomas and the Immune System: Implications for Therapeutic Strategies. Surgical Oncology Clinics of North America, 2012, 21, 341-355.	0.6	5
1023	Immune Protection Function of Multipotent Mesenchymal Stromal Cells: Role of Transforming Growth Factor-Î²1. Cancer Investigation, 2012, 30, 646-656.	0.6	15
1024	Effect of miR-513a-5p on etoposide-stimulating B7-H1 expression in retinoblastoma cells. Journal of Huazhong University of Science and Technology [Medical Sciences], 2012, 32, 601-606.	1.0	23
1025	The Relationship Between Tumor Inflammatory Cell Infiltrate and Outcome in Patients with Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2012, 19, 3581-3590.	0.7	61
1026	Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. Journal of Experimental Medicine, 2012, 209, 495-506.	4.2	273
1027	Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation. Cell Cycle, 2012, 11, 865-870.	1.3	37
1028	Cancer vaccines: should we be targeting patients with less aggressive disease?. Expert Review of Vaccines, 2012, 11, 721-731.	2.0	26
1029	Injectable PLGA Systems for Delivery of Vaccine Antigens. , 2012, , 429-458.		4
1030	Characterization of Immune Cell Infiltration Into Canine Intracranial Meningiomas. Veterinary Pathology, 2012, 49, 784-795.	0.8	22
1031	Mechanism of Action of the Anti-cancer Agent, Triptolide. , 2012, , 135-150.		4
1032	Can Tissue-Based Immune Markers be Used for Studying the Natural History of Cancer?. Annals of Epidemiology, 2012, 22, 520-530.	0.9	13
1033	Cannabinoid receptor 2: an innovative multi-targeted approach in the treatment of breast cancer and related skeletal metastasis. Journal of Pain, 2012, 13, S66.	0.7	1
1034	Assessment of the humoral immune response to cancer. Journal of Proteomics, 2012, 75, 4573-4579.	1.2	40
1035	Epithelial immune cell-like transition (EIT): A proposed transdifferentiation process underlying immune-suppressive activity of epithelial cancers. Differentiation, 2012, 83, 293-298.	1.0	22
1036	Profound tumor-specific Th2 bias in patients with malignant glioma. BMC Cancer, 2012, 12, 561.	1.1	25
1037	HLA-E expression in cervical adenocarcinomas: association with improved long-term survival. Journal of Translational Medicine, 2012, 10, 184.	1.8	42
1038	Effect of high-dose intravenous vitamin C on inflammation in cancer patients. Journal of Translational Medicine, 2012, 10, 189.	1.8	119
1039	Immunoediting: evidence of the multifaceted role of the immune system in self-metastatic tumor growth. Theoretical Biology and Medical Modelling, 2012, 9, 31.	2.1	33

#	Article	IF	Citations
1040	Linear quantification of lymphoid infiltration of the tumor margin: a reproducible method, developed with colorectal cancer tissues, for assessing a highly variable prognostic factor. Diagnostic Pathology, 2012, 7, 156.	0.9	28
1041	The immuno-oncology framework. OncoImmunology, 2012, 1, 334-339.	2.1	40
1042	Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. International Journal of Oncology, 2012, 41, 1297-1304.	1.4	82
1043	Anti-tumor immunity: Myeloid leukocytes control the immune landscape. Cellular Immunology, 2012, 278, 21-26.	1.4	19
1044	The Association Between Treatment-Related Lymphopenia and Survival in Newly Diagnosed Patients with Resected Adenocarcinoma of the Pancreas. Cancer Investigation, 2012, 30, 571-576.	0.6	130
1045	The immunosuppressive molecule HLA-G and its clinical implications. Critical Reviews in Clinical Laboratory Sciences, 2012, 49, 63-84.	2.7	157
1046	Adjuvant immunotherapy for non-small cell lung cancer. Cancer Treatment Reviews, 2012, 38, 650-661.	3.4	33
1047	Metronomic therapy for gynecologic cancers. Taiwanese Journal of Obstetrics and Gynecology, 2012, 51, 167-178.	0.5	19
1048	Immunosuppression and lung cancer of donor origin after bilateral lung transplantation. Lung Cancer, 2012, 76, 118-122.	0.9	18
1049	STAT Transcription Factors: Controlling All Aspects of NK Cell Biology. , 2012, , 187-204.		0
1050	Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nature Medicine, 2012, 18, 1224-1231.	15.2	406
1051	n-3 PUFAs as Modulators of Stem Cells in Prevention of Colorectal Cancer. Current Colorectal Cancer Reports, 2012, 8, 307-315.	1.0	0
1052	Metronomic Chemotherapy in Progressive Pediatric Malignancies: Old Drugs in New Package. Indian Journal of Pediatrics, 2012, 79, 1617-1622.	0.3	31
1053	Multifaceted Tumor Stromal Fibroblasts. Cancer Microenvironment, 2012, 5, 187-193.	3.1	12
1054	Long Acting Injections and Implants. , 2012, , .		24
1057	Adenovirus-Based Immunotherapy of Cancer: Promises to Keep. Advances in Cancer Research, 2012, 115, 147-220.	1.9	16
1059	Antigen-Receptor Gene-Modified T Cells For Treatment Of Glioma. Advances in Experimental Medicine and Biology, 2012, 746, 202-215.	0.8	7
1060	Trypanosoma cruzi Adjuvants Potentiate T Cell-Mediated Immunity Induced by a NY-ESO-1 Based Antitumor Vaccine. PLoS ONE, 2012, 7, e36245.	1.1	24

#	Article	IF	Citations
1061	Immune Sculpting of Norepinephrine on MHC-I, B7-1, IDO and B7-H1 Expression and Regulation of Proliferation and Invasion in Pancreatic Carcinoma Cells. PLoS ONE, 2012, 7, e45491.	1.1	21
1062	Depletion of Regulatory T Lymphocytes Reverses the Imbalance between Pro- and Anti-Tumor Immunities via Enhancing Antigen-Specific T Cell Immune Responses. PLoS ONE, 2012, 7, e47190.	1.1	25
1063	Mechanical Disruption of Tumors by Iron Particles and Magnetic Field Application Results in Increased Anti-Tumor Immune Responses. PLoS ONE, 2012, 7, e48049.	1.1	29
1064	Immune Microenvironment in Tumor Progression: Characteristics and Challenges for Therapy. Journal of Oncology, 2012, 2012, 1-10.	0.6	144
1065	Predictive Immunological Markers in Oncology. Frontiers in Immunology, 2012, 2, 86.	2.2	3
1066	Cancer-Associated Immune Deficiency: A Form of Accelerated Immunosenescence?. , 2012, , .		2
1067	Novel therapies for high-grade gliomas: A vision for future. Indian Journal of Neurosurgery, 2012, 01, 054-060.	0.1	2
1068	The immunomodulating roles of glycoproteins in epithelial ovarian cancer. Frontiers in Bioscience - Elite, 2012, E4, 631-650.	0.9	2
1069	A Comparison of HLA Genotype with Inflammation in Uveal Melanoma. , 2012, 53, 2640.		7
1070	The immune system endogenous anticancer mechanism. Frontiers in Bioscience - Elite, 2012, E4, 2354-2364.	0.9	7
1071	Association of MHC class-III gene polymorphisms with ER-positive breast cancer in Chinese Han population. Genetics and Molecular Research, 2012, 11, 4299-4306.	0.3	12
1072	Downregulation of C3 and C4A/B complement factor fragments in plasma from patients with squamous cell carcinoma of the penis. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2012, 38, 739-749.	0.7	10
1073	Mass spectrometry analyses of Îº and Î» fractions result in increased number of complementarityâ€determining region identifications. Proteomics, 2012, 12, 183-191.	1.3	8
1074	Microfluidic Devices Modulate Tumor Cell Line Susceptibility to NK Cell Recognition. Small, 2012, 8, 2886-2894.	5.2	29
1075	Cancer Vaccination Drives Nanog-Dependent Evolution of Tumor Cells toward an Immune-Resistant and Stem-like Phenotype. Cancer Research, 2012, 72, 1717-1727.	0.4	72
1076	The role of antigen-specific and non-specific immunotherapy in the treatment of cancer. Journal of Immunotoxicology, 2012, 9, 248-258.	0.9	34
1077	Head and neck cancer in transplant recipients. Laryngoscope, 2012, 122, 1566-1569.	1.1	20
1078	Inflammation: What role in pediatric cancer?. Pediatric Blood and Cancer, 2012, 58, 659-664.	0.8	8

#	Article	IF	Citations
1079	Serum MMPâ€8 levels increase in colorectal cancer and correlate with disease course and inflammatory properties of primary tumors. International Journal of Cancer, 2012, 131, E463-74.	2.3	55
1080	Activeâ€specific immunotherapy of human cancers with the heat shock protein Gp96â€”revisited. International Journal of Cancer, 2012, 130, 2219-2231.	2.3	51
1081	Expression of tumour-specific antigens underlies cancer immunoediting. Nature, 2012, 482, 405-409.	13.7	478
1082	Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature, 2012, 482, 400-404.	13.7	1,075
1083	The determinants of tumour immunogenicity. Nature Reviews Cancer, 2012, 12, 307-313.	12.8	343
1084	Cancer immunotherapy: a paradigm shift for prostate cancer treatment. Nature Reviews Urology, 2012, 9, 376-385.	1.9	31
1085	Asthma and risk of brain cancer in children. Cancer Causes and Control, 2012, 23, 617-623.	0.8	25
1086	A new hypothesis for the cancer mechanism. Cancer and Metastasis Reviews, 2012, 31, 247-268.	2.7	43
1087	Anticancer and Immunostimulatory Activity by Conjugate of Paclitaxel and Non-toxic Derivative of LPS for Combined Chemo-immunotherapy. Pharmaceutical Research, 2012, 29, 2294-2309.	1.7	30
1088	Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy. Cancer Immunology, Immunotherapy, 2012, 61, 453-468.	2.0	22
1089	Association of CD27 and CD70 gene polymorphisms with risk of sporadic breast cancer in Chinese women in Heilongjiang Province. Breast Cancer Research and Treatment, 2012, 133, 1105-1113.	1.1	14
1090	Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction. Clinical and Experimental Immunology, 2012, 167, 188-194.	1.1	24
1091	Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures. Cellular Immunology, 2012, 273, 1-9.	1.4	23
1092	Predictive value of peripheral blood lymphocyte count in breast cancer patients treated with primary chemotherapy. Breast, 2012, 21, 468-474.	0.9	49
1093	The Potential Beneficial Effects of Drugs on the Immune Response to Vaccination. Seminars in Oncology, 2012, 39, 340-347.	0.8	10
1094	Inflammation and immune surveillance in cancer. Seminars in Cancer Biology, 2012, 22, 23-32.	4.3	179
1095	A mathematical model of tumorâ€“immune interactions. Journal of Theoretical Biology, 2012, 294, 56-73.	0.8	136
1096	Status of cellular immunity lacks prognostic significance in vulvar squamous carcinoma. Gynecologic Oncology, 2012, 125, 186-193.	0.6	25

#	Article	IF	Citations
1097	Langerhans Cells and T Cells Sense Cell Dysplasia in Oral Leukoplakias and Oral Squamous Cell Carcinomas â€“ Evidence for Immunosurveillance. Scandinavian Journal of Immunology, 2012, 76, 39-48.	1.3	41
1098	Stat3: Linking inflammation to (gastrointestinal) tumourigenesis. Clinical and Experimental Pharmacology and Physiology, 2012, 39, 711-718.	0.9	37
1099	Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas. BMC Clinical Pathology, 2012, 12, 5.	1.8	32
1100	Macrophages in human colorectal cancer are proâ€inflammatory and prime T cells towards an antiâ€tumour typeâ€1 inflammatory response. European Journal of Immunology, 2012, 42, 89-100.	1.6	112
1101	Immunotherapeutic strategies for cancer treatment: A novel protein transfer approach for cancer vaccine development. Medicinal Research Reviews, 2012, 32, 1197-1219.	5.0	14
1102	The clinical implications of antitumor immunity in head and neck cancer. Laryngoscope, 2012, 122, 144-157.	1.1	52
1103	Immune Reconstitution in Chronic Lymphocytic Leukemia. Current Hematologic Malignancy Reports, 2012, 7, 13-20.	1.2	23
1104	HLA-DRB1,-DQA1 and -DQB1 Allele and Haplotype Frequencies in Female Patients with Early Onset Breast Cancer. Pathology and Oncology Research, 2012, 18, 49-55.	0.9	21
1106	Potential rescue, survival and differentiation of cancer stem cells and primary non-transformed stem cells by monocyte-induced split anergy in natural killer cells. Cancer Immunology, Immunotherapy, 2012, 61, 265-274.	2.0	23
1107	Tumorâ€associated autoantibody signature for the early detection of gastric cancer. International Journal of Cancer, 2013, 132, 137-147.	2.3	79
1108	Optimal chemotherapy in cancer treatment: state dependent Riccati equation control and extended Kalman filter. Optimal Control Applications and Methods, 2013, 34, 562-577.	1.3	58
1109	Targeting the immune system for management of NSCLC: the revival?. Current Respiratory Care Reports, 2013, 2, 22-39.	0.6	1
1110	Immune system: a double-edged sword in cancer. Inflammation Research, 2013, 62, 823-834.	1.6	140
1111	A high throughput method for enrichment of natural killer cells and lymphocytes and assessment of in vitro cytotoxicity. Journal of Immunological Methods, 2013, 394, 40-48.	0.6	10
1112	New Advances on Disease Biomarkers and Molecular Targets in Biomedicine. , 2013, , .		0
1113	The role of natural killer T cells in B cell malignancies. Tumor Biology, 2013, 34, 1349-1360.	0.8	40
1114	Therapeutic Cancer Vaccines. Advances in Cancer Research, 2013, 119, 421-475.	1.9	450
1115	Hypoxiaâ€inducible factors as key regulators of tumor inflammation. International Journal of Cancer, 2013, 132, 2721-2729.	2.3	60

#	Article	IF	Citations
1116	Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer. BMC Cancer, 2013, 13, 36.	1.1	67
1117	Cancer vaccines: Harnessing the potential of anti-tumor immunity. Veterinary Journal, 2013, 198, 28-33.	0.6	16
1118	A prospective analysis of telomere length and pancreatic cancer in the alpha-tocopherol beta-carotene cancer (ATBC) prevention study. International Journal of Cancer, 2013, 133, n/a-n/a.	2.3	53
1119	Digital pattern recognition-based image analysis quantifies immune infiltrates in distinct tissue regions of colorectal cancer and identifies a metastatic phenotype. British Journal of Cancer, 2013, 109, 1618-1624.	2.9	30
1120	Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity, 2013, 39, 1-10.	6.6	4,815
1121	Modulation of antitumour immune responses by intratumoural Stat1 expression. Immunology and Cell Biology, 2013, 91, 556-567.	1.0	11
1122	Can exercise-related improvements in immunity influence cancer prevention and prognosis in the elderly?. Maturitas, 2013, 76, 51-56.	1.0	60
1123	Breast Cancer Metastasis and Drug Resistance. , 2013, , .		12
1124	Immunology of Aging and Cancer Development. Interdisciplinary Topics in Gerontology, 2013, 38, 38-48.	3.6	26
1125	Cancer immunogenicity, danger signals, and DAMPs: What, when, and how?. BioFactors, 2013, 39, 355-367.	2.6	92
1126	Role of vaccine therapy for renal cell carcinoma in the era of targeted therapy. International Journal of Urology, 2013, 20, 744-755.	0.5	11
1127	InÂVitro Treatment with Ganciclovir Restores the Functionality of Exhausted T Cells from Cancer Patients. International Journal of Gerontology, 2013, 7, 171-176.	0.7	2
1128	Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma Patient Who Experienced a Durable Complete Tumor Regression. Journal of Immunology, 2013, 190, 6034-6042.	0.4	145
1129	Myeloid-Derived Suppressor Cells Enhance Stemness of Cancer Cells by Inducing MicroRNA101 and Suppressing the Corepressor CtBP2. Immunity, 2013, 39, 611-621.	6.6	366
1130	Immunology of melanoma. Clinics in Dermatology, 2013, 31, 156-165.	0.8	34
1131	Turning Tumors into Vaccines: Co-opting the Innate Immune System. Immunity, 2013, 39, 27-37.	6.6	93
1133	Interferon-gamma in ascites could be a predictive biomarker of outcome in ovarian carcinoma. Gynecologic Oncology, 2013, 131, 63-68.	0.6	20
1134	Molecular Pathways: Human Leukocyte Antigen G (HLA-G). Clinical Cancer Research, 2013, 19, 5564-5571.	3.2	118

#	Article	IF	Citations
1135	Tumor-Derived Lactate Modifies Antitumor Immune Response: Effect on Myeloid-Derived Suppressor Cells and NK Cells. Journal of Immunology, 2013, 191, 1486-1495.	0.4	552
1136	Rational combinations of immunotherapeutics that target discrete pathways. , 2013, 1, 16.		62
1137	Highly efficient differentiation of neural precursors from human embryonic stem cells and benefits of transplantation after ischemic stroke in mice. Stem Cell Research and Therapy, 2013, 4, 93.	2.4	42
1138	Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients. Journal of Translational Medicine, 2013, 11, 191.	1.8	53
1139	Primer on tumor immunology and cancer immunotherapy. , 2013, 1, 12.		63
1140	Expression of EPHRIN-A1, SCINDERIN and MHC class I molecules in head and neck cancers and relationship with the prognostic value of intratumoral CD8+T cells. BMC Cancer, 2013, 13, 592.	1.1	16
1141	Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases. Immunologic Research, 2013, 57, 311-325.	1.3	33
1142	The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities. Immunologic Research, 2013, 57, 52-69.	1.3	37
1143	Effect of low frequency magnetic fields on melanoma: tumor inhibition and immune modulation. BMC Cancer, 2013, 13, 582.	1.1	53
1144	IL-17, IL-22 and Their Producing Cells: Role in Inflammation and Autoimmunity. , 2013, , .		1
1145	Autoimmunity vs. cancer: Predator vs. alien?. Autoimmunity, 2013, 46, 287-293.	1.2	9
1146	Systems Biology of Tumor Dormancy. Advances in Experimental Medicine and Biology, 2013, , .	0.8	9
1147	Tumor Dormancy, Oncogene Addiction, Cellular Senescence, and Self-Renewal Programs. Advances in Experimental Medicine and Biology, 2013, 734, 91-107.	0.8	36
1148	Senescent Cells and Their Secretory Phenotype as Targets for Cancer Therapy. Interdisciplinary Topics in Gerontology, 2013, 38, 17-27.	3.6	95
1149	Revisiting Immune-Based Therapies for Aggressive Follicular Cellâ€“Derived Thyroid Cancers. Thyroid, 2013, 23, 529-542.	2.4	15
1150	The elimination of P-glycoprotein over-expressing cancer cells by antimicrobial cationic peptide NK-2: The unique way of multi-drug resistance modulation. Experimental Cell Research, 2013, 319, 1013-1027.	1.2	31
1151	Cancer Immunoediting. , 2013, , 85-99.		7
1152	Immune Escape. , 2013, , 149-164.		1

#	Article	IF	Citations
1153	Dendritic Cell Vaccines. , 2013, , 273-286.		1
1154	Viral Vector Vaccines To Treat Colorectal Cancer. Current Colorectal Cancer Reports, 2013, 9, 398-405.	1.0	2
1155	Common pathways to tumor rejection. Annals of the New York Academy of Sciences, 2013, 1284, 75-79.	1.8	17
1156	Characterization of immunoglobulin by mass spectrometry with applications for the clinical laboratory. Critical Reviews in Clinical Laboratory Sciences, 2013, 50, 91-102.	2.7	16
1157	HLA ligandome tumor antigen discovery for personalized vaccine approach. Expert Review of Vaccines, 2013, 12, 1211-1217.	2.0	87
1158	Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors. Cancer Discovery, 2013, 3, 1355-1363.	7.7	1,073
1159	Recognition and learning in a mathematical model for immune response against cancer. Discrete and Continuous Dynamical Systems - Series B, 2013, 18, 891-914.	0.5	15
1160	RNA pulsed dendritic cells: An approach for cancer immunotherapy. Vaccine, 2013, 31, 1141-1156.	1.7	30
1161	Increased apoptosis and elevated Fas expression in circulating natural killer cells in gastric cancer patients. Gastric Cancer, 2013, 16, 473-479.	2.7	38
1162	T cell responses against microsatellite instability-induced frameshift peptides and influence of regulatory T cells in colorectal cancer. Cancer Immunology, Immunotherapy, 2013, 62, 27-37.	2.0	46
1163	Differential expression of immune-related markers in breast cancer by molecular phenotypes. Breast Cancer Research and Treatment, 2013, 137, 417-429.	1.1	11
1164	Enforcement of Reproductive Synchrony via Policing in a Clonal Ant. Current Biology, 2013, 23, 328-332.	1.8	48
1165	Detection and isolation of circulating tumor cells: Principles and methods. Biotechnology Advances, 2013, 31, 1063-1084.	6.0	157
1166	Repercussions of occult malignancy â€“ An etiologic basis for rheumatic disease. Medical Hypotheses, 2013, 80, 447-451.	0.8	6
1167	Prognostic implications of human leukocyte antigen class I expression in patients who underwent surgical resection for nonâ€“small-cell lung cancer. Journal of Surgical Research, 2013, 181, e57-e63.	0.8	21
1168	Noncanonical roles of the immune system in eliciting oncogene addiction. Current Opinion in Immunology, 2013, 25, 246-258.	2.4	11
1169	Lesion HLA-F expression is irrelevant to prognosis for patients with gastric cancer. Human Immunology, 2013, 74, 828-832.	1.2	9
1170	Anti-inflammatory activity of a naphthyridine derivative (7-chloro-6-fluoro-N-(2-hydroxy-3-oxo-1-phenyl-3-(phenylamino)propyl)-4-oxo-1-(prop-2-yn-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxa possessing in vitro anticancer potential. International Immunopharmacology, 2013, 15, 606-613.	1.1	34

#	Article	IF	Citations
1171	IFN-Î³â€“Driven Intratumoral Microenvironment Exhibits Superior Prognostic Effect Compared with an IFN-Î±â€“Driven Microenvironment in Patients with Colon Carcinoma. American Journal of Pathology, 2013, 183, 1897-1909.	1.9	17
1172	The Tumor Growth Paradox and Immune System-Mediated Selection for Cancer Stem Cells. Bulletin of Mathematical Biology, 2013, 75, 161-184.	0.9	85
1173	Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift. Journal of the National Cancer Institute, 2013, 105, 256-265.	3.0	846
1174	Cancer stem cells as â€˜units of selectionâ€™. Evolutionary Applications, 2013, 6, 102-108.	1.5	66
1175	Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clinical and Experimental Immunology, 2012, 171, 36-45.	1.1	188
1176	T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. Journal of Translational Medicine, 2013, 11, 5.	1.8	27
1177	The cancer biology of whole-chromosome instability. Oncogene, 2013, 32, 4727-4736.	2.6	106
1178	Tumor dormancy and the neuroendocrine system: an undisclosed connection?. Cancer and Metastasis Reviews, 2013, 32, 189-200.	2.7	22
1179	Personalized Immune-Interception of Cancer and the Battle of Two Adaptive Systemsâ€”When Is the Time Right?. Cancer Prevention Research, 2013, 6, 173-176.	0.7	6
1180	Tumor Dormancy and Cancer Stem Cells: Two Sides of the Same Coin?. Advances in Experimental Medicine and Biology, 2013, 734, 145-179.	0.8	108
1181	Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer. Journal of Immunology, 2013, 190, 3783-3797.	0.4	483
1182	The therapeutic potential of mesenchymal stem cellâ€derived extracellular vesicles. Proteomics, 2013, 13, 1637-1653.	1.3	332
1183	Antigen presenting cell/ tumor cell fusion vaccines for cancer immunotherapy. Human Vaccines and Immunotherapeutics, 2013, 9, 1545-1548.	1.4	21
1184	Vaccines against advanced melanoma. Clinics in Dermatology, 2013, 31, 179-190.	0.8	20
1185	Biology of Renal Cell Carcinoma (Vascular Endothelial Growth Factor, Mammalian Target of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 182 T 0		
1186	Cancer stem cell antigen-based vaccines: the preferred strategy for active specific immunotherapy of metastatic melanoma?. Expert Opinion on Biological Therapy, 2013, 13, 643-656.	1.4	27
1187	Human papillomavirus and cervical cancer. Lancet, The, 2013, 382, 889-899.	6.3	812
1188	Exome sequencing in diagnostic evaluation of colorectal cancer predisposition in young patients. Scandinavian Journal of Gastroenterology, 2013, 48, 672-678.	0.6	14

#	Article	IF	Citations
1189	Myeloid derived suppressor cells. OncoImmunology, 2013, 2, e24117.	2.1	63
1190	Targeted Drug Delivery in Oncology: Current Paradigm and Challenges. RSC Polymer Chemistry Series, 2013, , 1-19.	0.1	1
1191	Cross talk between cancer and immune cells: exploring complex dynamics in a microfluidic environment. Lab on A Chip, 2013, 13, 229-239.	3.1	126
1192	Strategies for optimizing the response of cancer and normal tissues to radiation. Nature Reviews Drug Discovery, 2013, 12, 526-542.	21.5	335
1193	Cancer Immunotherapy. , 2013, , 198-214.		2
1195	Exploitation of adaptive evolution in glioma treatment. CNS Oncology, 2013, 2, 171-179.	1.2	8
1196	The Tumor Immunoenvironment. , 2013, , .		4
1197	MHC Class I Antigens In Malignant Cells. , 2013, , .		3
1198	Neoplasia in the Etiology of Sarcoidosis. American Journal of Medicine, 2013, 126, e17.	0.6	2
1199	From tumor cell metabolism to tumor immune escape. International Journal of Biochemistry and Cell Biology, 2013, 45, 106-113.	1.2	80
1200	Clinical Impact of Tumor-infiltrating Lymphocytes for Survival in Curatively Resected Stage IV Colon Cancer with Isolated Liver or Lung Metastasis. Annals of Surgical Oncology, 2013, 20, 697-702.	0.7	48
1201	Comparison of Vaccine-Induced Effector CD8 T Cell Responses Directed against Self- and Nonâ€“Self-Tumor Antigens: Implications for Cancer Immunotherapy. Journal of Immunology, 2013, 191, 3955-3967.	0.4	57
1202	Gene Expression Changes in Spleens and Livers of Tumour-Bearing Mice Suggest Delayed Inflammation and Attenuated Cachexia in Response to Oil Palm Phenolics. Journal of Nutrigenetics and Nutrigenomics, 2013, 6, 305-326.	1.8	9
1203	Immune microenvironment profiles of tumor immune equilibrium and immune escape states of mouse sarcoma. Cancer Letters, 2013, 340, 124-133.	3.2	52
1204	Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. British Journal of Cancer, 2013, 109, 2705-2713.	2.9	264
1205	Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications. Cancer Immunology, Immunotherapy, 2013, 62, 1547-1551.	2.0	20
1206	Blocking mtDNA Replication Upregulates the Expression of Stemness-related Genes in Prostate Cancer Cell Lines. Ultrastructural Pathology, 2013, 37, 258-266.	0.4	4
1207	Local targets for immune therapy to cancer: Tumor draining lymph nodes and tumor microenvironment. International Journal of Cancer, 2013, 132, 1971-1976.	2.3	68

#	Article	IF	Citations
1208	Do Inflammatory Bowel Disease Therapies Cause Cancer?. Inflammatory Bowel Diseases, 2013, 19, 1306-1321.	0.9	51
1210	Naturally Occurring Hydroxytyrosol: Synthesis and Anticancer Potential. Current Medicinal Chemistry, 2013, 20, 655-670.	1.2	83
1212	Evaluation of Molecular Species of Prostate-Specific Antigen Complexed with Immunoglobulin M in Prostate Cancer and Benign Prostatic Hyperplasia. Disease Markers, 2013, 35, 847-855.	0.6	5
1213	Tumor Microenvironment may Shape the Function and Phenotype of NK Cells Through the Induction of Split Anergy and Generation of Regulatory NK Cells. , 2013, , 361-381.		8
1214	Immunoediting and Antigen Loss: Overcoming the Achilles Heel of Immunotherapy with Antigen Non-Specific Therapies. Frontiers in Oncology, 2013, 3, 197.	1.3	36
1215	Metronomic therapy: Chemotherapy revisited. Indian Journal of Cancer, 2013, 50, 142.	0.2	18
1216	An evolutionary perspective on anti-tumor immunity. Frontiers in Oncology, 2012, 2, 202.	1.3	15
1217	Can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies?. Frontiers in Oncology, 2013, 3, 23.	1.3	3
1218	Magnetic Drug Targeting Reduces the Chemotherapeutic Burden on Circulating Leukocytes. International Journal of Molecular Sciences, 2013, 14, 7341-7355.	1.8	57
1219	Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma. Carcinogenesis, 2013, 34, 1081-1088.	1.3	60
1220	Presence of CD3+ tumor infiltrating lymphocytes is significantly associated with good prognosis in infiltrating ductal carcinoma of breast. Indian Journal of Cancer, 2013, 50, 239.	0.2	28
1221	Mathematical models of immune-induced cancer dormancy and the emergence of immune evasion. Interface Focus, 2013, 3, 20130010.	1.5	46
1222	Cancer Immunosurveillance and Immunoediting by Natural Killer Cells. Cancer Journal (Sudbury, Mass) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.6	52
1223	The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns. Epigenetics, 2013, 8, 1226-1235.	1.3	19
1224	The Etiology of Cancer. , 2013, , 1-29.		0
1225	Tumor STAT1 Transcription Factor Activity Enhances Breast Tumor Growth and Immune Suppression Mediated by Myeloid-derived Suppressor Cells. Journal of Biological Chemistry, 2013, 288, 11676-11688.	1.6	107
1226	GBP-1 acts as a tumor suppressor in colorectal cancer cells. Carcinogenesis, 2013, 34, 153-162.	1.3	85
1227	The Parity-Associated Microenvironmental Niche in the Omental Fat Band Is Refractory to Ovarian Cancer Metastasis. Cancer Prevention Research, 2013, 6, 1182-1193.	0.7	36

#	Article	IF	Citations
1228	The relationship between KRAS gene mutations and HLA class I antigen downregulation in the metastasis of non-small cell lung cancer. Journal of International Medical Research, 2013, 41, 1473-1483.	0.4	13
1229	Expression of CD137 on Hodgkin and Reedâ€“Sternberg Cells Inhibits T-cell Activation by Eliminating CD137 Ligand Expression. Cancer Research, 2013, 73, 652-661.	0.4	64
1230	The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence. Therapeutic Advances in Vaccines, 2013, 1, 33-47.	2.7	8
1231	Fibroblast-Specific Protein 1/S100A4â€“Positive Cells Prevent Carcinoma through Collagen Production and Encapsulation of Carcinogens. Cancer Research, 2013, 73, 2770-2781.	0.4	59
1232	Visualizing cellular interactions with a generalized proximity reporter. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8567-8572.	3.3	40
1233	Immune Modulation and Stereotactic Radiation: Improving Local and Abscopal Responses. BioMed Research International, 2013, 2013, 1-8.	0.9	66
1234	The Clinical Potential of Circulating Tumor Cells; The Need to Incorporate a Modern â€œImmunological Cocktailâ€•in the Assay. Cancers, 2013, 5, 1739-1747.	1.7	6
1235	Nonneuronal Cholinergic System in Breast Tumors and Dendritic Cells: Does It Improve or Worsen the Response to Tumor?. , 2013, 2013, 1-12.		2
1236	Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management. Scientifica, 2013, 2013, 1-19.	0.6	186
1237	Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation. OncoImmunology, 2013, 2, e22837.	2.1	24
1238	Infection and Cancer: Revaluation of the Hygiene Hypothesis. Clinical Cancer Research, 2013, 19, 2834-2841.	3.2	57
1239	The nuclear factorâ€ºB pathway downâ€regulates expression of the NKG 2D ligand H60a in vitro : implications for use of nuclear factorâ€ºB inhibitors in cancer therapy. Immunology, 2013, 139, 265-274.	2.0	6
1240	Usp18 deficient mammary epithelial cells create an antitumour environment driven by hypersensitivity to <scp>IFN</scp>â€» and elevated secretion of Cxcl10. EMBO Molecular Medicine, 2013, 5, 1035-1050.	3.3	83
1241	Cancer risk with alemtuzumab following kidney transplantation. Clinical Transplantation, 2013, 27, E264-71.	0.8	17
1242	Human VÎ³2VÎ´2 T cells limit breast cancer growth by modulating cell survivalâ€; apoptosisâ€related molecules and microenvironment in tumors. International Journal of Cancer, 2013, 133, 2133-2144.	2.3	35
1243	Bifurcations in Delay Differential Equations and Applications to Tumor and Immune System Interaction Models. SIAM Journal on Applied Dynamical Systems, 2013, 12, 1847-1888.	0.7	46
1244	Specificity of squamous cell carcinoma antigen (SCCA)â€IgM detection in patients with HCV infection and rheumatoid factor seropositivity. Journal of Medical Virology, 2013, 85, 1005-1008.	2.5	12
1245	Immune cells: plastic players along colorectal cancer progression. Journal of Cellular and Molecular Medicine, 2013, 17, 1088-1095.	1.6	62

#	Article	IF	Citations
1246	Role of Î±â€gal epitope/antiâ€Gal antibody reaction in immunotherapy and its clinical application in pancreatic cancer. Cancer Science, 2013, 104, 282-290.	1.7	21
1247	Extracellular Activities of Aminoacyl-tRNA Synthetases: New Mediators for Cellâ€“Cell Communication. Topics in Current Chemistry, 2013, 344, 145-166.	4.0	30
1248	Epithelialâ€“Mesenchymal Transition Induces an Antitumor Immune Response Mediated by NKG2D Receptor. Journal of Immunology, 2013, 190, 4408-4419.	0.4	89
1249	Identification of novel compounds that enhance colon cancer cell sensitivity to inflammatory apoptotic ligands. Cancer Biology and Therapy, 2013, 14, 436-449.	1.5	11
1250	Regulatory T Cells, Leptin and Angiogenesis. Chemical Immunology and Allergy, 2014, 99, 155-169.	1.7	24
1251	Tremelimumab: a review of development to date in solid tumors. Immunotherapy, 2013, 5, 215-229.	1.0	55
1252	Dysfunctional reproductive physiology, and not reproductive activation, triggers policing in experimental colonies of the clonal antCerapachys biroi. Communicative and Integrative Biology, 2013, 6, e24954.	0.6	0
1253	The delicate balance of melanoma immunotherapy. Clinical and Translational Immunology, 2013, 2, e5.	1.7	22
1254	Imaging burst kinetics and spatial coordination during serial killing by single natural killer cells. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6488-6493.	3.3	103
1255	The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells. Neuro-Oncology, 2013, 15, 1479-1490.	0.6	72
1256	Rationale for the design of an oncology trial using a generic targeted therapy multi-drug regimen for NSCLC patients without treatment options (Review). Oncology Reports, 2013, 30, 1535-1541.	1.2	7
1257	Salmonella engineered to express CD20-targeting antibodies and a drug-converting enzyme can eradicate human lymphomas. Blood, 2013, 122, 705-714.	0.6	79
1259	Interleukin-17 Produced by Malignant Mesothelioma-Polarized Immune Cells Promotes Tumor Growth and Invasiveness. European Journal of Inflammation, 2013, 11, 203-214.	0.2	1
1260	Non-Hodgkin Lymphomas: Advanced Diagnostics & Personalized Therapies. , 2013, , .		2
1261	Contribution of HIV infection to mortality among cancer patients in Uganda. Aids, 2013, 27, 2933-2942.	1.0	58
1262	Immune escape of AKT overexpressing ovarian cancer cells. International Journal of Oncology, 2013, 42, 1630-1635.	1.4	13
1263	Particle platforms for cancer immunotherapy. International Journal of Nanomedicine, 2013, 8, 1683.	3.3	48
1264	Immunogenicity and Tumorigenicity of Pluripotent Stem Cells and their Derivatives: Genetic and Epigenetic Perspectives. Current Stem Cell Research and Therapy, 2013, 9, 63-72.	0.6	53

#	Article	IF	Citations
1265	Interactions between Immune Cells and Tumor Cells. Journal of Korean Thyroid Association, 2013, 6, 96.	0.2	2
1266	Peripheral Immune Cell Gene Expression Changes in Advanced Non-Small Cell Lung Cancer Patients Treated with First Line Combination Chemotherapy. PLoS ONE, 2013, 8, e57053.	1.1	20
1267	Val-BoroPro Accelerates T Cell Priming via Modulation of Dendritic Cell Trafficking Resulting in Complete Regression of Established Murine Tumors. PLoS ONE, 2013, 8, e58860.	1.1	44
1268	Vector-Free and Transgene-Free Human iPS Cells Differentiate into Functional Neurons and Enhance Functional Recovery after Ischemic Stroke in Mice. PLoS ONE, 2013, 8, e64160.	1.1	69
1269	Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer â€“ A Substudy of the Neoadjuvant GeparQuinto Trial. PLoS ONE, 2013, 8, e79775.	1.1	187
1270	Dendritic Cell-Targeted Approaches to Modulate Immune Dysfunction in the Tumor Microenvironment. Frontiers in Immunology, 2013, 4, 436.	2.2	21
1271	Dual Functions of Natural Killer Cells in Selection and Differentiation of Stem Cells; Role in Regulation of Inflammation and Regeneration of Tissues. Journal of Cancer, 2013, 4, 12-24.	1.2	74
1272	STAT Transcription Factors in Tumor Development and Targeted Therapy of Malignancies. , 0, , .		4
1273	The Oncogenicity of Human Cytomegalovirus. , 0, , .		2
1274	Immune suppression and evasion in patients with head and neck cancer. Advances in Cellular and Molecular Otolaryngology, 2013, 1, 21809.	0.4	3
1275	The Tumor Microenvironment: A Target for Combination therapy of Breast Cancer. Critical Reviews in Oncogenesis, 2013, 18, 115-133.	0.2	72
1276	Interaction Between the Immune System and Melanoma. , 0, , .		1
1277	Avoidance of Cancer Cell Destruction by the Immune System. , 2014, , 434-443.		0
1278	Dietary Mushroom Intake May Reduce the Risk of Breast Cancer: Evidence from a Meta-Analysis of Observational Studies. PLoS ONE, 2014, 9, e93437.	1.1	40
1279	Intratumoral CD8+ Cytotoxic Lymphocyte Is a Favorable Prognostic Marker in Node-Negative Breast Cancer. PLoS ONE, 2014, 9, e95475.	1.1	63
1280	Dendritic Cell-Secreted Lipocalin2 Induces CD8+ T-Cell Apoptosis, Contributes to T-Cell Priming and Leads to a TH1 Phenotype. PLoS ONE, 2014, 9, e101881.	1.1	30
1281	Inflammasome Activation Is Critical to the Protective Immune Response during Chemically Induced Squamous Cell Carcinoma. PLoS ONE, 2014, 9, e107170.	1.1	21
1282	HLA Class I Expression and Its Alteration by Preoperative Hyperthermo-Chemoradiotherapy in Patients with Rectal Cancer. PLoS ONE, 2014, 9, e108122.	1.1	17

#	Article	IF	Citations
1283	Limited Density of an Antigen Presented by RMA-S Cells Requires B7-1/CD28 Signaling to Enhance T-Cell Immunity at the Effector Phase. PLoS ONE, 2014, 9, e108192.	1.1	1
1284	Analysis of FoxP3+ T-Regulatory Cells and CD8+T-Cells in Ovarian Carcinoma: Location and Tumor Infiltration Patterns Are Key Prognostic Markers. PLoS ONE, 2014, 9, e111757.	1.1	32
1285	Advances and Prospects in Cancer Immunotherapy. New Journal of Science, 2014, 2014, 1-13.	1.0	21
1286	Strategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen Modification. Vaccines, 2014, 2, 549-562.	2.1	8
1287	Colorectal cancer and immunity: What we know and perspectives. World Journal of Gastroenterology, 2014, 20, 3738.	1.4	105
1288	Immunotherapy in gastric cancer. World Journal of Gastroenterology, 2014, 20, 1657.	1.4	84
1289	Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy. ImmunoTargets and Therapy, 2014, 3, 151.	2.7	12
1290	Combined Treatment of Murine Fibrosarcoma with Chemotherapy (Paclitaxel), Radiotherapy, and Intratumoral Injection of Dendritic Cells. Annals of Dermatology, 2014, 26, 53.	0.3	7
1291	Complex role for the immune system in initiation and progression of pancreatic cancer. World Journal of Gastroenterology, 2014, 20, 11160.	1.4	111
1292	Role of SERPINB3 in hepatocellular carcinoma. Annals of Hepatology, 2014, 13, 722-727.	0.6	29
1293	The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment. Expert Review of Hematology, 2014, 7, 807-818.	1.0	62
1294	Increased Incidence and Characteristics of Alveolar Echinococcosis in Patients With Immunosuppression-Associated Conditions. Clinical Infectious Diseases, 2014, 59, 1095-1104.	2.9	103
1295	Tumor surveillance by circulating microRNAs: a hypothesis. Cellular and Molecular Life Sciences, 2014, 71, 4081-4087.	2.4	29
1296	IFNÎ± signaling through PKC-Î¸ is essential for antitumor NK cell function. OncoImmunology, 2014, 3, e948705.	2.1	10
1297	Cancer nanoimmunotherapy using advanced pharmaceutical nanotechnology. Nanomedicine, 2014, 9, 2587-2605.	1.7	31
1298	Raloxifene and Antiestrogenic Gonadorelin Inhibits Intestinal Tumorigenesis by Modulating Immune Cells and Decreasing Stem-like Cells. Cancer Prevention Research, 2014, 7, 300-309.	0.7	9
1299	Extinction Effects of Multiplicative Non-Gaussian LÃ©vy Noise in a Tumor Growth System with Immunization. Communications in Theoretical Physics, 2014, 61, 571-577.	1.1	2
1300	The orthotopic xenotransplant of human glioblastoma successfully recapitulates glioblastoma-microenvironment interactions in a non-immunosuppressed mouse model. BMC Cancer, 2014, 14, 923.	1.1	31

#	Article	IF	Citations
1301	Autoimmunity and tumor immunology: two facets of a probabilistic immune system. BMC Systems Biology, 2014, 8, 120.	3.0	9
1302	The Future of Glioblastoma Therapy: Synergism of Standard of Care and Immunotherapy. Cancers, 2014, 6, 1953-1985.	1.7	62
1303	Enhanced frequency and potential mechanism of B regulatory cells in patients with lung cancer. Journal of Translational Medicine, 2014, 12, 304.	1.8	51
1304	Emerging Nanotechniques in Proteomics. Comprehensive Analytical Chemistry, 2014, 63, 137-157.	0.7	0
1305	In vivo eradication of MLL/ENL leukemia cells by NK cells in the absence of adaptive immunity. Leukemia, 2014, 28, 1316-1325.	3.3	11
1306	Antigen delivery by virus-like particles for immunotherapeutic vaccination. Therapeutic Delivery, 2014, 5, 1223-1240.	1.2	35
1307	Immunomodulation and lymphoma in humans. Journal of Immunotoxicology, 2014, 11, 1-12.	0.9	23
1308	The immune escape in melanoma: role of the impaired dendritic cell function. Expert Review of Clinical Immunology, 2014, 10, 1395-1404.	1.3	56
1309	Does the Immune System Naturally Protect Against Cancer?. Frontiers in Immunology, 2014, 5, 197.	2.2	183
1310	Cancer Stem Cell Immunology: Key to Understanding Tumorigenesis and Tumor Immune Escape?. Frontiers in Immunology, 2014, 5, 360.	2.2	147
1311	Systemic Therapy for Merkel Cell Carcinoma: Whatâ€™s on the Horizon?. Cancers, 2014, 6, 1180-1194.	1.7	14
1312	Failure of immunological cells to eradicate tumor and cancer cells: an overview. Turkish Journal of Biology, 2014, 38, 786-799.	2.1	0
1313	Biological Basis for Increased Sensitivity to Radiation Therapy in HPV-Positive Head and Neck Cancers. BioMed Research International, 2014, 2014, 1-6.	0.9	33
1314	Filaggrin, Human Papillomavirus, and the Cervix. , 2014, , 333-342.		1
1315	Microenvironment of Tumor-Draining Lymph Nodes: Opportunities for Liposome-Based Targeted Therapy. International Journal of Molecular Sciences, 2014, 15, 20209-20239.	1.8	65
1316	Lentiviral vector-based therapy in head and neck cancer (Review). Oncology Letters, 2014, 7, 3-9.	0.8	7
1317	Combinations of Immunotherapy and Radiation in Cancer Therapy. Frontiers in Oncology, 2014, 4, 325.	1.3	205
1318	Induced Pluripotent Stem Cells: Challenges and Opportunities for Cancer Immunotherapy. Frontiers in Immunology, 2014, 5, 176.	2.2	35

#	Article	IF	Citations
1319	The Second Annual AACRâ€“Cancer Research Institute Lloyd J. Old Award in Cancer Immunology. Cancer Immunology Research, 2014, 2, 606-609.	1.6	0
1320	RepSox Slows Decay of CD34+ Acute Myeloid Leukemia Cells and Decreases T Cell Immunoglobulin Mucin-3 Expression. Stem Cells Translational Medicine, 2014, 3, 836-848.	1.6	7
1321	Periodic and chaotic oscillations in a tumor and immune system interaction model with three delays. Chaos, 2014, 24, 023101.	1.0	42
1322	Reâ€adapting T cells for cancer therapy: from mouse models to clinical trials. Immunological Reviews, 2014, 257, 145-164.	2.8	67
1323	Advances in Tumor Immunology and Immunotherapy. , 2014, , .		2
1324	Application of central immunologic concepts to cancer: Helping TÂcells and B cells become intolerant of tumors. European Journal of Immunology, 2014, 44, 1921-1924.	1.6	6
1325	Prognostic significance of the lymphocyte-to-monocyte ratio in patients with small cell lung cancer. Medical Oncology, 2014, 31, 323.	1.2	39
1326	The influence of epigenetics in relation to oral health. International Journal of Dental Hygiene, 2014, 12, 48-54.	0.8	37
1327	Antitumour immunity gets a boost. Nature, 2014, 515, 496-498.	13.7	90
1328	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature, 2014, 515, 577-581.	13.7	1,705
1329	Improving immunotherapy of hepatocellular carcinoma (<scp>HCC</scp>) using dendritic cells (<scp>DC</scp>) engineered to express <scp>IL</scp>â€12 in vivo. Liver International, 2014, 34, 447-461.	1.9	26
1330	A mammary adenocarcinoma murine model suitable for the study of cancer immunoediting. Journal of Biomedical Science, 2014, 21, 52.	2.6	3
1331	MICA/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer. BMC Cancer, 2014, 14, 957.	1.1	66
1332	Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-Î± in patients with metastatic melanoma: a randomised â€œproof-of-principleâ€•phase II study. Journal of Translational Medicine, 2014, 12, 209.	1.8	26
1333	Increase of IFN-Î³ and TNF-Î³ production in CD107a + NK-92 cells co-cultured with cervical cancer cell lines pre-treated with the HO-1 inhibitor. Cancer Cell International, 2014, 14, 100.	1.8	27
1334	Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response. Journal of Translational Medicine, 2014, 12, 262.	1.8	21
1335	Local tumour ablative therapies: Opportunities for maximising immune engagement and activation. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 510-523.	3.3	21
1336	Surveillance of Nonmelanoma Skin Cancer Incidence Rates in Kidney Transplant Recipients in Ireland. Transplantation, 2014, 98, 646-652.	0.5	13

#	Article	IF	Citations
1337	The heat shock protein-CD91 pathway mediates tumor immunosurveillance. OncoImmunology, 2014, 3, e28222.	2.1	18
1338	Intraperitoneal Oxidative Stress in Rabbits with Papillomavirus-Associated Head and Neck Cancer Induces Tumoricidal Immune Response That Is Adoptively Transferable. Clinical Cancer Research, 2014, 20, 4289-4301.	3.2	19
1339	The Immune Microenvironment: A Major Player in Human Cancers. International Archives of Allergy and Immunology, 2014, 164, 13-26.	0.9	63
1340	Influenza Virus Infection Elicits Protective Antibodies and T Cells Specific for Host Cell Antigens Also Expressed as Tumor-Associated Antigens: A New View of Cancer Immunosurveillance. Cancer Immunology Research, 2014, 2, 263-273.	1.6	34
1341	Lentivector Vaccines. , 2014, , 345-361.		1
1342	Could immunosignatures technology enable the development of a preventative cancer vaccine?. Expert Review of Vaccines, 2014, 13, 577-579.	2.0	1
1343	Nod-Like Receptors: Key Molecular Switches in the Conundrum of Cancer. Frontiers in Immunology, 2014, 5, 185.	2.2	19
1344	Intraperitoneal oxidative stress as an oncolytic immunomodulator?. OncoImmunology, 2014, 3, e955347.	2.1	1
1345	Evolutionary Dynamics of Cancer Cell Populations under Immune Selection Pressure and Optimal Control of Chemotherapy. Mathematical Modelling of Natural Phenomena, 2014, 9, 88-104.	0.9	5
1346	The Role of Inflammation in Lung Cancer. Advances in Experimental Medicine and Biology, 2014, 816, 1-23.	0.8	192
1347	Filaggrin. , 2014, , .		3
1348	Biological and clinical significance of cancer stem cell plasticity. Clinical and Translational Medicine, 2014, 3, 32.	1.7	40
1349	Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors. , 2014, , 143-205.		2
1350	Immune Response in Thyroid Cancer: Widening the Boundaries. Scientifica, 2014, 2014, 1-20.	0.6	22
1351	Sarcoma Immunotherapy: Past Approaches and Future Directions. Sarcoma, 2014, 2014, 1-13.	0.7	43
1352	A Role for Naturally Occurring Alleles of Endoplasmic Reticulum Aminopeptidases in Tumor Immunity and Cancer Pre-Disposition. Frontiers in Oncology, 2014, 4, 363.	1.3	56
1353	Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. , 2014, 2, 7.		105
1354	Quantitative reconstruction of leukocyte subsets using DNA methylation. Genome Biology, 2014, 15, R50.	13.9	124

#	Article	IF	Citations
1355	Immunotherapy of hepatocellular carcinoma. Hepatic Oncology, 2014, 1, 433-446.	4.2	5
1356	Natural killer cells as effectors of selection and differentiation of stem cells: Role in resolution of inflammation. Journal of Immunotoxicology, 2014, 11, 297-307.	0.9	25
1357	The interplay between HPV and host immunity in head and neck squamous cell carcinoma. International Journal of Cancer, 2014, 134, 2755-2763.	2.3	101
1358	The Yin and Yang of Toll-like receptors in cancer. Oncogene, 2014, 33, 3485-3495.	2.6	266
1359	Ion channels and anti-cancer immunity. Philosophical Transactions of the Royal Society B: Biological Sciences, 2014, 369, 20130106.	1.8	50
1360	Engineering T cells for cancer: our synthetic future. Immunological Reviews, 2014, 257, 7-13.	2.8	43
1361	Viral warfare! Front-line defence and arming theÂimmune system against cancer using oncolytic vaccinia and other viruses. Journal of the Royal College of Surgeons of Edinburgh, 2014, 12, 210-220.	0.8	7
1362	Opportunities and challenges in development of phosphoantigens as Vî³9Vî´2 T cell agonists. Biochemical Pharmacology, 2014, 89, 301-312.	2.0	26
1363	Concerted down-regulation of immune-system related genes predicts metastasis in colorectal carcinoma. BMC Cancer, 2014, 14, 64.	1.1	20
1364	Mechanisms of tumor escape from immune system: Role of mesenchymal stromal cells. Immunology Letters, 2014, 159, 55-72.	1.1	120
1366	Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. Nature Genetics, 2014, 46, 624-628.	9.4	320
1367	Immune selection of tumor cells in TCR Î²-chain transgenic mice. Journal of Immunotoxicology, 2014, 11, 393-399.	0.9	7
1368	Systems vaccinology for cancer vaccine development. Expert Review of Vaccines, 2014, 13, 711-719.	2.0	2
1369	A killer choice for cancer immunotherapy. Immunologic Research, 2014, 58, 300-306.	1.3	19
1370	Immunomodulation and Immune Reconstitution in Chronic Lymphocytic Leukemia. Seminars in Hematology, 2014, 51, 228-234.	1.8	43
1371	Antitumor effects of sulfated polysaccharides produced from marine algae. Biology Bulletin Reviews, 2014, 4, 122-132.	0.3	9
1372	DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival. International Journal of Cancer, 2014, 135, 598-610.	2.3	66
1373	IL-22+CD4+ T Cells Promote Colorectal Cancer Stemness via STAT3 Transcription Factor Activation and Induction of the Methyltransferase DOT1L. Immunity, 2014, 40, 772-784.	6.6	309

#	Article	IF	Citations
1374	Dendritic cell-based vaccines: clinical applications in breast cancer. Immunotherapy, 2014, 6, 349-360.	1.0	38
1375	Interaction of Immune and Cancer Cells. , 2014, , .		0
1376	The Molecular Basis for the Pharmacokinetics and Pharmacodynamics of Curcumin and Its Metabolites in Relation to Cancer. Pharmacological Reviews, 2014, 66, 222-307.	7.1	418
1377	Interplay between DNA repair and inflammation, and the link to cancer. Critical Reviews in Biochemistry and Molecular Biology, 2014, 49, 116-139.	2.3	128
1378	All-trans retinoic acid (ATRA) induces miR-23a expression, decreases CTSC expression and granzyme B activity leading to impaired NK cell cytotoxicity. International Journal of Biochemistry and Cell Biology, 2014, 49, 42-52.	1.2	37
1379	Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nature Reviews Cancer, 2014, 14, 135-146.	12.8	925
1380	The roles of extracellular vesicles in cancer biology: Toward the development of novel cancer biomarkers. Proteomics, 2014, 14, 412-425.	1.3	134
1381	Tumor-induced perturbations of cytokines and immune cell networks. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1845, 182-201.	3.3	235
1382	Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion. Nature Chemical Biology, 2014, 10, 69-75.	3.9	390
1383	Recognition of Tumors by the Innate Immune System and Natural Killer Cells. Advances in Immunology, 2014, 122, 91-128.	1.1	296
1384	Trial Watch. OncoImmunology, 2014, 3, e27878.	2.1	134
1385	Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients. British Journal of Cancer, 2014, 110, 459-468.	2.9	138
1386	Epidemiology of de novo malignancies after solid-organ transplantation: Immunosuppression, infection and other risk factors. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2014, 28, 1251-1265.	1.4	42
1387	Bioinformatics for cancer immunotherapy target discovery. Cancer Immunology, Immunotherapy, 2014, 63, 1235-1249.	2.0	25
1388	Indoleamine 2,3â€dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment. Cancer Science, 2014, 105, 966-973.	1.7	56
1389	Tumour-infiltrating CD4+ and CD8+ lymphocytes as predictors of clinical outcome in glioma. British Journal of Cancer, 2014, 110, 2560-2568.	2.9	279
1390	Human leukocyte antigen (HLA)-G and cervical cancer immunoediting: A candidate molecule for therapeutic intervention and prognostic biomarker?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 576-589.	3.3	25
1391	Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies. Expert Opinion on Biological Therapy, 2014, 14, 1769-1781.	1.4	4

#	Article	IF	Citations
1392	Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5998-6003.	3.3	64
1393	Sweeping lymph node micrometastases off their feet: an engineered model to evaluate natural killer cell mediated therapeutic intervention of circulating tumor cells that disseminate to the lymph nodes. Lab on A Chip, 2014, 14, 118-127.	3.1	19
1394	The Path to Reactivation of Antitumor Immunity and Checkpoint Immunotherapy. Cancer Immunology Research, 2014, 2, 926-936.	1.6	23
1395	Feasibility Analysis of p62 (SQSTM1)â€"Encoding DNA Vaccine as a Novel Cancer Immunotherapy. International Reviews of Immunology, 2014, 33, 375-382.	1.5	30
1396	Advancements of Mass Spectrometry in Biomedical Research. Advances in Experimental Medicine and Biology, 2014, , .	0.8	6
1397	Targeted liposomal drug delivery systems for the treatment of B cell malignancies. Journal of Drug Targeting, 2014, 22, 372-386.	2.1	12
1398	Acquired and intrinsic resistance in cancer immunotherapy. Molecular Oncology, 2014, 8, 1132-1139.	2.1	153
1399	Non-classical MHC-I human leukocyte antigen (HLA-G) in hepatotropic viral infections and in hepatocellular carcinoma. Human Immunology, 2014, 75, 1225-1231.	1.2	22
1400	Translational Medicine in Action: Anti-CD20 Therapy in Lymphoma. Journal of Immunology, 2014, 193, 1519-1524.	0.4	46
1401	CÃ¡ncer de riÃ±Ã³n en el paciente dializado y en el paciente trasplantado. EMC - UrologÃa, 2014, 46, 1-10.	0.0	0
1402	Suicide plus immune gene therapy prevents post-surgical local relapse and increases overall survival in an aggressive mouse melanoma setting. International Immunopharmacology, 2014, 22, 167-175.	1.7	8
1403	Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8+ T cell response: A comparative study. Journal of Controlled Release, 2014, 192, 209-218.	4.8	187
1404	NK Cells Are the Crucial Antitumor Mediators When STAT3-Mediated Immunosuppression Is Blocked in Hepatocellular Carcinoma. Journal of Immunology, 2014, 193, 2016-2023.	0.4	59
1405	Cancer Secretomes and Their Place in Supplementing Other Hallmarks of Cancer. Advances in Experimental Medicine and Biology, 2014, 806, 409-442.	0.8	38
1406	The bifacial role of helminths in cancer: Involvement of immune and non-immune mechanisms. Critical Reviews in Clinical Laboratory Sciences, 2014, 51, 138-148.	2.7	12
1407	The Cancer Stem Cell Hypothesis: A Guide to Potential Molecular Targets. Cancer Investigation, 2014, 32, 470-495.	0.6	77
1408	Isolation, Characterization, and Biological Activities of Polysaccharides from Medicinal Plants and Mushrooms. Studies in Natural Products Chemistry, 2014, 42, 117-151.	0.8	15
1409	Modeling putative therapeutic implications of exosome exchange between tumor and immune cells. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4165-E4174.	3.3	39

#	Article	IF	Citations
1410	The role of the inflammatory microenvironment in thyroid carcinogenesis. Endocrine-Related Cancer, 2014, 21, R85-R103.	1.6	83
1411	Pathways of Tumor development and progression in Drug-induced Nonmelanoma Skin Cancer: a New Hope or the Next Great Confusion?. Wiener Medizinische Wochenschrift, 2014, 164, 286-295.	0.5	0
1412	Association of interleukin-23 receptor gene polymorphisms with risk of bladder cancer in Chinese. Familial Cancer, 2014, 13, 619-623.	0.9	9
1413	Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions. Clinical Cancer Research, 2014, 20, 3401-3410.	3.2	364
1414	Primary testicular lymphoma. Blood, 2014, 123, 486-493.	0.6	166
1415	A novel multi-epitope peptide vaccine against cancer: An in silico approach. Journal of Theoretical Biology, 2014, 349, 121-134.	0.8	187
1416	Immunoscoring breast cancer: TILs remember what they target. Annals of Oncology, 2014, 25, 1455-1456.	0.6	15
1417	Tumor antigen discovery through translation of the cancer genome. Immunologic Research, 2014, 58, 292-299.	1.3	13
1418	CD 152 gene polymorphisms and risk of osteosarcoma in Chinese population. Tumor Biology, 2014, 35, 6809-6814.	0.8	5
1419	MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Molecular Cancer, 2014, 13, 129.	7.9	372
1420	USP18 is crucial for IFN-Î³-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity. Molecular Cancer, 2014, 13, 132.	7.9	31
1421	Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. British Journal of Cancer, 2014, 110, 1595-1605.	2.9	261
1423	The Natural Product Phyllanthusmin C Enhances IFN-Î³ Production by Human NK Cells through Upregulation of TLR-Mediated NF-ÎºB Signaling. Journal of Immunology, 2014, 193, 2994-3002.	0.4	46
1424	Indoleamine-2,3-dioxygenase elevated in tumor-initiating cells is suppressed by mitocans. Free Radical Biology and Medicine, 2014, 67, 41-50.	1.3	27
1425	Absolute lymphocyte count: A potential prognostic factor for Merkel cell carcinoma. Journal of the American Academy of Dermatology, 2014, 70, 1028-1035.	0.6	20
1426	A straightforward protocol for the preparation of high performance microarray displaying synthetic MUC1 glycopeptides. Biochimica Et Biophysica Acta - General Subjects, 2014, 1840, 1105-1116.	1.1	30
1427	Ly49 Family Receptors Are Required for Cancer Immunosurveillance Mediated by Natural Killer Cells. Cancer Research, 2014, 74, 3684-3694.	0.4	31
1428	Paraneoplasia, cancer development and immunity: what are the connections?. Nature Reviews Cancer, 2014, 14, 447-448.	12.8	2

#	Article	IF	Citations
1429	A dynamical model of tumour immunotherapy. Mathematical Biosciences, 2014, 253, 50-62.	0.9	40
1430	Induction of ATM/ATR pathway combined with VÎ³2VÎ´2 T cells enhances cytotoxicity of ovarian cancer cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1071-1079.	1.8	8
1431	Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking. Frontiers in Chemistry, 2014, 2, 105.	1.8	147
1432	Viruses, Autoimmunity, and Cancer. , 2014, , 509-520.		0
1433	The Immunoendocrine Network in Breast Cancer. Advances in Neuroimmune Biology, 2014, 5, 109-131.	0.7	5
1434	PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy. Cancer Control, 2014, 21, 231-237.	0.7	127
1436	Cluster of differentiation 45 activation is crucial in interleukin-10-dependent tumor-associated dendritic cell differentiation. Oncology Letters, 2014, 8, 620-626.	0.8	3
1438	Correlation of Tumor-Infiltrative Lymphocyte Subtypes Alteration with Neoangiogenesis before and after Neoadjuvant Chemotherapy Treatment in Breast Cancer Patients. International Journal of Biological Markers, 2014, 29, 193-203.	0.7	6
1439	Targeting immune checkpoints in melanoma: an update. Melanoma Management, 2015, 2, 339-352.	0.1	2
1440	Tumour, Oxidative Stress and Host T Cell Response: Cementing the Dominance. Scandinavian Journal of Immunology, 2015, 82, 477-488.	1.3	35
1441	Human leukocyte antigen <scp>(HLA)â€G</scp> gene polymorphism in patients with nonâ€small cell lung cancer. Thoracic Cancer, 2015, 6, 613-619.	0.8	9
1442	Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Science, 2015, 106, 945-950.	1.7	78
1443	Opposite Effects of M1 and M2 Macrophage Subtypes on Lung Cancer Progression. Scientific Reports, 2015, 5, 14273.	1.6	278
1446	Principles of Immunotherapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 670-672.	2.3	8
1447	Approaches to Passive and Active Vaccination against Neuroblastoma. Pediatric and Adolescent Medicine, 0, , 150-162.	0.4	0
1448	Endogenous Antibodies for Tumor Detection. Scientific Reports, 2014, 4, 5088.	1.6	7
1449	Regulation rewiring analysis reveals mutual regulation between STAT1 and miR-155-5p in tumor immunosurveillance in seven major cancers. Scientific Reports, 2015, 5, 12063.	1.6	19
1450	Identification of Anti-tumor Cells Carrying Natural Killer (NK) Cell Antigens in Patients With Hematological Cancers. EBioMedicine, 2015, 2, 1364-1376.	2.7	22

#	Article	IF	Citations
1451	The role of combined radiation and immunotherapy in breast cancer treatment. Journal of Radiation Oncology, 2015, 4, 347-354.	0.7	5
1452	Combining radiotherapy and immunotherapy for prostate cancer: two decades of research from preclinical to clinical trials. Journal of Radiation Oncology, 2015, 4, 365-375.	0.7	1
1453	Principles of immunology and its nuances in the central nervous system: Fig. 1.. Neuro-Oncology, 2015, 17, vii3-vii8.	0.6	28
1454	Quantitative evaluation of the immunodeficiency of a mouse strain by tumor engraftments. Journal of Hematology and Oncology, 2015, 8, 59.	6.9	43
1455	A proliferation saturation index to predict radiation response and personalize radiotherapy fractionation. Radiation Oncology, 2015, 10, 159.	1.2	93
1456	<scp>HCV</scp> genotype 3 and squamous cell carcinoma antigen (<scp>SCCA</scp>)â€IgM are independently associated with histological features of <scp>NASH</scp> in <scp>HCV</scp>â€infected patients. Journal of Viral Hepatitis, 2015, 22, 800-808.	1.0	12
1457	Time-Frequency Analysis of Peptide Microarray Data: Application to Brain Cancer Immunosignatures. Cancer Informatics, 2015, 14s2, CIN.S17285.	0.9	11
1458	Tumorâ€infiltrating CD8⁺ T lymphocytes associated with clinical outcome in anal squamous cell carcinoma. Journal of Surgical Oncology, 2015, 112, 421-426.	0.8	41
1459	The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 259-265.	0.6	171
1460	Adoptive transfer of regulatory T cells promotes intestinal tumorigenesis and is associated with decreased NK cells and ILâ€22 binding protein. Molecular Carcinogenesis, 2015, 54, 986-998.	1.3	15
1461	Ly49 receptors: evolution, genetic diversity, and impact on immunity. Immunological Reviews, 2015, 267, 137-147.	2.8	54
1462	Prognostic Significance of Tumor-infiltrating CD8+ or CD3+ T Lymphocytes and Interleukin-2 Expression in Radically Resected Non-small Cell Lung Cancer. Chinese Medical Journal, 2015, 128, 105-110.	0.9	39
1463	Targeting PD-1/PD-L1 in lung cancer: current perspectives. Lung Cancer: Targets and Therapy, 2015, 6, 55.	1.3	10
1464	Elucidating drivers of oral epithelial dysplasia formation and malignant transformation to cancer using RNAseq. Oncotarget, 2015, 6, 40186-40201.	0.8	37
1465	Tumor neoantigens: building a framework for personalized cancer immunotherapy. Journal of Clinical Investigation, 2015, 125, 3413-3421.	3.9	502
1466	Treating cancer stem cells and cancer metastasis using glucose-coated gold nanoparticles. International Journal of Nanomedicine, 2015, 10, 2065.	3.3	45
1467	Immunogenic cell death. International Journal of Developmental Biology, 2015, 59, 131-140.	0.3	181
1468	Immunotherapy and Radiation â€“ A New Combined Treatment Approach for Bladder Cancer?. Bladder Cancer, 2015, 1, 15-27.	0.2	19

#	Article	IF	Citations
1469	Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. Cancers, 2015, 7, 2397-2414.	1.7	61
1470	Review on vaccine design strategies against cancer. Journal of Cancer Research and Experimental Oncology, 2015, 7, 1-12.	0.1	0
1471	Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant State. Vaccines, 2015, 3, 597-619.	2.1	46
1472	Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy. Vaccines, 2015, 3, 662-685.	2.1	225
1473	K-Ras, Intestinal Homeostasis and Colon Cancer. Current Clinical Pharmacology, 2015, 10, 73-81.	0.2	33
1474	ANTI-TUMOR IMMUNE RESPONSES INDUCED BY RADIOTHERAPY: A REVIEW. Fukushima Journal of Medical Sciences, 2015, 61, 13-22.	0.1	20
1475	Systemic Monocytic-MDSCs Are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer Patients. PLoS ONE, 2015, 10, e0127028.	1.1	116
1476	Chronic Inflammation-Related HPV: A Driving Force Speeds Oropharyngeal Carcinogenesis. PLoS ONE, 2015, 10, e0133681.	1.1	14
1477	Immune Adjuvant Activity of Pre-Resectional Radiofrequency Ablation Protects against Local and Systemic Recurrence in Aggressive Murine Colorectal Cancer. PLoS ONE, 2015, 10, e0143370.	1.1	42
1478	Therapeutic strategy for cancer immunotherapy in head and neck cancer. Advances in Cellular and Molecular Otolaryngology, 2015, 3, 27690.	0.4	5
1479	Prolonged overall survival in gastric cancer patients after adoptive immunotherapy. World Journal of Gastroenterology, 2015, 21, 2777.	1.4	27
1480	Effect and Molecular Mechanisms of Traditional Chinese Medicine on Regulating Tumor Immunosuppressive Microenvironment. BioMed Research International, 2015, 2015, 1-12.	0.9	59
1481	MushroomÎ²-Glucan May Immunomodulate the Tumor-Associated Macrophages in the Lewis Lung Carcinoma. BioMed Research International, 2015, 2015, 1-15.	0.9	15
1482	Interferon-Î³-Mediated Natural Killer Cell Activation by an AqueousPanax ginsengExtract. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-11.	0.5	13
1483	Deficiency of AMPK in CD8+ T cells suppresses their anti-tumor function by inducing protein phosphatase-mediated cell death. Oncotarget, 2015, 6, 7944-7958.	0.8	38
1484	New Insights in Cutaneous Melanoma Immune-Therapy â€" Tackling Immune-Suppression and Specific Anti-Tumoral Response. , 0, , .		2
1485	Neutrophilâ€"Lymphocyte and Plateletâ€"Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Nonâ€"Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 280-285.	0.5	154
1486	Consensus nomenclature for CD8⁺T cell phenotypes in cancer. OncoImmunology, 2015, 4, e998538.	2.1	119

#	Article	IF	Citations
1487	X-shaped DNA potentiates therapeutic efficacy in colitis-associated colon cancer through dual activation of TLR9 and inflammasomes. Molecular Cancer, 2015, 14, 104.	7.9	18
1488	MHC-I modulation due to changes in tumor cell metabolism regulates tumor sensitivity to CTL and NK cells. OncoImmunology, 2015, 4, e985924.	2.1	48
1489	Methods to Study Tumor Surveillance Using Tumor Cell Transplantation into Genetically Engineered Mice. Methods in Molecular Biology, 2015, 1267, 439-456.	0.4	0
1490	Myeloid-Derived Suppressor Cells. Advances in Cancer Research, 2015, 128, 95-139.	1.9	419
1491	Modulation of inflammation by low and high doses of ionizing radiation: Implications for benign and malign diseases. Cancer Letters, 2015, 368, 230-237.	3.2	108
1492	Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS-126 in models of ovarian cancer. Archives of Gynecology and Obstetrics, 2015, 291, 131-141.	0.8	7
1493	Sarcostemma viminale activates macrophages to a pro-inflammatory phenotype. Comparative Clinical Pathology, 2015, 24, 817-826.	0.3	3
1494	Cancer Immunoediting: Immunosurveillance, Immune Equilibrium, and Immune Escape. , 2015, , 195-208.		2
1496	Suggested roles for microRNA in tumors. Biomolecular Concepts, 2015, 6, 149-155.	1.0	9
1497	PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer, 2015, 89, 181-188.	0.9	253
1498	Immunotherapy for malignant glioma. , 2015, 6, 68.		36
1499	Circulating microRNAs in Disease Diagnostics and their Potential Biological Relevance. Exs, 2015, , .	1.4	9
1500	Cancer risk in relatives of patients with a primary disorder of lymphocyte cytotoxicity: a retrospective cohort study. Lancet Haematology,the, 2015, 2, e536-e542.	2.2	32
1501	Checkpoint inhibitors in bladder and renal cancers: results and perspectives. Immunotherapy, 2015, 7, 1259-1271.	1.0	22
1503	Are Circulating microRNAs Involved in Tumor Surveillance?. Exs, 2015, 106, 269-280.	1.4	2
1504	Targeting the Immune System for Cancer Therapy: Lessons for Perioperative Management?. Current Anesthesiology Reports, 2015, 5, 257-267.	0.9	0
1505	Targeting the Immune System in Breast Cancer: Hype or Hope?: TILs and Newer Immune-Based Therapies Being Evaluated for HER2+ and TNBC. Current Breast Cancer Reports, 2015, 7, 203-209.	0.5	2
1506	Intravital imaging of multicolor-labeled tumor immune microenvironment through skin-fold window chamber. , 2015, , .		0

#	Article	IF	Citations
1507	Generation of CD8⁺T cells expressing two additional T-cell receptors (TETARs) for personalised melanoma therapy. Cancer Biology and Therapy, 2015, 16, 1323-1331.	1.5	20
1508	Master Regulators of Infiltrate Recruitment in Autoimmune Disease Identified through Network-Based Molecular Deconvolution. Cell Systems, 2015, 1, 326-337.	2.9	20
1509	Curcumin and tumor immune-editing: resurrecting the immune system. Cell Division, 2015, 10, 6.	1.1	105
1510	Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. Current Breast Cancer Reports, 2015, 7, 232-241.	0.5	0
1511	FINITE DURATION TREATMENT OF CANCER BY USING VACCINE THERAPY AND OPTIMAL CHEMOTHERAPY: STATE-DEPENDENT RICCATI EQUATION CONTROL AND EXTENDED KALMAN FILTER. Journal of Biological Systems, 2015, 23, 1-29.	0.5	21
1512	Lysosomal signaling molecules regulate longevity in Caenorhabditis elegans. Science, 2015, 347, 83-86.	6.0	211
1513	T lymphocyte-derived TNF and IFN-Î³ repress HFE expression in cancer cells. Molecular Immunology, 2015, 65, 259-266.	1.0	5
1514	Metronomic chemotherapy from rationale to clinical studies: A dream or reality?. Critical Reviews in Oncology/Hematology, 2015, 95, 46-61.	2.0	64
1515	Trial Watch: Peptide-based anticancer vaccines. OncoImmunology, 2015, 4, e974411.	2.1	97
1516	Decitabine: a promising epi-immunotherapeutic agent in solid tumors. Expert Review of Clinical Immunology, 2015, 11, 363-375.	1.3	31
1519	Clinical benefit in recurrent glioblastoma from adjuvant Novo TTF â€100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation. Cancer Medicine, 2015, 4, 383-391.	1.3	27
1520	Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk. Current Medical Research and Opinion, 2015, 31, 557-574.	0.9	75
1521	Dormant Cells: The Original Cause of Tumor Recurrence and Metastasis. Cell Biochemistry and Biophysics, 2015, 72, 317-320.	0.9	19
1522	Exploiting the critical perioperative period to improve long-term cancer outcomes. Nature Reviews Clinical Oncology, 2015, 12, 213-226.	12.5	352
1523	Th9 Cells: A Novel CD4 T-cell Subset in the Immune War against Cancer. Cancer Research, 2015, 75, 475-479.	0.4	56
1524	Multiple checkpoints on the long road towards cancer immunotherapy. Immunology and Cell Biology, 2015, 93, 323-325.	1.0	9
1525	Function of HLA-G in cancer immunoediting and its clinical benefits. Journal Africain Du Cancer, 2015, 7, 132-139.	0.1	3
1526	The RB tumor suppressor at the intersection of proliferation and immunity: relevance to disease immune evasion and immunotherapy. Cell Cycle, 2015, 14, 3812-3819.	1.3	42

#	Article	IF	Citations
1527	Translational Implications of Tumor Heterogeneity. Clinical Cancer Research, 2015, 21, 1258-1266.	3.2	424
1528	NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy. Journal of Translational Medicine, 2015, 13, 32.	1.8	81
1529	Utilizing population variation, vaccination, and systems biology to study human immunology. Trends in Immunology, 2015, 36, 479-493.	2.9	77
1530	Hydroxytyrosol-Derived Compounds: A Basis for the Creation of New Pharmacological Agents for Cancer Prevention and Therapy. Journal of Medicinal Chemistry, 2015, 58, 9089-9107.	2.9	76
1532	The DNA damage response and immune signaling alliance: Is it good or bad? Nature decides when and where. , 2015, 154, 36-56.		128
1533	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. OncoImmunology, 2015, 4, e1008814.	2.1	102
1534	Challenges and future perspectives of T cell immunotherapy in cancer. Immunology Letters, 2015, 166, 117-133.	1.1	41
1535	Unknown primary of the head and neck: A long-term follow-up. Journal of Cranio-Maxillo-Facial Surgery, 2015, 43, 574-579.	0.7	11
1536	The Role of Merkel Cell Polyomavirus and Other Human Polyomaviruses in Emerging Hallmarks of Cancer. Viruses, 2015, 7, 1871-1901.	1.5	41
1537	Changing Treatment Paradigms in Metastatic Breast Cancer. JAMA Oncology, 2015, 1, 528.	3.4	88
1538	The immunocheckpoints in modern oncology: the next 15 years. Expert Opinion on Biological Therapy, 2015, 15, 917-921.	1.4	24
1539	Concepts of immunotherapy for glioma. Journal of Neuro-Oncology, 2015, 123, 323-330.	1.4	12
1540	Cancer immunoediting: A process driven by metabolic competition as a predatorâ€“preyâ€“shared resource type model. Journal of Theoretical Biology, 2015, 380, 463-472.	0.8	32
1541	A mathematical model of pre-diagnostic glioma growth. Journal of Theoretical Biology, 2015, 380, 299-308.	0.8	17
1542	The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist, 2015, 20, 812-822.	1.9	198
1543	Spatial and Functional Heterogeneities Shape Collective Behavior of Tumor-Immune Networks. PLoS Computational Biology, 2015, 11, e1004181.	1.5	35
1544	Fat, fibre and cancer risk in African Americans and rural Africans. Nature Communications, 2015, 6, 6342.	5.8	761
1545	Bone specific immunity and its impact on metastasis. BoneKEy Reports, 2015, 4, 665.	2.7	37

#	Article	IF	Citations
1546	Tumor border sharpness correlates with HLA-G expression in low-grade gliomas. Journal of Neuroimmunology, 2015, 282, 1-6.	1.1	24
1547	Immunotherapeutic Strategies for Colon Cancer: Monoclonal Antibody Therapy. Current Colorectal Cancer Reports, 2015, 11, 84-91.	1.0	1
1548	Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma. Clinical Sarcoma Research, 2015, 5, 4.	2.3	55
1549	Immunotherapeutic approaches to ovarian cancer treatment. , 2015, 3, 7.		63
1551	IFN-Î³ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. British Journal of Cancer, 2015, 112, 1501-1509.	2.9	533
1552	Immunotherapy for canine cancer â€“ Is it time to go back to the future?. Journal of Small Animal Practice, 2015, 56, 229-241.	0.5	8
1553	FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas. Journal of the National Cancer Institute, 2015, 107, .	3.0	80
1554	Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients. BMC Cancer, 2015, 15, 101.	1.1	93
1555	Immunotherapeutic Approaches to Sarcoma. Current Treatment Options in Oncology, 2015, 16, 26.	1.3	48
1556	Tumor cell secretion of soluble factor(s) for specific immunosuppression. Scientific Reports, 2015, 5, 8913.	1.6	55
1557	Gold Nanoparticle-Enabled Blood Test for Early Stage Cancer Detection and Risk Assessment. ACS Applied Materials & Interfaces, 2015, 7, 6819-6827.	4.0	125
1558	Strategies to Target Tumor Immunosuppression. , 2015, , 73-86.		0
1559	TGF-Î² Regulates Hepatocellular Carcinoma Progression by Inducing Treg Cell Polarization. Cellular Physiology and Biochemistry, 2015, 35, 1623-1632.	1.1	90
1560	Proinflammatory Proteins S100A8/S100A9 Activate NK Cells via Interaction with RAGE. Journal of Immunology, 2015, 194, 5539-5548.	0.4	97
1561	Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express Î±-gal epitopes, targets pancreatic cancer stem cells. International Journal of Oncology, 2015, 46, 78-90.	1.4	16
1562	Immunotherapeutic approaches for cancer therapy: An updated review. Artificial Cells, Nanomedicine and Biotechnology, 2015, 44, 1-11.	1.9	41
1563	Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Seminars in Cancer Biology, 2015, 35, S185-S198.	4.3	1,122
1564	Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients. International Journal of Cancer, 2015, 137, 1095-1106.	2.3	79

#	Article	IF	Citations
1565	HuR Suppresses Fas Expression and Correlates with Patient Outcome in Liver Cancer. Molecular Cancer Research, 2015, 13, 809-818.	1.5	40
1566	T cell engineering as therapy for cancer and HIV: our synthetic future. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140374.	1.8	23
1567	Therapeutic Impact of Immune Responses in Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 221-245.	0.1	0
1568	In vivopotential of recombinant granulysin against human tumors. OncoImmunology, 2015, 4, e1036213.	2.1	15
1569	Immunotherapeutic options on the horizon in breast cancer treatment. , 2015, 156, 90-101.		17
1570	Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Annals of Oncology, 2015, 26, 2375-2391.	0.6	1,136
1571	Impaired gp100-Specific CD8 + T-Cell Responses in the Presence of Myeloid-Derived Suppressor Cells in a Spontaneous Mouse Melanoma Model. Journal of Investigative Dermatology, 2015, 135, 2785-2793.	0.3	19
1572	In vivoprofiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma. OncoImmunology, 2015, 4, e988458.	2.1	12
1574	70-kDa heat shock protein coated magnetic nanocarriers as a nanovaccine for induction of anti-tumor immune response in experimental glioma. Journal of Controlled Release, 2015, 220, 329-340.	4.8	66
1575	Evolution of metastasis revealed by mutational landscapes of chemically induced skin cancers. Nature Medicine, 2015, 21, 1514-1520.	15.2	93
1576	Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Medicine, 2015, 13, 202.	2.3	177
1577	Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53. Molecular Cancer Research, 2015, 13, 493-501.	1.5	53
1578	Autoantibodies in breast cancer sera are not epiphenomena and may participate in carcinogenesis. BMC Cancer, 2015, 15, 407.	1.1	34
1579	Post-transplantation malignancies: here today, gone tomorrow?. Nature Reviews Clinical Oncology, 2015, 12, 705-717.	12.5	53
1580	Loss of PTEN causes SHP2 activation, making lung cancer cells unresponsive to IFN-Î³. Biochemical and Biophysical Research Communications, 2015, 466, 578-584.	1.0	19
1581	Immunological landscape and immunotherapy of hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 681-700.	8.2	478
1582	Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner. Cell Death and Disease, 2015, 6, e1761-e1761.	2.7	74
1583	Dissecting the signaling pathways that mediate cancer in PTEN and LKB1 double-knockout mice. Science Signaling, 2015, 8, pe1.	1.6	23

#	Article	IF	Citations
1584	Lung cancer: Biology and treatment options. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1856, 189-210.	3.3	526
1585	Are Cancer Outcomes Worse in the Presence of HIV Infection?. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1165-1166.	1.1	4
1586	Checkpoint modulation - A new way to direct the immune system against renal cell carcinoma. Human Vaccines and Immunotherapeutics, 2015, 11, 1201-1208.	1.4	11
1587	Are BiTEs the â€œmissing linkâ€•in cancer therapy?. OncoImmunology, 2015, 4, e1008339.	2.1	59
1588	Immunology and Immunotherapy of Head and Neck Cancer. Journal of Clinical Oncology, 2015, 33, 3293-3304.	0.8	566
1589	Emerging strategies for cancer immunoprevention. Oncogene, 2015, 34, 6029-6039.	2.6	39
1590	Safety and Antitumor Activity of Antiâ€“PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. Journal of Clinical Oncology, 2015, 33, 4015-4022.	0.8	924
1591	Trial watch: Naked and vectored DNA-based anticancer vaccines. OncoImmunology, 2015, 4, e1026531.	2.1	26
1592	Breast cancer and immunology: biomarker and therapeutic developments. Expert Review of Anticancer Therapy, 2015, 15, 1215-1222.	1.1	9
1594	Active Immunotherapy of Cancer. Immunological Investigations, 2015, 44, 817-836.	1.0	41
1595	The mathematics of cancer: integrating quantitative models. Nature Reviews Cancer, 2015, 15, 730-745.	12.8	539
1596	Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-ÎºB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. Cancer Research, 2015, 75, 5034-5045.	0.4	439
1597	Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells. Molecular Oncology, 2015, 9, 2054-2062.	2.1	85
1598	Different cellular responses of dexmedetomidine at infected site and peripheral blood of emdotoxemic BALB/c mice. Environmental Toxicology, 2015, 30, 1416-1422.	2.1	10
1599	Review: Cancerâ€Induced Autoimmunity in the Rheumatic Diseases. Arthritis and Rheumatology, 2015, 67, 317-326.	2.9	90
1600	Tumoral Expression of IL-33 Inhibits Tumor Growth and Modifies the Tumor Microenvironment through CD8+ T and NK Cells. Journal of Immunology, 2015, 194, 438-445.	0.4	185
1601	Smoking is associated with mosaic loss of chromosome Y. Science, 2015, 347, 81-83.	6.0	163
1602	Genomic Instability and Cancer Metastasis. Cancer Metastasis - Biology and Treatment, 2015, , .	0.1	1

#	Article	IF	Citations
1603	NKG2D signaling in cancer immunosurveillance. International Journal of Cancer, 2015, 136, 1741-1750.	2.3	109
1604	Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity. Scientific Reports, 2014, 4, 5128.	1.6	94
1605	Targeting WNT1-inducible signaling pathway protein 2 alters human breast cancer cell susceptibility to specific lysis through regulation of KLF-4 and miR-7 expression. Oncogene, 2015, 34, 2261-2271.	2.6	59
1606	The Nonâ€“Small Cell Lung Cancer Immune Contexture. A Major Determinant of Tumor Characteristics and Patient Outcome. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 377-390.	2.5	204
1607	Amino Acids and Immune Response: A Role for Cysteine, Glutamine, Phenylalanine, Tryptophan and Arginine in T-cell Function and Cancer?. Pathology and Oncology Research, 2015, 21, 9-17.	0.9	112
1608	Mast Cells Boost Myeloid-Derived Suppressor Cell Activity and Contribute to the Development of Tumor-Favoring Microenvironment. Cancer Immunology Research, 2015, 3, 85-95.	1.6	59
1609	Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer. Cancer Immunology, Immunotherapy, 2015, 64, 51-59.	2.0	66
1611	Leukocytes as carriers for targeted cancer drug delivery. Expert Opinion on Drug Delivery, 2015, 12, 375-392.	2.4	58
1612	The Warburg effect: molecular aspects and therapeutic possibilities. Molecular Biology Reports, 2015, 42, 825-834.	1.0	77
1613	Analysing Molecular Mechanism Related to Therapy- Resistance in In-vitro Models of Ovarian Cancer. , 2016, , .		0
1615	Polarisation of Macrophage and Immunotherapy in the Wound Healing. , 2016, , .		1
1616	A retrospective evaluation of associations between chronic obstructive pulmonary disease, smoking, and efficacy of chemotherapy and selected laboratory parameters in patients with advanced non-small cell lung cancer. Wspolczesna Onkologia, 2016, 5, 407-413.	0.7	2
1617	Connections between Warburgâ€™s and Szentgyorgyiâ€™s Approach about the Causes of Cancer. Journal of Neoplasm, 2016, 01, .	0.1	0
1618	Tumor sialylation impedes T cell mediated anti-tumor responses while promoting tumor associated-regulatory T cells. Oncotarget, 2016, 7, 8771-8782.	0.8	99
1619	Immune checkpoint inhibitors and prostate cancer: a new frontier?. Oncology Reviews, 2016, 10, 293.	0.8	47
1620	Chronic Inflammation in Skin Malignancies. Journal of Molecular Signaling, 2016, 11, 2.	0.5	41
1621	Current Immunotherapeutic Treatments in Colon Cancer. , 2016, , .		2
1622	Eosinophils in Cancer: Favourable or Unfavourable?. Current Medicinal Chemistry, 2016, 23, 650-666.	1.2	128

#	Article	IF	Citations
1623	Nucleolin Transports Hsp72 to the Plasma Membrane Preparatory to its Release into the Microenvironment. Journal of Cell Science & Therapy, 2016, 07, .	0.3	0
1624	The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 34-42.	1.8	85
1625	Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium. Journal of Immunology Research, 2016, 2016, 1-14.	0.9	36
1626	Bacteria in Cancer Therapy: Renaissance of an Old Concept. International Journal of Microbiology, 2016, 2016, 1-14.	0.9	117
1627	Potential role of immunotherapy in advanced non-small-cell lung cancer. OncoTargets and Therapy, 2017, Volume 10, 21-30.	1.0	46
1628	The multifaceted role of autophagy in tumor evasion from immune surveillance. Oncotarget, 2016, 7, 17591-17607.	0.8	53
1629	Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment. Vaccines, 2016, 4, 41.	2.1	44
1630	Tumor Microenvironment Metabolism: A New Checkpoint for Anti-Tumor Immunity. Vaccines, 2016, 4, 46.	2.1	87
1631	Immunological Landscape and Clinical Management of Rectal Cancer. Frontiers in Immunology, 2016, 7, 61.	2.2	14
1632	Coupling of HIV-1 Antigen to the Selective Autophagy Receptor SQSTM1/p62 Promotes T-Cell-Mediated Immunity. Frontiers in Immunology, 2016, 7, 167.	2.2	16
1633	Focus on Nivolumab in NSCLC. Frontiers in Medicine, 2016, 3, 67.	1.2	7
1634	Cancer Immunosurveillance: Immunoediting. , 2016, , 396-405.		3
1635	Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?. Antibodies, 2016, 5, 1.	1.2	34
1636	A Bitter Sweet Symphony: Immune Responses to Altered O-glycan Epitopes in Cancer. Biomolecules, 2016, 6, 26.	1.8	42
1637	Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma. Cancers, 2016, 8, 87.	1.7	30
1638	Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type. International Journal of Molecular Sciences, 2016, 17, 1433.	1.8	104
1640	Mechanisms of Immune Escape in Cancer. Journal of the Nihon University Medical Association, 2016, 75, 152-155.	0.0	0
1641	Development and Preclinical Application of an Immunocompetent Transplant Model of Basal Breast Cancer with Lung, Liver and Brain Metastases. PLoS ONE, 2016, 11, e0155262.	1.1	13

#	Article	IF	Citations
1642	The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs. Journal of Cancer, 2016, 7, 484-489.	1.2	106
1643	Circulating EBV DNA, Globulin and Nodal Size Predict Distant Metastasis after Intensity-Modulated Radiotherapy in Stage II Nasopharyngeal Carcinoma. Journal of Cancer, 2016, 7, 664-670.	1.2	27
1644	The Walker 256 Breast Cancer Cell- Induced Bone Pain Model in Rats. Frontiers in Pharmacology, 2016, 7, 286.	1.6	38
1645	The Promise of Genomics and the Development of Targeted Therapies for Cutaneous Squamous Cell Carcinoma. Acta Dermato-Venereologica, 2016, 96, 3-16.	0.6	46
1646	Immunotherapy for gliomas. , 0, , 91-120.		0
1647	Current and emerging therapies in unresectable and recurrent gastric cancer. World Journal of Gastroenterology, 2016, 22, 4812.	1.4	45
1648	Combining a chimeric antigen receptor and a conventional Tâ€cell receptor to generate T cells expressing two additional receptors (<scp>TETAR</scp>s) for a multiâ€hit immunotherapy of melanoma. Experimental Dermatology, 2016, 25, 872-879.	1.4	27
1649	Targeting microRNAs as key modulators of tumor immune response. Journal of Experimental and Clinical Cancer Research, 2016, 35, 103.	3.5	160
1650	Analysis of a basic model of immune response with delay: Existence and stability of equilibria. , 2016, , .		0
1651	Cancer Vaccines. Advances in Anatomic Pathology, 2016, 23, 180-191.	2.4	22
1652	Protein Expression Analysis of Melanocyte Differentiation Antigen TRP-2. American Journal of Dermatopathology, 2016, 38, 201-207.	0.3	8
1653	Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants. Molecular Therapy, 2016, 24, 1675-1685.	3.7	29
1654	Panâ€cancer analysis of copy number changes in programmed deathâ€ligand 1 (PDâ€L1, CD274) â€“ associations with gene expression, mutational load, and survival. Genes Chromosomes and Cancer, 2016, 55, 626-639.	1.5	80
1655	PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker. SpringerPlus, 2016, 5, 805.	1.2	61
1656	Inflammatory immune infiltration in human tumors: Role in pathogenesis and prognostic and diagnostic value. Biochemistry (Moscow), 2016, 81, 1261-1273.	0.7	10
1657	Small-sized, stable lipid nanoparticle for the efficient delivery of siRNA to human immune cell lines. Scientific Reports, 2016, 6, 37849.	1.6	60
1658	Effects of active bufadienolide compounds on human cancer cells and CD4+CD25+Foxp3+ regulatory T cells in mitogen-activated human peripheral blood mononuclear cells. Oncology Reports, 2016, 36, 1377-1384.	1.2	27
1659	Effect of an immunomodulatory regimen for cancer prevention: A case report. Molecular and Clinical Oncology, 2016, 5, 540-544.	0.4	0

#	Article	IF	Citations
1660	Neurologic complications of immune checkpoint inhibitors. Current Opinion in Neurology, 2016, 29, 806-812.	1.8	179
1661	Role of immune cells in pancreatic cancer from bench to clinical application. Medicine (United States), 2016, 95, e5541.	0.4	118
1662	Milky spots: omental functional units and hotbeds for peritoneal cancer metastasis. Tumor Biology, 2016, 37, 5715-5726.	0.8	62
1664	Comparison of tumorâ€infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. Cancer Science, 2016, 107, 1730-1735.	1.7	125
1665	Profiling networks of distinct immune-cells in tumors. BMC Bioinformatics, 2016, 17, 263.	1.2	26
1666	Miming the cancer-immune system competition by kinetic Monte Carlo simulations. Journal of Chemical Physics, 2016, 145, 154108.	1.2	8
1667	Can Targeting Stroma Pave the Way to Enhanced Antitumor Immunity and Immunotherapy of Solid Tumors?. Cancer Immunology Research, 2016, 4, 269-278.	1.6	83
1669	Immunobiology and immunosurveillance in patients with intraductal papillary mucinous neoplasms (IPMNs), premalignant precursors of pancreatic adenocarcinomas. Cancer Immunology, Immunotherapy, 2016, 65, 771-778.	2.0	32
1670	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. Drugs, 2016, 76, 925-945.	4.9	123
1671	Potent antigen-specific immune response induced by infusion of spleen cells coupled with succinimidyl-4-(N-maleimidomethyl cyclohexane)-1-carboxylate (SMCC) conjugated antigens. International Immunopharmacology, 2016, 31, 158-168.	1.7	6
1672	Alarmins and Antitumor Immunity. Clinical Therapeutics, 2016, 38, 1042-1053.	1.1	46
1673	The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?. Targeted Oncology, 2016, 11, 593-603.	1.7	14
1674	The Role of the Immune System and Immunoregulatory Mechanisms Relevant to Melanoma. , 2016, , 31-65.		0
1675	The Role of Surgical Pathology in Guiding Cancer Immunotherapy. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 313-341.	9.6	15
1676	Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy. Cancer Immunology Research, 2016, 4, 582-591.	1.6	35
1677	Worse Survival in Elderly Patients with Extremity Soft-Tissue Sarcoma. Annals of Surgical Oncology, 2016, 23, 2577-2585.	0.7	50
1678	Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells. Journal of Leukocyte Biology, 2016, 100, 625-635.	1.5	39
1679	Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling. Cancer Research, 2016, 76, 3156-3165.	0.4	224

#	Article	IF	Citations
1680	The role of neoantigens in response to immune checkpoint blockade. International Immunology, 2016, 28, 411-419.	1.8	148
1681	Immune checkpoint inhibition in ovarian cancer. International Immunology, 2016, 28, 339-348.	1.8	122
1682	Human leukocyte antigen-G overexpression predicts poor clinical outcomes in low-grade gliomas. Journal of Neuroimmunology, 2016, 294, 27-31.	1.1	11
1683	Feedback Regulation in a Cancer Stem Cell Model can Cause an Allee Effect. Bulletin of Mathematical Biology, 2016, 78, 754-785.	0.9	40
1684	Tumor Heterogeneity and Tumor Immunity: A Chicken-and-Egg Problem. Trends in Immunology, 2016, 37, 349-351.	2.9	15
1685	Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness. Cancer Immunology Research, 2016, 4, 600-610.	1.6	86
1686	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nature Reviews Clinical Oncology, 2016, 13, 473-486.	12.5	831
1687	Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients. OncoImmunology, 2016, 5, e1178421.	2.1	15
1688	The Immune Biology of Microsatellite-Unstable Cancer. Trends in Cancer, 2016, 2, 121-133.	3.8	193
1689	HESI/FDA workshop on immunomodulators and cancer risk assessment: Building blocks for a weight-of-evidence approach. Regulatory Toxicology and Pharmacology, 2016, 75, 72-80.	1.3	13
1690	T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells. International Immunology, 2016, 28, 349-353.	1.8	45
1691	Role of Tregs in Cancer Dormancy or Recurrence. Immunological Investigations, 2016, 45, 759-766.	1.0	17
1692	Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: Summary and perspective. Journal of Cellular Immunotherapy, 2016, 2, 59-68.	0.6	46
1693	Regulatory T Cells and Cancer: A Two-Sided Story. Immunological Investigations, 2016, 45, 797-812.	1.0	36
1694	Immunology of Head and Neck Cancer. , 2016, , 133-148.		0
1696	Identification of Small Novel Coding Sequences, a Proteogenomics Endeavor. Advances in Experimental Medicine and Biology, 2016, 926, 49-64.	0.8	14
1697	The genomic landscape of breast cancer and its interaction with host immunity. Breast, 2016, 29, 241-250.	0.9	194
1698	Immunotherapy for Lung Cancer: No Longer an Abstract Concept. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 771-782.	0.8	12

#	Article	IF	Citations
1699	PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?. Medical Oncology, 2016, 33, 120.	1.2	23
1700	Stochastic stability and state shifts for a time-delayed cancer growth system subjected to correlated multiplicative and additive noises. Chaos, Solitons and Fractals, 2016, 93, 1-13.	2.5	16
1701	Therapeutic targets and new directions for antibodies developed for ovarian cancer. MAbs, 2016, 8, 1437-1455.	2.6	15
1702	Changes in Clinical Context for Kaposi's Sarcoma and Non-Hodgkin Lymphoma Among People With HIV Infection in the United States. Journal of Clinical Oncology, 2016, 34, 3276-3283.	0.8	31
1703	Inhibition of STAT3 enhances the radiosensitizing effect of temozolomide in glioblastoma cells in vitro and in vivo. Journal of Neuro-Oncology, 2016, 130, 89-98.	1.4	25
1704	Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving firstâ€line chemotherapy. Cancer Medicine, 2016, 5, 778-786.	1.3	30
1705	<scp>COPD</scp> and squamous cell lung cancer: aberrant inflammation and immunity is the common link. British Journal of Pharmacology, 2016, 173, 635-648.	2.7	95
1706	Immune signature of urothelial cancer associated with grade, recurrence, and invasion. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 418.e17-418.e26.	0.8	5
1707	Employing dynamical computational models for personalizing cancer immunotherapy. Expert Opinion on Biological Therapy, 2016, 16, 1373-1385.	1.4	29
1709	Cancer Cell Death-Inducing Radiotherapy: Impact on Local Tumour Control, Tumour Cell Proliferation and Induction of Systemic Anti-tumour Immunity. Advances in Experimental Medicine and Biology, 2016, 930, 151-172.	0.8	9
1710	PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1+ and CD8+ tumor-infiltrating T cells and outcome. Modern Pathology, 2016, 29, 1552-1564.	2.9	25
1711	Inflammation: the Common Link in Brain Pathologies. , 2016, , .		1
1712	TP53 dysfunction in CLL: Implications for prognosis and treatment. Best Practice and Research in Clinical Haematology, 2016, 29, 90-99.	0.7	14
1713	The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms. Leukemia, 2016, 30, 2413-2416.	3.3	60
1714	Squamous Cell Carcinoma Antigen-Immunoglobulin M (SCCA-IgM) as Biomarker in Liver Disease: Biological Aspects and Clinical Applications. Exposure and Health, 2016, , 1-22.	2.8	0
1716	From cell biology to immunology: Controlling metastatic progression of cancer via microRNA regulatory networks. OncoImmunology, 2016, 5, e1230579.	2.1	5
1717	Long non-coding RNA HOTAIR modulates HLA-G expression by absorbing miR-148a in human cervical cancer. International Journal of Oncology, 2016, 49, 943-952.	1.4	56
1718	Heralding a new paradigm in 3D tumor modeling. Biomaterials, 2016, 108, 197-213.	5.7	127

#	Article	IF	Citations
1719	Molecular Immunoevasion Strategies Targeting Antigen Processing and Presentation. , 2016, , 279-296.		0
1720	Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions. Immunotherapy, 2016, 8, 785-798.	1.0	7
1721	Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma: Prognostic Factors for Patient Outcome. Annals of Surgical Oncology, 2016, 23, 508-515.	0.7	49
1722	Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. New England Journal of Medicine, 2016, 375, 819-829.	13.9	2,430
1723	Mutation Drivers of Immunological Responses to Cancer. Cancer Immunology Research, 2016, 4, 789-798.	1.6	32
1724	DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer. Cancer Immunology, Immunotherapy, 2016, 65, 1061-1073.	2.0	40
1725	Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. BioDrugs, 2016, 30, 571-584.	2.2	93
1726	One microenvironment does not fit all: heterogeneity beyond cancer cells. Cancer and Metastasis Reviews, 2016, 35, 601-629.	2.7	58
1727	Immune cell recruitment in teratomas is impaired by increased Wnt secretion. Stem Cell Research, 2016, 17, 607-615.	0.3	32
1728	The tumor microenvironment disarms CD8⁺ T lymphocyte function via a miR-26a-EZH2 axis. OncoImmunology, 2016, 5, e1245267.	2.1	15
1730	Significance of cancer-associated fibroblasts in head and neck squamous cell carcinoma. Journal of Japan Society of Immunology & Allergology in Otolaryngology, 2016, 34, 211-219.	0.0	0
1731	Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs. Journal of Visualized Experiments, 2016, , .	0.2	9
1732	Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. Clinical Medicine Insights: Oncology, 2016, 10s1, CMO.S34540.	0.6	121
1733	Risk factors for developing colorectal cancer in Japanese patients with ulcerative colitis: a retrospective observational studyâ€"CAPITAL (Cohort and Practice for IBD total management in) Tj ETQq1 1 0.784314 rgBT /Overlock	3.1	
1734	Current Status of Immunotherapy Treatments for Pancreatic Cancer. Journal of Clinical Gastroenterology, 2016, 50, 836-848.	1.1	11
1735	Pharmacological Modulation of Proton Channel Hv1 in Cancer Therapy: Future Perspectives. Molecular Pharmacology, 2016, 90, 385-402.	1.0	17
1736	Checkpoint inhibition in meningiomas. Immunotherapy, 2016, 8, 721-731.	1.0	22
1737	Progress in Cancer Immunotherapy. Advances in Experimental Medicine and Biology, 2016, , .	0.8	6

#	Article	IF	Citations
1738	Radiobiology of Glioblastoma. Current Clinical Pathology, 2016, , .	0.0	2
1739	Mathematical model of tumorâ€“immune surveillance. Journal of Theoretical Biology, 2016, 404, 312-330.	0.8	63
1740	Landscape of tumor-infiltrating T cell repertoire of human cancers. Nature Genetics, 2016, 48, 725-732.	9.4	288
1741	The PD-1:PD-L1 immune inhibitory checkpoint in Helicobacter pylori infection and gastric cancer: a comprehensive review and future perspectives. Porto Biomedical Journal, 2016, 1, 4-11.	0.4	22
1742	Î²-1,3-Glucan reverses aflatoxin B1-mediated suppression of immune responses in mice. Life Sciences, 2016, 152, 1-13.	2.0	24
1743	Checkpoint inhibition for colorectal cancer: progress and possibilities. Immunotherapy, 2016, 8, 693-704.	1.0	5
1744	Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers. Breast Cancer Research, 2016, 18, 50.	2.2	56
1745	Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells. Oral Oncology, 2016, 58, 52-58.	0.8	58
1746	Phosphatidylinositol 3-Kinase. Pancreas, 2016, 45, 21-31.	0.5	11
1747	The Immune System and Its Contribution to the Radiotherapeutic Response of Glioblastoma. Current Clinical Pathology, 2016, , 155-175.	0.0	0
1748	Recent advances in the development of nanomaterials for DC-based immunotherapy. Science Bulletin, 2016, 61, 514-523.	4.3	9
1749	Intratumoral Immune Cell Densities Are Associated with Lung Adenocarcinoma Gene Alterations. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1403-1412.	2.5	48
1750	Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells. Leukemia, 2016, 30, 1805-1815.	3.3	32
1751	Targeting tumor tolerance: A new hope for pancreatic cancer therapy?. , 2016, 166, 9-29.		33
1752	Co-operation of Î±-galactosylceramide-loaded tumour cells and TLR9 agonists induce potent anti-tumour responses in a murine colon cancer model. Biochemical Journal, 2016, 473, 7-19.	1.7	13
1753	Yeast-Derived Particulate Î²-Glucan Treatment Subverts the Suppression of Myeloid-Derived Suppressor Cells (MDSC) by Inducing Polymorphonuclear MDSC Apoptosis and Monocytic MDSC Differentiation to APC in Cancer. Journal of Immunology, 2016, 196, 2167-2180.	0.4	86
1754	Modeling combined chemo- and immunotherapy of high-grade non-Hodgkin lymphoma. Leukemia and Lymphoma, 2016, 57, 1697-1708.	0.6	5
1755	CD4 + CD25 + regulatory T cells in tumor immunity. International Immunopharmacology, 2016, 34, 244-249.	1.7	102

#	Article	IF	Citations
1756	How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances. Oncologist, 2016, 21, 233-243.	1.9	71
1757	Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. International Immunology, 2016, 28, 383-391.	1.8	223
1758	Opposing effects of immunotherapy in melanoma using multisubtype interferon-alpha â€“ can tumor immune escape after immunotherapy accelerate disease progression?. OncoImmunology, 2016, 5, e1091147.	2.1	12
1759	The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. Advances in Immunology, 2016, 130, 25-74.	1.1	181
1761	Inflammatory Cells in Tumor Microenvironment. , 2016, , 27-50.		0
1762	Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway. Cancer Immunology, Immunotherapy, 2016, 65, 355-366.	2.0	13
1763	Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?. Expert Opinion on Biological Therapy, 2016, 16, 655-674.	1.4	21
1764	The Role of Microenvironment in the Control of Tumor Angiogenesis. , 2016, , .		3
1765	Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 1223-1230.	0.8	300
1766	C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. Nature Communications, 2016, 7, 10346.	5.8	224
1767	Immunization of stromal cell targeting fibroblast activation protein providing immunotherapy to breast cancer mouse model. Tumor Biology, 2016, 37, 10317-10327.	0.8	22
1768	The properties of the anti-tumor model with coupling non-Gaussian noise and Gaussian colored noise. Physica A: Statistical Mechanics and Its Applications, 2016, 449, 43-52.	1.2	11
1769	The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 789-800.	0.5	401
1770	Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas. Clinical Cancer Research, 2016, 22, 3182-3191.	3.2	109
1771	Breast cancer survival among young women: a review of the role of modifiable lifestyle factors. Cancer Causes and Control, 2016, 27, 459-472.	0.8	63
1772	PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. International Journal of Clinical Oncology, 2016, 21, 462-473.	1.0	255
1773	Coinhibitory Pathways in Immunotherapy for Cancer. Annual Review of Immunology, 2016, 34, 539-573.	9.5	718
1774	Genetically Engineered T Cells. , 2016, , 121-132.		0

#	Article	IF	Citations
1775	The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nature Reviews Clinical Oncology, 2016, 13, 273-290.	12.5	909
1776	Overview of Current Cancer Immunotherapy. , 2016, , 3-17.		0
1777	GRP94/gp96 in Cancer. Advances in Cancer Research, 2016, 129, 165-190.	1.9	59
1778	Asymptotic dynamics of some t-periodic one-dimensional model with application to prostate cancer immunotherapy. Journal of Mathematical Biology, 2016, 73, 867-883.	0.8	6
1779	Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy. Advances in Immunology, 2016, 130, 75-93.	1.1	74
1780	Epidemiology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 3-18.	1.0	15
1781	Identification of a highly immunogenic mouse breast cancer sub cell line, 4T1-S. Human Cell, 2016, 29, 58-66.	1.2	14
1782	Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nature Reviews Cancer, 2016, 16, 219-233.	12.8	580
1783	Trial Watchâ€"Small molecules targeting the immunological tumor microenvironment for cancer therapy. OncoImmunology, 2016, 5, e1149674.	2.1	46
1784	Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation. Journal of Controlled Release, 2016, 231, 17-28.	4.8	171
1785	STAT3 Establishes an Immunosuppressive Microenvironment during the Early Stages of Breast Carcinogenesis to Promote Tumor Growth and Metastasis. Cancer Research, 2016, 76, 1416-1428.	0.4	87
1786	Lymphocyte to monocyte ratio is associated with response to first-line platinum-based chemotherapy and prognosis of early-stage non-small cell lung cancer patients. Tumor Biology, 2016, 37, 5285-5293.	0.8	40
1787	The rapidly evolving therapies for advanced melanomaâ€"Towards immunotherapy, molecular targeted therapy, and beyond. Critical Reviews in Oncology/Hematology, 2016, 99, 91-99.	2.0	87
1788	Systems Immunology. , 2016, , 3-44.		0
1789	Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. Targeted Oncology, 2016, 11, 345-351.	1.7	56
1790	Immunologic approaches to cancer preventionâ€"current status, challenges, and future perspectives. Seminars in Oncology, 2016, 43, 161-172.	0.8	35
1791	Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma. OncoImmunology, 2016, 5, e1083669.	2.1	49
1792	Combining anaerobic bacterial oncolysis with vaccination that blocks interleukin-10 signaling may achieve better outcomes for late stage cancer management. Human Vaccines and Immunotherapeutics, 2016, 12, 599-606.	1.4	3

#	Article	IF	Citations
1793	Tumor-intrinsic oncogene pathways mediating immune avoidance. OncoImmunology, 2016, 5, e1086862.	2.1	120
1794	Cripto-1 modulates macrophage cytokine secretion and phagocytic activity via NF-Î²B signaling. Immunologic Research, 2016, 64, 104-114.	1.3	17
1795	Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer. Translational Research, 2016, 167, 67-79.	2.2	79
1796	CD4+ regulatory T cells in gastric cancer mucosa are proliferating and express high levels of IL-10 but little TGF-Î². Gastric Cancer, 2017, 20, 116-125.	2.7	72
1797	Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer. Pharmacogenomics Journal, 2017, 17, 528-534.	0.9	9
1798	Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026740.	2.9	25
1799	Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science, 2017, 355, .	6.0	988
1800	Optical Barcoding for Single-Clone Tracking to Study Tumor Heterogeneity. Molecular Therapy, 2017, 25, 621-633.	3.7	32
1801	A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy. Journal of Hematology and Oncology, 2017, 10, 1.	6.9	216
1802	Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. Critical Reviews in Oncology/Hematology, 2017, 110, 106-116.	2.0	33
1803	Circulating nucleic acids: An analysis of their occurrence in malignancies. Biomedical Reports, 2017, 6, 8-14.	0.9	29
1804	Management of Prostate Cancer. , 2017, , .		5
1805	Checkpoint inhibition: new treatment options in urologic cancer. Acta Clinica Belgica, 2017, 72, 24-28.	0.5	13
1806	Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models. Cancer Immunology Research, 2017, 5, 157-169.	1.6	36
1807	Breast Cancer Immunology and Immunotherapy. International Review of Cell and Molecular Biology, 2017, 331, 1-53.	1.6	47
1808	A Dynamic Model of Immune Responses to Antigen Presentation Predicts Different Regions of Tumor or Pathogen Elimination. Cell Systems, 2017, 4, 231-241.e11.	2.9	59
1809	Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8+ T Cells and Histone Acetyltransferases. Cancer Immunology Research, 2017, 5, 300-311.	1.6	20
1810	Energy metabolism drives myeloid-derived suppressor cell differentiation and functions in pathology. Journal of Leukocyte Biology, 2017, 102, 325-334.	1.5	38

#	Article	IF	Citations
1811	MYC: Master Regulator of Immune Privilege. Trends in Immunology, 2017, 38, 298-305.	2.9	70
1812	Targeting neoantigens to augment antitumour immunity. Nature Reviews Cancer, 2017, 17, 209-222.	12.8	724
1813	The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. Endocrine-Related Cancer, 2017, 24, R123-R144.	1.6	64
1814	Reversal of tumor acidosis by systemic buffering reactivates NK cells to express IFNâ€Î³ and induces NK cellâ€dependent lymphoma control without other immunotherapies. International Journal of Cancer, 2017, 140, 2125-2133.	2.3	80
1815	NLRC5/CITA: A Key Player in Cancer Immune Surveillance. Trends in Cancer, 2017, 3, 28-38.	3.8	59
1816	Cancer as a contagious disease. Hla, 2017, 89, 209-214.	0.4	1
1818	Annexin A1 influences in breast cancer: Controversies on contributions to tumour, host and immunoediting processes. Pharmacological Research, 2017, 119, 278-288.	3.1	25
1819	Escape from IFN-Î³-dependent immunosurveillance in tumorigenesis. Journal of Biomedical Science, 2017, 24, 10.	2.6	80
1820	Neutrophils as active regulators of the immune system in the tumor microenvironment. Journal of Leukocyte Biology, 2017, 102, 343-349.	1.5	153
1821	Autoantibodies: Opportunities for Early Cancer Detection. Trends in Cancer, 2017, 3, 198-213.	3.8	106
1822	Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. Cancer Discovery, 2017, 7, 750-765.	7.7	112
1823	Tumors arise from the excessive repair of damaged stem cells. Medical Hypotheses, 2017, 102, 112-122.	0.8	6
1824	Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance. Laboratory Investigation, 2017, 97, 657-668.	1.7	70
1825	Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell, 2017, 168, 707-723.	13.5	3,483
1826	Translation and Clinical Development of Bispecific Tâ€cell Engaging Antibodies for Cancer Treatment. Clinical Pharmacology and Therapeutics, 2017, 101, 634-645.	2.3	72
1827	Identifying the optimal anticancer targets from the landscape of a cancerâ€“immunity interaction network. Physical Chemistry Chemical Physics, 2017, 19, 7642-7651.	1.3	22
1828	Hypercholesterolemia Increases Colorectal Cancer Incidence by Reducing Production of NKT and Î³Î´ T Cells from Hematopoietic Stem Cells. Cancer Research, 2017, 77, 2351-2362.	0.4	46
1829	The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership. Critical Reviews in Oncology/Hematology, 2017, 111, 124-132.	2.0	93

#	Article	IF	Citations
1830	Radiotherapy in the age of cancer immunology: Current concepts and future developments. Critical Reviews in Oncology/Hematology, 2017, 112, 1-10.	2.0	19
1831	Asbestos and Mesothelioma. Current Cancer Research, 2017, , .	0.2	5
1833	The microbiome in anti-cancer therapy. Seminars in Immunology, 2017, 32, 74-81.	2.7	61
1834	Nanotechnology based therapeutic modality to boost anti-tumor immunity and collapse tumor defense. Journal of Controlled Release, 2017, 256, 26-45.	4.8	41
1835	Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy. American Journal of Clinical Dermatology, 2017, 18, 597-611.	3.3	11
1836	Tuning cancer fate: the unremitting role of host immunity. Open Biology, 2017, 7, 170006.	1.5	43
1837	Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy. Annals of Oncology, 2017, 28, 1658-1666.	0.6	26
1838	Identification of Immunogenic Epitopes by MS/MS. Cancer Journal (Sudbury, Mass), 2017, 23, 102-107.	1.0	19
1839	Regulatory T cells as suppressors of anti-tumor immunity: Role of metabolism. Cytokine and Growth Factor Reviews, 2017, 35, 15-25.	3.2	33
1841	Personalized T cell-mediated cancer immunotherapy: progress and challenges. Current Opinion in Biotechnology, 2017, 48, 142-152.	3.3	78
1842	Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. Journal of Urology, 2017, 198, 817-823.	0.2	31
1843	Host antitumor resistance improved by the macrophage polarization in a chimera model of patients with HCC. OncoImmunology, 2017, 6, e1299301.	2.1	24
1844	Exploring and Exploiting Acceptor Preferences of the Human Polysialyltransferases as a Basis for an Inhibitor Screen. ChemBioChem, 2017, 18, 1332-1337.	1.3	5
1845	The Immunobiology of Cancer: From Tumor Escape to Cancer Immunoediting Towards Immunotherapy in Gynecologic Oncology. , 2017, , 193-204.		3
1846	Chemokine Receptor Signaling and the Hallmarks of Cancer. International Review of Cell and Molecular Biology, 2017, 331, 181-244.	1.6	64
1847	Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discovery, 2017, 7, 188-201.	7.7	997
1848	Bone marrow T-cell percentage: A novel prognostic indicator in acute myeloid leukemia. International Journal of Hematology, 2017, 105, 453-464.	0.7	23
1849	Hide-and-seek: the interplay between cancer stem cells and the immune system. Carcinogenesis, 2017, 38, 107-118.	1.3	78

#	Article	IF	Citations
1850	The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System. Annals of the American Thoracic Society, 2017, 14, 1248-1260.	1.5	15
1851	Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. European Journal of Cancer, 2017, 81, 116-129.	1.3	443
1852	B7.1. , 2017, , 67-76.		0
1854	Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer. OncoImmunology, 2017, 6, e1339856.	2.1	8
1855	Intestine-Specific Homeobox Gene ISX Integrates IL6 Signaling, Tryptophan Catabolism, and Immune Suppression. Cancer Research, 2017, 77, 4065-4077.	0.4	28
1856	The JAK/STAT3 axis: A comprehensive drug target for solid malignancies. Seminars in Cancer Biology, 2017, 45, 13-22.	4.3	147
1857	<scp>PD</scp>â€1 and <scp>PDâ€L1</scp> in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma. Journal of Cutaneous Pathology, 2017, 44, 740-746.	0.7	32
1858	Novel â€œElementsâ€•of Immune Suppression within the Tumor Microenvironment. Cancer Immunology Research, 2017, 5, 426-433.	1.6	52
1859	Autophagy in natural and therapy-driven anticancer immunosurveillance. Autophagy, 2017, 13, 2163-2170.	4.3	52
1860	Checkpoint inhibitors for the treatment of non-small-cell lung cancer: news from the 2016 European Society for Medical Oncology Annual Congress. Drugs and Therapy Perspectives, 2017, 33, 126-132.	0.3	1
1861	Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook. Advanced Materials, 2017, 29, 1606036.	11.1	220
1862	Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies. Journal of Leukocyte Biology, 2017, 102, 393-406.	1.5	55
1863	An Introduction to Immunotherapy in the Treatment of Brain Tumors. , 2017, , 1-10.		0
1864	Microenvironment Tumor Metabolic Interactions Highlighted by qMSI: Application to the Tryptophan-Kynurenine Pathway in Immuno-Oncology. SLAS Discovery, 2017, 22, 1182-1192.	1.4	21
1865	Immunotherapeutic Approaches to Mesothelioma. Current Cancer Research, 2017, , 347-357.	0.2	0
1866	Catch and Release of Cytokines Mediated by Tumor Phosphatidylserine Converts Transient Exposure into Long-Lived Inflammation. Molecular Cell, 2017, 66, 635-647.e7.	4.5	34
1867	Problems of Cancer Treatment. Part I. Theory of Treatment Based on Known Mechanisms of Anticancer Immunological Responses. Advances in Cell Biology, 2017, 5, 72-95.	1.5	0
1868	The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies. Immunotherapy, 2017, 9, 579-587.	1.0	11

#	Article	IF	Citations
1869	New insights into the role of <scp>EMT</scp> in tumor immune escape. Molecular Oncology, 2017, 11, 824-846.	2.1	332
1870	Metastatic melanoma moves on: translational science in the era of personalized medicine. Cancer and Metastasis Reviews, 2017, 36, 7-21.	2.7	16
1871	Is there immune surveillance against chronic myeloid leukaemia? Possibly, but not much. Leukemia Research, 2017, 57, 109-111.	0.4	18
1872	Immunotherapy for head and neck cancer: the future of treatment?. Expert Opinion on Biological Therapy, 2017, 17, 701-708.	1.4	24
1873	Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 575-582.	1.4	20
1874	Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. Cancer Discovery, 2017, 7, 630-651.	7.7	48
1875	Overview of Basic Immunology for Clinical Investigators. Advances in Experimental Medicine and Biology, 2017, 995, 1-31.	0.8	4
1876	Threshold for extinction and survival in stochastic tumor immune system. Communications in Nonlinear Science and Numerical Simulation, 2017, 51, 1-12.	1.7	28
1877	Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility. Tumor Biology, 2017, 39, 101042831769502.	0.8	73
1878	Predictive role of serum and urinary cytokines in invasion and recurrence of bladder cancer. Tumor Biology, 2017, 39, 101042831769755.	0.8	41
1879	Suppressor of Cytokine Signaling 2 Negatively Regulates NK Cell Differentiation by Inhibiting JAK2 Activity. Scientific Reports, 2017, 7, 46153.	1.6	35
1881	Paper/PMMA Hybrid 3D Cell Culture Microfluidic Platform for the Study of Cellular Crosstalk. ACS Applied Materials & Interfaces, 2017, 9, 13092-13101.	4.0	32
1882	Current update of adoptive immunotherapy using cytokine-induced killer cells to eliminate malignant gliomas. Immunotherapy, 2017, 9, 411-421.	1.0	2
1883	Cancer immunotherapy: how low-level ionizing radiation can play a key role. Cancer Immunology, Immunotherapy, 2017, 66, 819-832.	2.0	49
1884	The Evolutionary Origins of Cancer andÂof Its Control by Immune PolicingÂand Genetic Suppression. , 2017, , 1-9.		3
1885	Stem cell transplantation therapy for multifaceted therapeutic benefits after stroke. Progress in Neurobiology, 2017, 157, 49-78.	2.8	127
1887	PTEN at the interface of immune tolerance and tumor suppression. Frontiers in Biology, 2017, 12, 163-174.	0.7	18
1888	Programmed death ligand 1 (PD-L1) expression and tumor microenvironment: Implications for patients with oral precancerous lesions. Oral Oncology, 2017, 68, 36-43.	0.8	71

#	Article	IF	Citations
1889	Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. European Journal of Cancer, 2017, 76, 152-166.	1.3	82
1890	Synthesis of end-functionalized glycopolymers containing Î±(2,8) disialic acids via Ï€-allyl nickel catalyzed coordinating polymerization and their interaction with Siglec-7. Chemical Communications, 2017, 53, 553-556.	2.2	13
1891	Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice. Cancer Immunology, Immunotherapy, 2017, 66, 451-460.	2.0	16
1892	Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation. Cancer Letters, 2017, 400, 243-251.	3.2	26
1893	Immune Cellâ€Mediated Biodegradable Theranostic Nanoparticles for Melanoma Targeting and Drug Delivery. Small, 2017, 13, 1603121.	5.2	63
1894	CD59 Regulation by SOX2 Is Required for Epithelial Cancer Stem Cells to Evade Complement Surveillance. Stem Cell Reports, 2017, 8, 140-151.	2.3	29
1895	The Different T-cell Receptor Repertoires in Breast Cancer Tumors, Draining Lymph Nodes, and Adjacent Tissues. Cancer Immunology Research, 2017, 5, 148-156.	1.6	87
1896	Preclinical evaluation of radiation and systemic, RGD-targeted, adeno-associated virus phage-TNF gene therapy in a mouse model of spontaneously metastatic melanoma. Cancer Gene Therapy, 2017, 24, 13-19.	2.2	4
1897	Comparison of nanomedicine-based chemotherapy, photodynamic therapy and photothermal therapy using reduced graphene oxide for the model system. Biomaterials Science, 2017, 5, 331-340.	2.6	63
1898	Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. Pathology, 2017, 49, 141-155.	0.3	112
1899	Identifying and Creating the Next Generation of Community-Based Cancer Prevention Studies: Summary of a National Cancer Institute Think Tank. Cancer Prevention Research, 2017, 10, 99-107.	0.7	11
1900	Targeting cancerâ€related inflammation in the era of immunotherapy. Immunology and Cell Biology, 2017, 95, 325-332.	1.0	128
1901	Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy. Immunotherapy, 2017, 9, 71-82.	1.0	5
1902	<scp>PD</scp> â€L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Molecular Medicine, 2017, 9, 167-180.	3.3	172
1903	Tumor-promoting effect of IL-23 in mammary cancer mediated by infiltration of M2 macrophages and neutrophils in tumor microenvironment. Biochemical and Biophysical Research Communications, 2017, 482, 1400-1406.	1.0	49
1904	Association of Cytokines and Chemokines in Pathogenesis of Breast Cancer. Progress in Molecular Biology and Translational Science, 2017, 151, 113-136.	0.9	43
1905	Integration of nano drug-delivery system with cancer immunotherapy. Therapeutic Delivery, 2017, 8, 987-1000.	1.2	34
1906	Overexpression of immunomodulatory mediators in oral precancerous lesions. Human Immunology, 2017, 78, 752-757.	1.2	37

#	Article	IF	Citations
1907	Prognostic and predictive role of FOXP3 positive tumor infiltrating lymphocytes (TILs) in curatively resected non small cell lung cancer other than stage IA. Journal of Oncological Science, 2017, 3, 102-106.	0.1	2
1908	Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. OncoImmunology, 2017, 6, e1386829.	2.1	209
1909	Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA. Journal of Controlled Release, 2017, 266, 287-300.	4.8	98
1910	Head and Neck Squamous Cell Carcinomas Are Characterized by a Stable Immune Signature Within the Primary Tumor Over Time and Space. Clinical Cancer Research, 2017, 23, 7641-7649.	3.2	22
1911	The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer. Human Pathology, 2017, 69, 110-117.	1.1	81
1912	Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses. Immunological Reviews, 2017, 280, 126-148.	2.8	325
1913	The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy. Science China Life Sciences, 2017, 60, 1058-1064.	2.3	19
1914	Nanotechnology-Based Immunotherapeutic Strategies for the Treatment of Cancer. , 2017, , 83-115.		1
1915	Immunomodulation by ionizing radiationâ€"impact for design of radioâ€immunotherapies and for treatment of inflammatory diseases. Immunological Reviews, 2017, 280, 231-248.	2.8	140
1916	Tristetraprolin inhibits macrophage IL-27-induced activation of antitumour cytotoxic T cell responses. Nature Communications, 2017, 8, 867.	5.8	31
1917	Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?. Annals of Oncology, 2017, 28, 2950-2961.	0.6	78
1918	MicroRNAs in the Diagnosis and Treatment of Cancer. Immunological Investigations, 2017, 46, 880-897.	1.0	52
1919	Checkpoint immunotherapy in head and neck cancers. Cancer and Metastasis Reviews, 2017, 36, 475-489.	2.7	33
1920	Prospects and progress of immunotherapy for bladder cancer. Expert Opinion on Biological Therapy, 2017, 17, 1-15.	1.4	29
1921	Aggressive Behavior in Silent Subtype III Pituitary Adenomas May Depend on Suppression of Local Immune Response: A Whole Transcriptome Analysis. Journal of Neuropathology and Experimental Neurology, 2017, 76, 874-882.	0.9	20
1922	Tumor Immunology meetsâ€¦Immunology: Modified cancer cells as professional APC for priming naÃ¯ve tumor-specific CD4+ T cells. OncoImmunology, 2017, 6, e1356149.	2.1	16
1923	The anti-tumor effect of intravesical administration of normal urothelial cells on bladder cancer. Cytotherapy, 2017, 19, 1233-1245.	0.3	5
1924	PD-1/PD-L1 and immunotherapy for pancreatic cancer. Cancer Letters, 2017, 407, 57-65.	3.2	235

#	Article	IF	Citations
1925	Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value. Scientific Reports, 2017, 7, 11671.	1.6	57
1926	Immune responses in the thyroid cancer microenvironment: making immunotherapy a possible mission. Endocrine-Related Cancer, 2017, 24, T311-T329.	1.6	23
1927	Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiotherapy and Oncology, 2017, 125, 80-88.	0.3	58
1928	Alcoholic liver disease is a strong predictor of colorectal polyps in liver transplant recipients. Endoscopy International Open, 2017, 05, E918-E923.	0.9	1
1929	CRISPR knock out CTLA-4 enhances the anti-tumor activity of cytotoxic T lymphocytes. Gene, 2017, 636, 36-41.	1.0	54
1930	Natural killer cell-mediated immunosurveillance of human cancer. Seminars in Immunology, 2017, 31, 20-29.	2.7	240
1931	Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy. Pancreas, 2017, 46, 1180-1187.	0.5	47
1932	A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition. Journal of the Royal Society Interface, 2017, 14, 20170320.	1.5	118
1933	Role of PD-1 in Immunity and Diseases. Current Topics in Microbiology and Immunology, 2017, 410, 75-97.	0.7	136
1934	Enhancing tumor specific immune responses by transcutaneous vaccination. Expert Review of Vaccines, 2017, 16, 1079-1094.	2.0	14
1935	Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma. OncoImmunology, 2017, 6, e1338237.	2.1	47
1936	Tumor Dormancy and Recurrence. Cancer Drug Discovery and Development, 2017, , .	0.2	2
1937	No patient left behind: The promise of immune priming with epigenetic agents. OncoImmunology, 2017, 6, e1315486.	2.1	11
1938	Immune modulatory microRNAs as a novel mechanism to revert immune escape of tumors. Cytokine and Growth Factor Reviews, 2017, 36, 49-56.	3.2	17
1939	Oncolytic virus-induced cell death and immunity: a match made in heaven?. Journal of Leukocyte Biology, 2017, 102, 631-643.	1.5	35
1940	Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone. Clinical Orthopaedics and Related Research, 2017, 475, 3071-3081.	0.7	14
1941	Cancer Immunotherapy in Older Patients. Cancer Journal (Sudbury, Mass), 2017, 23, 219-222.	1.0	18
1942	Secreted Tumor Antigens â€“ Immune Biomarkers for Diagnosis and Therapy. Proteomics, 2017, 17, 1600442.	1.3	27

#	Article	IF	Citations
1943	Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies. Cancer Immunology, Immunotherapy, 2017, 66, 1463-1471.	2.0	25
1944	Drug-eluting scaffold inhibited in vivo pancreatic tumorigenesis by engaging murine CCR4+CD8+ T cells. Colloids and Surfaces B: Biointerfaces, 2017, 158, 469-473.	2.5	15
1945	Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences. Cytokine and Growth Factor Reviews, 2017, 36, 25-31.	3.2	8
1946	Tumor Purity as an Underlying Key Factor in Glioma. Clinical Cancer Research, 2017, 23, 6279-6291.	3.2	372
1947	Loss of Chromosome Y in Leukocytes and Major Cardiovascular Events. Circulation: Cardiovascular Genetics, 2017, 10, e001820.	5.1	5
1949	An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection. Cancer Immunology, Immunotherapy, 2017, 66, 1529-1544.	2.0	12
1950	Cancer Immunity and Immune Evasion Mechanisms. , 2017, , 195-220.		1
1951	TAP1 down-regulation elicits immune escape and poor prognosis in colorectal cancer. OncoImmunology, 2017, 6, e1356143.	2.1	79
1952	Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma. Scientific Reports, 2017, 7, 16456.	1.6	12
1953	T cell receptor sequencing of early-stage breast cancer tumors identifies altered clonal structure of the T cell repertoire. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E10409-E10417.	3.3	53
1954	Uniform Persistence and Global Stability for a Brain Tumor and Immune System Interaction. Biophysical Reviews and Letters, 2017, 12, 187-208.	0.9	48
1955	Inflammation and Cancer. , 2017, , 17-24.		0
1956	Convergence of immunotherapy, radiotherapy and prostate cancer: challenges and opportunities. Immunotherapy, 2017, 9, 695-699.	1.0	0
1957	Iscador Qu inhibits doxorubicin-induced senescence of MCF7 cells. Scientific Reports, 2017, 7, 3763.	1.6	14
1958	An abscopal effect in a case of concomitant treatment of locally and peritoneally recurrent gastric cancer using adoptive Tâ€cell immunotherapy and radiotherapy. Clinical Case Reports (discontinued), 2017, 5, 380-384.	0.2	26
1959	Loss of chromosome Y (LOY) in blood cells is associated with increased risk for disease and mortality in aging men. Human Genetics, 2017, 136, 657-663.	1.8	96
1960	Predictive and prognostic significance of CD8+ tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy. Oncology Letters, 2017, 14, 337-344.	0.8	33
1961	Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyteâ€“Associated Protein Blockade. Clinical Cancer Research, 2017, 23, 6190-6202.	3.2	82

#	Article	IF	Citations
1962	Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization. Journal of Dermatological Science, 2017, 87, 300-306.	1.0	10
1963	Uncovering the underlying mechanism of cancer tumorigenesis and development under an immune microenvironment from global quantification of the landscape. Journal of the Royal Society Interface, 2017, 14, 20170105.	1.5	28
1964	Gene Expression Profiling of Peripheral Blood From Kidney Transplant Recipients for the Early Detection of Digestive System Cancer. Transplantation Proceedings, 2017, 49, 1056-1060.	0.3	1
1965	Addressing current challenges in cancer immunotherapy with mathematical and computational modelling. Journal of the Royal Society Interface, 2017, 14, 20170150.	1.5	71
1966	Immunosurveillance profile of oral squamous cell carcinoma and oral epithelial dysplasia through dendritic and Tâ€¢cell analysis. Journal of Oral Pathology and Medicine, 2017, 46, 928-933.	1.4	30
1967	Nodal skip metastasis in thoracic esophageal squamous cell carcinoma: a cohort study. BMC Surgery, 2017, 17, 49.	0.6	14
1968	Immunotherapy in head and neck cancer: aiming at EXTREME precision. BMC Medicine, 2017, 15, 110.	2.3	64
1969	The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. Immunotherapy, 2017, 9, 681-692.	1.0	94
1970	Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy?. International Journal of Radiation Oncology Biology Physics, 2017, 97, 323-332.	0.4	85
1971	Deciphering Genetic Intratumor Heterogeneity and Its Impact on Cancer Evolution. Annual Review of Cancer Biology, 2017, 1, 223-240.	2.3	20
1972	Friend or foe?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1867, 1-18.	3.3	54
1973	Immunotherapy in ovarian cancer. Current Problems in Cancer, 2017, 41, 48-63.	1.0	27
1974	Immunotherapy for Lung Malignancies. Chest, 2017, 151, 891-897.	0.4	17
1975	Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma. Oral Oncology, 2017, 71, 169-176.	0.8	16
1976	Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy. Journal of Pathology, 2017, 241, 10-24.	2.1	55
1977	Adaptive mechanisms of resistance to anti-neoplastic agents. MedChemComm, 2017, 8, 53-66.	3.5	12
1978	Leveraging the immune system to treat advanced thyroid cancers. Lancet Diabetes and Endocrinology,the, 2017, 5, 469-481.	5.5	58
1979	Radiation Therapy in Hematologic Malignancies. , 2017, , .		0

#	Article	IF	Citations
1980	DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis. Nature Chemical Biology, 2017, 13, 46-53.	3.9	208
1981	Loss of Anti-HER-3 CD4+ T-Helper Type 1 Immunity Occurs in Breast Tumorigenesis and is Negatively Associated with Outcomes. Annals of Surgical Oncology, 2017, 24, 407-417.	0.7	16
1982	Immunotherapy approaches in the treatment of malignant brain tumors. Cancer, 2017, 123, 734-750.	2.0	75
1983	Next generation predictive biomarkers for immune checkpoint inhibition. Cancer and Metastasis Reviews, 2017, 36, 179-190.	2.7	84
1984	Chemical Carcinogenesis Models of Cancer: Back to the Future. Annual Review of Cancer Biology, 2017, 1, 295-312.	2.3	30
1985	The pulse vaccination effects in mammary carcinoma. International Journal of Biomathematics, 2017, 10, 1750036.	1.5	0
1986	Circulating and disseminated tumour cells â€" mechanisms of immune surveillance and escape. Nature Reviews Clinical Oncology, 2017, 14, 155-167.	12.5	426
1988	Immune Checkpoint Blockade in Breast Cancer Therapy. Advances in Experimental Medicine and Biology, 2017, 1026, 383-402.	0.8	24
1989	Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy. Advances in Experimental Medicine and Biology, 2017, , .	0.8	9
1990	Informatics for cancer immunotherapy. Annals of Oncology, 2017, 28, xii56-xii73.	0.6	19
1991	Immunotherapy in ovarian cancer. Annals of Oncology, 2017, 28, viii1-viii7.	0.6	276
1992	Targeting Neoantigens in Glioblastoma. Neurosurgery, 2017, 64, 165-176.	0.6	24
1993	Adaptive Resistance to Cancer Immunotherapy. Advances in Experimental Medicine and Biology, 2017, 1036, 213-227.	0.8	15
1994	Water-soluble polyacetylene: a promising tool for sustainable drug delivery?. Therapeutic Delivery, 2017, 8, 929-932.	1.2	1
1995	Cancer resistance to treatment and antiresistance tools offered by multimodal multifunctional nanoparticles. Cancer Nanotechnology, 2017, 8, 7.	1.9	39
1996	Development of tumor vessel-injuring CAR-T cell therapy for refractory solid cancer. Drug Delivery System, 2017, 32, 184-191.	0.0	0
1998	Bioinformatics Approaches to Profile the Tumor Microenvironment for Immunotherapeutic Discovery. Current Pharmaceutical Design, 2017, 23, 4716-4725.	0.9	11
1999	Association between Toll-like Receptor and Tumor Necrosis Factor Immunological Pathways in Uterine Cervical Neoplasms. Tumori, 2017, 103, 81-86.	0.6	25

#	Article	IF	Citations
2001	Chimeric antigen receptor T cells for the treatment of lymphoma. Annals of Lymphoma, 2017, 1, 1-1.	4.5	0
2002	Programmed Death-Ligand 1 Expression in a Large Cohort of Pediatric Patients With Solid Tumor and Association With Clinicopathologic Features in Neuroblastoma. JCO Precision Oncology, 2017, 1, 1-12.	1.5	8
2003	Role of Kynurenine Pathway in Glioblastoma. , 2017, , .		1
2004	Cancer Immunotherapy in Older Patients. Cancer Journal (Sudbury, Mass), 2017, 23, 219-222.	1.0	4
2005	How cancer immunotherapy works. , 2017, , .		0
2006	Considerations for the Development of Innovative Therapies Against Aggressive Neuroblastoma: Immunotherapy and Twist1 Targeting. , 2017, , .		0
2007	Bilateral Uveitis and Keratitis Following Nivolumab Treatment for Metastatic Melanoma. Medical Case Reports (Wilmington, Del), 2017, 03, .	0.1	19
2008	Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer. Journal of Gynecologic Oncology, 2017, 28, e64.	1.0	45
2009	The Emerging Roles of Extracellular Vesicles As Communication Vehicles within the Tumor Microenvironment and Beyond. Frontiers in Endocrinology, 2017, 8, 194.	1.5	78
2010	The Immunoregulatory Potential of Particle Radiation in Cancer Therapy. Frontiers in Immunology, 2017, 8, 99.	2.2	52
2011	Antigen Loss Variants: Catching Hold of Escaping Foes. Frontiers in Immunology, 2017, 8, 175.	2.2	35
2012	Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma. Frontiers in Immunology, 2017, 8, 1617.	2.2	43
2013	Using Murine Models to Investigate Tumorâ€“Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma. Frontiers in Oncology, 2017, 7, 86.	1.3	1
2014	Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions. Frontiers in Oncology, 2017, 7, 156.	1.3	87
2015	Changes in regulatory T cells in dogs with B-cell lymphoma and association with clinical tumour stage. Veterinarni Medicina, 2017, 62, 647-653.	0.2	1
2016	Targeting Cancer Stem Cells and Their Niche: Current Therapeutic Implications and Challenges in Pancreatic Cancer. Stem Cells International, 2017, 2017, 1-9.	1.2	11
2017	Cancer-derived Circulating MicroRNAs Promote Tumor Angiogenesis by Entering Dendritic Cells to Degrade Highly Complementary MicroRNAs. Theranostics, 2017, 7, 1407-1421.	4.6	27
2018	Bioengineering of Artificial Antigen Presenting Cells and Lymphoid Organs. Theranostics, 2017, 7, 3504-3516.	4.6	54

#	Article	IF	Citations
2019	Integrin Î²1 activation induces an anti-melanoma host response. PLoS ONE, 2017, 12, e0175300.	1.1	9
2020	Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity. Tumori, 2017, 103, 405-421.	0.6	52
2021	CSPG4: a prototype oncoantigen for translational immunotherapy studies. Journal of Translational Medicine, 2017, 15, 151.	1.8	51
2023	The Mechanism of Checkpoint Inhibitors in Gynecologic Cancer. Journal of Carcinogenesis & Mutagenesis, 2017, 08, .	0.3	0
2024	Dual role of inflammatory mediators in cancer. Ecancermedicalscience, 2017, 11, 721.	0.6	119
2025	Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. Emerging Topics in Life Sciences, 2017, 1, 471-486.	1.1	5
2026	Cancer Immunotherapy. , 2017, , 32-65.		1
2027	NK Cells and Cancer. , 0, , .		1
2028	Management of intracranial melanomas in the era of precision medicine. Oncotarget, 2017, 8, 89326-89347.	0.8	16
2029	Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors. Oncotarget, 2017, 8, 41641-41669.	0.8	15
2030	Ubiquitination of tumor suppressor PML regulates prometastatic and immunosuppressive tumor microenvironment. Journal of Clinical Investigation, 2017, 127, 2982-2997.	3.9	55
2031	The concept of immune surveillance against tumors: The first theories. Oncotarget, 2017, 8, 7175-7180.	0.8	221
2032	South African Breast Cancer and HIV Outcomes Study: Methods and Baseline Assessment. Journal of Global Oncology, 2017, 3, 114-124.	0.5	32
2033	CAR-T cell therapy in ovarian cancer: from the bench to the bedside. Oncotarget, 2017, 8, 64607-64621.	0.8	44
2034	The Triple Immune Argument; Surveillance/Evasion/ Senescence and the Increased Incidence of Acute Myeloid Leukemia Observed with Age. American Journal of Immunology, 2017, 13, 233-252.	0.1	0
2035	Antigen-Presenting Cell/Tumour Cell Hybrid Vaccines in Cancer Immunotherapy. , 2017, , .		1
2036	Immune system and melanoma biology: a balance between immunosurveillance and immune escape. Oncotarget, 2017, 8, 106132-106142.	0.8	174
2037	Renal Toxicity in Patients Treated with Anti-Pd-1 Targeted Agents for Solid Tumors. Journal of Onco-Nephrology, 2017, 1, 132-142.	0.3	4

#	Article	IF	Citations
2038	The role of an immune checkpoint score in resected non-small cell lung cancer patientsâ€™ prognosis. Journal of Thoracic Disease, 2017, 9, 3480-3482.	0.6	1
2039	Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors. Oncotarget, 2017, 8, 53730-53739.	0.8	24
2040	Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes?. Modern Pathology, 2018, 31, 1012-1025.	2.9	25
2041	Prophylactic Vaccines for Nonviral Cancers. Annual Review of Cancer Biology, 2018, 2, 195-211.	2.3	8
2042	Resisting resistance to cancer immunotherapy. Thoracic Cancer, 2018, 9, 507-508.	0.8	8
2043	The possibility of cancer immune editing in gliomas. A critical review. OncoImmunology, 2018, 7, e1445458.	2.1	35
2044	Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma. Journal of Dental Research, 2018, 97, 622-626.	2.5	16
2045	Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review). International Journal of Oncology, 2018, 52, 1041-1056.	1.4	4
2046	Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. International Journal of Cancer, 2018, 143, 746-757.	2.3	19
2047	Genomics and emerging biomarkers for immunotherapy of colorectal cancer. Seminars in Cancer Biology, 2018, 52, 189-197.	4.3	112
2048	Hepatocellular carcinoma: Prospects for natural killer cell immunotherapy. Hla, 2018, 92, 3-11.	0.4	10
2049	On the learning control effects in the cancer-immune system competition. Physica A: Statistical Mechanics and Its Applications, 2018, 506, 462-475.	1.2	11
2050	Thematic Review Series: Exosomes and Microvesicles: Lipids as Key Components of their Biogenesis and Functions Extracellular vesicles and their content in bioactive lipid mediators: more than a sack of microRNA. Journal of Lipid Research, 2018, 59, 2037-2046.	2.0	129
2051	Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2018, 94, 153-160.	1.6	25
2052	Differential Reliance on Lipid Metabolism as a Salvage Pathway Underlies Functional Differences of T Cell Subsets in Poor Nutrient Environments. Cell Reports, 2018, 23, 741-755.	2.9	45
2053	Skin Diseases in the Immunosuppressed. , 2018, , .		2
2054	Regulatory T cells: a potential target in cancer immunotherapy. Annals of the New York Academy of Sciences, 2018, 1417, 104-115.	1.8	184
2055	The gut microbiota influences anticancer immunosurveillance and general health. Nature Reviews Clinical Oncology, 2018, 15, 382-396.	12.5	389

#	Article	IF	Citations
2056	Colorectal cancer prevention: Immune modulation taking the stage. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1869, 138-148.	3.3	53
2057	Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung. Journal of Thoracic Oncology, 2018, 13, 636-648.	0.5	67
2058	The tumour glyco-code as a novel immune checkpoint for immunotherapy. Nature Reviews Immunology, 2018, 18, 204-211.	10.6	303
2059	Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma. International Journal of Oral and Maxillofacial Surgery, 2018, 47, 836-845.	0.7	66
2061	Radiation therapy and immunotherapy: what is the optimal timing or sequencing?. Immunotherapy, 2018, 10, 299-316.	1.0	49
2062	Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy. Oncogenesis, 2018, 7, 2.	2.1	68
2063	Myeloid Neoplasms Following Solid Organ Transplantation. American Journal of Clinical Pathology, 2018, 149, 55-66.	0.4	11
2064	Tâ€cell crossâ€reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors. Scandinavian Journal of Immunology, 2018, 87, e12643.	1.3	24
2065	Angiogenesis and evading immune destruction are the main related transcriptomic characteristics to the invasive process of oral tongue cancer. Scientific Reports, 2018, 8, 2007.	1.6	13
2066	Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy. Clinical Cancer Research, 2018, 24, 2473-2481.	3.2	49
2067	The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer. Breast Care, 2018, 13, 16-21.	0.8	135
2068	Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road ahead. Expert Review of Molecular Diagnostics, 2018, 18, 297-305.	1.5	23
2071	Stress-induced cellular responses in immunogenic cell death: Implications for cancer immunotherapy. Biochemical Pharmacology, 2018, 153, 12-23.	2.0	104
2072	Blood and lymphatic vessels contribute to the impact of the immune microenvironment on clinical outcome in non-small-cell lung cancerâ€. European Journal of Cardio-thoracic Surgery, 2018, 53, 1205-1213.	0.6	12
2073	NK Cells Control Tumor-Promoting Function of Neutrophils in Mice. Cancer Immunology Research, 2018, 6, 348-357.	1.6	39
2074	Dually modified transmembrane proteoglycans in development and disease. Cytokine and Growth Factor Reviews, 2018, 39, 124-136.	3.2	31
2075	The dawn of vaccines for cancer prevention. Nature Reviews Immunology, 2018, 18, 183-194.	10.6	178
2076	Peptide-Based Therapeutic Cancer Vaccines. , 2018, , 249-261.		2

#	Article	IF	Citations
2077	Innate Immune Receptors in the Regulation of Tumor Immunity. , 2018, , 407-427.		0
2078	The Secrets of T Cell Polarization. , 2018, , 69-95.		0
2079	Monoclonal Antibodies Targeting the Immune System. , 2018, , 141-160.		0
2080	Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome. OncoImmunology, 2018, 7, e1423184.	2.1	38
2081	A Believerâ€™s Overview of Cancer Immunosurveillance and Immunotherapy. Journal of Immunology, 2018, 200, 385-391.	0.4	103
2082	Immunotherapy for cervical cancer: Can it do another lung cancer?. Current Problems in Cancer, 2018, 42, 148-160.	1.0	10
2083	Type, Frequency, and Spatial Distribution of Immune Cell Infiltrates in CNS Germinomas: Evidence for Inflammatory and Immunosuppressive Mechanisms. Journal of Neuropathology and Experimental Neurology, 2018, 77, 119-127.	0.9	23
2084	Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. Journal of Hematology and Oncology, 2018, 11, 31.	6.9	256
2085	Gut microbiome modulates efficacy of immune checkpoint inhibitors. Journal of Hematology and Oncology, 2018, 11, 47.	6.9	138
2086	Biliary Tract Cancer: Implicated Immune-Mediated Pathways and Their Associated Potential Targets. Oncology Research and Treatment, 2018, 41, 298-304.	0.8	8
2087	Treatment resistance in urothelial carcinoma: an evolutionary perspective. Nature Reviews Clinical Oncology, 2018, 15, 495-509.	12.5	37
2088	Differential effects of two therapeutic cancer vaccines on short- and long-term survival populations among patients with advanced lung cancer. Seminars in Oncology, 2018, 45, 52-57.	0.8	9
2089	MAGE-A antigens as targets for cancer immunotherapy. Cancer Treatment Reviews, 2018, 67, 54-62.	3.4	51
2090	Vaccine Therapy and Immunotherapy for Pancreatic Cancer. , 2018, , 1461-1505.		0
2091	The current landscape of early drug development for patients with sarcoma in the immunotherapy era. Future Oncology, 2018, 14, 1197-1211.	1.1	11
2092	Immunotherapy for pancreatic cancer: A long and hopeful journey. Cancer Letters, 2018, 425, 143-151.	3.2	35
2093	Armed oncolytic viruses: A kick-start for anti-tumor immunity. Cytokine and Growth Factor Reviews, 2018, 41, 28-39.	3.2	110
2094	Novel targeted therapies and immunotherapy for advanced thyroid cancers. Molecular Cancer, 2018, 17, 51.	7.9	168

#	Article	IF	Citations
2095	Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research, 2018, 24, 2851-2858.	3.2	65
2096	NF-Î²B pathways in the development and progression of colorectal cancer. Translational Research, 2018, 197, 43-56.	2.2	164
2097	Biomarker-driven targeted therapies for gastric/gastro-esophageal junction malignancies. Seminars in Oncology, 2018, 45, 133-150.	0.8	3
2098	Use of extracranial radiation therapy in metastatic melanoma patients receiving immunotherapy. Radiotherapy and Oncology, 2018, 127, 310-317.	0.3	22
2099	Tumor infiltrating lymphocytes in early breast cancer. Breast, 2018, 37, 207-214.	0.9	108
2100	The â€œAchilles' Heelâ€•of Cancer and Its Implications for the Development of Novel Immunotherapeutic Strategies. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a027086.	2.9	11
2101	The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy. Leukemia, 2018, 32, 429-437.	3.3	76
2102	Intrinsic and extrinsic causes of malignancies in patients with primary immunodeficiency disorders. Journal of Allergy and Clinical Immunology, 2018, 141, 59-68.e4.	1.5	99
2103	Personalized neoantigen vaccines: A new approach to cancer immunotherapy. Bioorganic and Medicinal Chemistry, 2018, 26, 2842-2849.	1.4	85
2104	Squamous Cell Carcinoma With Hyper-IgE Syndrome: A Case Report. Journal of Pediatric Hematology/Oncology, 2018, 40, e380-e382.	0.3	2
2105	Immunotherapy as an Option for Cancer Treatment. Archivum Immunologiae Et Therapiae Experimentalis, 2018, 66, 89-96.	1.0	19
2106	DAMP-TLR-cytokine axis dictates the fate of tumor. Cytokine, 2018, 104, 114-123.	1.4	71
2107	CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cellular and Molecular Life Sciences, 2018, 75, 689-713.	2.4	351
2108	A Practical Approach to Tumor Heterogeneity in Clinical Research and Diagnostics. Pathobiology, 2018, 85, 7-17.	1.9	13
2109	Humoral and Cellular Immune Dysregulation and Lung Cancer. , 2018, , 137-142.e3.		1
2110	Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas. Oncologist, 2018, 23, 71-83.	1.9	45
2111	Metastasectomy following incomplete response to highâ€dose interleukinâ€2. Journal of Surgical Oncology, 2018, 117, 572-578.	0.8	3
2112	Evolving Immunotherapy Approaches for Hepatocellular Carcinoma. Current Human Cell Research and Applications, 2018, , 93-110.	0.1	0

#	Article	IF	Citations
2114	Mechanisms of Tumor Cellâ€“Intrinsic Immune Evasion. Annual Review of Cancer Biology, 2018, 2, 213-228.	2.3	65
2115	Immuno-oncology from the perspective of somatic evolution. Seminars in Cancer Biology, 2018, 52, 75-85.	4.3	15
2116	CD56+ immune cell infiltration and MICA are decreased in breast lobules with fibrocystic changes. Breast Cancer Research and Treatment, 2018, 167, 649-658.	1.1	5
2117	Breast cancer genomics and immuno-oncological markers to guide immune therapies. Seminars in Cancer Biology, 2018, 52, 178-188.	4.3	111
2119	Melanoma Immunotherapy. Current Cancer Research, 2018, , 307-331.	0.2	0
2120	Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part Iâ€”The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer. Archives of Pathology and Laboratory Medicine, 2018, 142, 26-34.	1.2	30
2121	Cancer Inflammation and Cytokines. Cold Spring Harbor Perspectives in Biology, 2018, 10, a028662.	2.3	175
2122	Cytokines and soluble HLA-G levels in bone marrow stroma and their association with the survival rate of patients exhibiting childhood T-cell acute lymphoblastic leukemia. Cytokine, 2018, 102, 94-101.	1.4	9
2123	Pembrolizumab-Related Neuroinflammation: A Case Report and Review of the Literature. Neurographics, 2018, 8, 119-123.	0.2	1
2124	New horizons from immunotherapy in malignant pleural mesothelioma. Journal of Thoracic Disease, 2018, 10, S322-S332.	0.6	8
2125	Immunomodulation in hepatocellular cancer. Journal of Gastrointestinal Oncology, 2018, 9, 208-219.	0.6	22
2126	The evolving understanding of immunoediting and the clinical impact of immune escape. Journal of Thoracic Disease, 2018, 10, 1248-1252.	0.6	10
2128	The Pattern of Malignancies in Down Syndrome and Its Potential Context With the Immune System. Frontiers in Immunology, 2018, 9, 3058.	2.2	41
2129	Vaccines Developed for Cancer Immunotherapy. , 2018, , .		0
2130	Chinese medicine for immunological functions in women with breast cancer or a history of breast cancer. The Cochrane Library, 2018, , .	1.5	0
2131	The Adaptive Complexity of Cancer. BioMed Research International, 2018, 2018, 1-14.	0.9	17
2132	Dendritic Cells: The Tools for Cancer Treatment. , 0, , .		4
2133	Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma. Frontiers in Immunology, 2018, 9, 2431.	2.2	85

#	Article	IF	Citations
2134	Perspective: cancer vaccines in the era of immune checkpoint blockade. Mammalian Genome, 2018, 29, 703-713.	1.0	20
2135	Interferon-Î² signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells. Biochemical and Biophysical Research Communications, 2018, 507, 330-336.	1.0	52
2136	Advances in evidenceâ€based medicine for immunotherapy of nonâ€small cell lung cancer. Journal of Evidence-Based Medicine, 2018, 11, 278-287.	2.4	22
2137	Of Mice, Dogs, Pigs, and Men: Choosing the Appropriate Model for Immuno-Oncology Research. ILAR Journal, 2018, 59, 247-262.	1.8	40
2138	SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors. Toxins, 2018, 10, 470.	1.5	23
2139	Management of immunotherapy toxicities in older adults. Seminars in Oncology, 2018, 45, 226-231.	0.8	25
2140	Acquired resistance to immunotherapy in MMR-D pancreatic cancer. , 2018, 6, 127.		27
2141	Tumor Immunology, Immunotherapy and Its Application to Head and Neck Squamous Cell Carcinoma (HNSCC). , 2018, , 341-355.		2
2142	Immunotherapy in Non-Small Cell Lung Cancer: Biological Principles and Future Opportunities. Current Molecular Medicine, 2018, 17, 527-540.	0.6	20
2144	Cancer immunotherapy using PolyPurine Reverse Hoogsteen hairpins targeting the PD-1/PD-L1 pathway in human tumor cells. PLoS ONE, 2018, 13, e0206818.	1.1	16
2145	Radiotherapy and immune response: the systemic effects of a local treatment. Clinics, 2018, 73, e557s.	0.6	154
2146	Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer. Journal of Oncology, 2018, 2018, 1-14.	0.6	44
2147	Inflammation in Nonimmune-Mediated Chronic Kidney Disease. , 0, , .		5
2148	Overview of Basic Immunology and Translational Relevance for Clinical Investigators. Advances in Experimental Medicine and Biology, 2018, 995, 1-41.	0.8	6
2149	The Iceberg Map of germline mutations in childhood cancer. Current Opinion in Pediatrics, 2018, 30, 855-863.	1.0	16
2151	Gene landscape and correlation between B-cell infiltration and programmed death ligand 1 expression in lung adenocarcinoma patients from The Cancer Genome Atlas data set. PLoS ONE, 2018, 13, e0208459.	1.1	19
2152	Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. Genome Medicine, 2018, 10, 93.	3.6	121
2153	Neutrophils to lymphocytes ratio as a useful prognosticator for stage II colorectal cancer patients. BMC Cancer, 2018, 18, 1202.	1.1	46

#	Article	IF	Citations
2154	Establishment of inflammation biomarkers-based nomograms to predict prognosis of advanced colorectal cancer patients based on real world data. PLoS ONE, 2018, 13, e0208547.	1.1	11
2155	Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity. Frontiers in Oncology, 2018, 8, 609.	1.3	17
2156	Checkpoint Inhibition in Myeloma: Opportunities and Challenges. Frontiers in Immunology, 2018, 9, 2204.	2.2	45
2157	Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion. Frontiers in Oncology, 2018, 8, 386.	1.3	209
2158	The role of cancer stem cells in the modulation of anti-tumor immune responses. Seminars in Cancer Biology, 2018, 53, 189-200.	4.3	80
2159	Immunoregulatory influence of abundant <scp>MFG</scp>â€E8 expression by esophageal cancer treated with chemotherapy. Cancer Science, 2018, 109, 3393-3402.	1.7	16
2160	Stochastic modeling of tumor progression and immune evasion. Journal of Theoretical Biology, 2018, 458, 148-155.	0.8	15
2161	Is adaptive therapy natural?. PLoS Biology, 2018, 16, e2007066.	2.6	23
2162	The influence of time delay in a chaotic cancer model. Chaos, 2018, 28, 103101.	1.0	87
2163	<scp>CAR</scp>â€T cell therapy in melanoma: A future success story?. Experimental Dermatology, 2018, 27, 1315-1321.	1.4	55
2164	Combined Effect of IL-12RÎ²2 and IL-23R Expression on Prognosis of Patients with Laryngeal Cancer. Cellular Physiology and Biochemistry, 2018, 50, 1041-1054.	1.1	10
2165	The Pro-Tumoral Activity of Heparan Sulfate 3-O-Sulfotransferase 3B (HS3ST3B) in Breast Cancer MDA-MB-231 Cells Is Dependent on the Expression of Neuropilin-1. Molecules, 2018, 23, 2718.	1.7	9
2166	Vascular related pathologies in cardiovascular disease and cancer. Health Problems of Civilization, 2018, 12, 163-187.	0.1	0
2167	A genomic ruler to assess oncogenic transition between breast tumor and stroma. PLoS ONE, 2018, 13, e0205602.	1.1	6
2168	Profiling Immune Escape in Hodgkinâ€™s and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining. Cancers, 2018, 10, 415.	1.7	19
2170	Expression of PDâ€L1 and SOX2 during rectal tumourigenesis: Potential mechanisms for immune escape and tumour cell invasion. Oncology Letters, 2018, 16, 5761-5768.	0.8	7
2171	Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nature Reviews Clinical Oncology, 2018, 15, 748-762.	12.5	304
2172	The Utility of Pretreatment and Posttreatment Lymphopenia in Cervical Squamous Cell Carcinoma Patients Treated With Definitive Chemoradiotherapy. International Journal of Gynecological Cancer, 2018, 28, 1553-1559.	1.2	13

#	Article	IF	Citations
2173	Fluorine-19 MRI for detection and quantification of immune cell therapy for cancer. , 2018, 6, 105.		75
2174	Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer. Hematology/Oncology Clinics of North America, 2018, 32, 1025-1039.	0.9	11
2175	Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway. ACS Nano, 2018, 12, 11041-11061.	7.3	200
2177	Immune regulation of metastasis: mechanistic insights and therapeutic opportunities. DMM Disease Models and Mechanisms, 2018, 11, .	1.2	102
2178	Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. New England Journal of Medicine, 2018, 379, 2330-2341.	13.9	322
2179	Assessment of Age-Related Decline of Immunological Function and Possible Methods for Immunological Restoration in Elderly. , 2018, , 1-27.		0
2180	Immune Checkpoint Inhibitor Therapy in Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1259-1268.	2.3	32
2181	Low preâ€treatment nutritional index is significantly related to poor outcomes in small cell lung cancer. Thoracic Cancer, 2018, 9, 1483-1491.	0.8	19
2182	Immunoengineering through cancer vaccines â€“ A personalized and multi-step vaccine approach towards precise cancer immunity. Journal of Controlled Release, 2018, 289, 125-145.	4.8	31
2183	Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. European Journal of Cancer, 2018, 103, 7-16.	1.3	63
2184	Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models. Breast Cancer Research, 2018, 20, 108.	2.2	81
2185	Trial watch: Peptide-based vaccines in anticancer therapy. OncoImmunology, 2018, 7, e1511506.	2.1	121
2187	Combinations of Bevacizumab With Cancer Immunotherapy. Cancer Journal (Sudbury, Mass), 2018, 24, 193-204.	1.0	144
2188	Interferon-Î³ and Colorectal Cancer: an up-to date. Journal of Cancer, 2018, 9, 232-238.	1.2	26
2189	Translational Platform for Immuno-Oncology Discovery. Genetic Engineering and Biotechnology News, 2018, 38, 10-11.	0.1	1
2190	Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival. OncoImmunology, 2018, 7, e1509820.	2.1	80
2191	Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors. Current Rheumatology Reports, 2018, 20, 65.	2.1	39
2192	CD8+ and CD163+ infiltrating cells and PDâ€L1 immunoexpression in oral leukoplakia and oral carcinoma. Apmis, 2018, 126, 732-738.	0.9	36

#	Article	IF	Citations
2193	Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. Frontiers in Immunology, 2018, 9, 1878.	2.2	127
2194	Immunological-based approaches for cancer therapy. Clinics, 2018, 73, e429s.	0.6	7
2195	Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. Drug Design, Development and Therapy, 2018, Volume 12, 209-215.	2.0	29
2196	Immune Checkpoint Blockade and Immune Monitoring. , 0, , .		1
2197	MiRNAs: dynamic regulators of immune cell functions in inflammation and cancer. Cancer Letters, 2018, 431, 11-21.	3.2	88
2198	Cancer cell transmission via the placenta. Evolution, Medicine and Public Health, 2018, 2018, 106-115.	1.1	34
2199	Tâ€cell tracking using Cerenkov and radioluminescence imaging. Journal of Biophotonics, 2018, 11, e201800093.	1.1	13
2200	Novel non-invasive early detection of lung cancer using liquid immunobiopsy metabolic activity profiles. Cancer Immunology, Immunotherapy, 2018, 67, 1135-1146.	2.0	5
2201	Discovery of a polysaccharide from the fruiting bodies of Lepista sordida as potent inhibitors of indoleamine 2, 3-dioxygenase (IDO) in HepG2 cells via blocking of STAT1-mediated JAK-PKC-Î´ signaling pathways. Carbohydrate Polymers, 2018, 197, 540-547.	5.1	8
2202	Immune effectors responsible for the elimination of hyperploid cancer cells. OncoImmunology, 2018, 7, e1463947.	2.1	14
2203	A Theoretical Basis for the Efficacy of Cancer Immunotherapy and Immunogenic Tumor Dormancy: The Adaptation Model of Immunity. Advances in Cancer Research, 2018, 137, 17-36.	1.9	12
2204	Immuntherapie â€“ Die neue Ã„ra in der Onkologie. Laryngo- Rhino- Otologie, 2018, 97, S3-S47.	0.2	1
2205	Mechanistic considerations in chemotherapeutic activity of caffeine. Biomedicine and Pharmacotherapy, 2018, 105, 312-319.	2.5	29
2206	The Immune Biology of Microsatellite Unstable Cancer. , 2018, , 367-384.		4
2207	Current and future biomarkers in gastric cancer. Biomedicine and Pharmacotherapy, 2018, 103, 1688-1700.	2.5	44
2208	Thinking Cancer. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2018, 37, 117-125.	0.8	3
2209	Immune suppression and reversal of the suppressive tumor microenvironment. International Immunology, 2018, 30, 445-455.	1.8	110
2210	The Immune Response to Glioblastoma: Overview and Focus on Checkpoint Blockade. , 2018, , 653-668.		0

#	Article	IF	Citations
2211	Molecular mechanisms of the preventable causes of cancer in the United States. Genes and Development, 2018, 32, 868-902.	2.7	105
2212	CXCR4/CXCL12 Signaling and Protumor Macrophages in Primary Tumors and Sentinel Lymph Nodes Are Involved in Luminal B Breast Cancer Progression. Disease Markers, 2018, 2018, 1-9.	0.6	10
2213	Targeting of drug-loaded nanoparticles to tumor sites increases cell death and release of danger signals. Journal of Controlled Release, 2018, 285, 67-80.	4.8	19
2214	IKZF1 Enhances Immune Infiltrate Recruitment in Solid Tumors and Susceptibility to Immunotherapy. Cell Systems, 2018, 7, 92-103.e4.	2.9	48
2215	EGFR activation induced Snail-dependent EMT and myc-dependent PD-L1 in human salivary adenoid cystic carcinoma cells. Cell Cycle, 2018, 17, 1457-1470.	1.3	42
2216	Stem Cells and Cancer. , 2018, , 271-309.		0
2217	Immune interconnectivity of anatomically distant tumors as a potential mediator of systemic responses to local therapy. Scientific Reports, 2018, 8, 9474.	1.6	34
2218	Metastatic gynecologic malignancies: advances in treatment and management. Clinical and Experimental Metastasis, 2018, 35, 521-533.	1.7	11
2219	Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Tuberculosis and Respiratory Diseases, 2018, 81, 29.	0.7	24
2221	microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Antitumor Immune Response and Poor Outcomes of Patients. Gastroenterology, 2018, 155, 784-798.	0.6	70
2222	Clinical impact of pretreatment prognostic nutritional index (PNI) in small cell lung cancer patients treated with platinumâ€based chemotherapy. Clinical Respiratory Journal, 2018, 12, 2433-2440.	0.6	31
2223	Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types?. Frontiers in Physiology, 2018, 9, 113.	1.3	817
2224	Antitumor Activity of Extract From the Sporoderm-Breaking Spore of Ganoderma lucidum: Restoration on Exhausted Cytotoxic T Cell With Gut Microbiota Remodeling. Frontiers in Immunology, 2018, 9, 1765.	2.2	70
2225	An Update on Immunotherapy for Solid Tumors: A Review. Annals of Surgical Oncology, 2018, 25, 3404-3412.	0.7	66
2226	Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review. Frontiers in Immunology, 2017, 8, 1825.	2.2	39
2227	How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive. Frontiers in Immunology, 2018, 9, 262.	2.2	91
2228	Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy. Frontiers in Immunology, 2018, 9, 946.	2.2	19
2229	Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy. Haematologica, 2018, 103, 1256-1268.	1.7	69

#	Article	IF	Citations
2230	Effect of neoadjuvant chemotherapy on the immune microenvironment in nonâ€“small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. , 2018, 6, 48.		126
2231	Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy. Cancers, 2018, 10, 6.	1.7	158
2232	Advances in oncolytic adenovirus therapy for pancreatic cancer. Cancer Letters, 2018, 434, 56-69.	3.2	33
2233	Migration/Invasion of Malignant Gliomas and Implications for Therapeutic Treatment. International Journal of Molecular Sciences, 2018, 19, 1115.	1.8	72
2234	Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific. Nature Immunology, 2018, 19, 885-897.	7.0	152
2235	Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). , 2018, 6, 39.		329
2236	Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens. Pediatric Blood and Cancer, 2018, 65, e27313.	0.8	11
2237	Etiology of increased cancer incidence after solid organ transplantation. Transplantation Reviews, 2018, 32, 218-224.	1.2	51
2238	Tumor-Associated T-Lymphocytes and Macrophages are Decreased in Endometrioid Endometrial Carcinoma with MELF-Pattern Stromal Changes. Cancer Microenvironment, 2018, 11, 107-114.	3.1	10
2239	Dysfunction of Natural Killer Cells by FBP1-Induced Inhibition of Glycolysis during Lung Cancer Progression. Cell Metabolism, 2018, 28, 243-255.e5.	7.2	227
2240	Metabolic Symbiosis and Immunomodulation: How Tumor Cell-Derived Lactate May Disturb Innate and Adaptive Immune Responses. Frontiers in Oncology, 2018, 8, 81.	1.3	86
2241	MiR-544 promotes immune escape through downregulation of NCR1/NKp46 via targeting RUNX3 in liver cancer. Cancer Cell International, 2018, 18, 52.	1.8	23
2242	Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. Cancer Treatment Reviews, 2018, 66, 104-113.	3.4	78
2243	Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer. BMC Cancer, 2018, 18, 87.	1.1	33
2244	The prognostic value of preoperative prognostic nutritional index in patients with hypopharyngeal squamous cell carcinoma: a retrospective study. Journal of Translational Medicine, 2018, 16, 12.	1.8	23
2245	The signature of liver cancer in immune cells DNA methylation. Clinical Epigenetics, 2018, 10, 8.	1.8	51
2247	Immune Prophets of Lung Cancer: The Prognostic and Predictive Landscape of Cellular and Molecular Immune Markers. Translational Oncology, 2018, 11, 825-835.	1.7	45
2248	Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. Journal of Hematology and Oncology, 2018, 11, 104.	6.9	303

#	Article	IF	Citations
2249	Immunomodulation and the Risk for Neoplasia. , 2018, , 717-731.		0
2250	Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy. Frontiers in Oncology, 2018, 8, 285.	1.3	89
2251	Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nature Medicine, 2018, 24, 1459-1468.	15.2	437
2252	Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation. OncoImmunology, 2018, 7, e1468957.	2.1	15
2253	Prostaglandin E2 Secreted by Thyroid Cancer Cells Contributes to Immune Escape Through the Suppression of Natural Killer (NK) Cell Cytotoxicity and NK Cell Differentiation. Frontiers in Immunology, 2018, 9, 1859.	2.2	111
2254	HLA Class I Antigen Expression in Conjunctival Melanoma Is Not Associated With PD-L1/PD-1 Status. , 2018, 59, 1005.		12
2255	Role of regulatory Tï¿½cells and CD8+ï¿½T lymphocytes in the dissemination of circulating tumor cells in primary invasive breast cancer. Oncology Letters, 2018, 16, 3045-3053.	0.8	19
2256	Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: A review of cooperative mechanisms and clinical opportunities. Brachytherapy, 2018, 17, 995-1003.	0.2	23
2257	Checkpoint blockadeâ€based immunotherapy in the context of tumor microenvironment: Opportunities and challenges. Cancer Medicine, 2018, 7, 4517-4529.	1.3	34
2258	Effective nivolumab sequential thoracic radiotherapy in elderly patients with advanced squamous cell lung cancer: did radiation therapy play a role? A case report. OncoTargets and Therapy, 2018, Volume 11, 4621-4629.	1.0	6
2259	CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers. International Journal of Endocrinology, 2018, 2018, 1-10.	0.6	20
2260	Randomized controlled phase III trial of adjuvant chemoimmunotherapy with activated cytotoxic T cells and dendritic cells from regional lymph nodes of patients with lung cancer. Cancer Immunology, Immunotherapy, 2018, 67, 1231-1238.	2.0	23
2262	Immunotherapy Resistance by Inflammation-Induced Dedifferentiation. Cancer Discovery, 2018, 8, 935-943.	7.7	130
2263	Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy. Nature Communications, 2018, 9, 2351.	5.8	253
2264	Breast Cancer Immunotherapy: An Update. Breast Cancer: Basic and Clinical Research, 2018, 12, 117822341877480.	0.6	37
2265	Recent progress in therapeutic antibodies for cancer immunotherapy. Current Opinion in Chemical Biology, 2018, 44, 56-65.	2.8	21
2266	Immunomodulation and cancer: Using mechanistic paradigms to inform risk assessment. Current Opinion in Toxicology, 2018, 10, 98-110.	2.6	3
2267	Mathematical Immunology of Virus Infections. , 2018, , .		42

#	Article	IF	Citations
2268	Nanotechnology Approaches to Improving Cancer Immunotherapy. Advances in Cancer Research, 2018, 139, 35-56.	1.9	33
2269	Expression of multiple immune checkpoint molecules on TÃ¯Â¿Â½cells in malignant ascites from epithelial ovarian carcinoma. Oncology Letters, 2018, 15, 6457-6468.	0.8	37
2270	Development and Function of Natural Killer Cells and Its Importance in Cancer Immunotherapy. , 2018, , 117-140.		6
2271	Effects of immune suppression for transplantation on inflammatory colorectal cancer progression. Oncogenesis, 2018, 7, 46.	2.1	3
2272	Functional genomics: paving the way for more successful cancer immunotherapy. Briefings in Functional Genomics, 2019, 18, 86-98.	1.3	6
2273	Immunotherapy in CNS cancers: the role of immune cell trafficking. Neuro-Oncology, 2019, 21, 37-46.	0.6	76
2274	Cyclophosphamide with or without fluorouracil followed by subcutaneous or intravenous interleukin-2 use in solid tumors: A feasibility off-label experience. Cytokine, 2019, 113, 50-60.	1.4	5
2275	Silencing of the interferon-inducible gene Ifi204/p204 induces resistance to interferon-Î³-mediated cell growth arrest of tumor cells. Cytokine, 2019, 118, 80-92.	1.4	3
2276	Durch Nanopartikel vermittelter immunogener Zelltod ermÃ¶glicht und verstÃ¤rkt die Immuntherapie gegen Krebs. Angewandte Chemie, 2019, 131, 680-691.	1.6	22
2277	Next-generation sequencing technologies accelerate advances in T-cell therapy for cancer. Briefings in Functional Genomics, 2019, 18, 119-128.	1.3	4
2278	Immunomodulatory role of histamine H4 receptor in breast cancer. British Journal of Cancer, 2019, 120, 128-138.	2.9	29
2279	Nanoparticleâ€Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy. Angewandte Chemie - International Edition, 2019, 58, 670-680.	7.2	671
2280	Advances in the management of brain metastases from cancer of unknown primary. Future Oncology, 2019, 15, 2759-2768.	1.1	4
2281	Transcutaneous immunization with CD40 ligation boosts cytotoxic T lymphocyte mediated antitumor immunity independent of CD4 helper cells in mice. European Journal of Immunology, 2019, 49, 2083-2094.	1.6	8
2282	Melanoma Immunology and Immunotherapy. , 2019, , 651-665.		0
2283	miR-448 targets IDO1 and regulates CD8+ T cell response in human colon cancer. , 2019, 7, 210.		71
2284	Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a systematic review protocol. BMJ Open, 2019, 9, e026975.	0.8	18
2285	Emerging Roles of Th9 Cells as an Anti-tumor Helper T Cells. International Reviews of Immunology, 2019, 38, 204-211.	1.5	15

#	Article	IF	Citations
2286	Regulation of Immunity in Breast Cancer. Cancers, 2019, 11, 1080.	1.7	43
2287	Avelumab in gastric cancer. Immunotherapy, 2019, 11, 759-768.	1.0	17
2288	Thermostatted kinetic theory approach to the competition between cancer and immune system cells in an inhomogeneous system. AIP Conference Proceedings, 2019, , .	0.3	0
2289	Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma. Cancers, 2019, 11, 971.	1.7	87
2290	Prognostic impact of circulating monocyte subsets in pediatric solid tumors. Cancer Biomarkers, 2019, 25, 371-379.	0.8	2
2291	Extra-Adrenal Glucocorticoid Synthesis in the Intestinal Mucosa: Between Immune Homeostasis and Immune Escape. Frontiers in Immunology, 2019, 10, 1438.	2.2	46
2292	Cellular Therapy for Melanoma. , 2019, , 1-33.		0
2293	Granulocytic Myeloidâ€Derived Suppressor Cells Promote the Stemness of Colorectal Cancer Cells through Exosomal S100A9. Advanced Science, 2019, 6, 1901278.	5.6	116
2294	Contribution of Aging, Obesity, and Microbiota on Tumor Immunotherapy Efficacy and Toxicity. International Journal of Molecular Sciences, 2019, 20, 3586.	1.8	18
2295	Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer. PLoS ONE, 2019, 14, e0220306.	1.1	21
2296	High endothelial venules are associated with microsatellite instability, hereditary background and immune evasion in colorectal cancer. British Journal of Cancer, 2019, 121, 395-404.	2.9	20
2297	Tumor-Infiltrating Lymphocytes in a Contemporary Cohort of Women with Ductal Carcinoma In Situ (DCIS). Annals of Surgical Oncology, 2019, 26, 3337-3343.	0.7	16
2298	Cancer Immunoediting and Hijacking of the Immune System. Learning Materials in Biosciences, 2019, , 117-139.	0.2	0
2299	Downregulated expression of human leukocyte antigen class I heavy chain is associated with poor prognosis in nonâ€‘smallâ€‘cell lung cancer. Oncology Letters, 2019, 18, 117-126.	0.8	10
2300	Major fundamental factors hindering immune system in defense against tumor cells: The link between insufficiency of innate immune responses, metabolism, and neurotransmitters with effector immune cells disability. Immunology Letters, 2019, 212, 81-87.	1.1	7
2301	Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. Annals of Oncology, 2019, 30, 1466-1471.	0.6	97
2302	Dysregulation of helper T lymphocytes in esophageal squamous cell carcinoma (ESCC) patients is highly associated with aberrant production of miR-21. Immunologic Research, 2019, 67, 212-222.	1.3	18
2303	The Emerging Roles of Heparan Sulfate 3-O-Sulfotransferases in Cancer. Frontiers in Oncology, 2019, 9, 507.	1.3	33

#	Article	IF	Citations
2305	Primary Immunodeficiencies and Oncological Risk: The Experience of the Children's Hospital of Brescia. Frontiers in Pediatrics, 2019, 7, 232.	0.9	17
2306	Mouse CD8+NKT-like cells exert dual cytotoxicity against mouse tumor cells and myeloid-derived suppressor cells. Cancer Immunology, Immunotherapy, 2019, 68, 1303-1315.	2.0	27
2307	Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future. International Journal of Molecular Sciences, 2019, 20, 5129.	1.8	19
2308	The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma. Cellular Immunology, 2019, 345, 103964.	1.4	18
2309	Gastrointestinal Tract Dysbiosis Enhances Distal Tumor Progression through Suppression of Leukocyte Trafficking. Cancer Research, 2019, 79, 5999-6009.	0.4	21
2310	Postablation Immune Microenvironment: Synergy between Interventional Oncology and Immuno-oncology. Seminars in Interventional Radiology, 2019, 36, 334-342.	0.3	16
2311	Is the Combination of Immunotherapy and Radiotherapy in Non-small Cell Lung Cancer a Feasible and Effective Approach?. Frontiers in Medicine, 2019, 6, 244.	1.2	31
2312	Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. International Journal of Molecular Sciences, 2019, 20, 5452.	1.8	53
2313	Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga. Trends in Cancer, 2019, 5, 779-788.	3.8	22
2314	CD163 + macrophages infiltration correlates with the immunosuppressive cytokine interleukin 10 expression in tongue leukoplakia. Clinical and Experimental Dental Research, 2019, 5, 627-637.	0.8	16
2315	Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. Cancer Cell, 2019, 36, 471-482.	7.7	280
2316	The role and therapeutic implications of T cells in cancer of the lung. Clinical and Translational Immunology, 2019, 8, e1076.	1.7	25
2317	Allogeneic dendritic cells induce potent antitumor immunity by activating KLRG1+CD8 T cells. Scientific Reports, 2019, 9, 15527.	1.6	7
2318	Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapyâ€”Review of the Literature and Future Outlook. Journal of Clinical Medicine, 2019, 8, 1777.	1.0	87
2319	Regulation of programmed deathâ€ligand 1 expression in response to <scp>DNA</scp> damage in cancer cells: Implications for precision medicine. Cancer Science, 2019, 110, 3415-3423.	1.7	42
2320	Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. Seminars in Cancer Biology, 2019, 59, 236-250.	4.3	200
2321	Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies. Genes and Diseases, 2019, 6, 232-246.	1.5	44
2322	Expression of programmed cell deathâ€ligand 1 in primary testicular diffuse large B cell lymphoma: A retrospective study. Oncology Letters, 2019, 18, 2670-2676.	0.8	3

#	Article	IF	Citations
2323	E2 ubiquitin-conjugating enzymes in cancer: Implications for immunotherapeutic interventions. Clinica Chimica Acta, 2019, 498, 126-134.	0.5	33
2324	Common Molecular Alterations in Canine Oligodendroglioma and Human Malignant Gliomas and Potential Novel Therapeutic Targets. Frontiers in Oncology, 2019, 9, 780.	1.3	7
2325	Tumor-induced peripheral immunosuppression promotes brain metastasis in patients with non-small cell lung cancer. Cancer Immunology, Immunotherapy, 2019, 68, 1501-1513.	2.0	39
2326	Upregulation of Myc promotes the evasion of NK cellâ€'mediated immunity through suppression of NKG2D ligands in K562 cells. Molecular Medicine Reports, 2019, 20, 3301-3307.	1.1	10
2327	Innate lymphoid cells and cancer at border surfaces with the environment. Seminars in Immunology, 2019, 41, 101278.	2.7	11
2328	Ultrathin Metal-Organic-Layer Mediated Radiotherapy-Radiodynamic Therapy. Matter, 2019, 1, 1331-1353.	5.0	78
2329	CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing. BMC Cancer, 2019, 19, 895.	1.1	40
2330	The Crohn's-Like Lymphoid Reaction to Colorectal Cancer-Tertiary Lymphoid Structures With Immunologic and Potentially Therapeutic Relevance in Colorectal Cancer. Frontiers in Immunology, 2019, 10, 1884.	2.2	42
2331	Metformin Prevents Peritoneal Dissemination via Immune-suppressive Cells in the Tumor Microenvironment. Anticancer Research, 2019, 39, 4699-4709.	0.5	9
2332	The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resistance Updates, 2019, 46, 100645.	6.5	324
2334	Have Cells Harboring the HIV Reservoir Been Immunoedited?. Frontiers in Immunology, 2019, 10, 1842.	2.2	17
2335	Prognostic role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with midgut neuroendocrine tumors undergoing resective surgery. International Journal of Colorectal Disease, 2019, 34, 1849-1856.	1.0	11
2336	To each his own: a personalized vaccine for metastatic melanoma. Gland Surgery, 2019, 8, 329-333.	0.5	2
2337	NK Cells in the Treatment of Hematological Malignancies. Journal of Clinical Medicine, 2019, 8, 1557.	1.0	39
2338	RNA Transcription and Splicing Errors as a Source of Cancer Frameshift Neoantigens for Vaccines. Scientific Reports, 2019, 9, 14184.	1.6	32
2339	NK Cell Hyporesponsiveness: More Is Not Always Better. International Journal of Molecular Sciences, 2019, 20, 4514.	1.8	19
2340	Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status. Immunology Letters, 2019, 216, 43-50.	1.1	21
2343	The promising role of monoclonal antibodies for gastric cancer treatment. Immunotherapy, 2019, 11, 347-364.	1.0	10

#	Article	IF	Citations
2344	Unleash the power of the mighty T cells-basis of adoptive cellular therapy. Critical Reviews in Oncology/Hematology, 2019, 136, 1-12.	2.0	20
2345	Intratumoral, rather than stromal, CD8+ T cells could be a potential negative prognostic marker in invasive breast cancer patients. Translational Oncology, 2019, 12, 585-595.	1.7	36
2346	Two-way communication betweenex vivotissues on a microfluidic chip: application to tumorâ€“lymph node interaction. Lab on A Chip, 2019, 19, 1013-1026.	3.1	72
2347	Clonal Deletion of Tumor-Specific T Cells by Interferon-Î³ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. Immunity, 2019, 50, 477-492.e8.	6.6	93
2348	PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor. OncoImmunology, 2019, 8, e1541535.	2.1	32
2349	High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals. Blood Cancer Journal, 2019, 9, 8.	2.8	27
2350	Implications of altered O-glycosylation in tumour immune evasion. Journal of Biochemistry, 2019, 165, 387-390.	0.9	4
2351	Recent advances in the clinical development of immune checkpoint blockade therapy. Cellular Oncology (Dordrecht), 2019, 42, 609-626.	2.1	76
2352	Clonality of CD4+ Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma. Frontiers in Immunology, 2019, 10, 1336.	2.2	57
2353	Epidemiologic perspectives on immunosuppressed populations and the immunosurveillance and immunocontainment of cancer. American Journal of Transplantation, 2019, 19, 3223-3232.	2.6	31
2354	Immunomodulatory Nanosystems. Advanced Science, 2019, 6, 1900101.	5.6	255
2355	Asthma and risk of glioma: a population-based caseâ€“control study. BMJ Open, 2019, 9, e025746.	0.8	6
2356	Molecular and Cell Biology of Cancer. Learning Materials in Biosciences, 2019, , .	0.2	3
2357	Hyperprogression during immunotherapy: do we really want to know?. Annals of Oncology, 2019, 30, 1028-1031.	0.6	17
2358	Strategies based on metal-based nanoparticles for hypoxic-tumor radiotherapy. Chemical Science, 2019, 10, 6932-6943.	3.7	111
2359	Introduction. Advances in Experimental Medicine and Biology, 2019, 1151, 1-14.	0.8	3
2360	Organizing pneumonia after thoracic radiotherapy followed by antiâ€PDâ€1 antibody treatment for patients with lung cancer: Three case reports. Thoracic Cancer, 2019, 10, 1503-1507.	0.8	2
2361	Mathematical Modeling Reveals That the Administration of EGF Can Promote the Elimination of Lymph Node Metastases by PD-1/PD-L1 Blockade. Frontiers in Bioengineering and Biotechnology, 2019, 7, 104.	2.0	17

#	Article	IF	Citations
2362	Microbiota: Overview and Implication in Immunotherapy-Based Cancer Treatments. International Journal of Molecular Sciences, 2019, 20, 2699.	1.8	26
2363	Î²-Catenin Activation Promotes Immune Escape and Resistance to Antiâ€“PD-1 Therapy in Hepatocellular Carcinoma. Cancer Discovery, 2019, 9, 1124-1141.	7.7	498
2364	Assessment of tumor-associated immune cells in laryngeal squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1761-1772.	1.2	22
2365	Modeling Cell Reactions to Ionizing Radiation: From a Lesion to a Cancer. Dose-Response, 2019, 17, 155932581983843.	0.7	10
2366	Review: Targeting the Transforming Growth Factor-Beta Pathway in Ovarian Cancer. Cancers, 2019, 11, 668.	1.7	45
2367	Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents. Viruses, 2019, 11, 406.	1.5	11
2368	PD-1/PD-L1 blockade in paediatric cancers: What does the future hold?. Cancer Letters, 2019, 457, 74-85.	3.2	15
2369	Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology. Frontiers in Immunology, 2019, 10, 924.	2.2	31
2370	Integrated cancer tissue engineering models for precision medicine. PLoS ONE, 2019, 14, e0216564.	1.1	57
2371	Treg-mediated acquired resistance to immune checkpoint inhibitors. Cancer Letters, 2019, 457, 168-179.	3.2	148
2372	ICAM3-Fc Outperforms Receptor-Specific Antibodies Targeted Nanoparticles to Dendritic Cells for Cross-Presentation. Molecules, 2019, 24, 1825.	1.7	10
2373	Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis. OncoImmunology, 2019, 8, e1581547.	2.1	69
2374	Biliary tract cancers: current knowledge, clinical candidates and future challenges . Cancer Management and Research, 2019, Volume 11, 2623-2642.	0.9	78
2375	Tumor mechanisms of resistance to immune attack. Progress in Molecular Biology and Translational Science, 2019, 164, 61-100.	0.9	9
2376	Cancer stem cell immunology and immunotherapy: Harnessing the immune system against cancer's source. Progress in Molecular Biology and Translational Science, 2019, 164, 119-188.	0.9	32
2377	Facing the future: challenges and opportunities in adoptive T cell therapy in cancer. Expert Opinion on Biological Therapy, 2019, 19, 811-827.	1.4	27
2380	Immunotherapy in breast cancer: Current status and future directions. Advances in Cancer Research, 2019, 143, 295-349.	1.9	69
2381	A case of merkel leptomeningeal evolution after complete remission upon antiâ€“PD-1 treatment. European Journal of Cancer, 2019, 113, 55-57.	1.3	2

#	Article	IF	Citations
2382	Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors. Neuro-Oncology Practice, 2019, 6, 340-345.	1.0	7
2383	Squamous cell carcinoma antigen 1 is associated to poor prognosis in esophageal cancer through immune surveillance impairment and reduced chemosensitivity. Cancer Science, 2019, 110, 1552-1563.	1.7	21
2384	Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?. Cancers, 2019, 11, 472.	1.7	24
2385	MDA-9/Syntenin: An emerging global molecular target regulating cancer invasion and metastasis. Advances in Cancer Research, 2019, 144, 137-191.	1.9	17
2386	Neo-antigen specific memory T-cell responses in healthy individuals. OncoImmunology, 2019, 8, e1599640.	2.1	2
2387	Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. Journal of Hematology and Oncology, 2019, 12, 42.	6.9	58
2388	Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy. Frontiers in Cell and Developmental Biology, 2019, 7, 52.	1.8	222
2389	Positive Immuno-Modulation Following Radiofrequency Assisted Liver Resection in Hepatocellular Carcinoma. Journal of Clinical Medicine, 2019, 8, 385.	1.0	21
2390	3D models in the new era of immune oncology: focus on T cells, CAF and ECM. Journal of Experimental and Clinical Cancer Research, 2019, 38, 117.	3.5	78
2391	Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. EBioMedicine, 2019, 42, 363-374.	2.7	257
2392	Immunotherapy in colorectal cancer: rationale, challenges and potential. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 361-375.	8.2	1,039
2393	Tumor-Infiltrating Lymphocytes and Macrophages in Intrahepatic Cholangiocellular Carcinoma. Impact on Prognosis after Complete Surgery. Journal of Gastrointestinal Surgery, 2019, 23, 2216-2224.	0.9	32
2394	Programmed cell death ligand 1 <scp>d</scp>isruption by <scp>clustered regularly interspaced short palindromic repeats</scp>/Cas9â€genome editing promotes antitumor immunity and suppresses ovarian cancer progression. Cancer Science, 2019, 110, 1279-1292.	1.7	31
2395	Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 2019, 9, 122.	1.3	63
2396	Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies. Frontiers in Oncology, 2019, 9, 146.	1.3	123
2397	A nonlinear mathematical model of cell-mediated immune response for tumor phenotypic heterogeneity. Journal of Theoretical Biology, 2019, 471, 42-50.	0.8	16
2398	BLT-Immune Humanized Mice as a Model for Nivolumab-Induced Immune-Mediated Adverse Events: Comparison of the NOG and NOG-EXL Strains. Toxicological Sciences, 2019, 169, 194-208.	1.4	26
2399	Interactions between cancer stem cells, immune system and some environmental components: Friends or foes?. Immunology Letters, 2019, 208, 19-29.	1.1	66

#	Article	IF	Citations
2400	Haploinsufficiency of UNC13D increases the risk of lymphoma. Cancer, 2019, 125, 1848-1854.	2.0	8
2401	Collagen density regulates the activity of tumor-infiltrating T cells. , 2019, 7, 68.		239
2402	Convergent Identification and Interrogation of Tumor-Intrinsic Factors that Modulate Cancer Immunity InÂVivo. Cell Systems, 2019, 8, 136-151.e7.	2.9	14
2403	Tailoring Nanomaterials for Targeting Tumorâ€Associated Macrophages. Advanced Materials, 2019, 31, e1808303.	11.1	223
2404	Immunotherapy of pancreatic cancer. Progress in Molecular Biology and Translational Science, 2019, 164, 189-216.	0.9	41
2405	Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNÎ³ pathways. Nature Reviews Clinical Oncology, 2019, 16, 549-562.	12.5	72
2406	NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment. Frontiers in Immunology, 2019, 10, 661.	2.2	65
2407	Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation. Molecular Cancer, 2019, 18, 88.	7.9	93
2408	Toxoplasma gondii in cancer patients receiving chemotherapy: seroprevalence and interferon gamma level. Journal of Parasitic Diseases, 2019, 43, 464-471.	0.4	13
2409	IFN-Î³ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer. Journal of Surgical Research, 2019, 240, 115-123.	0.8	54
2410	Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing. Frontiers in Pharmacology, 2019, 10, 230.	1.6	89
2411	Immunotherapy of Cancer: Developments and Reference Points, an Unorthodox Approach. Integrative Cancer Therapies, 2019, 18, 153473541982709.	0.8	2
2412	A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy. , 2019, 7, 51.		12
2413	Glial TLR2â€driven innate immune responses and CD8⁺ T cell activation against brain tumor. Glia, 2019, 67, 1179-1195.	2.5	18
2414	Combined prognostic value of CD274 (PD-L1)/PDCDI (PD-1) expression and immune cell infiltration in colorectal cancer as per mismatch repair status. Modern Pathology, 2019, 32, 866-883.	2.9	38
2415	Prognostic value of CD8â€‰+â€‰PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer. , 2019, 7, 34.		75
2416	Multiparametric analysis of CD8⁺ T cell compartment phenotype in chronic lymphocytic leukemia reveals a signature associated with progression toward therapy. OncoImmunology, 2019, 8, e1570774.	2.1	6
2417	Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy. Advanced Materials, 2019, 31, e1803322.	11.1	205

#	Article	IF	Citations
2418	A mathematical solution to Petoâ€™s paradox using Polyaâ€™s urn model: implications for the aetiology of cancer in general. Theory in Biosciences, 2019, 138, 241-250.	0.6	3
2419	Tumor-associated macrophages: a short compendium. Cellular and Molecular Life Sciences, 2019, 76, 1447-1458.	2.4	71
2420	Effects of probiotics on chemotherapy in patients with lung cancer. Oncology Letters, 2019, 17, 2836-2848.	0.8	48
2421	Optimal control of tumour-immune model with time-delay and immuno-chemotherapy. Applied Mathematics and Computation, 2019, 353, 147-165.	1.4	48
2422	T Cell-Redirecting Strategies to â€˜STAbâ€™ Tumors: Beyond CARs and Bispecific Antibodies. Trends in Immunology, 2019, 40, 243-257.	2.9	32
2423	The pioneers behind immune checkpoint blockers awarded the Nobel Prize in physiology or medicine 2018. Acta OncolÃ³gica, 2019, 58, 1-8.	0.8	14
2425	New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an â€œESMO Open â€“ Cancer Horizonsâ€•Series. ESMO Open, 2019, 4, e000501.	2.0	6
2426	Prognostic and Therapeutic Implications of Lymphocytes in Hematological Disorders and Solid Malignancies. , 0, , .		0
2427	Cancer Vaccines. , 2019, , .		1
2428	The new revolution of immunotherapy: is it time to pair it with the old one? â€”Yellow Leader as a candidate. Longhua Chinese Medicine, 2019, 2, 7-7.	0.5	0
2429	Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries. BioMed Research International, 2019, 2019, 1-22.	0.9	9
2430	Repurposing Drugs for Cancer Radiotherapy. Cancer Journal (Sudbury, Mass), 2019, 25, 106-115.	1.0	8
2431	Lymphopaenia and accidental splenic doses: Do they have any prognostic value for locally advanced gastric cancer patients treated with radiochemotherapy?. Wspolczesna Onkologia, 2019, 23, 226-233.	0.7	1
2432	Microfluidics-assisted multiplexed biomarker detection for in situ mapping of immune cells in tumor sections. Microsystems and Nanoengineering, 2019, 5, 59.	3.4	24
2433	Minimum environmental enrichment is effective in activating antitumor immunity to transplanted tumor cells in mice. Experimental Animals, 2019, 68, 569-576.	0.7	11
2435	Immunotherapy: A Challenge of Breast Cancer Treatment. Cancers, 2019, 11, 1822.	1.7	106
2436	Detection of Circulating Tumor Cell Molecular Subtype in Pulmonary Vein Predicting Prognosis of Stage Iâ€“III Non-small Cell Lung Cancer Patients. Frontiers in Oncology, 2019, 9, 1139.	1.3	28
2437	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2019, 629, xxi-xl.	0.4	1

#	Article	IF	Citations
2438	Serum Squamous Cell Carcinoma Antigen-Immunoglobulin M complex levels predict survival in patients with cirrhosis. Scientific Reports, 2019, 9, 20126.	1.6	6
2439	Companion Animals as Models for Inhibition of STAT3 and STAT5. Cancers, 2019, 11, 2035.	1.7	3
2440	Mono-institutional phase 2 study of innovative Stereotactic Body RadioTherapy targeting PArtial Tumor HYpoxic (SBRT-PATHY) clonogenic cells in unresectable bulky non-small cell lung cancer: profound non-targeted effects by sparing peri-tumoral immune microenvironment. Radiation Oncology, 2019, 14, 212.	1.2	33
2441	IL-17 inhibits CXCL9/10-mediated recruitment of CD8+ cytotoxic T cells and regulatory T cells to colorectal tumors. , 2019, 7, 324.		68
2442	Single-Cell Omics: Strategies Towards Theranostic Biomarker Discovery Along the Continuum of Premalignant to Invasive Disease in Oncology. , 2019, , 105-128.		0
2443	Significance of TIM3 expression in cancer: From biology to the clinic. Seminars in Oncology, 2019, 46, 372-379.	0.8	49
2444	Longitudinal molecular trajectories of diffuse glioma in adults. Nature, 2019, 576, 112-120.	13.7	320
2445	Escape From ALL-CARTaz. Cancer Journal (Sudbury, Mass), 2019, 25, 217-222.	1.0	20
2446	Contribution of Angiogenesis to Inflammation and Cancer. Frontiers in Oncology, 2019, 9, 1399.	1.3	201
2447	Nonequilibrium physics in biology. Reviews of Modern Physics, 2019, 91, .	16.4	123
2448	Prognostic Significance of Hematological Indices in Malignant Melanoma Treated With Immune Checkpoint Inhibitors. Journal of Immunotherapy, 2019, 42, 251-264.	1.2	13
2449	Caveolin-2 deficiency induces a rapid anti-tumor immune response prior to regression of implanted murine lung carcinoma tumors. Scientific Reports, 2019, 9, 18970.	1.6	9
2450	The Intriguing History of Cancer Immunotherapy. Frontiers in Immunology, 2019, 10, 2965.	2.2	240
2451	Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity. Nature Immunology, 2019, 20, 1494-1505.	7.0	83
2452	The role of cancer-associated autoantibodies as biomarkers in paraneoplastic myositis syndrome. Current Opinion in Rheumatology, 2019, 31, 643-649.	2.0	32
2453	Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors. Neurologist, 2019, 24, 75-83.	0.4	31
2454	Prognostic role of disease extent and lymphocyteâ€“monocyte ratio in advanced melanoma. Melanoma Research, 2019, 29, 510-515.	0.6	12
2455	Immune landscapes associated with different glioblastoma molecular subtypes. Acta Neuropathologica Communications, 2019, 7, 203.	2.4	112

#	Article	IF	Citations
2456	CD147â€'mediated reprogrammed glycolytic metabolism potentially induces immune escape in the tumor microenvironment (Review). Oncology Reports, 2019, 41, 2945-2956.	1.2	8
2457	Mathematical modeling of tumor-immune competitive system, considering the role of time delay. Applied Mathematics and Computation, 2019, 340, 180-205.	1.4	57
2458	Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer. Clinical Cancer Research, 2019, 25, 1624-1638.	3.2	49
2459	Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy. British Journal of Cancer, 2019, 120, 346-355.	2.9	16
2460	Identification and editing of stem-like cells in methylcholanthrene-induced sarcomas. OncoImmunology, 2019, 8, e1404212.	2.1	4
2461	Modulation of radiation sensitivity and antitumor immunity by viral pathogenic factors: Implications for radio-immunotherapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 126-137.	3.3	12
2462	pSTAT3 expression associated with survival and mammographic density of breast cancer patients. Pathology Research and Practice, 2019, 215, 366-372.	1.0	13
2463	The diverse consequences of aneuploidy. Nature Cell Biology, 2019, 21, 54-62.	4.6	140
2464	Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics. OncoImmunology, 2019, 8, e1537691.	2.1	27
2465	Functional Nanomaterials Optimized to Circumvent Tumor Immunological Tolerance. Advanced Functional Materials, 2019, 29, 1806087.	7.8	21
2466	The role of myeloid-derived suppressor cells in chronic infectious diseases and the current methodology available for their study. Journal of Leukocyte Biology, 2019, 105, 857-872.	1.5	22
2467	Intratumoral delivery of antigen with complement C3-bound liposomes reduces tumor growth in mice. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 18, 326-335.	1.7	14
2468	Genomic and transcriptional Profiling of tumor infiltrated CD8⁺ T cells revealed functional heterogeneity of antitumor immunity in hepatocellular carcinoma. OncoImmunology, 2019, 8, e1538436.	2.1	17
2469	Gold Standard Assessment of Immunogenic Cell Death in Oncological Mouse Models. Methods in Molecular Biology, 2019, 1884, 297-315.	0.4	51
2470	Efficient PD-L1 gene silence promoted by hyaluronidase for cancer immunotherapy. Journal of Controlled Release, 2019, 293, 104-112.	4.8	51
2472	Application of carbon nanotubes in cancer vaccines: Achievements, challenges and chances. Journal of Controlled Release, 2019, 297, 79-90.	4.8	59
2473	Nearâ€infrared fluorescenceâ€labeled antiâ€PDâ€L1â€mAb for tumor imaging in human colorectal cancer xenografted mice. Journal of Cellular Biochemistry, 2019, 120, 10239-10247.	1.2	14
2474	An extended Moran process that captures the struggle for fitness. Mathematical Biosciences, 2019, 308, 81-104.	0.9	5

#	Article	IF	Citations
2475	Prognostic significance and population dynamics of peripheral monocytes in patients with oropharyngeal squamous cell carcinoma. Head and Neck, 2019, 41, 1880-1888.	0.9	18
2476	Uterine Cervical Cancer. , 2019, , .		3
2477	Neoantigen characteristics in the context of the complete predicted MHC class I self-immunopeptidome. OncoImmunology, 2019, 8, 1556080.	2.1	16
2478	Immunotherapy for Precancerous Lesions of the Uterine Cervix. , 2019, , 107-140.		0
2479	PTEN Hamartoma Tumor Syndrome and Immune Dysregulation. Translational Oncology, 2019, 12, 361-367.	1.7	33
2480	Rational combination immunotherapeutic approaches for effective cancer treatment. Journal of Controlled Release, 2019, 294, 114-130.	4.8	28
2481	Dysregulation of key microRNAs in pancreatic cancer development. Biomedicine and Pharmacotherapy, 2019, 109, 1008-1015.	2.5	48
2482	Coexistence of regulatory B cells and regulatory T cells in tumor-infiltrating lymphocyte aggregates is a prognostic factor in patients with breast cancer. Breast Cancer, 2019, 26, 180-189.	1.3	60
2483	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway. Journal of Medicinal Chemistry, 2019, 62, 1715-1730.	2.9	92
2484	Progression from low- to high-grade in a glioblastoma model reveals the pivotal role of immunoediting. Cancer Letters, 2019, 442, 213-221.	3.2	18
2485	Mechanisms of Resistance to Immune Checkpoint Blockade. American Journal of Clinical Dermatology, 2019, 20, 41-54.	3.3	83
2486	Current Treatment of Retroperitoneal Sarcomas. Updates in Surgery Series, 2019, , .	0.0	5
2487	Reasoning the effect of immunotherapy after chemoradiation in the PACIFIC trial. Future Oncology, 2019, 15, 81-94.	1.1	2
2488	Dysfunction of antigen processing and presentation by dendritic cells in cancer. Molecular Immunology, 2019, 113, 31-37.	1.0	75
2489	TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class Ilow cancers. Molecular Immunology, 2019, 113, 43-49.	1.0	36
2490	Mitochondrial metabolism: Inducer or therapeutic target in tumor immune-resistance?. Seminars in Cell and Developmental Biology, 2020, 98, 80-89.	2.3	14
2491	Antibody therapeutics and immunoregulation in cancer and autoimmune disease. Seminars in Cancer Biology, 2020, 64, 1-12.	4.3	93
2492	Hematologic malignancies: The exosome contribution in tumor progression. , 2020, , 81-100.		0

#	Article	IF	Citations
2493	Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cellular and Molecular Immunology, 2020, 17, 1-12.	4.8	273
2494	Immunological Consequences of Nanoparticleâ€Mediated Antitumor Photoimmunotherapy. Advanced Therapeutics, 2020, 3, 1900101.	1.6	13
2495	Immune Activation in Mismatch Repairâ€“Deficient Carcinogenesis: More Than Just Mutational Rate. Clinical Cancer Research, 2020, 26, 11-17.	3.2	61
2496	Immunity, Hypoxia, and Metabolismâ€“the MÃ©nage Ã Trois of Cancer: Implications for Immunotherapy. Physiological Reviews, 2020, 100, 1-102.	13.1	190
2497	Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression. Seminars in Cancer Biology, 2020, 65, 13-27.	4.3	170
2498	Immunologic and immunogenomic aspects of tumor progression. Seminars in Cancer Biology, 2020, 60, 249-261.	4.3	35
2499	The effects of longâ€term opioid treatment on the immune system in chronic nonâ€cancer pain patients: A systematic review. European Journal of Pain, 2020, 24, 481-496.	1.4	21
2500	Determinants of response and resistance to CAR T cell therapy. Seminars in Cancer Biology, 2020, 65, 80-90.	4.3	59
2501	Neutrophil-lymphocyte ratio and nutritional status are clinically useful in predicting prognosis in colorectal cancer patients. Nutrition and Cancer, 2020, 72, 1345-1354.	0.9	21
2503	Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PDâ€L1 immunohistochemistry for predicting response to antiâ€PDâ€1/PDâ€L1 immunotherapy. Thoracic Cancer, 2020, 11, 3-5.	0.8	1
2505	New Approaches on Cancer Immunotherapy. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036863.	2.9	17
2506	NLRC5: new cancer buster?. Molecular Biology Reports, 2020, 47, 2265-2277.	1.0	15
2507	Efficacy of PD-1 blockade therapy and T cell immunity in lung cancer patients. Immunological Medicine, 2020, 43, 10-15.	1.4	3
2508	Current issues and perspectives in PD-1 blockade cancer immunotherapy. International Journal of Clinical Oncology, 2020, 25, 790-800.	1.0	120
2510	Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy. Translational Oncology, 2020, 13, 262-274.	1.7	49
2511	Immunoregulatory Potential of Exosomes Derived from Cancer Stem Cells. Stem Cells and Development, 2020, 29, 327-335.	1.1	11
2512	Targeted therapies in gynaecological cancers. Histopathology, 2020, 76, 157-170.	1.6	30
2513	Glioblastoma models driven by different mutations converge to the proneural subtype. Cancer Letters, 2020, 469, 447-455.	3.2	13

#	Article	IF	Citations
2514	Study of the antitumour effects and the modulation of immune response by histamine in breast cancer. British Journal of Cancer, 2020, 122, 348-360.	2.9	14
2515	Gastroesophageal cancer: Navigating the immune and genetic terrain to improve clinical outcomes. Cancer Treatment Reviews, 2020, 84, 101950.	3.4	19
2516	Targeting innate sensing in the tumor microenvironment to improve immunotherapy. Cellular and Molecular Immunology, 2020, 17, 13-26.	4.8	76
2517	Immunotherapy for Gynecologic Cancer: Current Applications and Future Directions. Clinical Obstetrics and Gynecology, 2020, 63, 48-63.	0.6	27
2518	Developments in anticancer vaccination: budding new adjuvants. Biological Chemistry, 2020, 401, 435-446.	1.2	2
2519	Brain immunology and immunotherapy in brain tumours. Nature Reviews Cancer, 2020, 20, 12-25.	12.8	389
2520	Breast cancer vaccines: Heeding the lessons of the past to guide a path forward. Cancer Treatment Reviews, 2020, 84, 101947.	3.4	35
2521	A cytofluorimetric assay to evaluate T cell polyfunctionality. Methods in Enzymology, 2020, 631, 61-76.	0.4	0
2522	The Etiology of Cancer. , 2020, , 1-35.		1
2523	Prevalence and impact of hepatitis B virus infection in ovarian cancer patients in an endemic areaâ€"A retrospective cohort study. Journal of Viral Hepatitis, 2020, 27, 520-525.	1.0	6
2524	Sustained Coevolution in a Stochastic Model of Cancerâ€"Immune Interaction. Cancer Research, 2020, 80, 811-819.	0.4	11
2525	Advances of immune checkpoints in colorectal cancer treatment. Biomedicine and Pharmacotherapy, 2020, 123, 109745.	2.5	21
2526	m ⁶ A RNA methyltransferases METTL3/14 regulate immune responses to antiâ€PDâ€1 therapy. EMBO Journal, 2020, 39, e104514.	3.5	229
2527	Role of the Cyclooxygenase Pathway in the Association of Obstructive Sleep Apnea and Cancer. Journal of Clinical Medicine, 2020, 9, 3237.	1.0	5
2528	Healthy Donors Harbor Memory T Cell Responses to RAS Neo-Antigens. Cancers, 2020, 12, 3045.	1.7	9
2529	Papillary thyroid carcinoma with a high tumor mutation burden has a poor prognosis. International Immunopharmacology, 2020, 89, 107090.	1.7	12
2530	Comprehensive analysis of the immunological landscape of pituitary adenomas: implications of immunotherapy for pituitary adenomas. Journal of Neuro-Oncology, 2020, 149, 473-487.	1.4	18
2531	The clinical value of the changes of peripheral lymphocyte subsets absolute counts in patients with non-small cell lung cancer. Translational Oncology, 2020, 13, 100849.	1.7	26

#	Article	IF	Citations
2532	Lymph-directed immunotherapy â€“ Harnessing endogenous lymphatic distribution pathways for enhanced therapeutic outcomes in cancer. Advanced Drug Delivery Reviews, 2020, 160, 115-135.	6.6	18
2533	Expanded activated autologous lymphocyte infusions improve outcomes of low- and intermediate-risk childhood acute myeloid leukemia with low level of minimal residual disease. Cancer Letters, 2020, 493, 128-132.	3.2	0
2534	Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome. Cytotherapy, 2020, 22, 204-213.	0.3	9
2535	p.P476S mutation of RBPJL inhibits the efficacy of antiâ€PDâ€1 therapy in oesophageal squamous cell carcinoma by blunting Tâ€cell responses. Clinical and Translational Immunology, 2020, 9, e1172.	1.7	1
2536	Emerging role of immune checkpoint inhibitors and predictive biomarkers in head and neck cancers. Oral Oncology, 2020, 109, 104977.	0.8	10
2537	Tumor-related HSP70 released after cryo-thermal therapy targeted innate immune initiation in the antitumor immune response. International Journal of Hyperthermia, 2020, 37, 843-853.	1.1	15
2538	Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors. Medicine (United States), 2020, 99, e21273.	0.4	9
2539	Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion. Cancers, 2020, 12, 1872.	1.7	18
2540	Combinatorial Immunotherapies for Metastatic Colorectal Cancer. Cancers, 2020, 12, 1875.	1.7	19
2541	A Review of T-Cell Related Therapy for Osteosarcoma. International Journal of Molecular Sciences, 2020, 21, 4877.	1.8	10
2542	Natural Selection on Exonic SNPs Shapes Allelic Expression Imbalance (AEI) Adaptability in Lung Cancer Progression. Frontiers in Genetics, 2020, 11, 665.	1.1	1
2543	Immune Cell Confrontation in the Papillary Thyroid Carcinoma Microenvironment. Frontiers in Endocrinology, 2020, 11, 570604.	1.5	61
2544	Breast Cancer and Microcalcifications: An Osteoimmunological Disorder?. International Journal of Molecular Sciences, 2020, 21, 8613.	1.8	13
2545	Technical Advancements for Studying Immune Regulation of Disseminated Dormant Cancer Cells. Frontiers in Oncology, 2020, 10, 594514.	1.3	10
2546	Extracellular MicroRNAs as Intercellular Mediators and Noninvasive Biomarkers of Cancer. Cancers, 2020, 12, 3455.	1.7	26
2547	Local IFNÎ± enhances the anti-tumoral efficacy of systemic anti-PD1 to prevent tumor relapse. , 2020, 8, e000996.		1
2548	Imperfect Predictors for Lung Cancer Immunotherapyâ€"A Field for Further Research. Frontiers in Oncology, 2020, 10, 568174.	1.3	14
2549	Strategies for Cancer Immunotherapy Using Induced Pluripotency Stem Cells-Based Vaccines. Cancers, 2020, 12, 3581.	1.7	6

#	Article	IF	Citations
2550	A New Bioassay Platform Design for the Discovery of Small Molecules with Anticancer Immunotherapeutic Activity. Marine Drugs, 2020, 18, 604.	2.2	10
2551	Mesenchymal Characteristics and Predictive Biomarkers on Circulating Tumor Cells for Therapeutic Strategy. Cancers, 2020, 12, 3588.	1.7	9
2552	Exploring dynamical complexity in a time-delayed tumor-immune model. Chaos, 2020, 30, 123118.	1.0	29
2553	Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy. Journal of Immunology Research, 2020, 2020, 1-13.	0.9	76
2554	Current perspectives on the tumor microenvironment in hepatocellular carcinoma. Hepatology International, 2020, 14, 947-957.	1.9	46
2555	Autophagy mediated danger signaling regulates tumor immunosurveillance and may potentiate the effects of anti-cancer immunotherapy through increased adjuvanticity. , 2020, , 119-140.		1
2556	How to manage patients with corticosteroids in oncology in the era of immunotherapy?. European Journal of Cancer, 2020, 141, 239-251.	1.3	52
2557	Understanding the Mechanisms of Diet and Outcomes in Colon, Prostate, and Breast Cancer; Malignant Gliomas; and Cancer Patients on Immunotherapy. Nutrients, 2020, 12, 2226.	1.7	13
2558	Interactive Effects of PD-L1 Expression in Tumor and Immune Cells on Prognosis of Esophageal Squamous Cell Carcinoma: A One-Center Retrospective Cohort Study . OncoTargets and Therapy, 2020, Volume 13, 6565-6572.	1.0	4
2559	The pros and cons of interferons for oncolytic virotherapy. Cytokine and Growth Factor Reviews, 2020, 56, 49-58.	3.2	19
2560	A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Blood, 2020, 136, 2401-2409.	0.6	92
2561	Silicon Nanowires and Their Impact on Cancer Detection and Monitoring. ACS Applied Nano Materials, 2020, 3, 8522-8536.	2.4	22
2562	Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas. Clinical Cancer Research, 2020, 26, 5689-5700.	3.2	26
2563	Stromal regulation of tumor-associated lymphatics. Advanced Drug Delivery Reviews, 2020, 161-162, 75-89.	6.6	6
2564	Radiation Therapy and the In Situ Vaccination Approach. International Journal of Radiation Oncology Biology Physics, 2020, 108, 891-898.	0.4	46
2565	Prognostic significance of spatial immune profiles in human solid cancers. Cancer Science, 2020, 111, 3426-3434.	1.7	31
2566	Research Progress and Existing Problems for Abscopal Effect . Cancer Management and Research, 2020, Volume 12, 6695-6706.	0.9	8
2567	Effective combinations of radiotherapy and immunotherapy in the treatment of esophageal squamous cell carcinoma. Future Oncology, 2020, 16, 2537-2549.	1.1	9

#	Article	IF	Citations
2568	DNA Repair and Signaling in Immune-Related Cancer Therapy. Frontiers in Molecular Biosciences, 2020, 7, 205.	1.6	20
2569	Pre-operative prognostic nutritional index was associated with recurrence after surgery in giant cell tumor of bone patients. Journal of Bone Oncology, 2020, 25, 100324.	1.0	7
2570	NFE2L2 Is a Potential Prognostic Biomarker and Is Correlated with Immune Infiltration in Brain Lower Grade Glioma: A Pan-Cancer Analysis. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-26.	1.9	69
2571	Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types. Genome Medicine, 2020, 12, 90.	3.6	29
2573	The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma. Cell Communication and Signaling, 2020, 18, 174.	2.7	134
2574	Resident Memory T Cells in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1273, 39-68.	0.8	3
2575	Hispidulin: A promising flavonoid with diverse anti-cancer properties. Life Sciences, 2020, 259, 118395.	2.0	34
2576	Cancer cell CCR2 orchestrates suppression of the adaptive immune response. Journal of Experimental Medicine, 2020, 217, .	4.2	32
2577	New Insights into the Role of Sphingolipid Metabolism in Melanoma. Cells, 2020, 9, 1967.	1.8	15
2578	Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer. Molecules, 2020, 25, 3900.	1.7	21
2579	Characteristics of immunological synapse in mature Bâ€cell neoplasms. International Journal of Laboratory Hematology, 2020, 42, e294-e297.	0.7	0
2580	Epstein-Barr Virus Mediated Signaling in Nasopharyngeal Carcinoma Carcinogenesis. Cancers, 2020, 12, 2441.	1.7	25
2581	Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review. International Journal of Molecular Sciences, 2020, 21, 6176.	1.8	19
2582	Current advances in the diagnosis and personalized treatment of breast cancer: lessons from tumor biology. Personalized Medicine, 2020, 17, 399-420.	0.8	7
2583	Construction and validation of a TP53-associated immune prognostic model for gastric cancer. Genomics, 2020, 112, 4788-4795.	1.3	23
2584	TMPRSS2, a SARS-CoV-2 internalization protease is downregulated in head and neck cancer patients. Journal of Experimental and Clinical Cancer Research, 2020, 39, 200.	3.5	25
2585	Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy. Journal of Clinical Medicine, 2020, 9, 2967.	1.0	23
2587	Combination of High Dose Hypofractionated Radiotherapy with Anti-PD1 Single Dose Immunotherapy Leads to a Th1 Immune Activation Resulting in a Complete Clinical Response in a Melanoma Patient. International Journal of Molecular Sciences, 2020, 21, 6772.	1.8	2

#	Article	IF	Citations
2588	Searching for Goldilocks: How Evolution and Ecology Can Help Uncover More Effective Patient-Specific Chemotherapies. Cancer Research, 2020, 80, 5147-5154.	0.4	11
2589	Polydopamineâ€“Mesoporous Silica Coreâ€“Shell Nanoparticles for Combined Photothermal Immunotherapy. ACS Applied Materials & Interfaces, 2020, 12, 42499-42510.	4.0	69
2590	Lung Cancer and Immunity Markers. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2423-2430.	1.1	7
2591	Analyzing and validating the prognostic value and mechanism of colon cancer immune microenvironment. Journal of Translational Medicine, 2020, 18, 324.	1.8	48
2592	Evolutionary dynamics of neoantigens in growing tumors. Nature Genetics, 2020, 52, 1057-1066.	9.4	68
2593	EZH2 inhibition: aÂpromisingÂstrategy to prevent cancer immune editing. Epigenomics, 2020, 12, 1457-1476.	1.0	37
2594	Biomedical nanomaterials for immunological applications: ongoing research and clinical trials. Nanoscale Advances, 2020, 2, 5046-5089.	2.2	47
2595	Shaping of Dendritic Cell Function by the Metabolic Micro-Environment. Frontiers in Endocrinology, 2020, 11, 555.	1.5	28
2596	Photodynamic therapy, priming and optical imaging: Potential co-conspirators in treatment design and optimization â€" a Thomas Dougherty Award for Excellence in PDT paper. Journal of Porphyrins and Phthalocyanines, 2020, 24, 1320-1360.	0.4	48
2597	Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. Cancer Immunology Research, 2020, 8, 1365-1380.	1.6	37
2598	Robust antigen-specific CD8 T cell tolerance to a model prostate cancer neoantigen. OncoImmunology, 2020, 9, 1809926.	2.1	2
2599	Strength of immune selection in tumors varies with sex and age. Nature Communications, 2020, 11, 4128.	5.8	78
2600	Nanoscale Metalâ€“Organic Frameworks for Cancer Immunotherapy. Accounts of Chemical Research, 2020, 53, 1739-1748.	7.6	128
2601	Aspartate Î²-hydroxylase as a target for cancer therapy. Journal of Experimental and Clinical Cancer Research, 2020, 39, 163.	3.5	34
2602	Emerging advances in synthetic cancer nano-vaccines: opportunities and challenges. Expert Review of Vaccines, 2020, 19, 1053-1071.	2.0	23
2603	CD8+ T-cell lymphocytes infiltration predict clinical outcomes in Wilmsâ€™ tumor. Tumor Biology, 2020, 42, 101042832097597.	0.8	19
2604	Non-genetic Heterogeneity of Macrophages in Diseasesâ€"A Medical Perspective. Frontiers in Cell and Developmental Biology, 2020, 8, 613116.	1.8	10
2605	Current Trends in Cancer Immunotherapy. Biomedicines, 2020, 8, 621.	1.4	34

#	Article	IF	Citations
2606	The pancancer landscape of Wnt family expression reveals potential biomarkers in urinary system tumors. Cancer Gene Therapy, 2020, 28, 1035-1045.	2.2	1
2607	Toxicities from immunotherapy: From clinical trials to real-world clinical practice. Medicina ClÃnica (English Edition), 2020, 155, 541-547.	0.1	0
2608	The investigation of T-cell receptor subtypes in ovarian cancer: effects on survival and prognostic factors. Journal of Obstetrics and Gynaecology, 2021, 41, 951-955.	0.4	1
2609	Immune Modulation in Lung Cancer: Current Concepts and Future Strategies. Respiration, 2020, 99, 903-929.	1.2	18
2610	Some Like It Sweet: Dendritic Cells Add Sugar to Their T(ea). Cell, 2020, 183, 847-849.	13.5	0
2611	Moderne Aspekte der Immuntherapie mit Checkpoint-Inhibitoren bei Melanom. Karger Kompass Dermatologie, 2020, 8, 92-101.	0.0	0
2612	PrÃzisionsmedizin bei NSCLC im Zeitalter der Immuntherapie: Neue Biomarker zur Selektion der am besten geeigneten Therapie oder des am besten geeigneten Patienten. Karger Kompass Pneumologie, 2020, 8, 300-317.	0.0	1
2613	Cardiotoxicity danger in immunotherapy. IUBMB Life, 2020, 72, 1160-1167.	1.5	4
2614	Social Support and Antibody Responses to Vaccination: A Meta-Analysis. Annals of Behavioral Medicine, 2020, 54, 567-574.	1.7	11
2615	The Influence of the Genetic and Immunologic Context in the Development of Colorectal Adenoma: A Case Series Report. Acta Medica Portuguesa, 2020, 33, 297.	0.2	1
2616	Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5. Human Cell, 2020, 33, 1099-1111.	1.2	9
2617	Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis. Molecular Cancer, 2020, 19, 92.	7.9	147
2618	Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint. Frontiers in Immunology, 2020, 11, 951.	2.2	221
2619	CD8+ T-cellâ€“Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas. Clinical Cancer Research, 2020, 26, 4390-4401.	3.2	36
2620	Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. Cancers, 2020, 12, 1125.	1.7	43
2621	Plasma medical oncology: Immunological interpretation of head and neck squamous cell carcinoma. Plasma Processes and Polymers, 2020, 17, 1900258.	1.6	19
2622	The Synthesis and Antiâ€tumour Properties of Poly Ethoxy Ethyl Glycinamide (PEEâ˜G) Scaffolds with Multiple PDâ€1 Peptides Attached. ChemMedChem, 2020, 15, 1128-1138.	1.6	4
2623	Delicate Balances in Cancer Chemotherapy: Modeling Immune Recruitment and Emergence of Systemic Drug Resistance. Frontiers in Immunology, 2020, 11, 1376.	2.2	23

#	Article	IF	Citations
2624	The dormant cancer cell life cycle. Nature Reviews Cancer, 2020, 20, 398-411.	12.8	286
2625	A minority of T cells recognizing tumor-associated antigens presented in self-HLA can provoke antitumor reactivity. Blood, 2020, 136, 455-467.	0.6	11
2626	Regulation of Tumor Immunity by Lysophosphatidic Acid. Cancers, 2020, 12, 1202.	1.7	35
2627	The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics. Annals of Palliative Medicine, 2020, 9, 967-978.	0.5	29
2628	Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond. Current Oncology Reports, 2020, 22, 56.	1.8	23
2629	CRISPR screen in mechanism and target discovery for cancer immunotherapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188378.	3.3	25
2630	Identification of a four immuneâ€related genes signature based on an immunogenomic landscape analysis of clear cell renal cell carcinoma. Journal of Cellular Physiology, 2020, 235, 9834-9850.	2.0	24
2631	Targeting Inhibition of Foxp3 by MMP2/9 Sensitive Short Peptide Linked P60 Fusion Protein 6(P60â€MMPs) to Enhance Antitumor Immunity. Macromolecular Bioscience, 2020, 20, 2000098.	2.1	5
2632	Molecular Biochemical Aspects of Cancer. , 2020, , .		3
2633	NKG2D-Fc fusion protein promotes antitumor immunity through the depletion of immunosuppressive cells. Cancer Immunology, Immunotherapy, 2020, 69, 2147-2155.	2.0	7
2634	The special immune microenvironment of tumor budding and its impact on prognosis in gastric adenocarcinoma. Pathology Research and Practice, 2020, 216, 152926.	1.0	15
2635	Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade. Cancer Discovery, 2020, 10, 1140-1157.	7.7	97
2636	Immune-gene signature: a new tool for patient selection for checkpoint inhibitors?. Future Oncology, 2020, 16, 1327-1330.	1.1	2
2637	Tumor Endothelial Cellâ€“Mediated Antigen-Specific T-cell Suppression via the PD-1/PD-L1 Pathway. Molecular Cancer Research, 2020, 18, 1427-1440.	1.5	22
2638	The efficacy and safety comparison of PD-1/PD-L1 antibody, chemotherapy and supportive treatment for pretreated advanced esophagogastric cancer: a network meta-analysis. Annals of Palliative Medicine, 2020, 9, 1770-1781.	0.5	5
2639	Asymptotic Behavior Analysis of a Fractional-Order Tumor-Immune Interaction Model with Immunotherapy. Complexity, 2020, 2020, 1-12.	0.9	2
2640	Engineered Cellâ€Membraneâ€Coated Nanoparticles Directly Present Tumor Antigens to Promote Anticancer Immunity. Advanced Materials, 2020, 32, e2001808.	11.1	206
2641	Immune Microenvironment of Thyroid Cancer. Journal of Cancer, 2020, 11, 4884-4896.	1.2	26

#	Article	IF	Citations
2642	Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes. Cancer Treatment Reviews, 2020, 88, 102057.	3.4	28
2643	Modeling of the immune response in the pathogenesis of solid tumors and its prognostic significance. Cellular Oncology (Dordrecht), 2020, 43, 539-575.	2.1	9
2644	Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives. Cancer Treatment Reviews, 2020, 88, 102030.	3.4	44
2645	Manipulation of Metabolic Pathways and Its Consequences for Anti-Tumor Immunity: A Clinical Perspective. International Journal of Molecular Sciences, 2020, 21, 4030.	1.8	7
2646	Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab . OncoTargets and Therapy, 2020, Volume 13, 4021-4034.	1.0	5
2647	MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies. Nature Communications, 2020, 11, 2860.	5.8	45
2648	Resolving Petoâ€™s paradox: Modeling the potential effects of sizeâ€related metabolic changes, and of the evolution of immune policing and cancer suppression. Evolutionary Applications, 2020, 13, 1581-1592.	1.5	14
2649	Racial differences in CD8+ T cell infiltration in breast tumors from Black and White women. Breast Cancer Research, 2020, 22, 62.	2.2	24
2650	Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go. Current Treatment Options in Oncology, 2020, 21, 59.	1.3	12
2651	Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update. Expert Review of Molecular Diagnostics, 2020, 20, 653-664.	1.5	7
2652	Heterogeneity of Glucose Transport in Lung Cancer. Biomolecules, 2020, 10, 868.	1.8	19
2653	The emerging role of cancer cell plasticity and cell-cycle quiescence in immune escape. Cell Death and Disease, 2020, 11, 471.	2.7	25
2654	Implications of Hereditary Origin on the Immune Phenotype of Mismatch Repair-Deficient Cancers: Systematic Literature Review. Journal of Clinical Medicine, 2020, 9, 1741.	1.0	22
2655	Metabolism in tumor microenvironment: Implications for cancer immunotherapy. MedComm, 2020, 1, 47-68.	3.1	93
2656	Noncoding RNAs: the shot callers in tumor immune escape. Signal Transduction and Targeted Therapy, 2020, 5, 102.	7.1	37
2657	Regulation of Cancer Immune Checkpoints. Advances in Experimental Medicine and Biology, 2020, , .	0.8	7
2658	A critical evaluation of pembrolizumab in addition to lenalidomide and dexamethasone for the treatment of multiple myeloma. Expert Review of Hematology, 2020, 13, 435-445.	1.0	5
2659	Withania somnifera (L.) Dunal: A potential therapeutic adjuvant in cancer. Journal of Ethnopharmacology, 2020, 255, 112759.	2.0	30

#	Article	IF	Citations
2660	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2020, 635, xix-xxxviii.	0.4	0
2661	A TP53 -associated gene signature for prediction of prognosis and therapeutic responses in lung squamous cell carcinoma. OncoImmunology, 2020, 9, 1731943.	2.1	85
2662	Targeting interleukin-10 signalling for cancer immunotherapy, a promising and complicated task. Human Vaccines and Immunotherapeutics, 2020, 16, 2328-2332.	1.4	35
2663	Predictive value of prognostic nutritional index in patients with oral squamous cell carcinoma. Oral Diseases, 2020, 26, 903-911.	1.5	17
2664	Noncoding RNAs in cancer immunity: functions, regulatory mechanisms, and clinical application. Molecular Cancer, 2020, 19, 48.	7.9	64
2665	Immunotherapy in Multiple Myeloma. Cells, 2020, 9, 601.	1.8	27
2666	Progress in transdermal drug delivery systems for cancer therapy. Nano Research, 2020, 13, 1810-1824.	5.8	54
2667	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2020, 636, xvii-xxxvi.	0.4	0
2668	Immunogenic cell death in colon cancer prevention and therapy. Molecular Carcinogenesis, 2020, 59, 783-793.	1.3	65
2669	Recent Advances in Immunotherapy for Hepatocellular Carcinoma. Cancers, 2020, 12, 775.	1.7	70
2670	Mitochondrial targeted strategies and their application for cancer and other diseases treatment. Journal of Pharmaceutical Investigation, 2020, 50, 271-293.	2.7	34
2671	Transcriptomic Features of T Cell-Barren Tumors Are Conserved Across Diverse Tumor Types. Frontiers in Immunology, 2020, 11, 57.	2.2	8
2672	Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment. Frontiers in Immunology, 2020, 11, 159.	2.2	73
2673	Determinants of Resistance to Checkpoint Inhibitors. International Journal of Molecular Sciences, 2020, 21, 1594.	1.8	39
2674	Development of Tumor Cell-Based Vaccine with IL-12 Gene Electrotransfer as Adjuvant. Vaccines, 2020, 8, 111.	2.1	10
2675	Upâ€regulation of indoleamine 2,3â€dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients. Cancer Communications, 2020, 40, 3-15.	3.7	16
2676	Epidemiology of meningiomas. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2020, 169, 3-15.	1.0	17
2677	Nanotechnologies for enhancing cancer immunotherapy. Nano Research, 2020, 13, 2595-2616.	5.8	22

#	Article	IF	Citations
2678	Modulation of immune responses using adjuvants to facilitate therapeutic vaccination. Immunological Reviews, 2020, 296, 169-190.	2.8	56
2679	Superorganism Immunity: A Major Transition in Immune System Evolution. Frontiers in Ecology and Evolution, 2020, 8, .	1.1	19
2680	Mindin serves as a tumour suppressor gene during colon cancer progression through MAPK/ERK signalling pathway in mice. Journal of Cellular and Molecular Medicine, 2020, 24, 8391-8404.	1.6	7
2681	Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduction and Targeted Therapy, 2020, 5, 113.	7.1	299
2682	Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms. Cancers, 2020, 12, 1763.	1.7	17
2683	Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents. International Journal of Molecular Sciences, 2020, 21, 4778.	1.8	9
2684	Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC). Cancer Letters, 2020, 490, 12-19.	3.2	10
2685	Bone, a Secondary Growth Site of Breast and Prostate Carcinomas: Role of Osteocytes. Cancers, 2020, 12, 1812.	1.7	12
2686	How does autophagy affect tumor-infiltrating immune cells?. , 2020, , 75-84.		0
2687	Modeling and optimal control of cancer-immune system. , 2020, , 83-104.		1
2688	Fasten the seat belt: Increasing safety of CAR Tâ€cell therapy. Experimental Dermatology, 2020, 29, 1039-1045.	1.4	4
2689	The role of Human leukocyte antigen class I on patient survival in Gastrointestinal cancers: a systematic review and meta- analysis. Scientific Reports, 2020, 10, 728.	1.6	12
2690	CRISPR-engineered T cells in patients with refractory cancer. Science, 2020, 367, .	6.0	872
2691	The Multifaceted Effects of Autophagy on the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1225, 99-114.	0.8	18
2692	Recent progress in tumor photodynamic immunotherapy. Chinese Chemical Letters, 2020, 31, 1709-1716.	4.8	76
2693	Nutritional assessment and prognosis of oral cancer patients: a large-scale prospective study. BMC Cancer, 2020, 20, 146.	1.1	59
2694	The abscopal effect 67 years later: from a side story to center stage. British Journal of Radiology, 2020, 93, 20200042.	1.0	73
2695	Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration. British Journal of Cancer, 2020, 122, 1205-1210.	2.9	24

#	Article	IF	Citations
2696	Harnessing cancer immunotherapy during the unexploited immediate perioperative period. Nature Reviews Clinical Oncology, 2020, 17, 313-326.	12.5	60
2697	Nanoparticle formulated vaccines: opportunities and challenges. Nanoscale, 2020, 12, 5746-5763.	2.8	69
2698	Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment. Nature Communications, 2020, 11, 1137.	5.8	43
2699	Mathematical oncology and itâ€™s application in non melanoma skin cancer â€“ A primer for radiation oncology professionals. Oral Oncology, 2020, 103, 104473.	0.8	14
2700	Syngeneic murine model for prostate cancer using RM1 cells transfected with gp100. Prostate, 2020, 80, 424-431.	1.2	3
2701	Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, , .	0.8	1
2702	Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer. Cancers, 2020, 12, 376.	1.7	52
2703	A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone therapy. Journal of Molecular Medicine, 2020, 98, 375-382.	1.7	7
2706	The Diagnostic, Prognostic, and Therapeutic Potential of Adaptive Immune Receptor Repertoire Profiling in Cancer. Cancer Research, 2020, 80, 643-654.	0.4	28
2707	Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design. Seminars in Immunology, 2020, 47, 101389.	2.7	65
2708	Down-regulation of the human major histocompatibility complex class I chain-related gene A (MICA) and its receptor is mediated by microRNA-146b-5p and is a potential mechanism of immunoediting in papillary thyroid carcinoma. Experimental and Molecular Pathology, 2020, 113, 104379.	0.9	13
2709	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2020, 631, xxiii-xlii.	0.4	1
2710	TYK2 in Tumor Immunosurveillance. Cancers, 2020, 12, 150.	1.7	18
2711	Impact of BMI for clinical outcomes in Japanese breast cancer patients. Japanese Journal of Clinical Oncology, 2020, 50, 230-240.	0.6	8
2712	Prediagnostic Immune Cell Profiles and Breast Cancer. JAMA Network Open, 2020, 3, e1919536.	2.8	25
2713	Immune biological rationales for the design of combined radio- and immunotherapies. Cancer Immunology, Immunotherapy, 2020, 69, 293-306.	2.0	39
2714	Targeting PPAR ligands as possible approaches for metabolic reprogramming of T cells in cancer immunotherapy. Immunology Letters, 2020, 220, 32-37.	1.1	14
2715	Codelivery of Antiâ€PDâ€1 Antibody and Paclitaxel with Matrix Metalloproteinase and pH Dualâ€Sensitive Micelles for Enhanced Tumor Chemoimmunotherapy. Small, 2020, 16, e1906832.	5.2	80

#	Article	IF	Citations
2716	Non-Genetically Improving the Natural Cytotoxicity of Natural Killer (NK) Cells. Frontiers in Immunology, 2019, 10, 3026.	2.2	16
2717	Tumor Immunology and Tumor Evolution: Intertwined Histories. Immunity, 2020, 52, 55-81.	6.6	357
2718	Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer. Cancer Immunology, Immunotherapy, 2020, 69, 315-324.	2.0	12
2719	Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. OncoImmunology, 2020, 9, 1703449.	2.1	156
2720	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2020, 632, xxiii-xlii.	0.4	0
2721	A size and space structured model describing interactions of tumor cells with immune cells reveals cancer persistent equilibrium states in tumorigenesis. Journal of Theoretical Biology, 2020, 490, 110163.	0.8	8
2722	Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cellsâ€"An Update. Pharmaceutics, 2020, 12, 92.	2.0	46
2723	Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells. British Journal of Cancer, 2020, 122, 1005-1013.	2.9	52
2724	Toll-like Receptors from the Perspective of Cancer Treatment. Cancers, 2020, 12, 297.	1.7	60
2725	Poor clinical outcome in metastatic melanoma is associated with a microRNA-modulated immunosuppressive tumor microenvironment. Journal of Translational Medicine, 2020, 18, 56.	1.8	28
2726	Advancing patient age is associated with worse outcomes in lowâ€•and intermediateâ€grade primary chondrosarcoma of the pelvis. Journal of Surgical Oncology, 2020, 121, 638-644.	0.8	11
2727	PGE2-HIF1Î± reciprocal induction regulates migration, phenotypic alteration and immunosuppressive capacity of macrophages in tumor microenvironment. Life Sciences, 2020, 253, 117731.	2.0	22
2728	Immunotherapy in Renal Cell Carcinoma: The Future Is Now. International Journal of Molecular Sciences, 2020, 21, 2532.	1.8	126
2729	Development and functional analysis of an anticancer Tâ€cell medicine with immune checkpoint inhibitory ability. IUBMB Life, 2020, 72, 1649-1658.	1.5	2
2730	Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting. Cancers, 2020, 12, 915.	1.7	1
2731	Reprogramming Tumor Microenvironment with Photothermal Therapy. Bioconjugate Chemistry, 2020, 31, 1268-1278.	1.8	66
2733	Myeloidâ€derived suppressor cells promote epithelial ovarian cancer cell stemness by inducing the CSF2/pâ€STAT3 signalling pathway. FEBS Journal, 2020, 287, 5218-5235.	2.2	31
2734	Cell death induced by cytotoxic CD8⁺T cells is immunogenic and primes caspase-3â€"dependent spread immunity against endogenous tumor antigens. , 2020, 8, e000528.		46

#	Article	IF	Citations
2735	Editorial: HIV and Cancer Immunotherapy: Similar Challenges and Converging Approaches. Frontiers in Immunology, 2020, 11, 519.	2.2	7
2736	microRNAs in the Antitumor Immune Response and in Bone Metastasis of Breast Cancer: From Biological Mechanisms to Therapeutics. International Journal of Molecular Sciences, 2020, 21, 2805.	1.8	17
2737	The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy. Acta Pharmaceutica Sinica B, 2020, 10, 2156-2170.	5.7	178
2738	Combination therapy based on nano codelivery for overcoming cancer drug resistance. Medicine in Drug Discovery, 2020, 6, 100024.	2.3	66
2739	Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis. Scientific Reports, 2020, 10, 7010.	1.6	18
2740	Mutational landscape of immune surveillance genes in diffuse large B-cell lymphoma. Expert Review of Hematology, 2020, 13, 655-668.	1.0	3
2741	Human NKp44+ Group 3 Innate Lymphoid Cells Associate with Tumor-Associated Tertiary Lymphoid Structures in Colorectal Cancer. Cancer Immunology Research, 2020, 8, 724-731.	1.6	27
2742	Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma. International Journal of Molecular Sciences, 2020, 21, 2367.	1.8	34
2743	A review of glioblastoma immunotherapy. Journal of Neuro-Oncology, 2021, 151, 41-53.	1.4	159
2744	Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy. Advanced Drug Delivery Reviews, 2021, 168, 158-180.	6.6	111
2745	Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy. Immunological Medicine, 2021, 44, 10-15.	1.4	14
2746	Tumor-infiltrating lymphocytes benefit prediction of axillary pathologic response and prognostication of event-free survival in HER2-positive and biopsy-proven node-positive breast cancer treated with neoadjuvant therapy. Breast Cancer Research and Treatment, 2021, 185, 629-638.	1.1	2
2747	Optimal control problem for a general reactionâ€“diffusion tumorâ€“immune system with chemotherapy. Journal of the Franklin Institute, 2021, 358, 448-473.	1.9	6
2748	Deciphering the antitumoral potential of the bioactive metabolites from medicinal mushroom Inonotus obliquus. Journal of Ethnopharmacology, 2021, 265, 113321.	2.0	30
2749	FoxP3, CTLA-4, and IDO in Canine Melanocytic Tumors. Veterinary Pathology, 2021, 58, 42-52.	0.8	15
2750	High prognostic nutritional index (PNI) as a positive prognostic indicator for nonâ€small cell lung cancer patients with bone metastasis. Clinical Respiratory Journal, 2021, 15, 225-231.	0.6	20
2751	Progress in research into the role of abnormal glycosylation modification in tumor immunity. Immunology Letters, 2021, 229, 8-17.	1.1	12
2752	Of immune checkpoint maladies and remedies: The throwing of jabs in the oncogenic ring of PDAC. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188483.	3.3	7

#	Article	IF	Citations
2753	Targeting <scp>CTLA</scp>â€4 in cancer: Is it the ideal companion for <scp>PD</scp>â€1 blockade immunotherapy combinations?. International Journal of Cancer, 2021, 149, 31-41.	2.3	23
2754	Natural Killer Cell Defects in Breast Cancer: A Key Pathway for Tumor Evasion. International Reviews of Immunology, 2021, 40, 197-216.	1.5	8
2755	IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy. Cellular Immunology, 2021, 359, 104254.	1.4	141
2756	Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: An overview. Pharmacological Research, 2021, 164, 105309.	3.1	12
2757	Mitochondria as a Novel Target for Cancer Chemoprevention: Emergence of Mitochondrial-targeting Agents. Cancer Prevention Research, 2021, 14, 285-306.	0.7	45
2758	Cancer: An unknown territory; rethinking before going ahead. Genes and Diseases, 2021, 8, 655-661.	1.5	29
2759	Immune checkpoint inhibition in upper tract urothelial carcinoma. World Journal of Urology, 2021, 39, 1357-1367.	1.2	27
2760	A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion. Nature Reviews Immunology, 2021, 21, 116-128.	10.6	139
2761	Human immunology and immunotherapy: main achievements and challenges. Cellular and Molecular Immunology, 2021, 18, 805-828.	4.8	96
2762	The tumour immune landscape and its implications in cutaneous melanoma. Pigment Cell and Melanoma Research, 2021, 34, 529-549.	1.5	21
2763	Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment. Advanced Therapeutics, 2021, 4, 2000147.	1.6	2
2764	The synergistic antitumor activity of 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) and anti-PD-L1 antibody inducing immunogenic cell death. Drug Delivery, 2021, 28, 800-813.	2.5	7
2765	Depletion of NK Cells Resistant to Ionizing Radiation Increases Mutations in Mice After Whole-body Irradiation. In Vivo, 2021, 35, 1507-1513.	0.6	6
2766	Influence of tumor-infiltrating immune cells on local control rate, distant metastasis, and survival in patients with soft tissue sarcoma. OncoImmunology, 2021, 10, 1896658.	2.1	13
2767	Cancer Immunology and the Evolution of Immunotherapy. , 2021, , 3-29.		1
2768	Immune MAL2-practice: breast cancer immunoevasion via MHC class I degradation. Journal of Clinical Investigation, 2021, 131, .	3.9	9
2769	Inflammation Mediates the Development of Aggressive Breast Cancer Following Radiotherapy. Clinical Cancer Research, 2021, 27, 1778-1791.	3.2	13
2770	Immune cell infiltrates as prognostic biomarkers in pancreatic ductal adenocarcinoma: a systematic review and metaâ€analysis. Journal of Pathology: Clinical Research, 2021, 7, 99-112.	1.3	14

#	Article	IF	Citations
2771	Space-velocity thermostatted kinetic theory model of tumor growth. Mathematical Biosciences and Engineering, 2021, 18, 5525-5551.	1.0	3
2772	Double-edged effects of interferons on the regulation of cancer-immunity cycle. OncoImmunology, 2021, 10, 1929005.	2.1	18
2773	Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response. Journal of Clinical Investigation, 2021, 131, .	3.9	48
2774	Glioma immunoediting, a driver of tumor evolution, and the next battle for immunotherapy. Oncotarget, 2021, 12, 8-9.	0.8	2
2775	Association between dietary sodium, potassium intake and lung cancer risk: evidence from the prostate, lung, colorectal and ovarian cancer screening trial and the Womenâ€™s Health Initiative. Translational Lung Cancer Research, 2021, 10, 45-56.	1.3	16
2776	Elucidating tumor immunosurveillance and immunoediting: a comprehensive review. Ciencia Animal Brasileira, 0, 22, .	0.3	1
2777	T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword. Frontiers in Immunology, 2020, 11, 612244.	2.2	31
2778	Review of immune checkpoint inhibitors in immuno-oncology. Advances in Pharmacology, 2021, 91, 111-139.	1.2	43
2779	Cancer Immunology. , 2021, , .		0
2780	Tumor infiltrating neutrophil might play a major role in predicting the clinical outcome of breast cancer patients treated with neoadjuvant chemotherapy. BMC Cancer, 2021, 21, 68.	1.1	7
2781	Biohybrid Nanosystems for Cancer Treatment: Merging the Best of Two Worlds. Advances in Experimental Medicine and Biology, 2021, 1295, 135-162.	0.8	0
2782	Dormant Tumor Cell Vaccination: A Mathematical Model of Immunological Dormancy in Triple-Negative Breast Cancer. Cancers, 2021, 13, 245.	1.7	11
2783	IL-10 Signaling in the Tumor Microenvironment of Ovarian Cancer. Advances in Experimental Medicine and Biology, 2021, 1290, 51-65.	0.8	21
2784	Lipid Metabolism in Tumor-Associated Natural Killer Cells. Advances in Experimental Medicine and Biology, 2021, 1316, 71-85.	0.8	9
2785	Impaired Response to Immunotherapy in Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma?. Liver Cancer, 2021, 10, 289-295.	4.2	6
2786	Genetic Disease and Therapy. Annual Review of Pathology: Mechanisms of Disease, 2021, 16, 145-166.	9.6	21
2787	Nanoscale coordination polymers induce immunogenic cell death by amplifying radiation therapy mediated oxidative stress. Nature Communications, 2021, 12, 145.	5.8	131
2788	Immune-Targeted Nanomedicine. Advances in Medical Technologies and Clinical Practice Book Series, 2021, , 294-305.	0.3	0

#	Article	IF	Citations
2789	Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer. OncoImmunology, 2021, 10, 1901434.	2.1	34
2790	Immunochemo combination therapy in cancer treatment. , 2021, , 255-273.		0
2791	Tumor-infiltrating T-regulatory cells adapt to altered metabolism to promote tumor-immune escape. Current Research in Immunology, 2021, 2, 132-141.	1.2	27
2792	The Interplay of Exosomes and NK Cells in Cancer Biology. Cancers, 2021, 13, 473.	1.7	30
2793	The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy. Cancers, 2021, 13, 134.	1.7	67
2794	Therapeutic Approaches to Employ Monoclonal Antibody for Cancer Treatment. Advances in Medical Diagnosis, Treatment, and Care, 2021, , 42-88.	0.1	0
2795	The Jekyll and Hyde of Cellular Senescence in Cancer. Cells, 2021, 10, 208.	1.8	25
2796	Biological bases of cancer immunotherapy. Expert Reviews in Molecular Medicine, 2021, 23, e3.	1.6	14
2797	Inflammatory cells in tumor microenvironment. , 2021, , 75-112.		0
2798	Fundamentals of Digestive Cancers Immunology, Especially Gastric and Hepatocellular CarcinomasFondamentaux de lâ€™immunologie des Cancers Digestifs (Gastriques et HÃ©patocellulaires). Oncologie, 2021, 23, 47-59.	0.2	5
2799	Immune System Efficiency in Cancer and the Microbiota Influence. Pathobiology, 2021, 88, 170-186.	1.9	14
2800	Using methylcholanthrene-induced fibrosarcomas to study tumor immunology. Methods in Cell Biology, 2021, 163, 59-75.	0.5	2
2801	The use of immunotherapy for treatment of chemoresistant ovarian cancer. , 2021, , 79-96.		0
2802	The Significance of Exosomal RNAs in the Development, Diagnosis, and Treatment of Gastric Cancer. Genes, 2021, 12, 73.	1.0	12
2803	The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment. Cancers, 2021, 13, 210.	1.7	86
2804	Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities. Frontiers in Oncology, 2020, 10, 606368.	1.3	23
2805	Multi-color Flow Cytometry for Comprehensive Analysis of the Tumor Immune Infiltrate in a Murine Model of Breast Cancer. Bio-protocol, 2021, 11, e4012.	0.2	3
2806	Ion Channels Orchestrate Pancreatic Ductal Adenocarcinoma Progression and Therapy. Frontiers in Pharmacology, 2020, 11, 586599.	1.6	20

#	Article	IF	Citations
2807	Preface: Chemical carcinogenesis in mice as a model of human cancer: Pros and cons. Methods in Cell Biology, 2021, 163, xvii-xxv.	0.5	0
2808	Minimal Residual Disease, Metastasis and Immunity. Biomolecules, 2021, 11, 130.	1.8	21
2809	Identification of a two-gene prognostic model associated with cytolytic activity for colon cancer. Cancer Cell International, 2021, 21, 95.	1.8	4
2810	Nanomaterials-Mediated Immunomodulation for Cancer Therapeutics. Frontiers in Chemistry, 2021, 9, 629635.	1.8	15
2811	The role of radiotherapy in the age of immunotherapy. Japanese Journal of Clinical Oncology, 2021, 51, 513-522.	0.6	28
2812	Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO. Frontiers in Immunology, 2021, 12, 636081.	2.2	31
2813	A Functional Food Inhibits Azoxymethane/Dextran Sulfate Sodium-Induced Inflammatory Colorectal Cancer in Mice. OncoTargets and Therapy, 2021, Volume 14, 1465-1477.	1.0	4
2814	Transcriptome-Based Co-Expression of BRD4 and PD-1/PD-L1 Predicts Poor Overall Survival in Patients With Acute Myeloid Leukemia. Frontiers in Pharmacology, 2020, 11, 582955.	1.6	21
2815	Revealing the mechanism of lymphoid and myeloid cell differentiation and transdifferentiation through landscape quantification. Physical Review Research, 2021, 3, .	1.3	2
2816	The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy. International Journal of Molecular Sciences, 2021, 22, 1964.	1.8	27
2817	Chemokines as the critical factors during bladder cancer progression: an overview. International Reviews of Immunology, 2021, 40, 344-358.	1.5	3
2818	Tackling HLA Deficiencies Head on with Oncolytic Viruses. Cancers, 2021, 13, 719.	1.7	6
2819	Driving CAR T cells towards dermatologic oncology. JDDG - Journal of the German Society of Dermatology, 2021, 19, 359-362.	0.4	5
2820	Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review. World Journal of Clinical Oncology, 2021, 12, 69-94.	0.9	26
2821	Targeting Myeloid-Derived Suppressor Cells in Ovarian Cancer. Cells, 2021, 10, 329.	1.8	21
2822	The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpointÂinhibitors. ESMO Open, 2021, 6, 100008.	2.0	5
2823	Identifying key questions in the ecology and evolution of cancer. Evolutionary Applications, 2021, 14, 877-892.	1.5	58
2824	Understanding relevant immune mechanisms in gastrointestinal oncology. Journal of Oncology Pharmacy Practice, 2021, 27, 107815522199286.	0.5	0

#	Article	IF	Citations
2825	Non-canonical PD-1 signaling in cancer and its potential implications in clinic. , 2021, 9, e001230.		15
2826	Crosstalk between Macrophages, T Cells, and Iron Metabolism in Tumor Microenvironment. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-14.	1.9	40
2827	Prognostic Role of Nodal Skip Metastasis in Thoracic Esophageal Squamous Cell Carcinoma: A Large-Scale Multicenter Study. Annals of Surgical Oncology, 2021, 28, 6341-6352.	0.7	11
2828	Singleâ€cell RNA sequencing in cancer research. Journal of Experimental and Clinical Cancer Research, 2021, 40, 81.	3.5	128
2829	Dual-Sensitive PEG-Sheddable Nanodrug Hierarchically Incorporating PD-L1 Antibody and Zinc Phthalocyanine for Improved Immuno-Photodynamic Therapy. ACS Applied Materials & Interfaces, 2021, 13, 12845-12856.	4.0	35
2830	Utilizing Immunocytokines for Cancer Therapy. Antibodies, 2021, 10, 10.	1.2	24
2831	Type I and II Interferons in the Anti-Tumor Immune Response. Cancers, 2021, 13, 1037.	1.7	47
2832	The Peripheral Immune Landscape of Breast Cancer: Clinical Findings and In Vitro Models for Biomarker Discovery. Cancers, 2021, 13, 1305.	1.7	14
2833	How Cells Communicate with Each Other in the Tumor Microenvironment: Suggestions to Design Novel Therapeutic Strategies in Cancer Disease. International Journal of Molecular Sciences, 2021, 22, 2550.	1.8	14
2834	Recent advances in immune therapies for gastric cancer. Cancer Gene Therapy, 2021, 28, 924-934.	2.2	16
2835	Development of a poor-prognostic-mutations derived immune prognostic model for acute myeloid leukemia. Scientific Reports, 2021, 11, 4856.	1.6	7
2836	Dual role of endothelial Myct1 in tumor angiogenesis and tumor immunity. Science Translational Medicine, 2021, 13, .	5.8	35
2837	The Prolactin Inducible Protein Modulates Antitumor Immune Responses and Metastasis in a Mouse Model of Triple Negative Breast Cancer. Frontiers in Oncology, 2021, 11, 639859.	1.3	10
2838	Gene silencing-mediated immune checkpoint blockade for tumor therapy boosted by dendrimer-entrapped gold nanoparticles. Science China Materials, 2021, 64, 2045-2055.	3.5	19
2839	Promises and challenges of adoptive T-cell therapies for solid tumours. British Journal of Cancer, 2021, 124, 1759-1776.	2.9	113
2841	The Role of Macrophages in Oral Squamous Cell Carcinoma. Frontiers in Oncology, 2021, 11, 611115.	1.3	18
2842	Decipher the Glioblastoma Microenvironment: The First Milestone for New Groundbreaking Therapeutic Strategies. Genes, 2021, 12, 445.	1.0	43
2843	Postoperative Inflammatory Marker Surveillance in Colorectal Peritoneal Carcinomatosis. Annals of Surgical Oncology, 2021, 28, 6625-6635.	0.7	9

#	Article	IF	Citations
2844	Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors. International Journal of Molecular Sciences, 2021, 22, 2608.	1.8	13
2845	Biomarker Technologies to Support Early Clinical Immuno-oncology Development: Advances and Interpretation. Clinical Cancer Research, 2021, 27, 4147-4159.	3.2	5
2846	Aging, cancer, and antitumor immunity. International Journal of Clinical Oncology, 2022, 27, 316-322.	1.0	29
2847	Regulation of MHC I Molecules in Glioblastoma Cells and the Sensitizing of NK Cells. Pharmaceuticals, 2021, 14, 236.	1.7	15
2848	Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors. Cancer Immunology, Immunotherapy, 2021, 70, 2991-3000.	2.0	18
2849	The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy. Biomedicines, 2021, 9, 361.	1.4	7
2850	Lymphopenia in Esophageal Cancer: What Have We Learned?. Frontiers in Oncology, 2021, 11, 625963.	1.3	5
2851	Complete Spontaneous Regression of Lung Metastases after Resection of CIC-Rearranged Sarcoma: A Case Report. Case Reports in Oncology, 2021, 14, 152-159.	0.3	1
2852	Gendered energy relations at the crossroads of Asia: Electrification, empowerment, and mixed outcomes in northeastern Afghanistan. Energy Research and Social Science, 2021, 73, 101928.	3.0	6
2853	Boosting Immunity against Multiple Myeloma. Cancers, 2021, 13, 1221.	1.7	8
2854	Therapeutic applications of the cancer immunoediting hypothesis. Seminars in Cancer Biology, 2022, 78, 63-77.	4.3	29
2855	Nanovaccineâ€Based Strategies to Overcome Challenges in the Whole Vaccination Cascade for Tumor Immunotherapy. Small, 2021, 17, e2006000.	5.2	53
2856	MicroRNAs Regulating Tumor and Immune Cell Interactions in the Prediction of Relapse in Early Stage Breast Cancer. Biomedicines, 2021, 9, 421.	1.4	2
2857	Myeloid-Derived Suppressor Cells as Therapeutic Targets in Uterine Cervical and Endometrial Cancers. Cells, 2021, 10, 1073.	1.8	6
2858	Solid Organ Transplantation and Survival among Individuals with a History of Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1312-1319.	1.1	5
2859	Ultraviolet Radiation and Chronic Inflammationâ€"Molecules and Mechanisms Involved in Skin Carcinogenesis: A Narrative Review. Life, 2021, 11, 326.	1.1	31
2860	Semiflexible Immunobrushes Induce Enhanced T Cell Activation and Expansion. ACS Applied Materials & Interfaces, 2021, 13, 16007-16018.	4.0	14
2861	Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review. Cancer Cell International, 2021, 21, 239.	1.8	35

#	Article	IF	Citations
2862	Late Recurrence in Breast Cancer: To Run after the Oxen or to Try to Close the Barn?. Cancers, 2021, 13, 2026.	1.7	0
2865	Exploration of p53 plus interferon-beta gene transfer for the sensitization of human colorectal cancer cell lines to cell death. Cancer Biology and Therapy, 2021, 22, 301-310.	1.5	3
2866	Advances in Targeting Cutaneous Melanoma. Cancers, 2021, 13, 2090.	1.7	19
2867	Multiomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy. , 2021, 9, e002312.		21
2868	Targeting regulatory T cells for immunotherapy in melanoma. Molecular Biomedicine, 2021, 2, 11.	1.7	22
2870	Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of Cancer. Cancers, 2021, 13, 1926.	1.7	17
2871	Time to rejuvenate ultra-low dose whole-body radiotherapy of cancer. Critical Reviews in Oncology/Hematology, 2021, 160, 103286.	2.0	10
2873	Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas. Frontiers in Immunology, 2021, 12, 653081.	2.2	7
2874	Stability analysis of a fractional-order cancer model with chaotic dynamics. International Journal of Biomathematics, 2021, 14, 2150046.	1.5	21
2875	Tumor-Intrinsic Mechanisms Regulating Immune Exclusion in Liver Cancers. Frontiers in Immunology, 2021, 12, 642958.	2.2	12
2876	Cancer Stem Cells Are Possible Key Players in Regulating Anti-Tumor Immune Responses: The Role of Immunomodulating Molecules and MicroRNAs. Cancers, 2021, 13, 1674.	1.7	9
2877	Optimal control strategy for cancer remission using combinatorial therapy: A mathematical model-based approach. Chaos, Solitons and Fractals, 2021, 145, 110789.	2.5	25
2878	Clinical Experience and Recent Advances in the Development of Listeria-Based Tumor Immunotherapies. Frontiers in Immunology, 2021, 12, 642316.	2.2	32
2879	LncRNA influence sequential steps of hepatocellular carcinoma metastasis. Biomedicine and Pharmacotherapy, 2021, 136, 111224.	2.5	24
2880	Associations of highâ€resolutionâ€typingâ€defined MICA and MICB polymorphisms, and the levels of soluble MICA and MICB with Oral Squamous Cell Carcinoma in Bulgarian patients. Journal of Oral Pathology and Medicine, 2021, 50, 758-765.	1.4	6
2882	Contourner la rÃ©sistance Ã lâ€™immunothÃ©rapie des cancersÂ: interventions centrÃ©es sur le microbiome intestinal. Bulletin De L'Academie Nationale De Medecine, 2021, 205, 364-382.	0.0	0
2883	Thyroid Cancer Stem-Like Cells: From Microenvironmental Niches to Therapeutic Strategies. Journal of Clinical Medicine, 2021, 10, 1455.	1.0	11
2884	Is immunotherapy in the future of therapeutic management of sarcomas?. Journal of Translational Medicine, 2021, 19, 173.	1.8	18

#	Article	IF	Citations
2885	Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used. Cancer Immunology, Immunotherapy, 2021, 70, 3249-3258.	2.0	14
2886	Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials. Expert Opinion on Emerging Drugs, 2021, 26, 131-147.	1.0	5
2887	Cancer immunoediting: A game theoretical approach. In Silico Biology, 2021, 14, 1-12.	0.4	13
2888	Cancer as a form of life: Musings of the cancer and evolution symposium. Progress in Biophysics and Molecular Biology, 2021, 165, 120-139.	1.4	6
2889	The Emergence and Evolution of Borophene. Advanced Science, 2021, 8, 2001801.	5.6	98
2890	A six-gene signature related with tumor mutation burden for predicting lymph node metastasis in breast cancer. Translational Cancer Research, 2021, 10, 2229-2246.	0.4	3
2891	Inmunoterapia personalizada contra el cÃ¡ncer basada en neoantÃgenos. RevisiÃ³n de la literatura. Revista Facultad De Medicina, 2021, 69, e81633.	0.0	0
2892	High endothelial venules (HEVs) in immunity, inflammation and cancer. Angiogenesis, 2021, 24, 719-753.	3.7	64
2893	Identification of a prognostic signature based on immune-related genes in bladder cancer. Genomics, 2021, 113, 1203-1218.	1.3	5
2894	Redefining macrophage and neutrophil biology in the metastatic cascade. Immunity, 2021, 54, 885-902.	6.6	68
2895	Stochastic Simulation on a Minimal Model of Cancer Immunoediting Theory. International Journal of Bifurcation and Chaos in Applied Sciences and Engineering, 2021, 31, 2150088.	0.7	3
2896	Magnetic Nanostructures as Emerging Therapeutic Tools to Boost Anti-Tumour Immunity. Cancers, 2021, 13, 2735.	1.7	21
2897	Knockout of immunotherapy prognostic marker genes eliminates the effect of the anti-PD-1 treatment. Npj Precision Oncology, 2021, 5, 37.	2.3	4
2898	Recent Progress in Dendritic Cell-Based Cancer Immunotherapy. Cancers, 2021, 13, 2495.	1.7	26
2899	Suppression of DLBCL Progression by the E3 Ligase Trim35 Is Mediated by CLOCK Degradation and NK Cell Infiltration. Journal of Immunology Research, 2021, 2021, 1-13.	0.9	10
2900	The antigenâ€binding moiety in the driver's seat of CARs. Medicinal Research Reviews, 2022, 42, 306-342.	5.0	21
2901	Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. Journal of Hematology and Oncology, 2021, 14, 75.	6.9	107
2902	Signalâ€transducing innate receptors in tumor immunity. Cancer Science, 2021, 112, 2578-2591.	1.7	8

#	Article	IF	Citations
2903	Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors. International Journal of Molecular Sciences, 2021, 22, 5736.	1.8	29
2904	The role of dendritic cells in cancer and anti-tumor immunity. Seminars in Immunology, 2021, 52, 101481.	2.7	91
2905	Current status of cancer immunotherapy with immune checkpoint inhibitors. Journal of the Korean Medical Association, 2021, 64, 326-331.	0.1	1
2906	Therapeutic dendritic cell cancer vaccines in hematologic malignancies. Immunomedicine, 2021, 1, e1022.	0.7	0
2907	Checkpoint blockade accelerates a novel switch from an NKT-driven TNFÎ± response toward a T cell driven IFN-Î³ response within the tumor microenvironment. , 2021, 9, e002269.		2
2908	The Comprehensive â€œOmicsâ€•Approach from Metabolomics to Advanced Omics for Development of Immune Checkpoint Inhibitors: Potential Strategies for Next Generation of Cancer Immunotherapy. International Journal of Molecular Sciences, 2021, 22, 6932.	1.8	9
2909	MicroRNAs Regulating Tumor Immune Response in the Prediction of the Outcome in Patients With Breast Cancer. Frontiers in Molecular Biosciences, 2021, 8, 668534.	1.6	14
2910	Immunophenotypeâ€associated gene signature in ductal breast tumors varies by receptor subtype, but the expression of individual signature genes remains consistent. Cancer Medicine, 2021, 10, 5712-5720.	1.3	5
2911	Neoantigen load as a prognostic and predictive marker for stage II / III nonâ€small cell lung cancer in Chinese patients. Thoracic Cancer, 2021, 12, 2170-2181.	0.8	5
2912	Extracellular vesicles as antigen carriers for novel vaccination avenues. Advanced Drug Delivery Reviews, 2021, 173, 164-180.	6.6	49
2913	Longâ€term opioid treatment and endocrine measures in chronic nonâ€cancer pain patients: A systematic review and metaâ€analysis. European Journal of Pain, 2021, 25, 1859-1875.	1.4	2
2914	Symphony of nanomaterials and immunotherapy based on the cancerâ€“immunity cycle. Acta Pharmaceutica Sinica B, 2022, 12, 107-134.	5.7	70
2915	Chronic Obstructive Pulmonary Disease: Epidemiology, Biomarkers, and Paving the Way to Lung Cancer. Journal of Clinical Medicine, 2021, 10, 2889.	1.0	49
2916	Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges. Cancers, 2021, 13, 2853.	1.7	9
2917	Spatial distribution of immune checkpoint proteins in histological subtypes of lung adenocarcinoma. Neoplasia, 2021, 23, 584-593.	2.3	8
2918	Immunodiagnostic Biomarkers for Hepatocellular Carcinoma (HCC): The First Step in Detection and Treatment. International Journal of Molecular Sciences, 2021, 22, 6139.	1.8	18
2919	The value of tumor-infiltrating lymphocytes and CD8 expression as a predictor of response to anthracycline-based neoadjuvant chemotherapy in invasive breast carcinoma of no special type. Breast Disease, 2021, 40, S9-S14.	0.4	0
2920	A stealth antigen SPESP1, which is epigenetically silenced in tumors, is a suitable target for cancer immunotherapy. Cancer Science, 2021, 112, 2705-2713.	1.7	6

#	Article	IF	Citations
2921	ATP and cancer immunosurveillance. EMBO Journal, 2021, 40, e108130.	3.5	105
2922	Biomarkers of therapeutic response with immune checkpoint inhibitors. Annals of Translational Medicine, 2021, 9, 1040-1040.	0.7	3
2923	Frontiers in Pharmacology: Review Manuscript Targeting of the Neutrophil as an Adjunctive Strategy in Non-Small Cell Lung Cancer. Frontiers in Pharmacology, 2021, 12, 676399.	1.6	5
2924	Gene expression-based immune infiltration analyses of liver cancer and their associations with survival outcomes. Cancer Genetics, 2021, 254-255, 75-81.	0.2	1
2925	Serum IL-5 and IFN-Î³ Are Novel Predictive Biomarkers for Anti-PD-1 Treatment in NSCLC and GC Patients. Disease Markers, 2021, 2021, 1-7.	0.6	9
2926	Immunology of Lynch Syndrome. Current Oncology Reports, 2021, 23, 96.	1.8	10
2927	The possibilities of combination immunotherapy with radiation therapy for the treatment of patients with inoperable locally advanced non-small cell lung cancer. IssledovaniÃ¢ I Praktika V Medicine, 2021, 8, 109-123.	0.1	0
2928	Immunotherapy in endometrial cancer: rationale, practice and perspectives. Biomarker Research, 2021, 9, 49.	2.8	53
2929	Interleukins in cancer: from biology to therapy. Nature Reviews Cancer, 2021, 21, 481-499.	12.8	318
2930	CD1a- and CD83-positive dendritic cells as prognostic markers of metastasis development in early breast cancer patients. Breast Cancer, 2021, 28, 1328-1339.	1.3	19
2931	Decreased m6A Modification of CD34/CD276(B7-H3) Leads to Immune Escape in Colon Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 715674.	1.8	8
2932	The future of immune checkpoint combinations with tumor-targeted small molecule drugs. Emerging Topics in Life Sciences, 2021, 5, 675-680.	1.1	2
2933	Chiral nanomaterials for tumor therapy: autophagy, apoptosis, and photothermal ablation. Journal of Nanobiotechnology, 2021, 19, 220.	4.2	36
2934	Comparing immunotherapies to other frequently used treatments of gastric cancer. Expert Review of Clinical Pharmacology, 2021, 14, 1221-1232.	1.3	2
2935	Role of Systemic Inflammatory Reaction in Female Genital Organ Malignancies â€“ State of the Art. Cancer Management and Research, 2021, Volume 13, 5491-5508.	0.9	9
2936	Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nature Reviews Drug Discovery, 2022, 21, 495-508.	21.5	120
2937	DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduction and Targeted Therapy, 2021, 6, 254.	7.1	239
2938	Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. , 2021, 9, e002591.		105

#	Article	IF	Citations
2939	Predictive biomarkers of inhibitors immune checkpoints therapy in malignant tumors. Russian Journal of Pediatric Hematology and Oncology, 2021, 8, 73-83.	0.1	2
2940	Immunotherapy Strategies for Gastrointestinal Stromal Tumor. Cancers, 2021, 13, 3525.	1.7	18
2941	Inflammatory cell death induced by cytotoxic lymphocytes: a dangerous but necessary liaison. FEBS Journal, 2022, 289, 4398-4415.	2.2	17
2942	Predictive potential of Nomogram based on GMWG for patients with hepatocellular carcinoma after radical resection. BMC Cancer, 2021, 21, 817.	1.1	2
2943	A human CD137Ã—PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade. Nature Communications, 2021, 12, 4445.	5.8	54
2944	Reversing Epigenetic Gene Silencing to Overcome Immune Evasion in CNS Malignancies. Frontiers in Oncology, 2021, 11, 719091.	1.3	14
2945	Neoantigen Controversies. Annual Review of Biomedical Data Science, 2021, 4, 227-253.	2.8	9
2946	Prognostic and Immunological Role of Gasdermin E in Pan-Cancer Analysis. Frontiers in Oncology, 2021, 11, 706266.	1.3	12
2947	Recent advances in immunotherapy for hepatocellular carcinoma. Hepatobiliary and Pancreatic Diseases International, 2021, 20, 511-520.	0.6	29
2948	Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies. , 2021, 9, e002444.		12
2949	Immunotherapy in Glioblastoma: A Clinical Perspective. Cancers, 2021, 13, 3721.	1.7	16
2950	Design and Encapsulation of Immunomodulators onto Gold Nanoparticles in Cancer Immunotherapy. International Journal of Molecular Sciences, 2021, 22, 8037.	1.8	17
2951	Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting. Cells, 2021, 10, 1685.	1.8	15
2952	Dual mitigation of immunosuppression combined with photothermal inhibition for highly effective primary tumor and metastases therapy. Biomaterials, 2021, 274, 120856.	5.7	32
2953	Potential of Immunotherapies in Treating Hematological Cancer-Infection Comorbiditiesâ€”A Mathematical Modelling Approach. Cancers, 2021, 13, 3789.	1.7	2
2954	Regulation of the epigenetic landscape by immune cell oxidants. Free Radical Biology and Medicine, 2021, 170, 131-149.	1.3	8
2955	Establishment of a nomogram with EMP3 for predicting clinical outcomes in patients with glioma: A biâ€center study. CNS Neuroscience and Therapeutics, 2021, 27, 1238-1250.	1.9	7
2956	A novel prognostic signature of immune-related lncRNA pairs in lung adenocarcinoma. Scientific Reports, 2021, 11, 16794.	1.6	6

#	Article	IF	Citations
2957	Curcumin as an Adjuvant to Cancer Immunotherapy. Frontiers in Oncology, 2021, 11, 675923.	1.3	27
2958	Drug delivery strategies in maximizing anti-angiogenesis and anti-tumor immunity. Advanced Drug Delivery Reviews, 2021, 179, 113920.	6.6	18
2959	Immunoprofiling: An Encouraging Method for Predictive Factors Examination in Lung Cancer Patients Treated with Immunotherapy. International Journal of Molecular Sciences, 2021, 22, 9133.	1.8	4
2960	Nanotechnology for Boosting Cancer Immunotherapy and Remodeling Tumor Microenvironment: The Horizons in Cancer Treatment. ACS Nano, 2021, 15, 12567-12603.	7.3	112
2961	A mechanistic systems pharmacology modeling platform to investigate the effect of PD-L1 expression heterogeneity and dynamics on the efficacy of PD-1 and PD-L1 blocking antibodies in cancer. Journal of Theoretical Biology, 2021, 522, 110697.	0.8	1
2962	Identification of prognostic biomarkers related to the tumor microenvironment in thyroid carcinoma. Scientific Reports, 2021, 11, 16239.	1.6	7
2963	Tumor microenvironment of human breast cancer, and feline mammary carcinoma as a potential study model. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188587.	3.3	32
2964	To inhibit or to boost the ATP/P2RX7 pathway to fight cancerâ€"that is the question. Purinergic Signalling, 2021, 17, 619-631.	1.1	13
2965	Nano-ablative immunotherapy for cancer treatment. Nanophotonics, 2021, 10, 3247-3266.	2.9	4
2966	Deregulation of HLA-I in cancer and its central importance for immunotherapy. , 2021, 9, e002899.		73
2968	Lack of response to immunotherapy in non-alcoholic steatohepatitis related hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2021, 10, 522-525.	0.7	9
2969	No evidence that HLA genotype influences the driver mutations that occur in cancer patients. Cancer Immunology, Immunotherapy, 2022, 71, 819-827.	2.0	3
2970	Single-Cell Omics in Dissecting Immune Microenvironment of Malignant Gliomasâ€"Challenges and Perspectives. Cells, 2021, 10, 2264.	1.8	24
2971	Hallmarks of Cancers: Primary Antibody Deficiency Versus Other Inborn Errors of Immunity. Frontiers in Immunology, 2021, 12, 720025.	2.2	14
2972	Immunogenomic pan-cancer landscape reveals immune escape mechanisms and immunoediting histories. Scientific Reports, 2021, 11, 15713.	1.6	10
2973	CD73 Promotes Tumor Progression in Patients with Esophageal Squamous Cell Carcinoma. Cancers, 2021, 13, 3982.	1.7	11
2974	CXCL10 Produced by HPV-Positive Cervical Cancer Cells Stimulates Exosomal PDL1 Expression by Fibroblasts via CXCR3 and JAK-STAT Pathways. Frontiers in Oncology, 2021, 11, 629350.	1.3	19
2975	Asymptomatic incidental neuroblastoma in a patient with SH2D1A deficiency. Pediatric Blood and Cancer, 2022, 69, e29314.	0.8	0

#	Article	IF	Citations
2976	Biological factors of the tumour response to electrochemotherapy: Review of the evidence and a research roadmap. European Journal of Surgical Oncology, 2021, 47, 1836-1846.	0.5	25
2977	Immune-checkpoint inhibitors in pituitary malignancies. Anti-Cancer Drugs, 2021, Publish Ahead of Print, .	0.7	2
2978	Histological differentiation impacts the tumor immune microenvironment in gastric carcinoma: Relation to the immune cycle. World Journal of Gastroenterology, 2021, 27, 5259-5271.	1.4	6
2979	Peripheral Blood Lymphocyte Percentage May Predict Chemotolerance and Survival in Patients with Advanced Pancreatic Cancer. Association between Adaptive Immunity and Nutritional State. Current Oncology, 2021, 28, 3280-3296.	0.9	2
2980	In silico approaches in carcinogenicity hazard assessment: Current status and future needs. Computational Toxicology, 2021, 20, 100191.	1.8	19
2981	Bringing Macrophages to the Frontline against Cancer: Current Immunotherapies Targeting Macrophages. Cells, 2021, 10, 2364.	1.8	13
2982	Immune Checkpoints in Cancers: From Signaling to the Clinic. Cancers, 2021, 13, 4573.	1.7	35
2983	Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach. , 2022, 231, 107986.		30
2984	PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy. Frontiers in Pharmacology, 2021, 12, 731798.	1.6	134
2985	Evaluation of an RNAseq-Based Immunogenomic Liquid Biopsy Approach in Early-Stage Prostate Cancer. Cells, 2021, 10, 2567.	1.8	1
2986	Loss of Von Hippelâ€“Lindau (VHL) Tumor Suppressor Gene Function: VHLâ€“HIF Pathway and Advances in Treatments for Metastatic Renal Cell Carcinoma (RCC). International Journal of Molecular Sciences, 2021, 22, 9795.	1.8	32
2987	Development of an Interferon Gamma Response-Related Signature for Prediction of Survival in Clear Cell Renal Cell Carcinoma. Journal of Inflammation Research, 2021, Volume 14, 4969-4985.	1.6	7
2988	Protein Kinase D3 Promotes the Reconstruction of OSCC Immune Escape Niche Via Regulating MHC-I and Immune Inhibit Molecules Expression. Journal of Immunotherapy, 2021, Publish Ahead of Print, 339-347.	1.2	3
2990	Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer. Npj Breast Cancer, 2021, 7, 114.	2.3	3
2991	Programmed death ligand-1 protein expression difference in basal like and non-basal like triple negative breast cancer and its association with disease free survival and overall survival: A systematic review. Oncology Reviews, 2021, 15, 533.	0.8	0
2992	Effective Treatment of Established Bone Metastases Can Be Achieved by Combinatorial Osteoclast Blockade and Depletion of Granulocytic Subsets. Cancer Immunology Research, 2021, 9, 1400-1412.	1.6	11
2993	The Immune System of Mesothelioma Patients: A Window of Opportunity for Novel Immunotherapies. , 0, , .		0
2994	A ferroptosis-associated gene signature for the prediction of prognosis and therapeutic response in luminal-type breast carcinoma. Scientific Reports, 2021, 11, 17610.	1.6	4

#	Article	IF	Citations
2995	Characterization of Molecular Heterogeneity Associated With Tumor Microenvironment in Clear Cell Renal Cell Carcinoma to Aid Immunotherapy. Frontiers in Cell and Developmental Biology, 2021, 9, 736540.	1.8	9
2996	Lifeâ€years lost due to cancer among solid organ transplant recipients in the United States, 1987 to 2014. Cancer, 2022, 128, 150-159.	2.0	2
2997	Development and Validation of an Mesenchymal-Related Long Non-Coding RNA Prognostic Model in Glioma. Frontiers in Oncology, 2021, 11, 726745.	1.3	5
2998	Immune deserts in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment. Oral Oncology, 2021, 120, 105420.	0.8	20
2999	Immunomodulating Therapies in Breast Cancerâ€"From Prognosis to Clinical Practice. Cancers, 2021, 13, 4883.	1.7	15
3000	Therapeutic cancer vaccines revamping: technology advancements and pitfalls. Annals of Oncology, 2021, 32, 1537-1551.	0.6	36
3001	Opposing roles of the immune system in tumors. Science, 2021, 373, 1306-1307.	6.0	6
3002	Targeting immune checkpoints in gynecologic cancer: updates & perspectives for pathologists. Modern Pathology, 2022, 35, 142-151.	2.9	7
3003	Dissecting the biological heterogeneity of HER2-positive breast cancer. Breast, 2021, 59, 339-350.	0.9	41
3004	Immunobiology of Melanoma. Clinics in Plastic Surgery, 2021, 48, 561-576.	0.7	5
3005	A Nanoplatform to Amplify Apoptosis-to-Pyroptosis Immunotherapy via Immunomodulation of Myeloid-Derived Suppressor Cells. ACS Applied Materials & Interfaces, 2021, 13, 47407-47417.	4.0	35
3006	Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454â€"3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC. Chemico-Biological Interactions, 2021, 349, 109652.	1.7	29
3007	The impact of immunotherapy on a glioma immune interaction model. Chaos, Solitons and Fractals, 2021, 152, 111346.	2.5	14
3008	Mathematical modeling approach of cancer immunoediting reveals new insights in targeted-therapy and timing plan of cancer treatment. Chaos, Solitons and Fractals, 2021, 152, 111349.	2.5	3
3009	Metabolic reprogramming and immunity in cancer. , 2022, , 137-196.		1
3010	Intrinsic and acquired cancer immunotherapy resistance. , 2022, , 463-497.		0
3011	Dormancy in cancer bone metastasis. , 2022, , 393-410.		0
3012	Current Role of Immunotherapy. , 2022, , 905-911.		0

#	Article	IF	Citations
3013	Characterization of immune landscape in papillary thyroid cancer reveals distinct tumor immunogenicity and implications for immunotherapy. OncoImmunology, 2021, 10, e1964189.	2.1	24
3014	Nonlinear dynamics in tumor-immune system interaction models with delays. Discrete and Continuous Dynamical Systems - Series B, 2021, 26, 541-602.	0.5	13
3015	Development of an Oncogenic Driver Alteration Associated Immune-Related Prognostic Model for Stage I-II Lung Adenocarcinoma. Frontiers in Oncology, 2020, 10, 593022.	1.3	9
3016	Neutrophil-to-lymphocyte ratio and mortality in the United States general population. Scientific Reports, 2021, 11, 464.	1.6	131
3017	Role of Hypoxia-Mediated Autophagy in Tumor Cell Death and Survival. Cancers, 2021, 13, 533.	1.7	41
3019	Myeloid-Derived Suppressor Cell Differentiation in Cancer: Transcriptional Regulators and Enhanceosome-Mediated Mechanisms. Frontiers in Immunology, 2020, 11, 619253.	2.2	13
3020	Personalized cancer vaccination in head and neck cancer. Cancer Science, 2021, 112, 978-988.	1.7	34
3021	Extracellular vesicle-mediated crosstalk between melanoma and the immune system: Impact on tumor progression and therapy response. Journal of Leukocyte Biology, 2020, 108, 1101-1115.	1.5	13
3022	Undefined-Antigen Vaccines. , 2005, 123, 207-225.		1
3023	Evolutionary Design in Biological Physics and Materials Science. , 2006, , 541-562.		4
3024	Gene Profiling for the Prediction of Tumor Response to Treatment. , 2007, 593, 86-94.		2
3025	Immunotherapy of AML. Cancer Treatment and Research, 2009, 145, 237-255.	0.2	2
3026	Immune System, Inflammation, and Essential Fatty Acids and Their Metabolites in Cancer. , 2020, , 67-157.		1
3027	Characterization of tumor-directed cellular immune responses in humans. , 2008, , 157-167.		1
3028	Assessment of Age-related Decline of Immunological Function and Possible Methods for Immunological Restoration in Elderly. , 2009, , 1547-1570.		3
3029	Interleukin-21 and Cancer Therapy. , 2009, , 43-59.		2
3030	Memory T-Cell Responses and Survival in Human Cancer: Remember to Stay Alive. Advances in Experimental Medicine and Biology, 2010, 684, 166-177.	0.8	9
3031	Analysis of Vaccine-Induced T Cells in Humans with Cancer. Advances in Experimental Medicine and Biology, 2010, 684, 178-188.	0.8	7

#	Article	IF	Citations
3032	Immune Signatures Associated with the Cancer Bearing State. , 2011, , 169-186.		1
3033	Immune-Mediated Tumor Rejection. , 2011, , 281-304.		2
3034	Therapeutic Approaches Utilising NKT Cells. , 2012, , 111-128.		2
3035	Multifaceted Kinetics of Immuno-Evasion from Tumor Dormancy. Advances in Experimental Medicine and Biology, 2013, 734, 111-143.	0.8	7
3036	Animal Models for Vaccine Therapy. Advances in Experimental Medicine and Biology, 2012, 746, 143-150.	0.8	2
3037	Breast Cancer Stem Cells: Responsible for Therapeutic Resistance and Relapse?. , 2013, , 385-398.		1
3038	B Lymphocytes in Cancer Immunology. , 2011, , 37-57.		8
3039	Cancer Immunity. , 2019, , 191-208.		1
3040	Disseminated Tumor Cells and Dormancy in Breast Cancer Progression. Advances in Experimental Medicine and Biology, 2020, 1220, 35-43.	0.8	17
3041	Interleukin-8 in the Tumor Immune Niche: Lessons from Comparative Oncology. Advances in Experimental Medicine and Biology, 2020, 1240, 25-33.	0.8	19
3042	IL-17 Signaling in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1240, 47-58.	0.8	39
3043	Overview of Basic Immunology and Clinical Application. Advances in Experimental Medicine and Biology, 2020, 1244, 1-36.	0.8	8
3044	Challenges of Immunotherapy. , 2016, , 419-434.		1
3045	Mechanisms of Immune Evasion by Cancer. , 2016, , 199-232.		4
3046	Immuno-oncology of Dormant Tumours. Cancer Drug Discovery and Development, 2017, , 51-60.	0.2	1
3047	Cell-Cell Interactions in Solid Tumors â€" the Role of Cancer Stem Cells. SIMAI Springer Series, 2012, , 191-204.	0.4	2
3048	Therapeutic Cancer Vaccines. Advances in Experimental Medicine and Biology, 2016, 909, 139-167.	0.8	12
3049	Systemic Risks in the Evolution of Complex Social Systems. Evolutionary Economics and Social Complexity Science, 2017, , 19-49.	0.4	1

#	Article	IF	Citations
3050	Genetic Alterations and Checkpoint Expression: Mechanisms and Models for Drug Discovery. Advances in Experimental Medicine and Biology, 2020, 1248, 227-250.	0.8	1
3051	Neoplasia. , 2010, , 259-330.		26
3052	Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist. British Journal of Anaesthesia, 2020, 124, 251-260.	1.5	35
3053	Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting. Cytokine and Growth Factor Reviews, 2017, 36, 67-77.	3.2	71
3054	Toxicities from immunotherapy: From clinical trials to real-world clinical practice. Medicina ClÃ¬nica, 2020, 155, 541-547.	0.3	8
3055	Tissue-resident memory CD8+ T cells in cancer immunology and immunotherapy. Pharmacological Research, 2020, 159, 104876.	3.1	17
3056	The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer. Urologic Clinics of North America, 2020, 47, e17-e54.	0.8	39
3057	Mechanisms of tumor evasion from the immune response. Cancer Chemotherapy and Biological Response Modifiers, 2003, 21, 351-364.	0.5	29
3058	Cancer therapy-induced immune modulation. Cancer Chemotherapy and Biological Response Modifiers, 2005, , 325-341.	0.5	1
3060	MHC class I-independent activation of virtual memory CD8 T cells induced by chemotherapeutic agent-treated cancer cells. Cellular and Molecular Immunology, 2021, 18, 723-734.	4.8	23
3061	Radiation therapy and immunotherapy in breast cancer treatment: preliminary data and perspectives. Expert Review of Anticancer Therapy, 2021, 21, 501-510.	1.1	10
3062	Computational modelling of modern cancer immunotherapy. Physics in Medicine and Biology, 2020, 65, 24TR01.	1.6	14
3064	Introducing Evolutionary Thinking For Medicine. , 2007, , 3-16.		6
3065	Global spatial patterns of infectious diseases and human evolution. , 2007, , 19-30.		7
3066	Human genetic variation of medical significance. , 2007, , 51-62.		1
3067	Intimate relations: Evolutionary conflicts of pregnancy and childhood. , 2007, , 65-76.		5
3068	How hormones mediate trade-offs in human health and disease. , 2007, , 77-94.		12
3069	Functional significance of MHC variation in mate choice, reproductive outcome, and disease risk. , 2007, , 95-108.		3

#	Article	IF	Citations
3070	The ecology and evolution of antibiotic-resistant bacteria. , 2007, , 125-138.		9
3071	Pathogen evolution in a vaccinated world. , 2007, , 139-152.		11
3072	The evolution and expression of virulence. , 2007, , 153-168.		30
3073	Evolutionary origins of diversity in human viruses. , 2007, , 169-184.		2
3074	The population structure of pathogenic bacteria. , 2007, , 185-198.		4
3075	Emergence of new infectious diseases. , 2007, , 215-228.		7
3076	Evolutionary biology as a foundation for studying aging and aging-related disease. , 2007, , 241-252.		3
3077	Evolution, developmental plasticity, and metabolic disease. , 2007, , 253-264.		8
3078	Lifestyle, diet, and disease: comparative perspectives on the determinants of chronic health risks. , 2007, , 265-276.		8
3079	Overview of Lung Cancer Immunotherapy. Cancer Journal (Sudbury, Mass), 2020, 26, 473-484.	1.0	6
3093	Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging. JCI Insight, 2019, 4, .	2.3	90
3094	Emerging strategies for combination checkpoint modulators in cancer immunotherapy. Journal of Clinical Investigation, 2018, 128, 3209-3218.	3.9	170
3095	Integrating the quality of the cytotoxic response and tumor susceptibility into the design of protective vaccines in tumor immunotherapy. Journal of Clinical Investigation, 2003, 111, 595-597.	3.9	25
3096	Coordinated tumor immunity. Journal of Clinical Investigation, 2003, 111, 1116-1118.	3.9	10
3097	Coordinated tumor immunity. Journal of Clinical Investigation, 2003, 111, 1116-1118.	3.9	23
3098	TYK2 is a key regulator of the surveillance of B lymphoid tumors. Journal of Clinical Investigation, 2004, 114, 1650-1658.	3.9	50
3099	TYK2 is a key regulator of the surveillance of B lymphoid tumors. Journal of Clinical Investigation, 2004, 114, 1650-1658.	3.9	32
3100	Myeloid suppressor cells regulate the adaptive immune response to cancer. Journal of Clinical Investigation, 2006, 116, 2587-2590.	3.9	82

#	Article	IF	Citations
3101	Harnessing the immune system to treat cancer. Journal of Clinical Investigation, 2007, 117, 1130-1136.	3.9	103
3102	Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. Journal of Clinical Investigation, 2008, 118, 2427-37.	3.9	487
3103	Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. Journal of Clinical Investigation, 2009, 119, 3311-21.	3.9	171
3104	Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells. Journal of Clinical Investigation, 2012, 122, 2369-2383.	3.9	32
3105	Liver acid sphingomyelinase inhibits growth of metastatic colon cancer. Journal of Clinical Investigation, 2013, 123, 834-43.	3.9	32
3106	Type III TGF-Î² receptor downregulation generates an immunotolerant tumor microenvironment. Journal of Clinical Investigation, 2013, 123, 3925-3940.	3.9	94
3107	Radiation and immunotherapy: a synergistic combination. Journal of Clinical Investigation, 2013, 123, 2756-2763.	3.9	226
3108	Overcoming therapeutic resistance in glioblastoma: the way forward. Journal of Clinical Investigation, 2017, 127, 415-426.	3.9	354
3109	Emerging therapeutic agents for advanced non-small cell lung cancer. Journal of Hematology and Oncology, 2020, 13, 58.	6.9	161
3110	Vitamin C, Vitamin E, and b-Carotene in Cancer Chemoprevention. CRC Series in Modern Nutrition Science, 2004, , .	0.0	1
3111	Recent advances in understanding antitumor immunity. F1000Research, 2016, 5, 2545.	0.8	29
3112	Harnessing Soluble NK Cell Killer Receptors for the Generation of Novel Cancer Immune Therapy. PLoS ONE, 2008, 3, e2150.	1.1	30
3113	Prognostic Impact of Lymphocytes in Soft Tissue Sarcomas. PLoS ONE, 2011, 6, e14611.	1.1	96
3114	Plasma Proteome Profiles Associated with Inflammation, Angiogenesis, and Cancer. PLoS ONE, 2011, 6, e19721.	1.1	36
3115	CD1d-Expressing Breast Cancer Cells Modulate NKT Cell-Mediated Antitumor Immunity in a Murine Model of Breast Cancer Metastasis. PLoS ONE, 2011, 6, e20702.	1.1	85
3116	Immunosignaturing Can Detect Products from Molecular Markers in Brain Cancer. PLoS ONE, 2012, 7, e40201.	1.1	48
3117	IgM-Linked SerpinB3 and SerpinB4 in Sera of Patients with Chronic Liver Disease. PLoS ONE, 2012, 7, e40658.	1.1	22
3118	Distinct Innate Immune Gene Expression Profiles in Non-Melanoma Skin Cancer of Immunocompetent and Immunosuppressed Patients. PLoS ONE, 2012, 7, e40754.	1.1	19

#	Article	IF	Citations
3119	Association between CTLA-4 60G/A and -1661A/G Polymorphisms and the Risk of Cancers: A Meta-Analysis. PLoS ONE, 2013, 8, e83710.	1.1	21
3120	The Use of Anchored Agonists of Phagocytic Receptors for Cancer Immunotherapy: B16-F10 Murine Melanoma Model. PLoS ONE, 2014, 9, e85222.	1.1	16
3121	Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion. PLoS ONE, 2017, 12, e0176181.	1.1	86
3122	Lower expression level of IL-33 is associated with poor prognosis of pulmonary adenocarcinoma. PLoS ONE, 2018, 13, e0193428.	1.1	32
3123	The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, 34-42.	1.8	58
3124	Current Biochemical Applications and Future Prospects of Chlorotoxinin Cancer Diagnostics and Therapeutics. Advanced Pharmaceutical Bulletin, 2019, 9, 510-520.	0.6	9
3125	Indoleamine 2, 3-dioxygenase inhibitors in immunochemotherapy of breast cancer: challenges and opportunities. BioImpacts, 2019, 9, 1-3.	0.7	7
3126	Platinum-resistance and AKT Over-expression in Ovarian Cancer. International Journal of Gynecology & Clinical Practices, 2015, 2, .	0.1	2
3127	T lymphocytes against solid malignancies: winning ways to defeat tumours. Cell Stress, 2018, 2, 200-212.	1.4	22
3128	Immune system activation by natural products and complex fractions: a network pharmacology approach in cancer treatment. Cell Stress, 2020, 4, 154-166.	1.4	14
3129	Dendritic Cell Tumor Killing Activity and Its Potential Applications in Cancer Immunotherapy. Critical Reviews in Immunology, 2013, 33, 1-21.	1.0	38
3130	Peptide Mimotopes as Prototypic Templates of Broad-Spectrum Surrogates of Carbohydrate Antigens for Cancer Vaccination. Critical Reviews in Immunology, 2007, 27, 247-270.	1.0	8
3131	Optimization of Immunotherapy in Elderly Cancer Patients. Critical Reviews in Oncogenesis, 2013, 18, 573-583.	0.2	55
3132	The natural adaptive evolution of cancer: The metastatic ability of cancer cells. Bosnian Journal of Basic Medical Sciences, 2020, 20, 303-309.	0.6	3
3133	Tumor-associated macrophages, multi-tasking cells in the cancer landscape. Cancer Research Frontiers, 2015, 1, 149-161.	0.2	7
3134	The Value of Programmed Death Ligand 1 Expression in Cancer Patients Treated with Neoadjuvant Chemotherapy. Sultan Qaboos University Medical Journal, 2019, 19, 277.	0.3	3
3135	The Immunobiology of Cancer: An Update Review. Indonesian Biomedical Journal, 2017, 9, 53.	0.2	2
3136	Identification of an immune-related risk signature for predicting prognosis in clear cell renal cell carcinoma. Aging, 2020, 12, 2302-2332.	1.4	48

#	Article	IF	Citations
3137	A TP53-based immune prognostic model for muscle-invasive bladder cancer. Aging, 2021, 13, 1929-1946.	1.4	7
3138	Multiple myeloma cell lines and primary tumors proteome: protein biosynthesis and Immune system as potential therapeutic targets. Genes and Cancer, 2015, 6, 462-471.	0.6	16
3139	T-helper 1-type cytokines induce apoptosis and loss of HER-family oncodriver expression in murine and human breast cancer cells. Oncotarget, 2019, 10, 6006-6020.	0.8	14
3140	Autocrine interleukin-23 promotes self-renewal of CD133+ ovarian cancer stem-like cells. Oncotarget, 2016, 7, 76006-76020.	0.8	20
3141	Placental immune editing switch (PIES): learning about immunomodulatory pathways from a unique case report. Oncotarget, 2016, 7, 83817-83827.	0.8	6
3142	Broad-spectrum anti-tumor and anti-metastatic DNA vaccine based on p62-encoding vector. Oncotarget, 2013, 4, 1829-1835.	0.8	36
3143	Preoperative pulmonary function correlates with systemic inflammatory response and prognosis in patients with non-small cell lung cancer: results of a single-institution retrospective study. Oncotarget, 2017, 8, 27489-27501.	0.8	9
3144	Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic. Oncotarget, 2017, 8, 14416-14427.	0.8	70
3145	Alterations of immune response of non-small cell lung cancer with Azacytidine. Oncotarget, 2013, 4, 2067-2079.	0.8	336
3146	The antitumor activity and preliminary modeling on the potential mechanism of action of human peroxiredoxin-5. Oncotarget, 2017, 8, 27189-27198.	0.8	5
3147	Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC. Oncotarget, 2017, 8, 43555-43570.	0.8	10
3148	Interferon-inducible CXC-chemokines are crucial immune modulators and survival predictors in colorectal cancer. Oncotarget, 2017, 8, 89998-90012.	0.8	57
3149	Immunological landscape of consensus clusters in colorectal cancer. Oncotarget, 2017, 8, 105299-105311.	0.8	55
3150	Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer. Oncotarget, 2018, 9, 5652-5664.	0.8	105
3151	Semaphorin 4D in human head and neck cancer tissue and peripheral blood: A dense fibrotic peri-tumoral stromal phenotype. Oncotarget, 2018, 9, 11126-11144.	0.8	11
3152	A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer. Oncotarget, 2018, 9, 18985-18996.	0.8	83
3153	Stromal cells in breast cancer as a potential therapeutic target. Oncotarget, 2018, 9, 23761-23779.	0.8	30
3154	Prostaglandin E2 produced by myeloid-derived suppressive cells induces cancer stem cells in uterine cervical cancer. Oncotarget, 2018, 9, 36317-36330.	0.8	46

#	Article	IF	Citations
3155	Carbon ion irradiation enhances the antitumor efficacy of dual immune checkpoint blockade therapy both for local and distant sites in murine osteosarcoma. Oncotarget, 2019, 10, 633-646.	0.8	52
3156	IgG based immunome analyses of breast cancer patients reveal underlying signaling pathways. Oncotarget, 2019, 10, 3491-3505.	0.8	7
3157	CD80-CD28 signaling controls the progression of inflammatory colorectal carcinogenesis. Oncotarget, 2015, 6, 20058-20069.	0.8	24
3158	Prognostic significance of the combination of preoperative hemoglobin, albumin, lymphocyte and platelet in patients with gastric carcinoma: a retrospective cohort study. Oncotarget, 2015, 6, 41370-41382.	0.8	88
3159	PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget, 2016, 7, 15901-15914.	0.8	125
3160	Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer. Oncotarget, 2016, 7, 36632-36644.	0.8	15
3161	Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors. , 2019, 2, 744-761.		3
3162	Decoding cancerâ€™s camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade. , 2020, 3, 832-853.		7
3163	Uveal melanoma as a target for immune-therapy. Annals of Translational Medicine, 2016, 4, 172-172.	0.7	63
3164	Towards tumor immunodiagnostics. Annals of Translational Medicine, 2016, 4, 263-263.	0.7	11
3165	Immunity in cancer and atherosclerosis. Annals of Translational Medicine, 2019, 7, 204-204.	0.7	11
3166	Perioperative immunotherapy in muscle-invasive bladder cancer. Translational Cancer Research, 2020, 9, 6546-6553.	0.4	8
3167	Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 287-302.	0.7	20
3168	Immunological Synapse in the Biology of Chronic Lymphocytic Leukemia. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2018, 11, 313-318.	0.1	2
3169	Peptides for Diagnosis and Treatment of Colorectal Cancer. Current Medicinal Chemistry, 2014, 21, 2410-2416.	1.2	21
3170	Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules. Current Medicinal Chemistry, 2020, 27, 2402-2448.	1.2	12
3171	The Next Generation of Pattern Recognition Receptor Agonists: Improving Response Rates in Cancer Immunotherapy. Current Medicinal Chemistry, 2020, 27, 5654-5674.	1.2	13
3172	Immunotherapy for Uveal Melanoma - Current Knowledge and Perspectives. Current Medicinal Chemistry, 2020, 27, 1350-1366.	1.2	18

#	Article	IF	Citations
3173	Lentiviral Vectors: A Versatile Tool to Fight Cancer. Current Molecular Medicine, 2013, 13, 602-625.	0.6	27
3174	Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature. Recent Patents on Anti-Cancer Drug Discovery, 2019, 14, 100-112.	0.8	16
3175	Chemical Metabolic Inhibitors for the Treatment of Blood-Borne Cancers. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 223-232.	0.9	23
3176	The Role of Phenolic Compounds in the Fight against Cancer â€“ A Review. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 1236-1258.	0.9	211
3177	HLA Class II Antigen Presentation in Prostate Cancer Cells: A Novel Approach to Prostate Tumor Immunotherapy. The Open Cancer Immunology Journal, 2010, 3, 1-7.	0.2	13
3178	Immunoregulatory Function of Lymphatic Endothelial Cells in Tumor-draining Lymph Nodes of Human Gastric Cancer. Anticancer Research, 2017, 37, 2875-2883.	0.5	10
3181	Chemokines in Tumor Immunotherapy. Frontiers in Bioscience - Landmark, 2006, 11, 1024.	3.0	10
3182	Cancer vaccine development: Designing tumor cells for greater immunogenicity. Frontiers in Bioscience - Landmark, 2010, 15, 309.	3.0	1
3183	The immunomodulating roles of glycoproteins in epithelial ovarian cancer. Frontiers in Bioscience - Elite, 2012, E4, 631.	0.9	4
3184	Changing the paradigm: the potential for targeted therapy in laryngeal squamous cell carcinoma. Cancer Biology and Medicine, 2016, 13, 87-100.	1.4	21
3186	Combinations using checkpoint blockade to overcome resistance. Ecancermedicalscience, 2020, 14, 1148.	0.6	11
3187	Pretransplant Hepatic Malignancy Increases Risk of De Novo Malignancy after Liver Transplantation. Journal of Korean Medical Science, 2020, 35, e69.	1.1	5
3188	Development of an Immune-Related Risk Signature for Predicting Prognosis in Lung Squamous Cell Carcinoma. Frontiers in Genetics, 2020, 11, 978.	1.1	43
3189	Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. Antibodies, 2020, 9, 17.	1.2	14
3190	The Impact of Immunofunctional Phenotyping on the Malfunction of the Cancer Immunity Cycle in Breast Cancer. Cancers, 2021, 13, 110.	1.7	11
3191	Why Immunotherapy Fails in Multiple Myeloma. Hemato, 2021, 2, 1-42.	0.2	5
3192	Serious complications in a patient with generalized non-small cell lung cancer treated with pembrolizumab. Onkologie (Czech Republic), 2020, 14, 17-20.	0.0	1
3193	Autoantibodies: Potential clinical applications in early detection of esophageal squamous cell carcinoma and esophagogastric junction adenocarcinoma. World Journal of Gastroenterology, 2019, 25, 5049-5068.	1.4	14

#	Article	IF	Citations
3194	Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment. World Journal of Gastroenterology, 2020, 26, 134-153.	1.4	36
3195	Immunomodulatory effect of captopril and local irradiation on myeloid-derived suppressor cells. Radiation Oncology Journal, 2016, 34, 223-229.	0.7	4
3196	Tertiary Lymphoid Structures in Colorectal Cancers and Their Prognostic Value. Open Access Macedonian Journal of Medical Sciences, 2018, 6, 1824-1828.	0.1	19
3197	The roles of curcumin in regulating the tumor immunosuppressive microenvironment (Review). Oncology Letters, 2020, 19, 3059-3070.	0.8	21
3198	A mathematical model for the immunotherapeutic control of the Th1/Th2 imbalance in melanoma. Discrete and Continuous Dynamical Systems - Series B, 2013, 18, 1017-1030.	0.5	13
3199	Mathematical modeling of tumor growth: the MCF-7 breast cancer cell line. Mathematical Biosciences and Engineering, 2019, 16, 6512-6535.	1.0	21
3200	Impact of the immune system and immunotherapy in colorectal cancer. Journal of Gastrointestinal Oncology, 2015, 6, 208-23.	0.6	142
3201	Immunotherapy prospects in the treatment of lung cancer and mesothelioma. Translational Lung Cancer Research, 2014, 3, 34-45.	1.3	22
3202	Immunological interactions in radiotherapy-opening a new window of opportunity. Annals of Translational Medicine, 2016, 4, 51.	0.7	7
3204	Immune based therapy for melanoma. Indian Journal of Medical Research, 2016, 143, 135.	0.4	19
3205	Immunotherapy in breast cancer. Journal of Carcinogenesis, 2019, 18, 2.	2.5	56
3206	PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future. Journal of Pathology and Translational Medicine, 2019, 53, 199-206.	0.4	51
3207	Why Don't Immune Checkpoint Inhibitors Work in Colorectal Cancer?. Journal of Cancer Science and Research, 0, s2, .	0.1	1
3208	New era in cancer immunotherapy: Twenty years to the discovery of monoclonal antibodies harnessing the immune system to eradicate tumors. Advances in Bioscience and Biotechnology (Print), 2013, 04, 34-37.	0.3	1
3209	Cancer: Tumor Iron Metabolism, Mitochondrial Dysfunction and Tumor Immunosuppression; â€œA Tight Partnershipâ€”Was Warburg Correct?â€. Journal of Cancer Therapy, 2012, 03, 278-311.	0.1	21
3210	Clinical significance of tumor-infiltrating lymphocytes for gastric cancer in the era of immunology. World Journal of Gastrointestinal Oncology, 2017, 9, 293.	0.8	48
3211	Immunotherapy of cancer and perspectives of its development. Wspolczesna Onkologia, 2010, 2, 59-71.	0.7	4
3212	Blood classical monocytes phenotype is not altered in primary non-small cell lung cancer. World Journal of Clinical Oncology, 2014, 5, 1078.	0.9	5

#	Article	IF	Citations
3213	Present and future of immune checkpoint blockade: Monotherapy to adjuvant approaches. World Journal of Immunology, 2015, 5, 1.	0.5	4
3214	Stem and immune cells in colorectal primary tumour: Number and function of subsets may diagnose metastasis. World Journal of Immunology, 2015, 5, 68.	0.5	1
3215	Tumor-associated autoantibodies as diagnostic and prognostic biomarkers. BMB Reports, 2012, 45, 677-685.	1.1	67
3216	A primer on tumour immunology and prostate cancer immunotherapy. Canadian Urological Association Journal, 2016, 10, 60.	0.3	10
3217	Harnessing the Immune System to Fight Cancer: The Promise of Genetic Cancer Vaccines. , 0, , .		4
3218	Full Spectrum: Efficacy and Toxicity of Immunotherapy in Metastatic Melanoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, S-1-S-5.	2.3	5
3219	Eryngium foetidum Suppresses Inflammatory Mediators Produced by Macrophages. Asian Pacific Journal of Cancer Prevention, 2012, 13, 653-664.	0.5	35
3220	Low Counts of Î³Î´ T Cells in Peritumoral Liver Tissue are Related to More Frequent Recurrence in Patients with Hepatocellular Carcinoma after Curative Resection. Asian Pacific Journal of Cancer Prevention, 2014, 15, 775-780.	0.5	29
3221	Development and Evaluation of the Psychosocial Distress Nursing Intervention for Patients with Gynecological Cancer. Korean Journal of Adult Nursing, 2012, 24, 219-231.	0.2	5
3222	Mechanism of T cell regulation by microRNAs. Cancer Biology and Medicine, 2013, 10, 131-7.	1.4	48
3223	The newly-arisen Devil facial tumour disease 2 (DFT2) reveals a mechanism for the emergence of a contagious cancer. ELife, 2018, 7, .	2.8	47
3224	Topography of cancer-associated immune cells in human solid tumors. ELife, 2018, 7, .	2.8	206
3225	Cytotoxic T-cells mediate exercise-induced reductions in tumor growth. ELife, 2020, 9, .	2.8	93
3226	The effects of age and systemic metabolism on anti-tumor T cell responses. ELife, 2020, 9, .	2.8	34
3227	Bone Health in Cancer Patients. UNIPA Springer Series, 2021, , 365-380.	0.1	0
3228	Carriage of HLA-DRB1*11 and 1*12 alleles and risk factors in patients with breast cancer in Burkina Faso. Open Life Sciences, 2021, 16, 1101-1110.	0.6	4
3229	Cancer Immunotherapy Strategies: Basic Principles. Bioanalysis, 2021, , 29-49.	0.1	0
3230	Toxicidad tisular inducida por inmunoterapia. Papel del patÃ³logo en su diagnÃ³stico.. Archivos De PatologÃa, 2021, 2, 59-73.	0.1	0

#	Article	IF	Citations
3231	Autophagy in Tumor Immunity and Viral-Based Immunotherapeutic Approaches in Cancer. Cells, 2021, 10, 2672.	1.8	5
3232	Therapeutic melanoma inhibition by local micelle-mediated cyclic nucleotide repression. Nature Communications, 2021, 12, 5981.	5.8	13
3233	Lenvatinib Plus Anti-PD-1 Combination Therapy for Advanced Cancers: Defining Mechanisms of Resistance in an Inducible Transgenic Model of Thyroid Cancer. Thyroid, 2022, 32, 153-163.	2.4	13
3234	Challenges and Prospects for Designer T and NK Cells in Glioblastoma Immunotherapy. Cancers, 2021, 13, 4986.	1.7	6
3235	Nanocomplex of Berberine with C60 Fullerene Is a Potent Suppressor of Lewis Lung Carcinoma Cells Invasion In Vitro and Metastatic Activity In Vivo. Materials, 2021, 14, 6114.	1.3	5
3236	Patients With Microscopic Colitis Have Altered Levels of Inhibitory and Stimulatory Biomarkers in Colon Biopsies and Sera Compared to Non-inflamed Controls. Frontiers in Medicine, 2021, 8, 727412.	1.2	4
3237	Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma. , 2021, 9, e002836.		31
3238	CD8 T Cell Vaccines and a Cytomegalovirus-Based Vector Approach. Life, 2021, 11, 1097.	1.1	1
3239	A topography of immunotherapies against gastrointestinal malignancies. Panminerva Medica, 2022, 64, .	0.2	3
3240	Editorial: Genetic and Epigenetic Control of Immune Responses. Frontiers in Immunology, 2021, 12, 775101.	2.2	2
3241	Seeding metastases: The role and clinical utility of circulating tumour cells. Tumor Biology, 2021, 43, 285-306.	0.8	1
3242	IFNÎ³ Receptor-STAT1 Signaling and Cancer Immunoediting. , 2003, , 399-418.		0
3244	Immune Defects in T Cells From Cancer Patients. , 2004, , 35-48.		1
3245	Immunotherapy for Human Cancer. , 2004, , 507-528.		0
3246	EVIDENCE FOR THE EXISTENCE OF CANCER IMMUNOSURVEILLANCE. Annals of Cancer Research and Therapy, 2004, 12, 9-32.	0.1	0
3247	Microarrays. , 2005, , 285-301.		0
3250	Peptide Vaccines for Cancer Treatment. , 2006, , 499-505.		0
3251	Prinzipien der Tumorimmunologie. , 2006, , 101-169.		0

#	Article	IF	Citations
3253	Cancer, aging and the immune system. Aging Health, 2006, 2, 229-239.	0.3	0
3254	Vaccines and Beneficial Immunity in Glioma Patients. , 2006, , 265-291.		0
3255	Immune Surveillance â€“ Cancer, Effects of Stress on. , 2007, , 477-480.		0
3256	The evolutionary context of human aging and degenerative disease. , 2007, , 301-312.		2
3257	Health consequences of ecogenetic variation. , 2007, , 43-50.		1
3258	Cancer as a microevolutionary process. , 2007, , 289-300.		0
3259	Evolution of parasites. , 2007, , 229-238.		6
3260	Perspectives on human health and disease from evolutionary and behavioral ecology. , 2007, , 109-122.		1
3261	Medically relevant variation in the human genome. , 2007, , 31-42.		0
3262	Cancer: evolutionary origins of vulnerability. , 2007, , 277-288.		0
3263	Whole-genome analysis of pathogen evolution. , 2007, , 199-214.		0
3264	New Treatments and New Strategies. , 2008, , 567-585.		0
3265	The Immune Synapse as a Novel Target for Therapy. , 2008, , .		1
3266	Harnessing the Power of Immunity to Battle Cancer: Much Ado about Nothing or All's Well That Ends Well?. , 2008, , 293-306.		0
3267	Immunobiology and Immunotherapy of Multiple Myeloma. , 2008, , 143-166.		0
3268	Dendritic Cell Vaccines for Gliomas. Translational Medicine Series, 2008, , 83-108.	0.0	0
3269	Diagnostic Approaches for Selecting Patient-Customized Therapies, Obviating Tumor Variability to Maximize Therapeutic Effect. Translational Medicine Series, 2008, , 181-204.	0.0	0
3271	Immunomics of Immune Rejection. , 2009, , 87-105.		0

#	Article	IF	Citations
3272	Restoring Host Antitumoral Immunity: How Coregulatory Molecules Are Changing the Approach to the Management of Renal Cell Carcinoma. , 2009, , 367-403.		0
3273	Immune Responses to Stem Cells and Cancer Stem Cells. , 2009, , 505-518.		0
3274	Tumor-Associated Inflammation and Impact on Dendritic Cell Function. , 2009, , 157-170.		0
3275	The Biology of Cancer Metastasis. Medical Radiology, 2009, , 117-128.	0.0	0
3276	Cancer Biology Relating to Minimal Access Management. , 2009, , 11-27.		0
3277	Immunology and the Role of Immunotherapy in Breast Cancer. , 2009, , 595-601.		0
3278	Targeting Brain Cancer Stem Cells in the Clinic. , 2009, , 275-286.		1
3279	New Strategies to Improve Tumor Cell Vaccine Therapy. , 2009, , 117-131.		0
3280	Role of the Immune System in Cancer Development and Therapeutic Implications. Medical Radiology, 2009, , 129-145.	0.0	0
3281	Cancer Vaccines. , 2009, , 365-397.		0
3282	Effects of Tumor Microenvironment on Immunity and Consequent Clinical Considerations. , 2009, , 157-179.		0
3283	Distal Tumors Elicit Distinctive Gene Expression Changes in Mouse Brain, Different from Those Induced by Arthritis. The Open Neuroscience Journal, 2009, 3, 13-25.	0.8	0
3284	Cancer in Context: Importance of the Tumor Microenvironment. , 2010, , 43-63.		0
3285	Vaccine Therapy and Immunotherapy for Pancreatic Cancer. , 2010, , 1269-1318.		0
3286	Immunkontrolle. , 2010, , 97-102.		0
3287	Macrophages in the Tumor Microenvironment. , 2010, , 371-383.		1
3288	The Immune Response to Oncogenic Retroviruses. , 2010, , 219-258.		0
3289	Obesity and Cancer: yin/yan Effects of Nutrition. The Open Obesity Journal, 2010, 2, 38-42.	0.1	0

#	Article	IF	Citations
3292	The Immune Rejection: Lessons from Experimental Models. , 2011, , 17-25.		0
3293	Counteracting Subversion of MHC Class II Antigen Presentation by Tumors. , 2011, , 173-194.		0
3294	Epidemiology and Risk Factors. , 2011, , 3-25.		1
3296	Immune Surveillance and Tumor Evasion. , 2011, , 193-210.		0
3297	Cancer, Inflammasomes, and Adjuvanticity. , 2011, , 151-163.		0
3298	Immunology of Head and Neck Cancer. , 2011, , 107-119.		1
3299	Significance of Foxp3 Positive Regulatory T Cell and Tumor Infiltrating T Lymphocyte in Triple Negative Breast Cancer. Korean Journal of Pathology, 2011, 45, 53.	1.2	3
3302	Molecular targeting of cancer stem cells. , 2011, , 202-216.		0
3303	The Immune System of Cancer Patients. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2011, 10, 262-274.	1.1	0
3305	The stem cell vascular niche in brain tumorigenesis. Cureus, 2011, , .	0.2	0
3306	Immunomodulatory Functions of Cancer Stem Cells. , 2012, , 301-332.		0
3307	Utilizing Mouse Models of Human Cancer for Assessing Immune Modulation of Cancer Development. , 2012, , 443-463.		0
3308	Four Aspects of Autoimmunity and How to Regain Tolerance to Self From an Autoimmune Disease Utilizing the Modified Vaccination Technique. , 0, , .		1
3309	Entering a New Era â€“ Prostate Cancer Immuno-Therapy After the FDA Approval for Sipuleucel-T. , 0, , .		0
3310	Transcription Regulation and Epigenetic Control of Expression of Natural Killer Cell Receptors and Their Ligands. , 0, , .		0
3311	Targeting Signal Transducer and Activator of Transcription (STAT) for Anticancer Therapy. , 2012, , 299-321.		0
3312	Recent Advances in Cancer Immunotherapy. Practica Otologica, 2012, 105, 87-94.	0.0	0
3313	B-lymphocyte, Macrophage and Mast Cell Density in the Stroma Underlying HPV-Related Cervical Squamous Epithelial Lesions and their Relationship to Disease Severity: an Immunohistochemical Study. , 2012, 02, .		0

#	Article	IF	Citations
3314	The Role of Immunotherapy in the Treatment of Mesothelioma. , 0, , .		0
3315	Immunotherapy in Urologic Malignancies: The Evolution and Future of Pattern Recognition Receptors. , 0, , .		0
3316	Targeting Molecular Pathways for Prevention of High Risk Breast Cancer: A Model for Cancer Prevention. , 0, , .		1
3317	Role of IL-17 and IL-17 Family Cytokines on Tumor Development. , 2013, , 219-230.		0
3319	Psychoneuroimmunology and Cancer: Incidence, Progression, and Quality of Life. , 2013, , 1-11.		3
3320	Activation of Immune-Mediated Tumor Cell Death by Chemotherapy. , 2013, , 373-399.		0
3321	WAPing Out Pathogens and Disease in the Mucosa: Roles for SLPI and Trappin-2. , 2013, , 141-166.		0
3322	Aging, Nutrient Signaling, Hematopoietic Senescence, and Cancer. Critical Reviews in Oncogenesis, 2013, 18, 559-571.	0.2	0
3323	Laser Immunotherapy for Cancer Treatment. , 2013, , .		0
3324	Development of Antitumor Cellular Immunity. , 2013, , 107-133.		0
3325	Principles of tumor immunology. , 2013, , 925-934.		0
3326	Impact of Obesity and Aging on the Tumor Immuno-Environment. , 2013, , 223-250.		0
3327	Identification of Tumor Antigens as Targets for Novel Antitumor Therapies. , 2013, , 217-230.		0
3328	B7.1. , 2013, , 1-10.		0
3329	Immunity and the Emergence of Individuality. , 2013, , 77-96.		13
3330	Overview of MHC Class I Antigens. , 2013, , 1-11.		0
3331	Immune Cells Within the Tumor Microenvironment. , 2014, , 1-23.		2
3332	The Immune System in Head and Neck Squamous Cell Carcinoma: Interactions and Therapeutic Opportunities. , 2014, , 275-321.		0

#	Article	IF	Citations
3333	The Cancer Super-Chaperone Hsp90: Its Posttranslational Regulation and Drug Targeting. , 2013, , 253-270.		0
3334	Immunotherapy: CTLA4, PD-1, PD-L1, IL-18, and IL-21. , 2013, , 343-358.		0
3335	Inhibition of Oncogenes Affects the Expression of NKG2D Ligands in Cancer Cells. Journal of Life Science, 2013, 23, 1216-1222.	0.2	1
3336	Genotyping of Human Leukocyte Antigen (HLA) Ancestral Haplotypes as Prognostic Marker in Cancer Using PCR Analysis. Methods in Molecular Biology, 2014, 1102, 353-366.	0.4	0
3337	Cancer and the Immune System. , 2014, , 1-7.		0
3338	Developing Cancer Immunotherapies as Drugs: Setting the Stage Through Methodological Progress. , 2014, , 53-62.		0
3339	Cancer Development in Competitive and Hostile Environments. , 2014, , 205-227.		0
3340	Granulocyte Therapy for Cancer: A Prospective Review. Science Insights, 2014, 7, 139-143.	0.1	1
3341	Immunotherapy for Cancer: A Newer Dimension in Chemoprevention. , 2014, 4, 1-8.		0
3342	Immunosenescence, Oxidative Stress, and Cancers. , 2015, , 377-393.		0
3345	The Overview of Tumor-Related Immunosuppressive Molecules. Advances in Clinical Medicine, 2015, 05, 78-83.	0.0	0
3347	Stem Cells of the Distal Bronchiolar Airways. Pancreatic Islet Biology, 2015, , 113-126.	0.1	0
3348	Role of Kynurenine Pathway in Hematological Malignancies. , 2015, , 297-305.		0
3349	Bacterial Cancer Therapy: How Patients Might Benefit from Salmonella Infections. , 2015, , 335-376.		0
3351	Cancer in the Kidney Transplant Recipient. , 2015, , 319-350.		0
3352	Comorbid Development of Infection and Cancer. , 2015, , 315-332.		0
3355	Cancer and the Immune System. , 2016, , 133-138.		0
3356	Inmunoterapia en melanoma: vacunas de cÃ©lulas dendrÃticas. Revista Peruana De Medicina De Experimental Y Salud Publica, 2015, 32, 555.	0.1	0

#	Article	IF	Citations
3357	CURRENT UNDERSTANDING OF ANTITUMOR IMMUNITY. , 2015, 14, 19-28.	0.3	2
3358	Advanced skin melanoma â€“ systemic treatment. OnCOReview, 2015, 5, 133-138.	0.1	0
3359	Clinical Use of the Interferon Inducer IIBI in Patients with Refractory Hodgkinâ€™s Lymphoma. International Journal of Biomedicine, 2015, 5, 214-218.	0.1	0
3360	Signal Transducer and Activation of Transcription 3: A Master Regulator of Myeloid-Derived Suppressor Cells. SpringerBriefs in Immunology, 2016, , 73-90.	0.1	0
3361	Brain Tumors and Inflammation. , 2016, , 253-280.		0
3362	Translational Research and Immunotherapy in Lung Cancer. , 2016, , 255-296.		0
3363	New Treatments and New Therapies. , 2016, , 681-710.		0
3365	More Than Just a Case of Polymyalgia Rheumatica. European Journal of Case Reports in Internal Medicine, 2016, 3, 000374.	0.2	0
3366	Cellular immune response in rats with 1,2-dimethylhydrazine-induced colon cancer after transplantation of placenta-derived multipotent cells. Cell and Organ Transplantology, 2016, 4, 55-60.	0.2	3
3367	Significance of Expression of Complement C4d in Esophageal Squamous Cell Carcinoma. Anticancer Research, 2016, 36, 4553-4558.	0.5	0
3368	Primary Testicular Lymphoma. , 2017, , 129-141.		2
3369	Chapter 9 Tracking of Dendritic Cells. , 2016, , 243-282.		0
3372	The Future of Checkpoint Blockade to Treat Cancer Patients. Journal of Cancer Prevention & Current Research, 2016, 6, .	0.1	0
3373	Immunosurveillance of Tumors. , 2017, , 2234-2236.		0
3374	å…ç–«ãƒã‚§ãƒƒã‚¯ãƒã‚¤ãƒ³ãƒˆé˜»å®³å‰¤ã®åŸºç¤Ž. Skin Cancer, 2017, 32, 101-105.	0.1	0
3375	Basic Immunobiology. Molecular and Integrative Toxicology, 2017, , 1-93.	0.5	0
3376	Role of Proteases in Tumor Immune Evasion. , 2017, , 265-296.		0
3377	Vaccine Therapy and Immunotherapy for Pancreatic Cancer. , 2017, , 1-45.		0

#	Article	IF	Citations
3378	Post-transplant Complications: Hypertension, Renal Dysfunction, Diabetes Mellitus, Malignancy, Arrhythmias, Osteoporosis, Sexual Dysfunction. , 2017, , 577-605.		0
3379	Immunotherapy and Targeted Therapies in Advanced Castration Resistant Prostate Cancer. , 2017, , 357-377.		1
3380	Squamous Cell Carcinoma Antigen-Immunoglobulin M (SCCA-IgM) as Biomarker in Liver Disease: Biological Aspects and Clinical Applications. Biomarkers in Disease, 2017, , 559-580.	0.0	0
3381	ImmunoPET/CT imaging for assessing radiation-induced PD-L1 upregulation and its clinical application in head and neck cancer. Japanese Journal of Head and Neck Cancer, 2017, 43, 333-338.	0.0	0
3382	Immunological consequences of ageing microvascular hemodynamic changes in view of cancer development and treatment. Oncotarget, 2017, 8, 69047-69061.	0.8	0
3385	5. Current Potential and Clinical Questions of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-small Cell Lung Cancer. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 1117-1124.	0.0	0
3387	Communicate or Die â€“ A Model for HPV+ and HPVâ€“ CSCs and Their Interactions with SDF-1Î±. Anticancer Research, 2017, 37, 4827-4836.	0.5	4
3388	DcR3 combined with hematological traits serves as a valuable biomarker for the diagnosis of cancer metastasis. Oncotarget, 2017, 8, 107612-107620.	0.8	2
3389	Immunosenescence and Cutaneous Malignancies. , 2018, , 185-202.		2
3390	æ”¾å°„ç·šã«ã‚ˆã‚‹å…ç–«ãƒ–ãƒ¼ã‚¹ãƒˆåŠ¹æžœã¨å…ç–«æ”¾å°„ç·šæ²»ç™‚ï¼ˆImmunoï¼Radiotherapyï¼‰ã®è‡¨åºŠè©¦é¨“ã€‚ Skin Can		
3391	Immunotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC). Current Cancer Research, 2018, , 365-396.	0.2	0
3393	Modelling of Experimental Infections. , 2018, , 97-152.		0
3394	GASTRIC CANCER. CURRENT STATE OF MORBIDITY, DIAGNOSIS AND TREATMENT. Bulletin of Problems Biology and Medicine, 2018, 1.1, 62.	0.0	0
3396	Immune Response in Melanoma: A Basis to Understand the Role of Immunotherapy with Immune Checkpoint Inhibitors. Journal of the Portuguese Society of Dermatology and Venereology, 2018, 76, 47-52.	0.0	0
3400	Personalized Cancer Immunotherapy: Todayâ€™s Challenge and Tomorrowâ€™s Promise. Journal of Immunotherapy and Precision Oncology, 2018, 1, 56-67.	0.6	4
3401	Genomics Role in Cancer Immunosurveillance: Impact on Immunotherapy Response. International Journal of Cancer Management, 2018, In Press, .	0.2	1
3403	Why is Immunohistochemical Detection of Metastasized Breast Cancer Cells in the Immunocompetent Host Not Always Easy?. Journal of Analytical Oncology, 0, 7, 72-81.	0.1	0
3405	3D Tissue Model of Cancers. Biomaterials Science Series, 2019, , 294-311.	0.1	0

#	Article	IF	Citations
3406	The Complex Nature of Soft Tissue Sarcomas, Including Retroperitoneal Sarcomas. Updates in Surgery Series, 2019, , 21-32.	0.0	0
3407	Correlation of Apolipoprotein B mRNA-editing Enzyme, Catalytic Polypeptide- like 3G Genetic Variant rs8177832 with HIV-1 Predisposition in Pakistani Population. Current HIV Research, 2019, 16, 297-301.	0.2	2
3408	Introduction to Melanoma Immunology. , 2019, , 1-15.		0
3409	Principles of Immuno-Oncology. , 2019, , 113-120.		0
3410	Melanoma Immunology and Immunotherapy. , 2019, , 1-15.		0
3411	Immunotherapy in Breast Cancer. , 2019, , 541-552.		1
3412	Immunological Treatment in Gastrointestinal Cancers. , 2019, , 465-477.		0
3413	Role of Inflammatory Cytokines in the Initiation and Progression of Pancreatic Cancer. , 2019, , 133-156.		1
3414	Assessment of Age-Related Decline of Immunological Function and Possible Methods for Immunological Restoration in Elderly. , 2019, , 2767-2793.		1
3415	Usefulness of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as a predictor of disease-free survival in breast cancer: A cross-sectional study. F1000Research, 0, 8, 306.	0.8	1
3416	Internal Medicine, 2019, 108, 430-437.	0.0	0
3417	Current Status and Future Direction of Immune Checkpoint Inhibitors. Japanese Journal of Lung Cancer, 2019, 59, 217-223.	0.0	0
3418	No significant association between immunosuppression in solid organ transplantation and prostate cancer risk: a meta-analysis of cohort studies. Translational Cancer Research, 2019, 8, 939-949.	0.4	1
3421	A thorny pathway of macrophage activating factor (GcMAF): from bench to bedside. Vavilovskii Zhurnal Genetiki I Selektsii, 2019, 23, 624-631.	0.4	6
3424	Cancer immunotherapy: Role of the immune system in malignant transformation. Revista MÃ©dica Del Hospital General De MÃ©xico, 2019, 82, .	0.0	0
3425	Immunotherapy in Oral Cancer: A Fourth Dimension of Cancer Treatment. , 2020, , 129-154.		1
3426	Immunotherapy in Oncology. , 2020, , 3-6.		0
3427	Immunopathology as a Basis for Immunotherapy of Head and Neck Squamous Cell Carcinoma. , 2020, , 333-354.		0

#	Article	IF	Citations
3428	Genetic Variation in Response to Global Warming in a Coral Reef Species, Porites lobata. Avicenna Journal of Environmental Health Engineering, 2020, 7, 29-34.	0.3	0
3429	Extracellular Vesicles and Their Roles in Cancer Progression. Methods in Molecular Biology, 2021, 2174, 143-170.	0.4	82
3431	Biomarkers for Immune Checkpoint Inhibitors. , 2021, , 449-463.		0
3432	Angiogenesis Pathway in Kidney Renal Clear Cell Carcinoma and Its Prognostic Value for Cancer Risk Prediction. Frontiers in Medicine, 2021, 8, 731214.	1.2	4
3433	Key Activating and Inhibitory Ligands Involved in the Mobilization of Natural Killer Cells for Cancer Immunotherapies. ImmunoTargets and Therapy, 2021, Volume 10, 387-407.	2.7	9
3434	Pattern of Immunocompetent Peripheral Blood Cell Subpopulations in B-Cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2020, 13, 395-405.	0.1	0
3435	Differences in circulating Î³Î´ T cells in patients with primary colon cancer and relation with prognostic factors. PLoS ONE, 2020, 15, e0243545.	1.1	9
3436	Expression features of antigens involved in the formation of immunological synapse in splenic marginal zone lymphoma. Oncogematologiya, 2020, 15, 18-28.	0.1	0
3437	Lung Cancer Survival in Patients With Autoimmune Disease. JAMA Network Open, 2020, 3, e2029917.	2.8	16
3438	Nonclassical roles for IFN-Î³ and IL-10 in a murine model of immunoedition. Future Science OA, 2020, 6, FSO589.	0.9	1
3439	The Impact of splenic irradiation during chemoradiation for Gastric and Gastroesophageal junctional cancers in the development of acute hematological toxicity. IP Journal of Diagnostic Pathology and Oncology, 2020, 5, 381-385.	0.0	0
3440	Antitumor immune responses induced by photodynamic and sonodynamic therapy: a narrative review. Journal of Bio-X Research, 2021, 4, 77-86.	0.3	3
3441	Review of Standardized Incidence Ratios (SIR) of non-lymphoid de novo malignancies after liver transplantation: Structured analysis of global differences. Transplantation Reviews, 2022, 36, 100670.	1.2	5
3442	Immunology and immunotherapy in CRC. , 2022, , 435-453.		0
3443	CRC: A Darwinian model of cellular immunoselection. , 2022, , 529-541.		0
3444	Combined therapy for treating solid tumors with chemotherapy and angiogenic inhibitors. Discrete and Continuous Dynamical Systems - Series B, 2020, .	0.5	0
3445	Immunology and Immunotherapy of Colorectal Cancer. , 2020, , 261-289.		1
3446	Construction of PD1/CD28 Fusion Receptor Enhances Anti-Tumor Ability of c-Met CAR-T in Gastric Cancer. SSRN Electronic Journal, 0, , .	0.4	0

#	Article	IF	Citations
3447	How do we approach to the difficultï¼toï¼treat Japanese case. Combination therapy of Immunotherapy and Radiotherapyï¼^Immunoï¼radiotherapyï¼‰. Skin Cancer, 2020, 35, 98-104.	0.1	0
3448	Tight Interplay Between Therapeutic Monoclonal Antibodies and the Tumour Microenvironment in Cancer Therapy. Advances in Experimental Medicine and Biology, 2020, 1277, 127-141.	0.8	0
3449	Allergies and Cancers. , 2020, , 585-598.		0
3450	Cancer Immunoediting: Immunosurveillance, Immune Equilibrium, and Immune Escape. , 2020, , 291-305.		1
3451	Immunosenescence, Oxidative Stress, and Cancers. , 2020, , 513-531.		0
3452	Mechanisms of Immune-Related Adverse Events. , 2020, , 179-186.		1
3453	Dermatologic Toxicities of Immunotherapy. , 2020, , 253-258.		0
3454	Cellular Therapy for Melanoma. , 2020, , 1267-1299.		0
3455	Alpha and Omega: from the Sagrada Familia to Placenta and Cancer. Journal of Science Humanities and Arts - JOSHA, 2015, 7, .	0.0	1
3456	Immunotherapy and Radiosurgery. , 2020, , 423-436.		0
3457	CHAPTER 10. Intratumoral Fibrosis: Emerging Concepts and Therapeutic Opportunities. RSC Drug Discovery Series, 2020, , 259-306.	0.2	1
3458	Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors. JCO Precision Oncology, 2021, 5, 1625-1638.	1.5	10
3459	The value of immunotherapy in pediatric leukemia and lymphoma. Memo - Magazine of European Medical Oncology, 2021, 14, 397-401.	0.3	2
3460	Tumor Marker B7-H6 Bound to the Coiled Coil Peptide-Polymer Conjugate Enables Targeted Therapy by Activating Human Natural Killer Cells. Biomedicines, 2021, 9, 1597.	1.4	2
3461	The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer. Current Treatment Options in Oncology, 2021, 22, 113.	1.3	9
3462	Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies. International Journal of Molecular Sciences, 2021, 22, 12015.	1.8	9
3463	CCR4 as a Therapeutic Target for Cancer Immunotherapy. Cancers, 2021, 13, 5542.	1.7	47
3464	Advances in plant-derived natural products for antitumor immunotherapy. Archives of Pharmacal Research, 2021, 44, 987-1011.	2.7	12

#	Article	IF	Citations
3465	Tumor Vasculature Targeted TNFÎ± Therapy: Reversion of Microenvironment Anergy and Enhancement of the Anti-tumor Efficiency. Current Medicinal Chemistry, 2020, 27, 4233-4248.	1.2	2
3466	CTLA-4-immunoglobulin and indoleamine 2,3-dioxygenase in dominant tolerance. , 2008, , 87-106.		1
3467	Dynamic Nature of Tumour-Host Interactions Within the Tumor Microenvironment. , 2005, , 177-187.		0
3468	Monitoring Antigen-specific T Cell Responses. , 2005, , 1-7.		0
3470	Impact of Tumour Cell Death on the Activation of Anti-tumour Immune Response. , 2009, , 347-370.		1
3471	Polynucleotide Immunization for Cancer Therapy. , 2005, , 185-197.		0
3472	Genetic Immunotherapy Approaches. , 2005, , 129-141.		2
3473	p53-Based Immunotherapy of Cancer. , 2006, , 491-505.		1
3474	Vesicular Stomatitis Virus and RNA Viruses as Gene Therapy Vectors. , 2007, , 121-140.		0
3475	Experimental Models of Cytokines and Cancer Prevention. , 2007, , 211-230.		0
3477	Combination of Chemotherapy and Cytokine Therapy in Treatment of Cancers. , 2021, , 169-182.		0
3481	Does Immunodeficiency Matter in ENT?. , 2021, , 457-469.		0
3482	Real-accessible novelties in immunotherapy from the perspective of a medical oncologist working in the Czech Republic. Onkologie (Czech Republic), 2020, 14, 199-204.	0.0	0
3483	Probiotics and Cancer: Boosting the Immune System. , 2021, , 47-67.		3
3484	Protective low-avidity anti-tumour CD8+ T cells are selectively attenuated by regulatory T cells. Immunotherapy Advances, 2021, 1, ltaa001.	1.2	5
3485	Stress proteins and initiation of immune response: chaperokine activity of hsp72. Exercise Immunology Review, 2005, 11, 34-45.	0.4	132
3486	The role of TGF-beta-1 protein and TGF-beta-R-1 receptor in immune escape mechanism in bladder cancer. MedGenMed: Medscape General Medicine, 2007, 9, 34.	0.2	7
3487	Melanoma cell extravasation under flow conditions is modulated by leukocytes and endogenously produced interleukin 8. MCB Molecular and Cellular Biomechanics, 2005, 2, 145-59.	0.3	55

#	Article	IF	Citations
3488	Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immunity, 2007, 7, 10.	3.2	56
3489	Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immunity, 2007, 7, 12.	3.2	102
3490	In vivo major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells is regulated by gammadelta T and NK cells during the early steps of tumor growth. Cancer Immunity, 2009, 9, 10.	3.2	17
3491	The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. Cancer Immunity, 2009, 9, 1.	3.2	57
3492	Global gene expression profiling in interleukin-12-induced activation of CD8(+) cytotoxic T lymphocytes against mouse mammary Carcinoma. Cellular and Molecular Immunology, 2004, 1, 357-66.	4.8	5
3493	Current status of immunotherapy for the treatment of lung cancer. Journal of Thoracic Disease, 2010, 2, 237-44.	0.6	21
3494	Immunity, cancer and aging: lessons from mouse models. , 2011, 2, 512-23.		16
3498	MUTYH the base excision repair gene family member associated with colorectal cancer polyposis. Gastroenterology and Hepatology From Bed To Bench, 2013, 6, S1-S10.	0.6	9
3500	Anti-tumor immune response in early stage non small cell lung cancer (NSCLC): implications for adjuvant therapy. Translational Lung Cancer Research, 2013, 2, 415-22.	1.3	2
3501	Expression and function analysis of indoleamine 2 and 3-dioxygenase in bladder urothelial carcinoma. International Journal of Clinical and Experimental Pathology, 2015, 8, 1768-75.	0.5	12
3503	Tailoring the Treatment of Melanoma: Implications for Personalized Medicine. Yale Journal of Biology and Medicine, 2015, 88, 389-95.	0.2	3
3505	Revisiting the hallmarks of cancer. American Journal of Cancer Research, 2017, 7, 1016-1036.	1.4	292
3507	Potential Cancer Prevention and Treatment by Silencing the Killer Cell Immunoglobulin-like Receptor Gene in Natural Killer Cells Derived from Induced Pluripotent Stem Cells. Enliven Journal of Stem Cell Research & Regenerative Medicine, 2016, 3, .	0.2	0
3508	Synergistic anticancer activity of a novel oral chemotherapeutic agent containing trifluridine and tipiracil in combination with anti-PD-1 blockade in microsatellite stable-type murine colorectal cancer cells. American Journal of Cancer Research, 2017, 7, 2032-2040.	1.4	7
3510	Promising new treatments for pancreatic cancer in the era of targeted and immune therapies. American Journal of Cancer Research, 2019, 9, 1871-1888.	1.4	12
3511	Abnormal Î²-catenin expression and reduced tumor-infiltrating T cells are related to poor progression in non-small cell lung cancer. International Journal of Clinical and Experimental Pathology, 2017, 10, 11572-11579.	0.5	1
3512	Ultrathin metal-organic layer-mediated radiotherapy-radiodynamic therapy enhances immunotherapy of metastatic cancers. Matter, 2019, 1, 1331-1353.	5.0	20
3513	Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer. American Journal of Cancer Research, 2021, 11, 3628-3644.	1.4	3

#	Article	IF	Citations
3514	Lungenmetastasen. Springer Reference Medizin, 2019, , 1-8.	0.0	0
3515	The Art of Oncoimmunovaccinomics. World Journal of Vaccines, 2021, 11, 50-66.	0.8	1
3516	The potential role of exosomal circRNAs in the tumor microenvironment: insights into cancer diagnosis and therapy. Theranostics, 2022, 12, 87-104.	4.6	54
3517	Combination of IDO1high and CCL19low expression in the tumor tissue reduces survival in HPV positive cervical cancer. Journal of Reproductive Immunology, 2022, 149, 103454.	0.8	3
3518	The Growing Relevance of Immunoregulation in Pediatric Brain Tumors. Cancers, 2021, 13, 5601.	1.7	7
3520	CRISPR/Cas9-mediated TGFÎ²RII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro. Journal of Translational Medicine, 2021, 19, 482.	1.8	14
3521	Homeoprotein SIX1 compromises antitumor immunity through TGF-Î²-mediated regulation of collagens. Cellular and Molecular Immunology, 2021, 18, 2660-2672.	4.8	5
3522	TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment. , 2022, 9, e003134.		32
3523	IFNÎ³ Signaling in Natural and Therapy-Induced Antitumor Responses. Clinical Cancer Research, 2022, 28, 1243-1249.	3.2	15
3524	Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination. Frontiers in Immunology, 2021, 12, 786286.	2.2	8
3525	Construction of a novel ferroptosis-related gene signature for predicting prognosis and immune microenvironment in acute myeloid leukemia. Bosnian Journal of Basic Medical Sciences, 2021, , .	0.6	9
3526	Injectable and Biodegradable Chitosan Hydrogel-Based Drug Depot Contributes to Synergistic Treatment of Tumors. Biomacromolecules, 2021, 22, 5339-5348.	2.6	17
3527	Baseline lymphopenia as prognostic factor in patients with metastatic breast cancer treated with palbociclib. Oncology Letters, 2021, 23, 25.	0.8	10
3528	A size and space structured model of tumor growth describes a key role for protumor immune cells in breaking equilibrium states in tumorigenesis. PLoS ONE, 2021, 16, e0259291.	1.1	4
3529	The Role of Decorin and Biglycan Signaling in Tumorigenesis. Frontiers in Oncology, 2021, 11, 801801.	1.3	36
3530	Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape. Science Immunology, 2021, 6, eabc6424.	5.6	64
3531	The Emerging Interplay Between Recirculating and Tissue-Resident Memory T Cells in Cancer Immunity: Lessons Learned From PD-1/PD-L1 Blockade Therapy and Remaining Gaps. Frontiers in Immunology, 2021, 12, 755304.	2.2	2
3532	Harnessing the combined potential of cancer immunotherapy and nanomedicine: A new paradigm in cancer treatment. Nanomedicine: Nanotechnology, Biology, and Medicine, 2022, 40, 102492.	1.7	4

#	Article	IF	Citations
3533	Survival Trends of Right- and Left-Sided Colon Cancer across Four Decades: A Norwegian Population-Based Study. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 342-351.	1.1	7
3534	Transdermal Drug Delivery: A Step towards Treatment of Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2022, 17, 253-267.	0.8	6
3535	Impact of immune cells on the hallmarks of cancer: A literature review. Critical Reviews in Oncology/Hematology, 2021, 168, 103541.	2.0	27
3536	Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma. JAMA Network Open, 2021, 4, e2136823.	2.8	29
3537	Checkpoint-Inhibition: Bremsen gelÃ¶st. , 0, , .		0
3538	Immune System in Action. Advances in Experimental Medicine and Biology, 2021, 1342, 1-43.	0.8	0
3539	A Darwinian perspective on tumor immune evasion. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188671.	3.3	6
3540	Mechanisms of Resistance and Relapse After CAR-T Cell Therapy. Cancer Drug Discovery and Development, 2022, , 207-219.	0.2	1
3541	Control of Tumors by Antigen-Specific CD8+ T Cells through PDL1-Targeted Delivery of Antigenic Peptide. Journal of Immunology Research, 2022, 2022, 1-8.	0.9	0
3542	Mechanisms of Antitumor Immunity and Immunosurveillance. Methods in Molecular Biology, 2022, 2435, 1-6.	0.4	1
3543	Immune Landscape and Role of Immunotherapy in Treatment of HPV-Associated Head and Neck Squamous Cell Carcinoma (HNSCC). Current Otorhinolaryngology Reports, 2022, 10, 96-107.	0.2	0
3544	Basics of immunotherapy for epithelial ovarian cancer. Journal of Gynecology Obstetrics and Human Reproduction, 2022, 51, 102283.	0.6	4
3545	Therapeutic potential of CAR T cell in malignancies: A scoping review. Biomedicine and Pharmacotherapy, 2022, 146, 112512.	2.5	56
3546	Dihydroartemisinin inhibits Lewis Lung carcinoma progression by inducing macrophages M1 polarization via AKT/mTOR pathway. International Immunopharmacology, 2022, 103, 108427.	1.7	10
3547	Isolation of TCR genes with tumor-killing activity from tumor-infiltrating and circulating lymphocytes in a tumor rejection cynomolgus macaque model. Molecular Therapy - Oncolytics, 2022, 24, 77-86.	2.0	3
3548	Selection of tumorâ€'resistant variants following sustained natural killer cellâ€'mediated immune stress. Oncology Reports, 2020, 45, 582-594.	1.2	0
3551	Gene essentiality for tumour growth influences neoantigenâ€đirected immunoediting. Clinical and Translational Medicine, 2022, 12, e714.	1.7	0
3552	Pro-Resolving Factor Administration Limits Cancer Progression by Enhancing Immune Response Against Cancer Cells. Frontiers in Immunology, 2021, 12, 812171.	2.2	3

#	Article	IF	Citations
3553	Personalized <scp>HLA</scp> typing leads to the discovery of novel <scp>HLA</scp> alleles and tumorâ€specific <scp>HLA</scp> variants. Hla, 2022, 99, 313-327.	0.4	7
3554	Applications of Antibody-Based Antigen Delivery Targeted to Dendritic Cells In Vivo. Antibodies, 2022, 11, 8.	1.2	8
3555	Bacterial couriers as cancer vaccines. Nature Biomedical Engineering, 2022, 6, 3-5.	11.6	3
3556	Immunotherapeutic Strategies in Cancer and Atherosclerosisâ€"Two Sides of the Same Coin. Frontiers in Cardiovascular Medicine, 2021, 8, 812702.	1.1	2
3557	Bystander CD4⁺ T cells infiltrate human tumors and are phenotypically distinct. OncoImmunology, 2022, 11, .	2.1	13
3558	NLRP4 negatively regulates type I interferon response and influences the outcome in antiâ€programmed cell death protein (PD)â€1/PDâ€ligand 1 therapy. Cancer Science, 2021, , .	1.7	7
3559	Variegated Outcomes of T Cell Activation by Dendritic Cells in the Steady State. Journal of Immunology, 2022, 208, 539-547.	0.4	8
3560	LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis. Molecular Therapy, 2022, 30, 1564-1577.	3.7	37
3561	Phototheranostic Metal-Phenolic Networks with Antiexosomal PD-L1 Enhanced Ferroptosis for Synergistic Immunotherapy. Journal of the American Chemical Society, 2022, 144, 787-797.	6.6	142
3562	Hormone-Related Cancer and Autoimmune Diseases: A Complex Interplay to be Discovered. Frontiers in Genetics, 2021, 12, 673180.	1.1	4
3563	A Novel Prognostic Signature for Survival Prediction and Immune Implication Based on SARS-CoV-2â€"Related Genes in Kidney Renal Clear Cell Carcinoma. Frontiers in Bioengineering and Biotechnology, 2021, 9, 744659.	2.0	8
3564	Exosomes in cancer immunoediting and immunotherapy. Asian Journal of Pharmaceutical Sciences, 2022, 17, 193-205.	4.3	21
3565	T and NK cell abundance defines two distinct subgroups of renal cell carcinoma. OncoImmunology, 2022, 11, 1993042.	2.1	16
3566	Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade. Frontiers in Immunology, 2021, 12, 799455.	2.2	76
3567	A new perspective on immune evasion: escaping immune surveillance by inactivating tumor suppressors. Signal Transduction and Targeted Therapy, 2022, 7, 15.	7.1	5
3569	A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression. Journal of Experimental and Clinical Cancer Research, 2022, 41, 38.	3.5	17
3570	A KRAS-Associated Signature for Prognostic Prediction in Colon Cancer. SSRN Electronic Journal, 0, , .	0.4	0
3571	Serum amyloid A 1 induces suppressive neutrophils through the Tollâ€like receptor 2â€"mediated signaling pathway to promote progression of breast cancer. Cancer Science, 2022, 113, 1140-1153.	1.7	8

#	Article	IF	Citations
3572	Current Advances in Immune Checkpoint Inhibition and Clinical Genomics in Upper Tract Urothelial Carcinoma: State of the Art. Current Oncology, 2022, 29, 687-697.	0.9	9
3573	Deciphering the Immuneâ€“Tumor Interplay During Early-Stage Lung Cancer Development via Single-Cell Technology. Frontiers in Oncology, 2021, 11, 716042.	1.3	5
3574	Identification of Key Pathways and Genes Related to Immunotherapy Resistance of LUAD Based on WGCNA Analysis. Frontiers in Oncology, 2021, 11, 814014.	1.3	5
3575	Mast Cellâ€“Tumor Interactions: Molecular Mechanisms of Recruitment, Intratumoral Communication and Potential Therapeutic Targets for Tumor Growth. Cells, 2022, 11, 349.	1.8	25
3576	Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer. Clinical Cancer Research, 2022, 28, 1335-1344.	3.2	14
3577	Immunometabolism in biofilm infection: lessons from cancer. Molecular Medicine, 2022, 28, 10.	1.9	18
3578	Immune Checkpoint Blockade Augments Changes Within Oncolytic Virus-induced Cancer MHC-I Peptidome, Creating Novel Antitumor CD8 T Cell Reactivities. Molecular and Cellular Proteomics, 2022, 21, 100182.	2.5	3
3579	cMET: a prognostic marker in papillary renal cell carcinoma?. Human Pathology, 2022, 121, 1-10.	1.1	3
3580	Methylation of Immune-Related Genes in Peripheral Blood Leukocytes and Breast Cancer. Frontiers in Oncology, 2022, 12, 817565.	1.3	2
3581	Regulating trained immunity with nanomedicine. Nature Reviews Materials, 2022, 7, 465-481.	23.3	45
3582	The War Is on: The Immune System against Glioblastomaâ€”How Can NK Cells Drive This Battle?. Biomedicines, 2022, 10, 400.	1.4	5
3583	LLT1-CD161 Interaction in Cancer: Promises and Challenges. Frontiers in Immunology, 2022, 13, 847576.	2.2	15
3584	ERAP2 Inhibition Induces Cell-Surface Presentation by MOLT-4 Leukemia Cancer Cells of Many Novel and Potentially Antigenic Peptides. International Journal of Molecular Sciences, 2022, 23, 1913.	1.8	5
3585	Tegaserod Maleate Inhibits Breast Cancer Progression and Enhances the Sensitivity of Immunotherapy. Journal of Oncology, 2022, 2022, 1-12.	0.6	1
3586	The Past, Present, and Future of Clinically Applied Chimeric Antigen Receptor-T-Cell Therapy. Pharmaceuticals, 2022, 15, 207.	1.7	5
3587	Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and ClinicalÂImplications. Journal of the American College of Cardiology, 2022, 79, 577-593.	1.2	34
3588	Metabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions. Journal of Hepatology, 2022, 77, 219-236.	1.8	16
3589	Recent advance in nanomaterials for cancer immunotherapy. Chemical Engineering Journal, 2022, 435, 134145.	6.6	16

#	Article	IF	Citations
3590	Identification and characterization of three Siglec15-related immune and prognostic subtypes of breast-invasive cancer. International Immunopharmacology, 2022, 106, 108561.	1.7	5
3591	Confirmed complete response to nivolumab for advanced gastric cancer with peritoneal dissemination: a case report. Journal of Medical Case Reports, 2021, 15, 604.	0.4	6
3592	The role of alternative splicing in human cancer progression. American Journal of Cancer Research, 2021, 11, 4642-4667.	1.4	3
3593	Regulatory landscape in the approval of cancer vaccine. , 2022, , 325-348.		0
3594	The Relationship between Radiation Therapy and Immunotherapy. Advances in Clinical Medicine, 2022, 12, 1014-1021.	0.0	0
3595	Efficacy of Bivalent <i>CEACAM6/4-1BBL</i> Genetic Vaccine Combined with Anti-PD1 Antibody in MC38 Tumor Model of Mice. SSRN Electronic Journal, 0, , .	0.4	0
3596	Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors. Experientia Supplementum (2012), 2022, 113, 1-57.	0.5	8
3597	Oncolytic viruses for antigen delivery. , 2022, , 1-19.		0
3598	Advanced Nanovaccines Based on Engineering Nanomaterials for Accurately Enhanced Cancer Immunotherapy. SSRN Electronic Journal, 0, , .	0.4	0
3599	Cancer immunotherapy. , 2022, , 295-311.		1
3601	Identification and Quantification of Iron Metabolism Landscape on Therapy and Prognosis in Bladder Cancer. Frontiers in Cell and Developmental Biology, 2022, 10, 810272.	1.8	5
3602	Current Status of Malignant Tumors after Organ Transplantation. BioMed Research International, 2022, 2022, 1-12.	0.9	7
3603	Cell membrane coated-nanoparticles for cancer immunotherapy. Acta Pharmaceutica Sinica B, 2022, 12, 3233-3254.	5.7	61
3604	Role of Hypoxia in the Interferon Response. Frontiers in Immunology, 2022, 13, 821816.	2.2	5
3605	Healthy Immunity on Preventive Medicine for Combating COVID-19. Nutrients, 2022, 14, 1004.	1.7	9
3606	Cancer Vaccine in Cold Tumors: Clinical Landscape, Challenges, and Opportunities. Current Cancer Drug Targets, 2022, 22, 437-453.	0.8	2
3607	Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma. Journal of Hematology and Oncology, 2022, 15, 17.	6.9	46
3608	Identification and Quantification of Necroptosis Landscape on Therapy and Prognosis in Kidney Renal Clear Cell Carcinoma. Frontiers in Genetics, 2022, 13, 832046.	1.1	28

#	Article	IF	Citations
3609	IL-12RB1: a novel immune prognostic biomarker for oral squamous cell carcinoma and linked to PD-1/PD-L1 expression in the tumor immune microenvironment. Annals of Translational Medicine, 2022, 10, 144-144.	0.7	0
3610	TLR4 and pSTAT3 Expression on Circulating Tumor Cells (CTCs) and Immune Cells in the Peripheral Blood of Breast Cancer Patients: Prognostic Implications. Cancers, 2022, 14, 1053.	1.7	7
3611	Topâ€down stepwise refinement identifies coding and noncoding RNAâ€associated epigenetic regulatory maps in malignant glioma. Journal of Cellular and Molecular Medicine, 2022, 26, 2230-2250.	1.6	2
3613	Long-term opioid treatment and endocrine measures in patients with cancer-related pain: aÂsystematic review. Scandinavian Journal of Pain, 2022, 22, 421-435.	0.5	2
3614	Decoding the influence of the immune system and immunotherapy targets on carcinomas: A hidden prism in oral cancer therapy. Disease-a-Month, 2023, 69, 101353.	0.4	4
3615	Reframing How Physical Activity Reduces The Incidence of Clinically-Diagnosed Cancers: Appraising Exercise-Induced Immuno-Modulation As An Integral Mechanism. Frontiers in Oncology, 2022, 12, 788113.	1.3	18
3617	Genomics Driving Diagnosis and Treatment of Inborn Errors of Immunity with Cancer Predisposition. Journal of Allergy and Clinical Immunology: in Practice, 2022, , .	2.0	2
3618	Cancerâ€™s Camouflage â€" Microvesicle Shedding from Cholesterol-Rich Tumor Plasma Membranes Might Blindfold First-Responder Immunosurveillance Strategies. European Journal of Cell Biology, 2022, 101, 151219.	1.6	0
3619	Cancer's second genome: Microbial cancer diagnostics and redefining clonal evolution as a multispecies process. BioEssays, 2022, 44, e2100252.	1.2	12
3620	Basic cancer immunology for radiation oncologists. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 508-518.	0.9	2
3621	Comprehensive Analysis and Validation of Competing Endogenous RNA Network and Tumor-infiltrating Immune Cells in Lung Adenocarcinoma. Combinatorial Chemistry and High Throughput Screening, 2022, 25, 2240-2254.	0.6	2
3622	Mono a Mano: ZBP1â€™s Loveâ€"Hate Relationship with the Kissing Virus. International Journal of Molecular Sciences, 2022, 23, 3079.	1.8	5
3623	Betulin Attenuates TGF-Î²1- and PGE₂-Mediated Inhibition of NK Cell Activity to Suppress Tumor Progression and Metastasis in Mice. Biological and Pharmaceutical Bulletin, 2022, 45, 339-353.	0.6	1
3624	Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Antiâ€"Programmed Cell Death 1 Immunotherapy. JAMA Network Open, 2022, 5, e220587.	2.8	23
3625	Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future. Cancers, 2022, 14, 1406.	1.7	13
3626	Targeting cancer-associated glycans as a therapeutic strategy in leukemia. International Journal of Transgender Health, 2022, 15, 378-433.	1.1	2
3627	Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation. American Journal of Transplantation, 2022, 22, 1671-1682.	2.6	31
3628	Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma. Cancers, 2022, 14, 1526.	1.7	7

#	Article	IF	Citations
3629	A Novel Defined Pyroptosis-Related Gene Signature for Predicting Prognosis and Treatment of Glioma. Frontiers in Oncology, 2022, 12, 717926.	1.3	10
3630	Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers. Cancers, 2022, 14, 1681.	1.7	64
3631	mRNA cancer vaccines: Advances, trends and challenges. Acta Pharmaceutica Sinica B, 2022, 12, 2969-2989.	5.7	55
3632	Cytokine-Induced Senescence in the Tumor Microenvironment and Its Effects on Anti-Tumor Immune Responses. Cancers, 2022, 14, 1364.	1.7	13
3633	B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nature Reviews Clinical Oncology, 2022, 19, 441-457.	12.5	176
3634	Immunosuppressive niche engineering at the onset of human colorectal cancer. Nature Communications, 2022, 13, 1798.	5.8	19
3635	Cell Trafficking at the Intersection of the Tumorâ€“Immune Compartments. Annual Review of Biomedical Engineering, 2022, 24, 275-305.	5.7	9
3636	Impact of Lipid Metabolism on Antitumor Immune Response. Cancers, 2022, 14, 1850.	1.7	18
3637	Nanodrug shows spatiotemporally controlled release of anti-PD-L1 antibody and STING agonist to effectively inhibit tumor progression after radiofrequency ablation. Nano Today, 2022, 43, 101425.	6.2	15
3638	Tumor draining lymph nodes, immune response, and radiotherapy: Towards a revisal of therapeutic principles. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188704.	3.3	24
3639	Understanding initiation and progression of hepatocellular carcinoma through single cell sequencing. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188720.	3.3	26
3640	Cell-mediated immunity and expression of MHC class I and class II molecules in dogs naturally infected by canine transmissible venereal tumor: Is there complete spontaneous regression outside the experimental CTVT?. Research in Veterinary Science, 2022, 145, 193-204.	0.9	4
3641	Neue Strategien fÃ¼r die onkologische Therapie: Interleukine im Fokus. , 0, , .		0
3642	Neurobiology of cancer: Definition, historical overview, and clinical implications. Cancer Medicine, 2022, 11, 903-921.	1.3	14
3643	Prognostic Model Construction and Immune Microenvironment Analysis of Breast Cancer Based on Ferroptosis-Related lncRNAs. International Journal of General Medicine, 2021, Volume 14, 9817-9831.	0.8	7
3644	Co-dimension two bifurcations analysis of a delayed tumor model with Allee effect. Advances in Difference Equations, 2021, 2021, .	3.5	1
3645	Long-term memory T cells as preventive anticancer immunity elicited by TuA-derived heteroclitic peptides. Journal of Translational Medicine, 2021, 19, 526.	1.8	3
3647	Survival Advantage Following TAG-72 Antigen-Directed Cancer Surgery in Patients With Colorectal Carcinoma: Proposed Mechanisms of Action. Frontiers in Oncology, 2021, 11, 731350.	1.3	5

#	Article	IF	Citations
3648	Platelet CLEC2-Podoplanin Axis as a Promising Target for Oral Cancer Treatment. Frontiers in Immunology, 2021, 12, 807600.	2.2	23
3649	Activation of Innate Immunity by Therapeutic Nucleic Acids. International Journal of Molecular Sciences, 2021, 22, 13360.	1.8	13
3650	Peritoneal Metastasis: Current Status and Treatment Options. Cancers, 2022, 14, 60.	1.7	21
3651	Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives. Precision Clinical Medicine, 2021, 4, 258-270.	1.3	18
3652	Smart Lipid-Based Nanosystems for Therapeutic Immune Induction against Cancers: Perspectives and Outlooks. Pharmaceutics, 2022, 14, 26.	2.0	15
3654	Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma. Frontiers in Molecular Biosciences, 2022, 9, 777775.	1.6	3
3655	The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma. Cancer Immunology, Immunotherapy, 2022, 71, 2731-2742.	2.0	6
3656	Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents. Acta Pharmaceutica Sinica B, 2022, 12, 4446-4457.	5.7	15
3657	Inflammasomes in Cancer Progression and Anti-Tumor Immunity. Frontiers in Cell and Developmental Biology, 2022, 10, 839041.	1.8	14
3658	Identification of a key glioblastoma candidate gene, FUBP3, based on weighted gene co-expression network analysis. BMC Neurology, 2022, 22, 139.	0.8	3
3659	Consideration of possible effects of vitamin D on established cancer, with reference to malignant melanoma. Pigment Cell and Melanoma Research, 2022, 35, 408-424.	1.5	8
3660	Genetics of Colorectal Cancer Racial Disparities. , 0, , .		0
3661	Engineered cellular immunotherapies in cancer and beyond. Nature Medicine, 2022, 28, 678-689.	15.2	106
3712	Immunologic Approaches to Lung Cancer Therapy. , 0, , 334-351.		0
3717	Immunomodulatory effects of Blaps rynchopetera extract. Acta Cirurgica Brasileira, 2022, 37, e370205.	0.3	2
3718	Characterization of a Pyroptosis-Related Signature for Prognosis Prediction and Immune Microenvironment Infiltration in Prostate Cancer. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-51.	0.7	4
3719	A Comprehensive Prognostic and Immune Analysis of Ferroptosis-Related Genes Identifies SLC7A11 as a Novel Prognostic Biomarker in Lung Adenocarcinoma. Journal of Immunology Research, 2022, 2022, 1-13.	0.9	5
3720	Recent Reviews on Dendrimers as an Immunotherapy-based Nanosystem for the Effective Treatment of Cancer. Drug Delivery Letters, 2022, 12, 243-257.	0.2	2

#	Article	IF	Citations
3721	Multilevel mechanism of immune checkpoint inhibitor action in solid tumors: History, present issues and future development (Review). Oncology Letters, 2022, 23, 190.	0.8	1
3722	Prognostic Characteristics and Immune Effects of N6-Methyladenosine and 5-Methylcytosine-Related Regulatory Factors in Clear Cell Renal Cell Carcinoma. Frontiers in Genetics, 2022, 13, 864383.	1.1	5
3723	Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition. Frontiers in Immunology, 2022, 13, 869676.	2.2	24
3724	Oxidative Stress in Cancer Immunotherapy: Molecular Mechanisms and Potential Applications. Antioxidants, 2022, 11, 853.	2.2	10
3725	Probiotics as an Adjuvant for Management of Gastrointestinal Cancers through their Anti-inflammatory Effects: A Mechanistic Review. Current Medicinal Chemistry, 2023, 30, 390-406.	1.2	4
3726	Regulation of Carcinogenesis by Sensory Neurons and Neuromediators. Cancers, 2022, 14, 2333.	1.7	12
3727	Laser ablation: Heating up the anti-tumor response in the intracranial compartment. Advanced Drug Delivery Reviews, 2022, 185, 114311.	6.6	20
3728	Considerations for personalized neoantigen vaccination in Malignant glioma. Advanced Drug Delivery Reviews, 2022, 186, 114312.	6.6	13
3729	Immunogenicity-boosted cancer immunotherapy based on nanoscale metal-organic frameworks. Journal of Controlled Release, 2022, 347, 183-198.	4.8	23
3730	Macrophage density is an adverse prognosticator for ipsilateral recurrence in ductal carcinoma in situ. Breast, 2022, 64, 35-40.	0.9	3
3732	Cancer evolution: special focus on the immune aspect of cancer. Seminars in Cancer Biology, 2022, , .	4.3	4
3733	Cancer vaccines: past, present and future; a review article. Discover Oncology, 2022, 13, 31.	0.8	24
3734	Identification of Novel Characteristics in TP53-Mutant Hepatocellular Carcinoma Using Bioinformatics. Frontiers in Genetics, 2022, 13, .	1.1	7
3735	A tumor metastasisâ€associated molecule <scp>TWIST1</scp> is a favorable target for cancer immunotherapy due to its immunogenicity. Cancer Science, 2022, 113, 2526-2535.	1.7	4
3736	Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature, 2022, 606, 389-395.	13.7	80
3737	Cancer Immunoediting in the Era of Immuno-oncology. Clinical Cancer Research, 2022, 28, 3917-3928.	3.2	31
3738	Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. Journal of Hematology and Oncology, 2022, 15, 61.	6.9	120
3739	The importance of N6-methyladenosine modification in tumor immunity and immunotherapy. Experimental Hematology and Oncology, 2022, 11, 30.	2.0	8

#	Article	IF	Citations
3740	Tissue-Resident Memory CD4+ T Cells Play a Dominant Role in the Initiation of Antitumor Immunity. Journal of Immunology, 2022, 208, 2837-2846.	0.4	10
3741	p53 missense mutant G242A subverts natural killer cells in sheltering mouse breast cancer cells against immune rejection. Experimental Cell Research, 2022, 417, 113210.	1.2	4
3742	ANXA1: An Important Independent Prognostic Factor and Molecular Target in Glioma. Frontiers in Genetics, 0, 13, .	1.1	5
3743	Modeling cancer immunoediting in tumor microenvironment with system characterization through the ising-model Hamiltonian. BMC Bioinformatics, 2022, 23, .	1.2	7
3744	The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment. Frontiers in Pharmacology, 0, 13, .	1.6	94
3745	Epigenetics Regulates Antitumor Immunity in Melanoma. Frontiers in Immunology, 2022, 13, .	2.2	7
3746	Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer. Frontiers in Medicine, 2022, 9, .	1.2	19
3747	Natural killer cells and acute myeloid leukemia: promises and challenges. Cancer Immunology, Immunotherapy, 2022, 71, 2849-2867.	2.0	5
3749	The Outside-In Journey of Tissue Transglutaminase in Cancer. Cells, 2022, 11, 1779.	1.8	10
3750	Leukocyte modulation by natural products from herbal medicines and potential as cancer immunotherapy. Journal of Leukocyte Biology, 2022, 112, 185-200.	1.5	1
3751	A Prognostic Signature for Clear Cell Renal Cell Carcinoma Based on Ferroptosis-Related lncRNAs and Immune Checkpoints. Frontiers in Genetics, 0, 13, .	1.1	8
3752	HLA-I-restricted CD8+ TÂcell immunity may accelerate tumorigenesis in conjunction with VHL inactivation. IScience, 2022, 25, 104467.	1.9	1
3753	Peptide vaccine-treated, long-term surviving cancer patients harbor self-renewing tumor-specific CD8+ T cells. Nature Communications, 2022, 13, .	5.8	8
3754	The theory of tumor ecosystem. Cancer Communications, 2022, 42, 587-608.	3.7	40
3757	Role of Cytokines as Immunomodulators. , 2022, , 371-414.		2
3759	Prevention and Treatment of Side Effects of Immunotherapy for Bladder Cancer. Frontiers in Oncology, 0, 12, .	1.3	5
3760	Altered mucosal immunity in HIV-positive colon adenoma: decreased CD4+ T cell infiltration is correlated with nadir but not current CD4+ T cell blood counts. International Journal of Clinical Oncology, 0, , .	1.0	0
3761	Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. Molecules, 2022, 27, 3798.	1.7	29

#	Article	IF	Citations
3762	Targeting Triple Negative Breast Cancer With Oncolytic Adenoviruses. Frontiers in Molecular Biosciences, 0, 9, .	1.6	0
3763	The Burden of Hepatitis B, Hepatitis C, and Human Immunodeficiency Viruses in Ovarian Cancer Patients in Nairobi, Kenya. Infectious Disease Reports, 2022, 14, 433-445.	1.5	2
3764	A KRAS-Associated Signature for Prognostic, Immune and Chemical Anti-Cancer Drug-Response Prediction in Colon Cancer. Frontiers in Pharmacology, 0, 13, .	1.6	2
3765	Thrombospondin-2 acts as a bridge between tumor extracellular matrix and immune infiltration in pancreatic and stomach adenocarcinomas: an integrative pan-cancer analysis. Cancer Cell International, 2022, 22, .	1.8	10
3766	Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer. Frontiers in Genetics, 0, 13, .	1.1	3
3767	Recent Insight on Regulations of FBXW7 and Its Role in Immunotherapy. Frontiers in Oncology, 0, 12, .	1.3	6
3768	An iron metabolism and immune related gene signature for the prediction of clinical outcome and molecular characteristics of triple-negative breast cancer. BMC Cancer, 2022, 22, .	1.1	2
3769	Serum immunoinflammatory-related protein complexes as personalized biomarkers for monitoring disease progression and response to treatment in lung cancer patients. Clinica Chimica Acta, 2022, 533, 53-62.	0.5	2
3770	Intra-tumor heterogeneity and its impact on cytotoxic therapy in a two-dimensional vascular tumor growth model. Chemical Engineering Science, 2022, 259, 117792.	1.9	1
3771	A direct RBF-PU method for simulating the infiltration of cytotoxic T-lymphocytes into the tumor microenvironment. Communications in Nonlinear Science and Numerical Simulation, 2022, 114, 106616.	1.7	3
3774	Cancer immunoediting hypothesis: history, clinical implications and controversies. Central-European Journal of Immunology, 2022, 47, 168-174.	0.4	8
3775	Data mining and mathematical models in cancer prognosis and prediction. Medical Review, 2022, .	0.3	1
3776	Clinical and Biological Aspects of Disseminated Tumor Cells and Dormancy in Breast Cancer. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	12
3777	Natural products and their derivatives as immune check point inhibitors: Targeting cytokine/chemokine signalling in cancer. Seminars in Cancer Biology, 2022, 86, 214-232.	4.3	21
3778	Charting roadmaps towards novel and safe synergistic immunotherapy combinations. Nature Cancer, 2022, 3, 665-680.	5.7	18
3779	The Role of Immunosuppression for Recurrent Cholangiocellular Carcinoma after Liver Transplantation. Cancers, 2022, 14, 2890.	1.7	2
3780	Analysis of the Equilibrium Phase in Immune-Controlled Tumors Provides Hints for Designing Better Strategies for Cancer Treatment. Frontiers in Oncology, 0, 12, .	1.3	2
3781	Nanotechnology-Based siRNA Delivery Systems to Overcome Tumor Immune Evasion in Cancer Immunotherapy. Pharmaceutics, 2022, 14, 1344.	2.0	8

#	Article	IF	Citations
3782	A Novel Defined Endoplasmic Reticulum Stress-Related lncRNA Signature for Prognosis Prediction and Immune Therapy in Glioma. Frontiers in Oncology, 0, 12, .	1.3	4
3783	Safety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients. Veterinary Sciences, 2022, 9, 327.	0.6	5
3784	Novel Signatures Based on the Lymphocyte-to-C-Reactive Protein Ratio Predict the Prognosis of Patients with Early Breast Cancer: A Retrospective Study. Journal of Inflammation Research, 0, Volume 15, 3957-3974.	1.6	2
3785	Co-dependencies in the tumor immune microenvironment. Oncogene, 2022, 41, 3821-3829.	2.6	8
3786	Prognostic value of tumor immune biomarkers in biopsies from patients with refractory solid cancers. Cancer Treatment and Research Communications, 2022, 32, 100611.	0.7	0
3787	Neoantigens and NK Cells: â€œTrick or Treatâ€•the Cancers?. Frontiers in Immunology, 0, 13, .	2.2	4
3788	A Novel Prognostic Signature Associated With the Tumor Microenvironment in Kidney Renal Clear Cell Carcinoma. Frontiers in Oncology, 0, 12, .	1.3	4
3789	Cancer vaccines: Building a bridge over troubled waters. Cell, 2022, 185, 2770-2788.	13.5	82
3790	A novel inflammationâ€‘associated prognostic signature for clear cell renal cell carcinoma. Oncology Letters, 2022, 24, .	0.8	11
3791	A Proposed Link Between Acute Thymic Involution and Late Adverse Effects of Chemotherapy. Frontiers in Immunology, 0, 13, .	2.2	5
3792	Validation of the Optimum Timing of Assessment of Tumor Infiltrating Lymphocytes During Preoperative Chemotherapy for Breast Cancer. Cancer Diagnosis & Prognosis, 2022, 2, 443-451.	0.3	0
3793	Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration. Cancer Research Communications, 2022, 2, 739-753.	0.7	2
3794	PINK1/Parkin-mediated mitophagy is activated to protect against AFB1-induced immunosuppression in mice spleen. Toxicology Letters, 2022, 366, 33-44.	0.4	7
3795	Targeting Toll-like Receptor 9 with CpG Oligodeoxynucleotides Enhances Tumor Response to Fractionated Radiotherapy. Clinical Cancer Research, 2005, 11, 361-369.	3.2	136
3796	Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma. Biomedicines, 2022, 10, 1763.	1.4	4
3797	The expression pattern of Immune checkpoints after chemo/radiotherapy in the tumor microenvironment. Frontiers in Immunology, 0, 13, .	2.2	2
3798	LncRNA profiles from Notch signaling: Implications for clinical management and tumor microenvironment of colorectal cancer. Frontiers in Immunology, 0, 13, .	2.2	3
3799	Resilient T-cell responses in patients with advanced cancers. International Journal of Hematology, 2023, 117, 634-639.	0.7	6

#	Article	IF	Citations
3800	Emerging advances in nanomedicine for breast cancer immunotherapy: opportunities and challenges. Immunotherapy, 2022, 14, 957-983.	1.0	3
3801	HLA Class I Antigen Down-Regulation in Primary Ovary Carcinoma Lesions: Association with Disease Stage. Clinical Cancer Research, 2005, 11, 67-72.	3.2	91
3805	Immunology and immunotherapy in breast cancer. Cancer Biology and Medicine, 2022, 19, 609-618.	1.4	10
3806	Boosting Antitumor Immunity with an Expanded Neoepitope Landscape. Cancer Research, 2022, 82, 3637-3649.	0.4	4
3807	Targeting myeloid cells with bispecific antibodies as novel immunotherapies of cancer. Expert Opinion on Biological Therapy, 2022, 22, 983-995.	1.4	4
3808	The yinâ€“yang effects of immunity: From monoclonal gammopathy of undetermined significance to multiple myeloma. Frontiers in Immunology, 0, 13, .	2.2	1
3809	Therapeutic Strategies to Enhance Tumor Antigenicity: Making the Tumor Detectable by the Immune System. Biomedicines, 2022, 10, 1842.	1.4	5
3810	Tumor immune microenvironment modulation by cholesterol in hepatocellular carcinoma. , 0, , 21-39.		1
3811	Cyclic Hypoxia Induces Transcriptomic Changes in Mast Cells Leading to a Hyperresponsive Phenotype after FcÎµRI Cross-Linking. Cells, 2022, 11, 2239.	1.8	1
3812	Comprehensive Bioinformatics Analysis of Toll-Like Receptors (TLRs) in Pan-Cancer. BioMed Research International, 2022, 2022, 1-21.	0.9	2
3813	A multi-omic approach reveals utility of CD45 expression in prognosis and novel target discovery. Frontiers in Genetics, 0, 13, .	1.1	7
3815	Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity. Journal of Hematology and Oncology, 2022, 15, .	6.9	50
3816	Adipose Tissue-Derived Mesenchymal Stromal/Stem Cells, Obesity and the Tumor Microenvironment of Breast Cancer. Cancers, 2022, 14, 3908.	1.7	17
3818	Differential expression of HAVCR2 gene in pan-cancer: A potential biomarker for survival and immunotherapy. Frontiers in Genetics, 0, 13, .	1.1	7
3819	A Novel Ferroptosis-Related Gene Signature for Prognosis Prediction in Ewing Sarcoma. Analytical Cellular Pathology, 2022, 2022, 1-22.	0.7	3
3820	Metabolic adaption of cancer cells toward autophagy: Is there a role for ER-phagy?. Frontiers in Molecular Biosciences, 0, 9, .	1.6	3
3821	The Use of Immunotherapy for Treatment of Gynecologic Malignancies. , 0, , 105-127.		1
3823	Application of lipid-based nanoparticles in cancer immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	10

#	Article	IF	Citations
3824	Integration of miRNA:mRNA Co-Expression Revealed Crucial Mechanisms Modulated in Immunogenic Cancer Cell Death. Biomedicines, 2022, 10, 1896.	1.4	2
3825	Combined fibrinogen and neutrophilâ€“lymphocyte ratio as a biomarker in predicting recurrence of giant cell tumor ofÂbone. Future Oncology, 2022, 18, 3191-3197.	1.1	1
3826	Innate lymphoid cells in early tumor development. Frontiers in Immunology, 0, 13, .	2.2	6
3827	Identifying immune cells-related phenotype to predict immunotherapy and clinical outcome in gastric cancer. Frontiers in Immunology, 0, 13, .	2.2	2
3828	The Role of Fluorescence In Situ Hybridization in the Surveillance of Non-Muscle Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis. Diagnostics, 2022, 12, 2005.	1.3	0
3829	Sex-related disparities in outcomes of cholangiocarcinoma patients in treatment trials. Frontiers in Oncology, 0, 12, .	1.3	0
3830	Road testing new CAR design strategies in multiple myeloma. Frontiers in Immunology, 0, 13, .	2.2	3
3831	Distinctive gene expression patterns in pregnancy-associated breast cancer. Frontiers in Genetics, 0, 13, .	1.1	3
3832	Preclinical Characterization of Relatlimab, a Human LAG-3â€“Blocking Antibody, Alone or in Combination with Nivolumab. Cancer Immunology Research, 2022, 10, 1175-1189.	1.6	21
3833	Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents. Cancers, 2022, 14, 4064.	1.7	11
3834	Unblinding the watchmaker: cancer treatment and drug design in the face of evolutionary pressure. Expert Opinion on Drug Discovery, 2022, 17, 1081-1094.	2.5	1
3835	Melanoma risk during immunomodulating treatment. Melanoma Research, 0, Publish Ahead of Print, .	0.6	0
3836	A comprehensive analysis of gasdermin family gene as therapeutic targets in pan-cancer. Scientific Reports, 2022, 12, .	1.6	3
3837	Advanced nanovaccines based on engineering nanomaterials for accurately enhanced cancer immunotherapy. Coordination Chemistry Reviews, 2022, 472, 214788.	9.5	7
3838	Interleukin 4 Controls the Pro-Tumoral Role of Macrophages in Mammary Cancer Pulmonary Metastasis in Mice. Cancers, 2022, 14, 4336.	1.7	11
3839	Site-specific decreases in DNA methylation in replicating cells following exposure to oxidative stress. Human Molecular Genetics, 2023, 32, 632-648.	1.4	0
3840	Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction. Bioorganic and Medicinal Chemistry, 2022, 73, 117001.	1.4	9
3841	Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert. Seminars in Cancer Biology, 2022, 86, 14-27.	4.3	21

#	Article	IF	Citations
3842	Early Immune Pressure Initiated by Tissue-Resident Memory T Cells Sculpts Tumour Evolution in Non-Small Cell Lung Cancer. SSRN Electronic Journal, 0, , .	0.4	0
3843	Cancer prognosis and immune system. , 2022, , 75-144.		0
3844	Role of regulatory T cells in cancer. , 2022, , 113-136.		10
3845	PparÎ³ Signaling in Hepatocarcinogenesis: Mechanistic Insights for Cellular Reprogramming and Therapeutic Implications. SSRN Electronic Journal, 0, , .	0.4	0
3846	Characterization of the Tumor Microenvironment in Osteosarcoma Identifies Prognostic- and Immunotherapy-Relevant Gene Signatures. Journal of Immunology Research, 2022, 2022, 1-25.	0.9	2
3847	Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy. Journal of Hematology and Oncology, 2022, 15, .	6.9	42
3848	Prognostic implications of immune classification using IDO1 expression in extrahepatic bile duct carcinoma. Oncology Letters, 2022, 24, .	0.8	0
3849	Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after â€œIFN-Î³ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancerâ€• British Journal of Cancer, 2023, 128, 461-467.	2.9	9
3850	Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy. ELife, 0, 11, .	2.8	23
3851	Immune Cells in Head-and-Neck Tumor Microenvironments. Journal of Personalized Medicine, 2022, 12, 1521.	1.1	6
3852	COVID-19 vs. Cancer Immunosurveillance: A Game of Thrones within an Inflamed Microenviroment. Cancers, 2022, 14, 4330.	1.7	4
3853	Advanced Research on Immune Checkpoint Inhibitor Therapy. Journal of Clinical Medicine, 2022, 11, 5392.	1.0	0
3854	GSTA4 Governs Melanoma Immune Resistance and Metastasis. Molecular Cancer Research, 2023, 21, 76-85.	1.5	0
3855	In ovo model in cancer research and tumor immunology. Frontiers in Immunology, 0, 13, .	2.2	14
3856	Risk factors and prognostic role of renal adverse event in patients receiving immune checkpoint inhibitor therapy: analysis of data from a retrospective cohort study. Annals of Translational Medicine, 2022, 10, 967-967.	0.7	3
3857	Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). , 2022, 10, e005413.		6
3858	Engraftment of Allotransplanted Tumor Cells in Adult rag2 Mutant Xenopus tropicalis. Cancers, 2022, 14, 4560.	1.7	2
3859	Somatic variation in normal tissues: friend or foe of cancer early detection?. Annals of Oncology, 2022, 33, 1239-1249.	0.6	12

#	Article	IF	Citations
3860	Associating resistance to immune checkpoint inhibitors with immunological escape in colorectal cancer. Frontiers in Oncology, 0, 12, .	1.3	0
3861	Development of Inhibitors Targeting the V-Domain Ig Suppressor of T Cell Activation Signal Pathway. Journal of Medicinal Chemistry, 2022, 65, 11900-11912.	2.9	3
3862	Integrated Analysis of C16orf54 as a Potential Prognostic, Diagnostic, and Immune Marker across Pan-Cancer. Disease Markers, 2022, 2022, 1-25.	0.6	3
3863	Spatiotemporal analysis of tumour-infiltrating immune cells in biliary carcinogenesis. British Journal of Cancer, 0, , .	2.9	2
3864	Nanoparticle-Based Drug Delivery Systems Targeting Tumor Microenvironment for Cancer Immunotherapy Resistance: Current Advances and Applications. Pharmaceutics, 2022, 14, 1990.	2.0	17
3865	Hypothesis: can transfer of primary neoplasm-derived extracellular vesicles and mitochondria contribute to the development of donor cellâ€“derived hematologic neoplasms after allogeneic hematopoietic cell transplantation?. Cytotherapy, 2022, 24, 1169-1180.	0.3	1
3866	The soldiers needed to be awakened: Tumor-infiltrating immune cells. Frontiers in Genetics, 0, 13, .	1.1	4
3867	Cancer Resistance to Immunotherapy: Molecular Mechanisms and Tackling Strategies. International Journal of Molecular Sciences, 2022, 23, 10906.	1.8	7
3868	Emerging Trends in Immunotherapy for Cancer. Diseases (Basel, Switzerland), 2022, 10, 60.	1.0	17
3869	Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. Frontiers in Immunology, 0, 13, .	2.2	6
3870	The new progress in cancer immunotherapy. Clinical and Experimental Medicine, 2023, 23, 553-567.	1.9	6
3871	Targeting RNA N6-methyladenosine modification: a precise weapon in overcoming tumor immune escape. Molecular Cancer, 2022, 21, .	7.9	15
3872	Impact of gender on response to immune checkpoint inhibitors in patients with non-small cell lung cancer undergoing second- or later-line treatment. Translational Lung Cancer Research, 2022, 11, 1866-1876.	1.3	1
3873	Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms. Frontiers in Immunology, 0, 13, .	2.2	1
3874	Prognostic value of combined inflammatory and nutritional biomarkers in HCC within the Milan criteria after hepatectomy. Frontiers in Oncology, 0, 12, .	1.3	4
3875	Efficacy of bivalent CEACAM6/4-1BBL genetic vaccine combined with anti-PD1 antibody in MC38 tumor model of mice. Heliyon, 2022, 8, e10775.	1.4	0
3876	Therapeutic Implications of UVB Irradiation in Cancer by Enhancing Antiâ€Tumor Immunity ^{â€}. Photochemistry and Photobiology, 0, , .	1.3	0
3877	Oncolytic Viruses in the Therapy of Lymphoproliferative Diseases. Molecular Biology, 2022, 56, 684-695.	0.4	1

#	Article	IF	Citations
3878	The DNA damage induced immune response: Implications for cancer therapy. DNA Repair, 2022, 120, 103409.	1.3	6
3879	Novel <scp>NRF2</scp>â€activated cancer treatments utilizing synthetic lethality. IUBMB Life, 2022, 74, 1209-1231.	1.5	7
3881	Three Pillars or Three Illusions of Oncoimmunology. , 2022, , 1-19.		0
3882	The innovative approach to combat cancer: Liquid biopsy and immunotherapy. , 0, 14, 18-25.		0
3883	Identification of a New Prediction Model for Bladder Cancer Related to Immune Functions and Chemotherapy Using Gene Sets of Biological Processes. BioMed Research International, 2022, 2022, 1-21.	0.9	0
3884	Identification of RUNX1 and IFNGR2 as prognostic-related biomarkers correlated with immune infiltration and subtype differentiation of low-grade glioma. Bosnian Journal of Basic Medical Sciences, 0, , .	0.6	2
3886	Immune Checkpoint Inhibitors and Other Immune Therapies in Breast Cancer: A New Paradigm for Prolonged Adjuvant Immunotherapy. Biomedicines, 2022, 10, 2511.	1.4	10
3887	Genomic instability, origin and evolution of cancer, and personalized immunotherapy. Vacunas (English Edition), 2022, 23, 222-233.	0.3	0
3888	Redeployment of Placental Gene Programming: Can Invasive Placentation Molecular Switches Complement the Hallmarks of Cancer?. Journal of Clinical and Medical Research, 0, , .	0.0	0
3889	Importance of TGFÎ² in Cancer and Nematode Infection and Their Interactionâ€"Opinion. Biomolecules, 2022, 12, 1572.	1.8	4
3890	The Influence of Physical Training on the Immune System of Rats during N-methyl-N-nitrosourea-Induced Carcinogenesis. Journal of Clinical Medicine, 2022, 11, 6371.	1.0	0
3891	Modeling Obesity-Driven Pancreatic Carcinogenesisâ€"A Review of Current In Vivo and In Vitro Models of Obesity and Pancreatic Carcinogenesis. Cells, 2022, 11, 3170.	1.8	1
3892	Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development. Biochemical Journal, 2022, 479, 2219-2260.	1.7	6
3893	What Are the Reasons for Continuing Failures in Cancer Therapy? Are Misleading/Inappropriate Preclinical Assays to Be Blamed? Might Some Modern Therapies Cause More Harm than Benefit?. International Journal of Molecular Sciences, 2022, 23, 13217.	1.8	9
3894	Prognostic value of antitumor drug targets prediction using integrated bioinformatic analysis for immunogenic cell death-related lncRNA model based on stomach adenocarcinoma characteristics and tumor immune microenvironment. Frontiers in Pharmacology, 0, 13, .	1.6	7
3895	A novel ferroptosisâ€'related gene signature for overall survival prediction and immune infiltration in patients with breast cancer. International Journal of Oncology, 2022, 61, .	1.4	1
3896	Liquid Biopsy for Uveal Melanoma. Does It Make Sense?. Oftalmologiya, 2022, 19, 594-602.	0.2	3
3897	Loss of LXN promotes macrophage M2 polarization and PD-L2 expression contributing cancer immune-escape in mice. Cell Death Discovery, 2022, 8, .	2.0	2

#	Article	IF	Citations
3898	Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers. Trends in Immunology, 2022, 43, 932-946.	2.9	22
3899	Advances in immunotherapy for MMR proficient colorectal cancer. Cancer Treatment Reviews, 2022, 111, 102480.	3.4	11
3900	PPARÎ³ signaling in hepatocarcinogenesis: Mechanistic insights for cellular reprogramming and therapeutic implications. , 2022, 240, 108298.		15
3901	Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy. International Immunopharmacology, 2022, 113, 109365.	1.7	6
3902	Peri-tumoral infiltrate in OSCC: â€œThe simpler, the betterâ€•temptation. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2023, 44, 103666.	0.6	0
3903	Antigen specific active immunotherapy: lessons from the first decade. Swiss Medical Weekly, 0, , .	0.8	2
3904	The Tumor Microenvironment. Environmental Chemistry for A Sustainable World, 2022, , 1-49.	0.3	0
3905	Combination of Baseline and Variation of Prognostic Nutritional Index Enhances the Survival Predictive Value of Patients With Advanced Non-Small Cell Lung Cancer Treated With Programmed Cell Death Protein 1 Inhibitor. Clinical Medicine Insights: Oncology, 2022, 16, 117955492211371.	0.6	2
3906	Dual Role of Interferon in Cancer Immunity. , 2022, , 1-23.		0
3907	Ovarian cancer stem cells: Critical roles in anti-tumor immunity. Frontiers in Genetics, 0, 13, .	1.1	1
3908	The mechanisms on evasion of anti-tumor immune responses in gastric cancer. Frontiers in Oncology, 0, 12, .	1.3	3
3909	NK cells with decreased expression of multiple activating receptors is a dominant phenotype in pediatric patients with acute lymphoblastic leukemia. Frontiers in Oncology, 0, 12, .	1.3	4
3910	On modeling the synergy of cancer immunotherapy with radiotherapy. Communications in Nonlinear Science and Numerical Simulation, 2023, 118, 106987.	1.7	3
3911	Peripheral Blood Lymphocyte Subsets as a Risk Predictor of Patients with Endometrioid Endometrial Cancer. Journal of Inflammation Research, 0, Volume 15, 6153-6163.	1.6	0
3912	Excavation of Molecular Subtypes of Endometrial Cancer Based on DNA Methylation. Genes, 2022, 13, 2106.	1.0	0
3913	Neutrophils as immune effector cells in antibody therapy in cancer. Immunological Reviews, 2023, 314, 280-301.	2.8	12
3914	Challenges in neoantigen-directed therapeutics. Cancer Cell, 2023, 41, 15-40.	7.7	27
3915	Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy. Acta Pharmaceutica Sinica B, 2022, 12, 4327-4347.	5.7	78

#	Article	IF	Citations
3916	The tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives. Advanced Drug Delivery Reviews, 2022, 191, 114614.	6.6	59
3917	Tumor Immune Microenvironment and Immunotherapy in Non-Small Cell Lung Cancer: Update and New Challenges. , 2022, 13, 1615.		21
3921	Epigenetically suppressed tumor cell intrinsic STING promotes tumor immune escape. Biomedicine and Pharmacotherapy, 2023, 157, 114033.	2.5	8
3922	Immune System-Related Biomarkers as a Tool for Diagnosis in Oral Cancer. , 2022, , 1-21.		0
3923	Activation of B cells in Tertiary Lymphoid Structures in cancer: Anti-tumor or anti-self?. Seminars in Immunology, 2023, 65, 101703.	2.7	11
3924	Endogenous/exogenous stimulies inspired polyprodrug nano-inducer switches pyroptosis path for promoting antitumor immunity. Nano Today, 2023, 48, 101727.	6.2	16
3925	The Janus-Faced Role of Cell-Mediated Immune Responses in Pancreatic Cancer. European Medical Journal Oncology, 0, , 62-69.	0.0	0
3926	The Tumor Microenvironment in Hepatocellular Carcinoma. , 2022, , 107-137.		0
3927	Identification of genes and cellular response factors related to immunotherapy response in mismatch repair-proficient colorectal cancer: a bioinformatics analysis. Journal of Gastrointestinal Oncology, 2022, .	0.6	0
3928	Allergy: the risk of cancer and the impact on cancer care. , 2022, , 118-122.		0
3929	Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma. Cancers, 2022, 14, 5676.	1.7	3
3930	DNA and mRNA Vaccines for Chronic Viral Infections and Cancer: Rationale, Mechanisms, and Progress. Cancers, 2022, 14, 5874.	1.7	1
3931	Advances in the Lung Cancer Immunotherapy Approaches. Vaccines, 2022, 10, 1963.	2.1	6
3932	Targeting PIM Kinases to Improve the Efficacy of Immunotherapy. Cells, 2022, 11, 3700.	1.8	4
3933	A deubiquitination module essential for T _{reg} fitness in the tumor microenvironment. Science Advances, 2022, 8, .	4.7	14
3934	Metabolism in Cancer Stem Cells: Targets for Clinical Treatment. Cells, 2022, 11, 3790.	1.8	5
3935	Cancer immunosurveillance in respiratory diseases. , 2022, , 1-14.		2
3936	Modern aspects of immunotherapy with checkpoint inhibitors in melanoma. Medical Alphabet, 2022, , 35-40.	0.0	2

#	Article	IF	Citations
3938	Targeted Pyroptosis Is a Potential Therapeutic Strategy for Cancer. Journal of Oncology, 2022, 2022, 1-15.	0.6	5
3939	Screening and identification of an anti-PD-1 nanobody with antitumor activity. Bioscience Reports, 2023, 43, .	1.1	3
3940	What Are the Roles of Proprotein Convertases in the Immune Escape of Tumors?. Biomedicines, 2022, 10, 3292.	1.4	5
3941	Role of Immunosuppressive and Immunomodulatory Agents in Cancer. , 0, , .		0
3942	Immunotherapy Options for Acral Melanoma, A fast-growing but Neglected Malignancy. Archives of Medical Research, 2022, 53, 794-806.	1.5	5
3943	Tumor-derived extracellular vesicles in the colorectal cancer immune environment and immunotherapy. , 2023, 241, 108332.		4
3944	Integrated molecular analyses of an interferon-Î³ based subtype with regard to outcome, immune characteristics, and immunotherapy in bladder cancer and experimental verification. Heliyon, 2022, 8, e12102.	1.4	0
3945	Nanodroplet-enhanced sonodynamic therapy potentiates immune checkpoint blockade for systemic suppression of triple-negative breast cancer. Acta Biomaterialia, 2023, 158, 547-559.	4.1	7
3946	Identification of a signature based on nonâ€apoptotic regulatory cell death to improve prognosis prediction in acute myeloid leukaemia. British Journal of Haematology, 0, , .	1.2	1
3947	Some New Aspects of Genetic Variability in Patients with Cutaneous T-Cell Lymphoma. Genes, 2022, 13, 2401.	1.0	1
3948	Tumor-Derived Extracellular Vesicles in Cancer Immunoediting and Their Potential as Oncoimmunotherapeutics. Cancers, 2023, 15, 82.	1.7	5
3949	Discrete and continuum models for the coevolutionary dynamics between CD8+ cytotoxic T lymphocytes and tumour cells. Mathematical Medicine and Biology, 0, , .	0.8	2
3950	Three-dimensional Imaging Reveals Immune-driven Tumor-associated High Endothelial Venules as a Key Correlate of Tumor Rejection Following Depletion of Regulatory T Cells. Cancer Research Communications, 2022, 2, 1641-1656.	0.7	2
3951	Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer. Cancers, 2022, 14, 6034.	1.7	6
3952	Novel Roles of Nanog in Cancer Cells and Their Extracellular Vesicles. Cells, 2022, 11, 3881.	1.8	3
3953	Optimizing the synthesis of interleukinâ€12â€loaded PLGA nanospheres (rmILâ€12ns) via ultrasonication for treatment of metastatic osteosarcoma. Journal of Orthopaedic Research, 2023, 41, 1565-1581.	1.2	1
3954	Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors. Cancers, 2022, 14, 6145.	1.7	10
3955	CAF-immune cell crosstalk and its impact in immunotherapy. Seminars in Immunopathology, 2023, 45, 203-214.	2.8	10

#	Article	IF	Citations
3956	T-cell repertoire diversity: friend or foe for protective antitumor response?. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	11
3958	Expression of Three Clones of PD-L1 in Lung Cancer: A Single-center Experience. In Vivo, 2023, 37, 233-241.	0.6	1
3959	Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors. Cancer and Metastasis Reviews, 2023, 42, 161-182.	2.7	10
3960	Epigenetics and Metabolism Reprogramming Interplay into Glioblastoma: Novel Insights on Immunosuppressive Mechanisms. Antioxidants, 2023, 12, 220.	2.2	4
3961	Exploring the landscape of immunotherapy approaches in sarcomas. Frontiers in Oncology, 0, 12, .	1.3	1
3962	Postoperative adjuvant therapy for hepatocellular carcinoma with microvascular invasion. World Journal of Gastrointestinal Surgery, 0, 15, 19-31.	0.8	4
3963	Downregulation of MICA/B tumor surface expressions and augmented soluble MICA serum levels correlate with disease stage in breast cancer. Breast Disease, 2023, 41, 471-480.	0.4	0
3964	Microfluidically-generated Encapsulated Spheroids (Î¼-GELS): An All-Aqueous Droplet Microfluidics Platform for Multicellular Spheroids Generation. ACS Biomaterials Science and Engineering, 2023, 9, 1043-1052.	2.6	1
3965	Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome. Cancers, 2023, 15, 321.	1.7	21
3966	Time to Sleep: Immunologic Niche Switches Tumor Dormancy at Metastatic Sites. , 2023, , 1-27.		0
3968	SN38-loaded nanomedicine mediates chemo-radiotherapy against CD44-expressing cancer growth. Cancer Nanotechnology, 2023, 14, .	1.9	1
3969	Radiation-Induced Immunoediting of Cancer. , 2023, , 1-20.		0
3970	Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characteristics in pancreatic adenocarcinoma. Cancer Cell International, 2023, 23, .	1.8	4
3971	Chemo-immunoablation of solid tumors: A new concept in tumor ablation. Frontiers in Immunology, 0, 13, .	2.2	3
3972	The Effects of Clonal Heterogeneity on Cancer Immunosurveillance. Annual Review of Cancer Biology, 2023, 7, 131-147.	2.3	3
3973	Cisplatin-loaded gold nanoshells mediate chemo-photothermal therapy against primary and distal lung cancers growth. Biomedicine and Pharmacotherapy, 2023, 158, 114146.	2.5	6
3974	MHC-dressing on dendritic cells: Boosting anti-tumor immunity via unconventional tumor antigen presentation. Seminars in Immunology, 2023, 66, 101710.	2.7	5
3975	Recent advancements in immunotherapy of melanoma using nanotechnology-based strategies. Biomedicine and Pharmacotherapy, 2023, 159, 114243.	2.5	4

#	Article	IF	Citations
3976	Research progress of Astragalus membranaceus in treating peritoneal metastatic cancer. Journal of Ethnopharmacology, 2023, 305, 116086.	2.0	7
3977	Role of Natural Products in Combating Cancer. , 0, , .		4
3978	TILâ€™s lymphocyte expression in patient with Colorectal cancer. Progress in Health Sciences, 2022, 12, 62-66.	0.1	0
3979	Dendritic Cell-Triggered Immune Activation Goes along with Provision of (Leukemia-Specific) Integrin Beta 7-Expressing Immune Cells and Improved Antileukemic Processes. International Journal of Molecular Sciences, 2023, 24, 463.	1.8	3
3980	Immunogenic Cell Death in Cancer. , 2023, , .		0
3981	Circulating Tumor Cells in Breast Cancer. , 2023, , .		0
3982	Immunomodulatory Therapy in Head and Neck Squamous Cell Carcinoma: Recent Advances and Clinical Prospects. Technology in Cancer Research and Treatment, 2023, 22, 153303382211505.	0.8	7
3983	Introduction on Cancer Immunodiagnosis. , 2023, , 1-24.		0
3984	Tumor immunology. , 2023, , 245-452.		0
3985	Cancer-Associated B Cells in Sarcoma. Cancers, 2023, 15, 622.	1.7	3
3986	Two lateral parametria in radical hysterectomy: History and outcome. Journal of Obstetrics and Gynaecology Research, 0, , .	0.6	3
3987	Genitourinary cancers immune biomarkers: a comprehensive overview. , 2023, , 389-409.		0
3988	Advances in Natural Killer Cells and Immunotherapy for Gastric Cancer. , 0, , .		0
3989	Peripheral blood lymphocytes differentiation patterns in responses / outcomes to immune checkpoint blockade therapies in non-small cell lung cancer: a retrospective study. BMC Cancer, 2023, 23, .	1.1	3
3990	Yin and yang roles of B lymphocytes in solid tumors: Balance between antitumor immunity and immune tolerance/immunosuppression in tumor-draining lymph nodes. Frontiers in Oncology, 0, 13, .	1.3	2
3991	HLA-G: A Novel Immune Checkpoint for Solid Cancer Immunotherapy. , 2023, , 1-27.		0
3992	Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle. European Medical Journal Oncology, 0, , 70-76.	0.0	1
3993	A phase I dose-escalation study of neoantigen-activated haploidentical T cell therapy for the treatment of relapsed or refractory peripheral T-cell lymphoma. Frontiers in Oncology, 0, 12, .	1.3	3

#	Article	IF	Citations
3994	Immuno-oncology in head and neck squamous cell carcinoma - a narrative review. Brazilian Journal of Medical and Biological Research, 0, 56, .	0.7	1
3995	Neoadjuvant chemotherapy modulates exhaustion of T cells in breast cancer patients. PLoS ONE, 2023, 18, e0280851.	1.1	2
3996	æ¬¡ä¸–ä»£ãƒªãƒ¼ãƒ€ãƒ¼è育æˆ€•éé¸éƒ¨ç™Œã«å¯¾ã™ã‚‹å……ç–«ç™‚æ³•ã®æœ€å‰ç·šçš€•. Nihon Jibi Inkoka Tokubu Gekka Gakkai Ka	0.0	0
3997	Tumor-associated macrophages employ immunoediting mechanisms in colorectal tumor progression: Current research in Macrophage repolarization immunotherapy. International Immunopharmacology, 2023, 116, 109569.	1.7	12
3998	Highlights into historical and current immune interventions for cancer. International Immunopharmacology, 2023, 117, 109882.	1.7	2
3999	NLRC5-CIITA Fusion Protein as an Effective Inducer of MHC-I Expression and Antitumor Immunity. International Journal of Molecular Sciences, 2023, 24, 7206.	1.8	2
4000	Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date. International Immunopharmacology, 2023, 117, 109881.	1.7	8
4001	Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial. Clinical Cancer Research, 2023, 29, 2456-2465.	3.2	1
4002	Immunotherapy for neuroblastoma by hematopoietic cell transplantation and post-transplant immunomodulation. Critical Reviews in Oncology/Hematology, 2023, 185, 103956.	2.0	0
4003	S-allylmercaptocysteine promotes anti-tumor immunity by suppressing PD-L1 expression. Biomedicine and Pharmacotherapy, 2023, 161, 114446.	2.5	0
4005	Reversing T Cell Dysfunction to Boost Glioblastoma Immunotherapy by Paroxetineâ€Mediated GRK2 Inhibition and Blockade of Multiple Checkpoints through Biomimetic Nanoparticles. Advanced Science, 2023, 10, .	5.6	9
4006	High soluble OX40 levels correlate with metastatic gastric cancer. Journal of Surgical Oncology, 2022, 126, 139-143.	0.8	1
4007	IMMUNOLOGICAL FEATURES OF BREAST CANCER. LaboratornaÃ¢ I KliniÄeskaÃ¢ Medicina FarmaciÃ¢, 2022, , 27-36.	0.1	0
4008	Immunomodulatory nanosystems: An emerging strategy to combat viral infections. Biomaterials and Biosystems, 2023, 9, 100073.	1.0	3
4009	Epigenetic modification of CSDE1 locus dictates immune recognition of nascent tumorigenic cells. Science Translational Medicine, 2023, 15, .	5.8	7
4010	Vaccination-Based Immunoprevention of Colorectal Tumors. Journal of Clinical Gastroenterology, 2023, 57, 246-252.	1.1	1
4011	Locally sourced: site-specific immune barriers to metastasis. Nature Reviews Immunology, 2023, 23, 522-538.	10.6	9
4012	Immunotherapies against HER2-Positive Breast Cancer. Cancers, 2023, 15, 1069.	1.7	4

#	Article	IF	Citations
4014	Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. Frontiers in Immunology, 0, 14, .	2.2	19
4015	Identification and characterization of a novel molecular classification incorporating oxidative stress and metabolism-related genes for stomach adenocarcinoma in the framework of predictive, preventive, and personalized medicine. Frontiers in Endocrinology, 0, 14, .	1.5	8
4016	Clinical Significance of Tumour-Infiltrating B Lymphocytes (TIL-Bs) in Breast Cancer: A Systematic Literature Review. Cancers, 2023, 15, 1164.	1.7	4
4017	Tumorâ€Specific Photothermalâ€Therapyâ€Assisted Immunomodulation via Multiresponsive Adjuvant Nanoparticles. Advanced Materials, 2023, 35, .	11.1	13
4018	Immune-related risk score: An immune-cell-pair-based prognostic model for cutaneous melanoma. Frontiers in Immunology, 0, 14, .	2.2	1
4019	The Prognostic Impact of Gender, Therapeutic Strategies, Molecular Background, and Tumor-Infiltrating Lymphocytes in Glioblastoma: A Still Unsolved Jigsaw. Genes, 2023, 14, 501.	1.0	5
4020	Overview of the synergistic use of radiotherapy and immunotherapy in cancer treatment: current challenges and scopes of improvement. Expert Review of Anticancer Therapy, 2023, 23, 135-145.	1.1	6
4021	Heterogeneous expression of predictive biomarkers PD-L1 and TIGIT in non-mucinous lung adenocarcinoma and corresponding lymph node metastasis: A challenge for clinical biomarker testing. Neoplasia, 2023, 38, 100884.	2.3	3
4022	New Biomarkers Based on Dendritic Cells for Breast Cancer Treatment and Prognosis Diagnosis. International Journal of Molecular Sciences, 2023, 24, 4058.	1.8	0
4023	Immunotherapy of Cancer: Towards a New Era. European Medical Journal Oncology, 0, , 76-82.	0.0	0
4024	RAGA prevents tumor immune evasion of LUAD by promoting CD47 lysosome degradation. Communications Biology, 2023, 6, .	2.0	3
4025	The Two Faces of Immune-Related lncRNAs in Head and Neck Squamous Cell Carcinoma. Cells, 2023, 12, 727.	1.8	6
4026	PMN-MDSCs modulated by CCL20 from cancer cells promoted breast cancer cell stemness through CXCL2-CXCR2 pathway. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	17
4027	Insight into the Crosstalk between Photodynamic Therapy and Immunotherapy in Breast Cancer. Cancers, 2023, 15, 1532.	1.7	6
4028	Acral Melanoma Is Infiltrated with cDC1s and Functional Exhausted CD8 T Cells Similar to the Cutaneous Melanoma of Sun-Exposed Skin. International Journal of Molecular Sciences, 2023, 24, 4786.	1.8	0
4029	Cancer Initiation and Inflammation. , 2023, , 1-15.		0
4030	Dancing with the Surgeon: Neoadjuvant and Adjuvant Immunotherapies from the Medical Oncologistâ€™s Perspective. Journal of Chest Surgery, 2023, 56, 67-74.	0.2	2
4031	The role of tumor activation and inhibition with saturation effects in a mathematical model of tumor and immune system interactions undergoing oncolytic viral therapy. Mathematical Methods in the Applied Sciences, 2023, 46, 10787-10813.	1.2	1

#	Article	IF	Citations
4032	N6-methyladenosine related gene expression signatures for predicting the overall survival and immune responses of patients with colorectal cancer. Frontiers in Genetics, 0, 14, .	1.1	1
4033	Low-dose metronomic gemcitabine pretreatments overcome the resistance of breast cancer to immune checkpoint therapy. Immunotherapy, 2023, 15, 429-442.	1.0	3
4034	Immune Compartments and Extracellular Matrix Crosstalk Involved in Tumor Dissemination. , 2023, , 1-22.		0
4035	Tissue-resident Lachnospiraceae family bacteria protect against colorectal carcinogenesis by promoting tumor immune surveillance. Cell Host and Microbe, 2023, 31, 418-432.e8.	5.1	44
4036	The Undesirable and Desirable Functions of DAMPs in Allograft and Tumor Rejection. , 2023, , 659-673.		0
4037	IFNÎ³ blockade in capillary leak site improves tumour chemotherapy by inhibiting lactate-induced endocytosis of vascular endothelial-cadherins. International Journal of Biological Sciences, 2023, 19, 1490-1508.	2.6	0
4038	SESN2 Could Be a Potential Marker for Diagnosis and Prognosis in Glioma. Genes, 2023, 14, 701.	1.0	3
4039	Pyroptosisâ€Mediated Synergistic Photodynamic and Photothermal Immunotherapy Enabled by a Tumorâ€Membraneâ€Targeted Photosensitive Dimer. Advanced Materials, 2023, 35, .	11.1	34
4040	The current understanding of the immune landscape relative to radiotherapy across tumor types. Frontiers in Immunology, 0, 14, .	2.2	5
4041	Pan-cancer analysis identifies PD-L2 as a tumor promotor in the tumor microenvironment. Frontiers in Immunology, 0, 14, .	2.2	2
4042	Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?. Frontiers in Oncology, 0, 13, .	1.3	3
4043	Current literature review on the tumor immune micro-environment, its heterogeneity and future perspectives in treatment of advanced non-small cell lung cancer. Translational Lung Cancer Research, 2023, .	1.3	1
4044	Computational systems biology approach for permanent tumor elimination and normal tissue protection using negative biasing: Experimental validation in malignant melanoma as case study. Mathematical Biosciences and Engineering, 2023, 20, 9572-9606.	1.0	0
4045	Immune modulations of the tumor microenvironment in response to phototherapy. Journal of Innovative Optical Health Sciences, 2023, 16, .	0.5	2
4046	Boron Derivatives Inhibit the Proliferation of Breast Cancer Cells and Affect Tumor-Specific T Cell Activity In Vitro by Distinct Mechanisms. Biological Trace Element Research, 2023, 201, 5692-5707.	1.9	5
4047	m6Aâ€•and immuneâ€•related lncRNA signature confers robust predictive power for immune efficacy in lung squamous cell carcinoma. View, 2023, 4, .	2.7	4
4048	Single cell analysis in head and neck cancer reveals potential immune evasion mechanisms during early metastasis. Nature Communications, 2023, 14, .	5.8	9
4049	Therapeutic Cancer Vaccines for Nonmelanoma Skin Cancer. Current Treatment Options in Oncology, 2023, 24, 496-514.	1.3	1

#	Article	IF	Citations
4050	Immunotherapy: A new target for cancer cure (Review). Oncology Reports, 2023, 49, .	1.2	0
4051	Role of C-Type Lectins in the Tumor Microenvironment. , 2023, , 1-23.		0
4052	Enhancement of immune surveillance in breast cancer by targeting hypoxic tumor endothelium: Can it be an immunological switch point?. Frontiers in Oncology, 0, 13, .	1.3	4
4053	Controversies and management of deficient mismatch repair gastrointestinal cancers in the neoadjuvant setting. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592311625.	1.4	0
4054	T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. Cell, 2023, 186, 1432-1447.e17.	13.5	49
4055	Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis. Frontiers in Immunology, 0, 14, .	2.2	2
4056	Chiral inorganic nanostructures for theranostics. , 2023, 53, 0303.		1
4057	Neoantigen-directed therapeutics in the clinic: where are we?. Trends in Cancer, 2023, 9, 503-519.	3.8	4
4058	Inflammatory Cells Can Alter the Levels of H3K9ac and Î³H2AX in Dysplastic Cells and Favor Tumor Phenotype. Journal of Personalized Medicine, 2023, 13, 662.	1.1	1
4059	Novel strategies for cancer immunotherapy: counter-immunoediting therapy. Journal of Hematology and Oncology, 2023, 16, .	6.9	14
4060	T Cell Based Immunotherapy for Cancer: Approaches and Strategies. Vaccines, 2023, 11, 835.	2.1	9
4062	The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy. Cancers, 2023, 15, 2323.	1.7	14
4063	Converging on a Cure: The Roads to Predictive Immunotherapy. Cancer Discovery, 2023, 13, 1053-1057.	7.7	3
4065	Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy in patients with extensive-stage small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Oncology, 0, 13, .	1.3	2
4066	Cancer Surveillance. , 2023, , 271-341.		0
4067	Role of voltage-gated proton channel (Hv1) in cancer biology. Frontiers in Pharmacology, 0, 14, .	1.6	1
4069	TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer. Nature Immunology, 2023, 24, 792-801.	7.0	28
4070	Early immune pressure initiated by tissue-resident memory TÂcells sculpts tumor evolution in non-small cell lung cancer. Cancer Cell, 2023, 41, 837-852.e6.	7.7	9

#	Article	IF	Citations
4075	The Changing Fortune of Cancer Immunotherapy. , 2017, , 97-125.		0
4088	Cancerâ€"avoiding immune detection. , 2024, , 157-176.e4.		0
4089	Tumor immune surveillance. , 2024, , 115-128.e3.		0
4090	Vaccines and active immunization against cancer. , 2024, , 177-194.e3.		0
4108	Immunotherapy for Pancreatic Cancer. , 2023, , 1-27.		0
4118	Chiral inorganic nanomaterials: Harnessing chirality-dependent interactions with living entities for biomedical applications. Nano Research, 2023, 16, 11107-11124.	5.8	3
4126	Cancer Vaccines. , 2023, , 191-210.e9.		0
4131	Safety and efficacy of immune checkpoint inhibitors after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 0, , .	1.3	0
4139	Circulating tumor cells and host immunity: A tricky liaison. International Review of Cell and Molecular Biology, 2023, , 131-157.	1.6	0
4170	Nanomedicine â€“ Immune System Interactions: Limitations and Opportunities for the Treatment of Cancer. Handbook of Experimental Pharmacology, 2023, , .	0.9	0
4192	Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients. Methods in Cell Biology, 2023, , .	0.5	0
4197	Leveraging mesoporous silica nanomaterial for optimal immunotherapeutics against cancer. In Vitro Models, 2023, 2, 153-169.	1.0	0
4209	Editorial: Rising stars in cancer immunity and immunotherapy 2022. Frontiers in Immunology, 0, 14, .	2.2	0
4210	Immune Effects of Ablation. , 2023, , 1-17.		0
4231	Recent Advances of RNA m6A Modifications in Cancer Immunoediting and Immunotherapy. Cancer Treatment and Research, 2023, , 49-94.	0.2	0
4237	Myeloid-derived suppressor cells in cancer and cancer therapy. Nature Reviews Clinical Oncology, 2024, 21, 147-164.	12.5	1
4240	Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy. Cancer and Metastasis Reviews, 2024, 43, 175-195.	2.7	0
4250	Immune System Influence on Hematopoietic Stem Cells and Leukemia Development. Advances in Experimental Medicine and Biology, 2023, , 125-135.	0.8	0

#	Article	IF	Citations
4270	Proteomics: Unraveling the Cross Talk Between Innate Immunity and Disease Pathophysiology, Diagnostics, and Treatment Options. Advances in Experimental Medicine and Biology, 2024, , 221-242.	0.8	0
4282	The role of artificial intelligence in radiology and interventional oncology. , 2024, , 193-200.		0